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1 Synopsis
Clinical Trial Protocol Number MS200527-0086
Title A Randomized, Double-Blind, 
Placebo-Controlled Phase II Study of M2951 with 
a Parallel, Open-Label, Active Control Group
(Tecfidera), in Patients with Relapsing Multiple 
Sclerosis to Evaluate Efficacy, Safety, 
Tolerability, Pharmacokinetics, and Biological 
Activity.
Trial Phase II
IND Number 129428
FDA covered trial Yes
EudraCT Number 2016-001448-21
Coordinating Investigator
 
Sponsor For all countries except the USA:
Merck KGaA Frankfurter Str. 250,
64293 Darmstadt, Germany. 
For the USA only:
EMD Serono Research and Development 
Institute, Inc.
45A Middlesex Turnpike
Billerica, MA, 01821 USA
Trial centers/countries This trial will be conducted at approximately 100
sites globally in Europe, USA, and in the rest of 
the world (RoW).
Planned trial period
(first subject in-last subject out)
First subject in: Q3, 2016
Last subject out: Q4, 2018
Trial Registry ClinicalTrials.gov, EudraCT
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Objectives: 
Primary Objective
The primary objective is to evaluate the efficacy and dose-response of M2951 on the number 
of gadolinium-positive (Gd+) T1 magnetic resonance imaging (MRI) lesions versus placebo 
after 24 weeks of treatment.
Secondary Objectives
The key secondary objectives are as follows:
! To evaluate the efficacy and dose-response of M2951 on clinical endpoints over 24 weeks
versus placebo
! To evaluate the safety of M2951
Additional secondary objectives are as follows:
! To evaluate the efficacy of M2951 on additional MRI parameters over 24 weeks versus 
placebo 
! To evaluate the efficacy of M2951 on clinical and MRI endpoints from Weeks 24 to 48
! To evaluate the efficacy of Tecfidera on clinical and MRI endpoints over 24 weeks
! To evaluate the efficacy of Tecfidera on clinical and MRI endpoints from Weeks 24 to 48
! To evaluate the safety of Tecfidera
Exploratory Objectives
The exploratory objectives are as follows:
 
! To explore the benefit of M2951 treatment on patient-reported health related quality of life 
(HRQoL) versus placebo, and to evaluate the effect of Tecfidera on HRQoL
Methodology: The study will be a randomized, double-blind, placebo-controlled study in 
subjects with relapsing multiple sclerosis (MS), with a parallel, open-label active control group
(Tecfidera) involving 5 treatment groups with 3 doses of M2951, placebo, and active control 
(Tecfidera). 
The study will consist of 3 major periods; a Screening period of 4 weeks, active treatment with 
3 dose groups of M2951, active control (Tecfidera), or placebo for 24 weeks, and a 24-week 
extension on active treatment with M2951 or active control (Tecfidera) for 24 weeks, where 
subjects on placebo will be switched to M2951. Following completion or early termination of 
treatment, subjects will return after 4 weeks for safety evaluation. A separate open-label 
extension protocol will be developed allowing continued dosing, provided that safety and 
tolerability are acceptable.
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An interim analysis (IA) for futility may be conducted during the placebo-controlled portion 
of the treatment period when the first 50% of subjects enrolled out of the planned enrollment 
have reached the end of 24 weeks of treatment. If conducted, this analysis will evaluate overall 
futility for the highest dose of M2951 to determine whether or not to continue with the study. 
It is planned that placebo subjects will be switched to the 25 mg M2951 once daily (QD) dose
after Week 24; however, consideration will be given to changing this dose based on data from 
the IA. The Sponsor may decide not to perform the IA if the IA trigger date is sufficiently close 
(ie, within approximately 4 months) of the primary analysis trigger date.
Placebo, M2951, and Tecfidera will be administered orally daily. After Day 1, subjects will 
return every 4 weeks for trial visits and will be assessed for safety and efficacy.  
 
 
An independent data monitoring committee (IDMC) will be responsible for both safety 
monitoring and futility analyses. The IDMC will consist of at least the following core members:
2 clinicians and 1 biostatistician. 
Planned number of subjects: Approximately 50 subjects will be enrolled in each treatment 
group, for a total of approximately 250 enrolled subjects.
Primary endpoint: Total number of gadolinium-enhancing T1 lesions at Weeks 12, 16, 20, 
and 24.
Secondary endpoints: 
Key secondary endpoints to evaluate the efficacy and safety of M2951 compared to placebo:
! Annualized relapse rate (ARR), based on protocol-defined qualified relapses, at Week 24 
! Proportion of subjects who remain qualified relapse-free at Week 24
! Change from Baseline in Expanded Disability Status Scale (EDSS) at Week 24
! Safety as assessed by the nature, severity, and incidence of adverse events (AEs); vital 
signs; electrocardiograms (ECGs); absolute concentrations and change from Baseline in 
immunoglobulin (Ig) levels; absolute numbers and change from Baseline in B cells; and 
clinical laboratory safety parameters (duration of placebo treatment group is limited to 
24 weeks).
Additional secondary endpoints:
To evaluate the efficacy of M2951 compared to placebo:
! Total number of new Gd+ T1 lesions at Weeks 12, 16, 20, and 24
! Mean per-scan number of Gd+ T1 lesions at Weeks 12, 16, 20, and 24
! Total number of new or enlarging T2 lesions at Weeks 12, 16, 20, and 24
! Change from Baseline in the volume of Gd+ T1 lesions at Week 24
! Change from Baseline in the volume of T2 lesions at Week 24
?
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To evaluate efficacy within M2951 dose groups:
! Total number of Gd+ T1 lesions at Week 48
! Total number of new Gd+ T1 lesions at Week 48
! Annualized relapse rate, based on protocol-defined qualified relapses, at Week 48
! Proportion of subjects who remain qualified relapse-free at Week 48
! Change from Baseline in EDSS at Week 48
! Total number of new or enlarging T2 lesions at Week 48
! Change from Baseline in the volume of Gd+ T1 lesions at Week 48
! Change from Baseline in the volume of T2 lesions at Week 48
To evaluate the efficacy and safety of Tecfidera:
! Total number of gadolinium-enhancing T1 lesions at Weeks 12, 16, 20, and 24
! Annualized relapse rate, based on protocol-defined qualified relapses at Week 24
! Proportion of subjects who remain qualified relapse-free at Week 24
! Change from Baseline EDSS at Week 24
! Safety as assessed by the nature, severity, and incidence of AEs; vital signs; ECGs;
absolute concentrations and change from Baseline in Ig levels; absolute numbers and 
change from Baseline in B cells; and clinical laboratory safety parameters
! Total number of new Gd+ T1 lesions at Weeks 12, 16, 20, 24
! Mean per-scan number of Gd+ T1 lesions at Weeks 12, 16, 20, and 24
! Total number of new or enlarging T2 lesions at Weeks 12, 16, 20, and 24
! Change from Baseline in the volume of Gd+ T1 lesions at Week 24
! Change from Baseline in the volume of T2 lesions at Week 24
! Total number of Gd+ T1 lesions at Week 48
! Total number of new Gd+ T1 lesions at Week 48
! Annualized relapse rate, based on protocol-defined qualified relapses, at Week 48 
! Proportion of subjects who remain qualified relapse-free at Week 48 
! Change from Baseline in EDSS at Week 48
! Total number of new or enlarging T2 lesions at Week 48
! Change from Baseline in the volume of Gd+ T1 lesions at Week 48
! Change from Baseline in the volume of T2 lesions at Week 48
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Exploratory endpoints: 
Exploratory endpoints are as follows:
! Change in HRQoL as measured with SF-36v2 (physical component summary [PCS]/mental 
component summary [MCS] and sub-domains) over time (area under the curve) in all 
subjects
! Change in HRQoL as measured with SF-36v2 (PCS/MCS and sub-domains) from Baseline 
to Week 24 and from Baseline to Week 48 in all subjects
Pharmacodynamics: 
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Diagnosis and key inclusion and exclusion criteria: Male or female subjects aged 
18-65 years with relapsing MS or secondary progressive MS (SPMS) with superimposed 
relapses. Subjects should have 1 or more documented relapses within the 2 years before 
Screening, with either 1 relapse occurring within the year before randomization or the presence 
of at least 1 gadolinium positive T1 lesion within 6 months prior to randomization. The subject
should also have an EDSS score of 0 to 6.
Subjects will be excluded if they are diagnosed with primary progressive MS or SPMS without 
evidence of relapse. Subjects who have a disease duration > 15 years and an EDSS ≤ 2. 
Subjects will be excluded if they have received treatment with: ritixumab, ocrelizumab, 
mitoxantrone, or lymphocyte-depleting therapies (eg, alemtuzumab, cladribine, 
cyclophosphamide, total body irradiation, bone marrow transplantation) within 48 weeks prior 
to randomization; lymphocyte trafficking blockers within 24 weeks prior to randomization (eg, 
natalziumb, fingolimod); intravenous (IV) Ig, plasmapheresis, and immunosuppressive 
treatments within the 4 weeks prior to randomization; glatiramer acetate and B-interferons 
within 4 weeks prior to randomization; systemic glucocorticoids within 4 weeks prior to 
randomization; treatment with teriflunomide within 12 weeks prior to randomization; had 
exposure to Tecfidera within 6 months prior to randomization; has any allergy, 
contraindication, or inability to tolerate Tecfidera; or has not been on a stable dose of 
dalfampridine for ≥ 30 days prior to Screening. Subjects will also be excluded if they have a 
history of splenectomy; any major surgery within 2 months prior to Screening; history of 
myocardial infarction or cerebrovascular event within 6 months prior to Screening; current 
active angina pectoris, symptomatic heart failure, uncontrolled seizures, untreated 
hypertension, gastrointestinal (GI) bleeding; a history of attempted suicide within the last 6 
months prior to Screening; an episode of major depression within the last 6 months prior to 
Screening; significant cytopenia; or any other significant active medical condition in the 
Investigator’s opinion.
Investigational Medicinal Product: dose/mode of administration/ dosing schedule:
M2951 (25 mg tablets) will be administered orally daily for 48 weeks as needed based on the 
dose (eg, 3 x 25 mg tablets for a 75 mg dose). Dosing will be either 25 mg QD, 75 mg QD, or 
75 mg twice daily (BID). Matched placebo tablets will be provided.
Reference therapy: dose/mode of administration/dosing schedule: Tecfidera (120 or 
240 mg hard capsules) will be used as an active control. For the first 7 days, Tecfidera is 
administered orally at 120 mg BID. Following this and for the duration of treatment, Tecfidera
is administered orally at 240 mg BID orally. Detailed recommendations for the use of this 
product are described in the summary of product characteristics or prescribing information.
Planned trial and treatment duration per subject: Total duration of subject participation is 
approximately 392 days (56 weeks), which includes:
! Screening: 28 days (4 weeks)
! Treatment: 168 days (24 weeks)
! Blinded treatment extension: 168 days (24 weeks)
! 4-week Safety Follow-Up/End of Trial Visit: 28 days (4 weeks).
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Statistical methods:
A per-group sample size of 44 evaluable subjects provides 85% power to detect a decrease of 
90% in the total number of gadolinium-enhancing T1 lesions, summed over scans at Weeks 
12, 16, 20, and 24, between a given M2951 group versus placebo at the 2-sided 5% level, using 
the Wilcoxon rank-sum test, where the p-value is evaluated using a continuity-corrected normal 
approximation to the test statistic. 
Eligible subjects will be randomized 1:1:1:1:1 to treatment with placebo, low-dose M2951 
(25 mg QD), mid-dose M2951 (75 mg QD), high-dose M2951 (75 mg BID), or Tecfidera
(administered BID at a final dose of 240 mg), through a central randomization process by an 
Interactive Web Response System (IWRS), stratified according to region (US or Western 
Europe, Eastern Europe and , Eastern Europe and , Rest of 
World). Approximately 50 subjects will be randomized per group to protect against a loss of 
information due to a 12% drop-out rate over one year.
There will be 3 analyses: (1) an IA, triggered when the first 50% of subjects enrolled out of the
planned enrollment reach Week 24 of treatment, or prematurely discontinue from treatment, 
and (2) a primary analysis, triggered when 100% of subjects enrolled reach Week 24 of 
treatment, or prematurely discontinue from treatment, and (3) a final analysis, triggered when 
100% of subjects enrolled complete all study parts, or discontinue prematurely from study.  
The Sponsor may decide not to perform the IA if the IA trigger date is sufficiently close (ie, 
within approximately 4 months) of the primary analysis trigger date.
If performed, the IA for futility will be conducted during the placebo-controlled portion of the 
treatment period when the first 50% of subjects enrolled out of the planned enrollment have 
reached the end of 24 weeks of treatment. The IA will test for futility, not efficacy, so will not 
affect the 0.05 Type I error rate available at the primary analysis. The Family-wise Type I error
rate (FWER) at the primary analysis, due to multiple comparisons of M2951 dose to placebo 
based on the primary endpoint, will be controlled at the 2-sided 0.05 significance level using 
the Hochberg procedure.
?
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Primary Endpoint
The primary analysis of total number of Gd+ T1 lesions, Weeks 12, 16, 20, and 24, will be an 
estimate of lesion rate ratio, together with associated 95% confidence interval (CI) and p-value, 
comparing each M2951 dose group to placebo, based on a negative binomial (NB) model, 
where the offset will be based on the log of number of scans, with M2951 dose or placebo 
group as a factor, and adjustment for covariates based on randomization strata. Other 
covariates, such as baseline MRI activity, may be included in the model. Should the model fail 
to converge, the primary analysis will be an estimate of the shift in location of the distribution 
of total number of Gd+ T1 lesions via the Hodges-Lehman estimate, together with associated 
95% CI and p-value based on the Wilcoxon rank sum test, comparing each M2951 dose group
to placebo. Descriptive statistics for the total number of Gd+ T1 lesions, Weeks 12, 16, 20, and 
24, will be provided for each treatment group. The primary analysis will be based on only the 
M2951 dose groups and placebo group.
Other Efficacy Endpoints, Baseline to 24 weeks:
The comparison of a M2951 treatment group to placebo group using ARR at Week 24 will be 
based on a Poisson model for qualified relapse count, with offset equal to the log of years on 
study, with M2951 dose group or placebo group as a factor, and adjustment for covariates based 
on randomization strata. The comparison of a M2951 treatment group to placebo group using 
proportion qualified relapse-free at Week 24 will be based on a logistic model for the odds of 
a subject being qualified relapse-free, where subjects who discontinue prior to Week 24 without 
having a qualified relapse are counted as not being qualified relapse-free at Week 24, with 
M2951 dose group or placebo group as a factor, and adjustment for covariates based on 
randomization strata. The comparison of a M2951 treatment group to placebo group using 
change from Baseline in EDSS at Week 24 will be based on a rank analysis of covariance 
(ANCOVA) model, with M2951 dose group or placebo group as a factor, and adjustment for
Baseline, and covariates based on randomization strata. The analysis of mean per-scan number
of Gd+ T1 lesions, at Weeks 12, 16, 20, and 24, change from Baseline in volume of Gd+ T1 
lesions at Week 24, and change from Baseline in volume of T2 lesions at Week 24, will be 
based on an ANCOVA model of the appropriately transformed variable. The comparison of a 
M2951 treatment group to placebo using total number of new Gd+ T1 lesions, or total number 
of new or enlarging T2 lesions, at Weeks 12, 16, 20, and 24, will be based on a NB model, 
similar to that used for the primary analysis. In the analysis of each secondary endpoint, other 
covariates, such as baseline MRI activity, may be included in the model.
Descriptive statistics for MRI and clinical endpoints, Baseline to Week 24, will be provided 
for the M2951 dose arms, the placebo arm, and the Tecfidera arm. No inferential analyses 
comparing the Tecfidera group to any other treatment group will be conducted. 
Other Efficacy Endpoints, Baseline to 48 weeks:
Descriptive statistics for MRI and clinical endpoints, Baseline to Week 48, will be provided 
for the M2951 dose arms, the placebo/M2951 arm, and the Tecfidera arm.
?
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The total number of Gd+ T1 lesions, total number of new Gd+ T1 lesions, total number of new 
and enlarging T2 lesions, the change from Baseline in Gd+ T1 lesion volume, and change from 
Baseline in T2 lesion volume, will be summarized by timepoint (Baseline and Weeks 12, 16, 
20, 24, and 48) and treatment group (placebo, 3 M2951 dose groups, and Tecfidera).
Annualized relapse rate from Baseline to Week 24 and from Baseline to Week 48 will be 
summarized by treatment group. The proportion of subjects remaining qualifying relapse-free 
at Week 24 and at Week 48 will be summarized by treatment group. The change from Baseline 
in EDSS will be summarized by treatment group and timepoint (Weeks 4, 8, 12, 16, 20, 24, 36, 
48, and the 4-week Safety Follow-up/End of Trial Visit).
Safety
Safety data for all treatment groups (M2951 dose groups, placebo group, tecfidera group) will 
be listed and summarized using descriptive statistics.
Patient-reported Health Related Quality of Life (HRQoL)
HRQoL data for all treatment groups and timepoints will be summarized using descriptive 
statistics. Change in HRQoL for PCS/MCS and sub-domains over time (area under the curve) 
will be compared between M2951 treatment arms and placebo.
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Table 1 Schedule of Assessments
Activity/Assessment Screeninga On Treatment Visits
Unscheduled 
Visit for 
Neurological 
Worsening 
and Relapse 
Assessmentb
End of 
Treatment 
4-week
Safety
Follow-up/
End of 
Trial Visit
Visit number 1 2 3 4 5 6 7 8 9 10 11
Study Week D1 W4 W8 W12 W16 W20 W24 W36 W48 W52
Study Day ± Visit Windowc -28 to -1 1 28±3 56±3 84±3 112±3 140±3 168±3 252±3 336±3 364±5
Obtain ICFd X
Inclusion / Exclusion criteria X X
Medical historye / demographics X
MS history X
Physical examinatione X X X X
Vital signsf X X X X X X X X X X X X
Neurological examinationg X X X X X X X X X X X X
Quantiferon tuberculosis test, viral 
serology testingh X
Randomizationi X
Hematology, chemistryj X X X X X X X X X X X
Immunoglobulin levelsk X X X X X
Urinalysis (microscopy, urine 
protein/creatinine ratio)l X X X X X X
Coagulation (INR, PTT)m X
B,  cell countn X X X X X
Serum pregnancy testo X
Urine pregnancy testo X X X X X X X X X X
12-lead ECGp X X X X
Chest X-rayp X
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Activity/Assessment Screeninga On Treatment Visits
Unscheduled 
Visit for 
Neurological 
Worsening 
and Relapse 
Assessmentb
End of 
Treatment 
4-week
Safety
Follow-up/
End of 
Trial Visit
Visit number 1 2 3 4 5 6 7 8 9 10 11
Study Week D1 W4 W8 W12 W16 W20 W24 W36 W48 W52
Study Day ± Visit Windowc -28 to -1 1 28±3 56±3 84±3 112±3 140±3 168±3 252±3 336±3 364±5
EDSSq X X X X X X X X X X X X
Relapse assessmentr X X X X X X X X X X
MRI scans X X X X X X
Concomitant medications and 
procedurest X X X X X X X X X X X X
AE evaluationu X X X X X X X X X X X X
Dispense IMPv X X X X X X X X
IMP Administration Oral Administration
IMP compliancew X X X X X X X X
HRQoLaa X X X X X X X X X X
C-SSRSbb X
AE=adverse event, , C-SSRS=Columbia-Suicide Severity Rating Scale, , 
ECG=electrocardiogram, eCRF=electronic case report form, EDSS=expanded disability status scale, FSH=follicle stimulating hormone, HBsAg=hepatitis B surface 
antigen, HBV=hepatitis B virus, HCV=hepatitis C virus, HIV=human immunodeficiency virus, HRQoL=health-related quality of life, ICF=informed consent form, 
Ig=immunoglobulin, IMP=investigational medicinal product, INR=international normalized ratio, MRI=magnetic resonance imaging, MS=multiple sclerosis, 
, , PTT=partial thromboplastin time, SF-36v2=Short Form 36-item Health Status Survey version 2.0.
a. Screening procedures will be performed within 28 days prior to the first administration of placebo/M2951 or Tecfidera.
b. These unscheduled visits will occur if a subject relapses and it is not feasible to wait for an upcoming scheduled study visit. 
c. Trial visits will occur within the range of days noted for each week on trial. The 4-week Safety Follow-up/End of Trial Visit will take place 28 days after the End 
of Treatment Visit.
d. Informed consent must be obtained at the Screening visit prior to initiating any Screening procedures or collecting any data.
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e. Medical history includes both disease and medication history. Records from physical examinations will be retained at each site and will not be captured in the 
eCRF. Abnormal findings from the physical exam conducted before informed consent is obtained should be reported as medical history.
f. Vital signs, including oral temperature, seated blood pressure, pulse rate, and respiratory rate, and weight are assessed predose at every trial visit. Height is 
measured as Screening only.
g. Neurological examinations will be conducted at Screening, Day 1, and all subsequent trial visits. Records from physical examinations will be retained at each 
site and will not captured in the eCRF.
h. Blood samples for tuberculosis (Quantiferon) testing will be obtained at Screening. Additional samples should be taken for viral serology testing at Screening: 
HBV core antigen, HBV antibodies, HBsAg, and HCV antibodies. HIV testing will be done at Screening only where required as per local regulations (see Table 
5).
i. Randomization should occur on Day 1 after all Screening procedures have been completed; subject eligibility must be reviewed again and confirmed at the 
site on Day 1 prior to randomization.
j. Blood samples for hematology and chemistry (Table 5) to be obtained at Screening, predose at all Visits except Day 1.
k. Samples for total Ig levels (IgM, IgA, IgG) will be obtained at Screening and predose on Days 1, 28, 112, 168, and 336 (see Section 7.4.5). Results will not be 
disclosed to the sites, sponsor, or representative, to avoid unblinding. However, the IDMC will have access to these data as applicable.
l. Urine samples for urinalysis will be obtained at Screening, predose on Days, 84, 168, 336, and Day 364. If local urinalysis by dipstick is abnormal, urine 
microscopy should be performed by a central laboratory. If at least 1+ protein is detected, urine protein/creatinine ratio should be determined.
m. Coagulation tests (INR and PTT) will be obtained at Screening only.
n. Blood samples for B,  cell numbers and B, cell subclasses will be obtained predose on Days 1, 28, 168, and 336. An additional sample 
will be collected at the 4-week Safety Follow-up/End of Trial Visit (see Sections 7.4.6 and 7.6.3).
o. Serum pregnancy test collected at Screening, and urine tests collected predose at every trial visit, women of childbearing potential only. If necessary to 
confirm postmenopausal status, FSH testing will be done at Screening in postmenopausal women.
p. ECG and posteroanterior chest X-ray performed at Screening. Subjects who have previously had a chest x-ray for clinical reasons within 3 months prior to 
Day 1 do not need to have the chest X-ray repeated if the results are available and show no sign of active infective process or any other clinically significant 
abnormalities. ECGs will also be conducted at Days 168 and 336.
q. EDSS will be assessed at Screening, Day 1, and all subsequent trial visits.
r. Relapse assessments will be conducted at Day 28 and all subsequent trial visits.
s. MRIs will be conducted at Screening and at Days 84, 112, 140, 168, and 336.
t. Concomitant medications and procedures will be recorded at Screening and Day 1, and any changes elicited/recorded at every trial visit.
u. Any AEs occurring during the Screening period will be recorded, and AEs will be elicited/recorded at every trial visit.
v. The IMP will be dispensed after randomization on Day 1 and at each visit thereafter. All remaining IMP will be collected on Day 336. 
w. On trial visit days, the previous week’s IMP adherence will be documented using pill counts.
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aa. HRQoL will be assessed with the SF-36v2 questionnaire at Screening, Day 1, and all subsequent trial visits except the 4-week Safety Follow-up/End of Trial
Visit. Questionnaire to be completed before any other procedure takes place.
bb. The C-SSRS should be administered as part of the inclusion/exclusion criteria at Screening (see Section 5.3.2).
 
?
?
CCI
C
C
I
C
C
I
M2951 A Study of Efficacy and Safety of M2951 in Relapsing Multiple Sclerosis
MS200527-0086
24/90
2 Sponsor, Investigators and Trial Administrative Structure
This clinical trial will be sponsored by: 
! EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts, USA.
! Merck KGaA, Darmstadt, Germany in countries outside the USA.
The trial will be conducted at approximately 100 sites in Western and Eastern Europe, in USA,
and rest of the world (RoW).
The Coordinating Investigator,  
, represents all Investigators for decisions and discussions regarding this trial, 
consistent with the International Council for Harmonisation (ICH) Topic E6 Good Clinical 
Practice (GCP; hereafter referred to as ICH GCP). The Coordinating Investigator will provide
expert medical input and advice relating to trial design and execution and is responsible for the 
review and signoff of the clinical trial report. 
Signature pages for the Protocol Lead and the Coordinating Investigator as well as a list of Sponsor 
responsible persons are in Appendix I.
The trial will appear in the following clinical trial registries: ClinicalTrials.gov and EUDRACT.
The Sponsor will enlist the support of a contract research organization (CRO), to conduct the 
clinical part of the trial including trial set-up, operation of an Interactive Web Response System 
(IWRS) for randomization, coordination, monitoring, medical oversight, data capture, data 
management, statistical analysis, and clinical trial reporting. The Sponsor will also make use of 
the CRO’s central laboratory for sample analyses, storage, and shipment to specialized 
bioanalytical laboratories. The Sponsor will supervise all outsourced activities.
An independent data monitoring committee (IDMC) will be responsible for both safety monitoring 
and the futility analysis. The IDMC will consist of at least the following core members: 2 clinicians 
and 1 biostatistician. The full list of IDMC members and responsibilities will be included in the 
IDMC charter. 
The CRO will also provide a qualified neurologist who will adjudicate the relapses (to confirm 
qualified relapse) and systematically review the EDSS to determine if there is lack of 
efficacy/disease progression. The scope of this review will be described in detail in the Medical 
Monitoring Plan.
Investigational medicinal product (IMP) will be supplied by the Clinical Trial Supply Department 
at Merck, except Tecfidera for the US. In the US Tecfidera will be sourced locally by the clinical 
trial sites. IMP supplied by the Clinical Trial Supply Department at Merck will be packaged and 
labeled by a designated contract manufacturing organization.
Details of structures and associated procedures will be defined in a separate Manual of Operations, 
which will be prepared under the supervision of the clinical trial leader.
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3 Background Information
Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central nervous 
system and the most common cause of serious neurological disability in young adults. 
Approximately 85% of patients with MS initially present with relapsing MS (RMS), which is 
characterized by periodic acute exacerbations of disease activity (multifocal inflammatory lesion, 
relapses) and periods of remission, consisting of partial or complete recovery. With recurring 
relapses, disability tends to accumulate (1).
Currently there is no cure for MS, but the course of the disease can be altered favorably with 
disease-modifying drugs (DMDs) with varying levels of efficacy, and distinct safety and 
tolerability profiles. Most active RMS patients initiate treatment with an interferon-beta or 
glatiramer acetate (Copaxone®) therapy. Tecfidera has recently been added as a first-line therapy 
and is the most prescribed first-line therapy in an oral formulation. If responding suboptimally, 
patients can be treated with an alternative, second-line therapy such as fingolimod (Gilenya®) or 
natalizumab (Tysabri®). Generally, DMDs perceived to be more efficacious have also been shown 
to be associated with more significant adverse effects, ranging from serious infections (ie, 
progressive multifocal leukoencephalopathy [PML]) to autoimmunity and cancer. Switching 
among these DMDs occurs primarily due to perceived lack of efficacy or the occurrence of adverse 
events (AEs), as well as individual patient preferences.
Despite the recent approvals of newer therapies for the treatment of MS, there remains an unmet 
need for highly effective and well-tolerated therapies for patients with RMS at all stages of the 
disease. Early treatment with a highly efficacious, but safe DMD could be extremely advantageous 
for long-term quality of life for MS patients and might slow the process of brain atrophy, which 
accompanies axonal damage and loss in grey and white matter. An oral and safe solution for the 
treatment of MS patients with high disease activity would be an attractive treatment choice for 
patients switching therapy. Using the US as an example, we assume that there are approximately
20,000 new MS patients (naïve = 8%) per year, and 60,000 patients (24%) that are switching 
therapy per year. If the efficacy and safety profile for M2951 are as predicted with a favorable 
benefit to risk profile, it could be utilized throughout the course of the disease (early, mid and late 
stage) – capturing naïve and early switch patients. 
M2951 is an oral, highly selective, irreversible inhibitor of Bruton’s Tyrosine kinase (BTK) in 
development for the treatment of autoimmune and inflammatory diseases, including rheumatoid 
arthritis (RA), systemic lupus erythematosus (SLE) and MS. BTK mediates signaling through the 
B cell receptor and has been described downstream of several other receptors, including Fc 
receptor, Toll Like (TLR) and Integrin receptors, expressed in innate immune cells. Inhibition of 
BTK blocks both B cell function and innate immune activation and may therefore offer advantages 
over B cell-only directed therapies. 
BTK is a clinically validated target in oncology and although BTKi competitor companies are 
planning for point-of-care in several inflammatory indications including pemphigus/bullous
pemphigoid and rheumatoid arthritis (RA), none of them is currently preparing for the MS 
indication. M2951 has a superior kinase selectivity profile vs. ibrutinib and spebrutinib which may 
translate into a clinically relevant safety advantage.
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Robust, high-efficacy clinical proof of concept was recently demonstrated with B cell depleting
anti-CD20 therapies in Phase II and Phase III clinical trials in RMS and progressive MS (2-5).
Ocrelizumab inhibited the formation of new inflammatory magnetic resonance imaging (MRI)
lesions up to 90% (Hauser, 2008) in Phase II RMS trials and high efficacy on MRI (-94%), 
annualized relapse rate (ARR) (- 46%) and 6-month disease progression (-40%) was also reached 
in ORACLE Phase I, II, and III trials against interferon-β. Translational mechanism of action
studies in anti-CD20 treated RMS patients show diminished proliferation and proinflammatory 
differentiation of T cells (6), pointing towards abrogation of antigen presenting cell function as the 
primary mechanism. In addition to the role of anti-CD20 in B cell antigen presentation, a recent 
publication of Li et al (7) describes a diminished proinflammatory myeloid cell response in 
Ocrelizumab-treated MS subjects. M2951 shows inhibition of myeloid cell activation by immune 
complexes.
Anti-CD20 like efficacy is anticipated with BTK inhibition given the overlap on B cell-related 
activities of BTKi molecules in key in vitro assays targeting B cell antigen presentation, 
proliferation/differentiation, and cytokine production. Preclinical proof of concept with M2951 
has been demonstrated for systemic lupus erythematous/lupus nephritis, experimental autoimmune 
encephalomyelitis (EAE), RA and passive cutaneous anaphylaxis. Oral M2951 does not deplete B 
cells in the studies carried out to date and, upon withdrawal, restoration of immune function can 
be obtained in days vs. months with anti-CD20 therapies, should the need to interrupt or stop 
therapy arise. This suggests a more favorable benefit to risk profile for M2951 vs. anti-CD20 
therapies. In addition, BTKi might have broader efficacy than B cell depletion alone, due to the 
importance of BTK activation downstream of various receptors expressed in myeloid cells, 
suggesting a direct effect of M2951 on innate immune cell activation induced by immune 
complexes, cytokines/chemokines, or TLR activation (8-10). A direct myeloid silencing activity 
also best explains the significant reduction of clinical score, relapse rate, and time to first relapse 
in T cell-dependent EAE models, in which anti-CD20 antibodies do not work. 
3.1 Trial Rationale
This study is designed to determine efficacy and safety of M2951 in patients with RMS, and to 
determine a dose to take forward into Phase III development.
The findings in Section 3 clearly support the pathogenic contribution of B cells to MS damage. In 
contrast, a failed clinical trial with another B cell targeting agent, atacicept, supports the notion 
that certain B cell subtypes may mediate beneficial anti-inflammatory effects (11). Novel 
non-depleting B cell therapies may deliver a more favorable benefit risk profile than current B 
cell-directed therapeutic approaches.
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Refer to the Investigator’s Brochure for further information about the nonclinical and clinical 
programs and Guidance for the Investigator.
3.2 Benefit-Risk
M2951 is being considered for the treatment of autoimmune diseases, including RA and SLE as 
well as MS. To date, no efficacy data are available. However, M2951 is the first agent with a
mechanism of action that directly targets both B cells and myeloid cells, and it is reasonable to 
anticipate that M2951 may represent a significant advance in the treatment of MS and other 
autoimmune diseases. 
No identified risks or new potential risks emerged from the FIM trial, Trial EMR200527-001. 
M2951 was well tolerated at single doses up to 500 mg and at multiple doses up to 200 mg for 
14 days.
Important potential risks to subjects are based on nonclinical safety data of M2951 and clinical 
data on adverse drug effects associated with compounds of a similar pharmacological class. They 
include infection, leukopenia, thrombocytopenia, hemorrhage, gastrointestinal (GI) intolerance, 
renal toxicity, hepatocellular injury, atrial fibrillation, drug-drug interactions, and embryofetal 
toxicity. 
Risk minimization measures inherent to early phase clinical trials are considered adequate for the 
proposed clinical trial in patients with MS. An IDMC will be set up to continually review available 
safety and tolerability data and will be mandated to make immediate decisions regarding the 
conduct of the trial; no additional risk minimization measures are proposed.
The doses of M2951 (up to 75 mg BID) selected for the proposed trial are within the dose ranges 
studied in Trial EMR200527-001 and were associated with high levels of target occupancy in 
healthy volunteers. 
This clinical trial will be conducted in compliance with the clinical trial protocol, ICH GCP, and 
any additional applicable regulatory requirements.
Based on the available nonclinical and clinical data to date and benefit-risk considerations, the 
conduct of the trial specified in this protocol is considered justifiable.
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4 Trial Objectives
4.1 Primary Objectives
The primary objective is to evaluate the efficacy and dose-response of M2951 on the number of 
gadolinium-positive (Gd+) T1 MRI lesions versus placebo after 24 weeks of treatment.
4.2 Secondary Objectives
The key secondary objectives are as follows:
! To evaluate the efficacy and dose-response of M2951 on clinical endpoints over 24 weeks 
versus placebo
! To evaluate the safety of M2951
Additional secondary objectives are as follows:
! To evaluate the efficacy of M2951 on additional MRI parameters over 24 weeks versus placebo 
! To evaluate the efficacy of M2951 on clinical and MRI endpoints from Weeks 24 to 48
! To evaluate the efficacy of Tecfidera on clinical and MRI endpoints over 24 weeks 
! To evaluate the efficacy of Tecfidera on clinical and MRI endpoints from Weeks 24 to 48
! To evaluate the safety of Tecfidera
4.3 Exploratory Objectives
The exploratory objectives are as follows: 
! To explore the benefit of M2951 treatment on patient-reported health-related quality of life 
(HRQoL) versus placebo, and to evaluate the effect of Tecfidera on HRQoL
5 Investigational Plan
5.1 Overall Trial Design and Plan
This will be a randomized, double-blind, placebo-controlled study in subjects with relapsing 
multiple sclerosis, with a parallel, open-label active control group (Tecfidera) involving 5
treatment groups with 3 doses of M2951, placebo, and active control (Tecfidera). The assessing 
Investigator and radiologist will be treatment blinded.
The study will consist of 3 major periods; a Screening period of 4 weeks, active treatment with 
3 dose groups of M2951, active control (Tecfidera), or placebo for 24 weeks, and a 24 week 
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extension on M2951 or active control (Tecfidera) for 24 weeks, where subjects on placebo will be 
switched to M2951. Following completion or early termination of treatment, subjects will return 
after 4 weeks for safety evaluation. A separate open-label extension protocol will be developed 
allowing continued dosing, provided that safety and tolerability are acceptable.
An interim analysis (IA) for futility may be conducted during the placebo-controlled portion of the 
treatment period when the first 50% of subjects enrolled out of the planned enrollment have 
reached the end of 24 weeks of treatment. If conducted, this analysis will evaluate overall futility 
for the highest dose of M2951 to determine whether or not to continue with the study. It is planned 
that placebo subjects will be switched to the 25 mg once daily (QD) dose after Week 24; however, 
consideration will be given to changing this dose based on data from the IA. The Sponsor may 
decide not to perform this IA if the IA trigger date is sufficiently close (i.e., within approximately
4 months) of the primary analysis trigger date.
Approximately 50 subjects will be enrolled in each treatment group to obtain 44 evaluable subjects 
per group (total = approximately 250), assuming a 12% drop-out rate per year, and to compile an 
adequate safety database.
Figure 1 Trial Design
ARR=annualized relapse rate; EDSS=expanded disability status scale; Gd+=gadolinium-positive; MRI=magnetic 
resonance imaging.
A detailed schedule of study procedures is provided in Table 1.
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5.2 Discussion of Trial Design
5.2.1 Scientific Rationale for Trial Design
This trial is modeled after the ocrelizumab Phase II trial design (12). The first part of the study will 
compare M2951 versus placebo for the main study objective of evaluating M2951 efficacy and 
dose-response. It is becoming more difficult to perform placebo-controlled trials in MS due to the 
wide range of efficacious therapies. It is still however necessary to have placebo-controlled data 
to accurately measure the size of the treatment effect and assess safety. The number of subjects 
exposed to placebo (up to 50) and short duration (24 weeks) is acceptable. Furthermore, all placebo 
subjects will be switched to M2951 during the blinded treatment extension phase. A futility 
analysis may be carried out when 50% of the subjects planned to be enrolled have completed 
24 weeks of treatment to aid in making a go-no-go decision. 
An active control group will also be enrolled. Tecfidera has been chosen as the control as it is the 
oral first-line therapy for RMS and has significant efficacy on early MRI endpoints. As it is very 
difficult to blind Tecfidera due to its specific safety profile, it will be administered in an open-label 
fashion.
The second phase of the study, from Weeks 24 to 48, will be continued in a blinded fashion.
5.2.2 Justification for Dose
 
 
 
 
 
 
 
 
 
 
 
M2951, at a dose of 75 mg QD, is being used in the 4-week SLE study (Trial EMR200527-002: 
A Phase Ib Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, 
Tolerability, Pharmacokinetics and Biological Effect of MSC2364447C in Systemic Lupus 
Erythematosus).  
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Finally, 1 lower dose (expected suboptimal therapeutic dose) should be chosen.  
 
From a safety perspective, the doses of M2951 (25 mg QD, 75 mg QD, 75 mg BID) selected for 
this trial are within the dose ranges studied in clinical trial EMR200527-001. Single doses up to 
 were well-tolerated in healthy volunteers 
and no safety signals were identified.
The placebo group will be switched to M2951 25 mg QD during the second part of the study from 
Weeks 24 to 48; however, flexibility will be maintained in deciding to use this dose or an 
alternative dose, based on data from the interim and/or primary analyses.
5.2.3 Rationale for Endpoints
The primary endpoint chosen is a standard one for RMS Phase II studies. For early treatment 
effects to be seen, MRI endpoints are used. The most sensitive is the total number of Gd+ T1 
lesions on MRI summed over scans at Weeks 12, 16, 20, and 24. MRIs will be carried out at 
Screening and every 4 weeks from Weeks 12 to 24. MRIs will also be carried out at Week 48 in 
the blinded treatment extension phase.
Other MRI measures will be used as secondary measures. These include the total number of new 
Gd+ T1 lesions, total number of new or enlarging T2 lesions, mean per-scan number of Gd+ T1 
lesions, Gd+ T1 lesion volume change from Baseline, and T2 lesion volume change from Baseline.
MRI measures alone may not predict final clinical outcome. Therefore, ARR will be assessed at 
Week 24 and Week 48 in the blinded treatment extension phase.
Other clinical endpoints will be measured including change from Baseline in Expanded Disability 
Status Scale (EDSS), proportion of subjects who remain qualifying relapse-free, and 
patient-reported outcome measures.
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The SF-36v2 is one of the most widely used generic patient-reported HRQoL instruments and has 
been applied in a number of MS studies. The SF-36v2 is an essential part of a number of other 
more comprehensive MS instruments like the MSQoL-54 or the MSQLI. The SF-36v2 is a 
multi-purpose, short-form health survey with only 36 questions. It yields an 8-scale profile of 
functional health and well-being scores as well as psychometrically-based physical and mental 
health summary (13).
5.2.4 Inclusion of Special Populations
Not applicable.
5.3 Selection of Trial Population
Only subjects meeting all inclusion criteria and no exclusion criteria may be enrolled into the trial 
as subjects. Prior to performing any trial assessments not part of the subject’s routine medical care, 
the Investigator will ensure that the subject or the subject’s legal representative has provided 
written informed consent following the procedure described in Section 9.2.
Subjects who do not meet the inclusion/exclusion criteria within the first Screening period and are 
considered screen failures may undergo rescreening once after approval by the Medical Monitor. 
The second Screening period is a new 28-day Screening period, and the subject will receive a new 
identification number. All other testing is required to be redone at rescreening.
5.3.1 Inclusion Criteria
1. Subjects with a diagnosis of relapsing multiple sclerosis (may include subjects with 
Secondary PMS [SPMS] with superimposed relapses provided they meet the other criteria)
in accordance with revised McDonald criteria for MS (14, 15) and Lublin and Reingold 
(16).
2. Male or female aged 18 to 65 years
3. One or more documented relapses within the 2 years before Screening with either:
a) One relapse which occurred within the last year prior to randomization
or
b) the presence of at least 1 Gd+ T1 lesion within 6 months prior to randomization would 
make the patient eligible.
4. Expanded Disability Status Scale score of 0 to 6 at Baseline
5. Women of childbearing potential must use a supplementary barrier method together with 
a highly effective method of contraception (according to ICH guidance M3[R2]) for 4 
weeks prior to randomization, throughout the trial, and for 90 days after the last dose of 
IMP. For the purposes of this trial:
! Women are considered of childbearing potential unless they are postmenopausal. 
Females who are postmenopausal (age-related amenorrhea ≥ 12 consecutive months 
and increased follicle-stimulating hormone [FSH] > 40 mIU/mL) or who have 
undergone hysterectomy or bilateral oophorectomy are exempt from pregnancy 
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testing. If necessary to confirm postmenopausal status, an FSH will be drawn at 
Screening.
! Highly effective contraception includes:
! Combined (estrogen and progestogen containing) hormonal contraception 
associated with inhibition of ovulation; oral, intravaginal or transdermal
! Progestogen-only hormonal contraception associated with inhibition of 
ovulation; oral, injectable or implantable
! Intrauterine device (IUD)
! Intrauterine hormone-releasing system (IUS)
! Bilateral tubal occlusion
! Vasectomized partner
! Sexual abstinence
! Supplementary barrier methods include:
! Male or female condom with or without spermicide 
! Cap, diaphragm or sponge with spermicide
! Men must agree to use and have their female partners use a supplementary barrier 
method together with a highly effective contraceptive method as defined above for 
at least 90 days after the last IMP administration.
! Women of childbearing potential must have a negative serum pregnancy test at the 
Screening Visit and a negative urine pregnancy test at randomization on Day 1
before dosing.
6. Signed and dated informed consent (subject must be able to understand the informed 
consent) indicating that the subject has been informed of all the pertinent aspects of the 
trial prior to enrollment and will comply with the requirements of the protocol.
5.3.2 Exclusion Criteria
1. Progressive MS either Primary or Secondary if Secondary is without evidence of relapse.
2. Disease duration > 15 years (subject reported adequate in absence of written medical 
record) in subjects with EDSS of 2 or less
3. Treatment with rituximab, ocrelizumab, mitoxantrone, or lymphocyte-depleting therapies 
(eg, alemtuzumab, anti-CD4, cladribine, cyclophosphamide, total body irradiation, bone 
marrow transplantation) which should not be used within 48 weeks prior to randomization.
4. Use of lymphocyte trafficking blockers (eg, natalizumab, fingolimod) within 24 weeks
prior to randomization
5. Use of intravenous (IV) immunoglobulins (Ig), plasmapheresis, and immunosuppressive 
treatments within 4 weeks prior to randomization
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6. Treatment with B-interferons or glatiramer acetate within 4 weeks prior to randomization
7. Systemic glucocorticoids within 4 weeks prior to randomization
8. Treatment with teriflunomide within 12 weeks prior to randomization
9. Exposure to Tecfidera within 6 months prior to randomization
10. Any allergy, contraindication, or inability to tolerate Tecfidera
11. Treatment with dalfampridine (fampridine, Ampyra) unless on a stable dose for ≥ 30 days 
prior to randomization
12. Inability to comply with MRI scanning, including contra-indications to MRI such as known 
allergy to gadolinium contrast media, claustrophobia, presence of a pacemaker, cochlear 
implants, ferromagnetic devices or clips, intracranial vascular clips, insulin pumps, nerve 
stimulators
13. Immunologic disorder other than MS, with the exception of secondary well-controlled 
diabetes or thyroid disorder, or any other condition requiring oral, IV, intramuscular, or 
intra-articular corticosteroid therapy
14. Vaccination with live or live-attenuated virus vaccine within 1 month prior to Screening
15. Severe drug allergy or history of anaphylaxis, or allergy to the IMP or any of its incipients
16. Active, clinically significant viral, bacterial, or fungal infection, or any major episode of 
infection requiring hospitalization or treatment with parenteral anti-infectives within 4 
weeks of Screening, or completion of oral anti-infectives within 2 weeks before or during 
Screening, or a history of recurrent infections (ie, 3 or more of the same type of infection 
in a 12-month rolling period). Vaginal candidiasis, onychomycosis, and genital or oral 
herpes simplex virus considered by the Investigator to be sufficiently controlled would not 
be exclusionary.
17. History of or positive testing for human immunodeficiency virus (HIV), hepatitis C (HCV) 
antibody and/or polymerase chain reaction, hepatitis B surface antigen (HBsAg) (+) and/or 
hepatitis B core total, and/or IgM antibody (+) at Screening. Testing for HIV will only be 
conducted where required as per local regulation.
18. The subject:
! Has a history of or current diagnosis of active tuberculosis (TB)
or
! Is currently undergoing treatment for latent TB infection (LTBI)
or
! Has an untreated LTBI as determined by documented results within 3 months of the 
Screening visit of a positive TB skin test with purified protein derivative with induration 
≥ 5 mm
or
! Has a positive QuantiFERON®-TB test at Screening. 
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Subjects with documented completed appropriate LTBI treatment would not be excluded 
and are not required to be tested. 
19. Indeterminate QuantiFERON®-TB tests may be repeated once, and will be considered 
positive if retest results are positive or indeterminate.
20. Subjects with current household contacts with active TB will also be excluded
21. History of splenectomy at any time, or any major surgery within 2 months prior to 
Screening
22. History of myocardial infarction or cerebrovascular event within 6 months prior to 
Screening, or current active angina pectoris, symptomatic heart failure, uncontrolled 
seizures, untreated hypertension, GI bleeding, or any other significant active medical 
condition in the Investigator’s opinion 
23. A history of attempted suicide within 6 months prior to Screening or a positive response to 
items 4 or 5 of Columbia-Suicide Severity Rating Scale (C-SSRS)
24. An episode of major depression within the last 6 months prior to Screening (clinically 
stable minor depression is not exclusionary)
25. On anticoagulation, fish oil supplements, or antiplatelet therapy other than daily aspirin for 
cardioprotection and treatment of Tecfidera induced flushing 
26. History of cancer, except adequately treated basal cell or squamous cell carcinoma of the 
skin (no more than 3 lesions requiring treatment in lifetime) or carcinoma in situ/cervical 
intraepithelial neoplasia of the uterine cervix, unless considered cured > 5 years
27. Breastfeeding/lactating or pregnant women
28. Participation in any investigational drug trial within 1 month or 5 half-lives of the 
investigational drug, whichever is longest, prior to Screening 
29. Subjects currently receiving (or unable to stop using prior to receiving the first dose of 
IMP) medications or herbal supplements known to be potent inhibitors of 
cytochrome P450 3A (CYP3A) (must stop at least 1 week prior), potent inducers of 
CYP3A (must stop at least 3 weeks prior), or drugs mainly metabolized by CYP3A with a 
narrow therapeutic index (must stop at least 1 day prior).
30. History of or current alcohol or substance abuse
! Excessive alcohol use is defined as alcohol and/or substance abuse or dependence 
(as defined by the Diagnostic and Statistical Manual of Mental Disorders, 
5th edition) in the past year or a history of alcohol or substance abuse, as determined 
by the Investigator
31. Clinically significant abnormality on electrocardiogram (ECG), or an active infective 
process or any other clinically significant abnormality on Screening chest X-ray (CXR) 
taken within 4 weeks of the first dose, per Investigator opinion. If a CXR has been taken 
within the previous 3 months and results are available and normal, the CXR does not need 
to be carried out
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32. Estimated glomerular filtration rate (eGFR) by the 4-variable Modification of Diet in Renal 
Disease equation of < 45 mL/min/1.73 m2 or any renal condition that would preclude the 
administration of gadolinium (eg, acute renal insufficiency)
33. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), amylase, or lipase 
> 2X above upper limit of normal (ULN) of laboratory reference range, total bilirubin 
> 1.5X ULN, any other clinically significant laboratory abnormality
34. B cell (CD19) count < 50% of the lower limit of normal at Screening
35. Significant cytopenia, including neutrophil count < 1,500/mm3, platelet count 
< 75,000/mm3, absolute lymphocyte count < 800/mm3, or a white blood cell count
< 3500/mm3
5.4 Criteria for Randomization and Initiation of Trial Treatment
Randomization should occur on Day 1 after all Screening procedures have been completed; subject 
eligibility must be reviewed again and confirmed at the site on Day 1 prior to randomization. If a 
subject does not meet eligibility criteria, the subject can be retested and rescreened once after the 
approval of the Medical Monitor as described in Section 5.3.
Eligible subjects will be randomized to treatment with M2951 (25 mg QD, 75 mg QD, or 75 mg 
BID), Tecfidera, or placebo through a central randomization process by an IWRS. Stratification 
will occur by region (US or Western Europe, Eastern Europe and , Eastern Europe 
and , RoW). 
5.5 Criteria for Subject Withdrawal
Subjects will be informed that they have the right to withdraw from the trial at any time, without 
prejudice to their medical care, and they are not obliged to state a reason for withdrawing. Any 
withdrawal must be fully documented in the electronic case report form (eCRF) and source 
documents, and should be followed up by the Investigator.
The Investigator may withdraw a subject at any time if this is considered to be in the subject’s best 
interest.
5.5.1 Withdrawal from Trial Therapy
Subjects who withdraw from therapy must immediately return for an End of Treatment Visit 
followed by the 4-week Safety Follow-Up/End of Trial visit 4 weeks later (see Section 7.1.4 and 
7.1.5). A subject must be withdrawn if any of the following occur:
! Withdrawn from study (see Section 5.5.2)
! Adverse events, if discontinuation of IMP is desired or considered necessary by the Investigator 
and/or subject
! Use of prohibited medications, as defined in Section 6.4.2. However, any medications that are 
considered necessary for the subject’s well-being may be given at the discretion of the 
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Investigator. Use of a prohibited medication may be cause for a subject to withdraw, however 
each incident should be discussed on a case by case basis with the study and medical monitor.
! Pregnancy
! Lack of efficacy and/or progression of MS
! Disability progression, which does not apply in cases of relapse, is defined as an increase of 
≥ 1.0 points from the Baseline EDSS score (see Section 7.3.2) that is not attributable to 
another etiology (eg, fever, concurrent illness, or concomitant medication) when the 
Baseline score is ≤ 5.5. When the Baseline EDSS is > 5.5, an increase of ≥ 0.5 points is 
considered disease progression. Disability progression is considered sustained when the 
increase in EDSS is confirmed at a regularly scheduled visit at least 12 or 24 weeks after the 
initial documentation of neurological worsening. 
! Any events that unacceptably endanger the safety of the subject.
! If any of the following occur while a subject is receiving Tecfidera (17, 18)
! Any instance of lymphocyte counts < 200/mm3 or < 500/mm3 for > 24 weeks
! In the event of serious infection, Tecfidera should be withheld until the infection is resolved
! At the first sign or symptom suggestive of PML
! More than 1 instance of dose reduction due to a flushing reaction (see Section 6.4.4 or the 
local label [17, 18]) and GI disturbances
Withdrawal due to special precautions is described in Section 6.4.4.
5.5.2 Withdrawal from the Trial
Subjects may withdraw from the trial at any time without giving a reason. Withdrawal of consent 
will be considered withdrawal from the trial. Subjects who withdraw from the trial while still on 
the IMP should return immediately for an End of Treatment Visit upon discontinuation of the IMP 
and a Safety Follow-Up/End of Trial Visit 4 weeks after the last administered dose of IMP. 
Subjects who withdraw and are no longer on the IMP must complete the 4-week Safety 
Follow-up/End of Trial Visit assessments described in Section 7.1.5. 
A subject must be withdrawn if any of the following occur during the trial:
! Pregnancy (for further details in case of pregnancy, see Section 7.4.2)
! Subject withdrew consent
! Participation in another clinical trial
! Lost to follow-up
! Any events that endanger the safety of the subject.
! Sponsor decision to end clinical trial
?
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If a subject fails to return for the post-treatment safety visit, all attempts should be made to contact 
the subject to ensure the reason for not returning is not an AE. Likewise, if a subject wishes to 
discontinue from the trial (eg, for personal reasons), attempts should be made to establish the true 
reason is not an AE (bearing in mind the subject is not obliged to state the reasons).
If IMP is prematurely discontinued, the primary reason for discontinuation must be recorded in the
appropriate section of the eCRF, and all efforts will be made to complete and report the 
observations as thoroughly as possible. A complete final evaluation at the time of the subject's 
withdrawal should be made and any AEs followed up until resolution or a period of 30 days after 
the last Safety Visit (or withdrawal from the trial).
If a subject has failed to attend scheduled trial assessments, the Investigator must determine the 
reasons and the circumstances as completely and accurately as possible.
Subjects who are withdrawn after randomization (eg, due to AEs or lack of efficacy) will not be 
replaced. Subjects who are withdrawn from the trial will not be allowed to re-enroll in the trial.
Participation in any other trial during the duration of this trial will not be allowed.
At least 3 attempts to contact lost to follow-up subjects should be made and documented (2 phone 
calls and 1 acknowledgement of receipt letter).
5.6 Premature Termination of the Trial
The clinical trial may be terminated prematurely or suspended at the request of Health Authorities 
or if new safety or efficacy information leads to an unfavorable risk benefit judgment for any IMP.
The Sponsor may discontinue the trial if the IA indicates that the trial is unlikely to achieve the 
primary endpoint at the time of the primary analysis, the trial becomes unjustifiable for medical or 
ethical reasons, the trial experiences poor enrollment, or due to discontinuation of clinical 
development of an IMP or withdrawal of an IMP or comparator from the market for safety reasons.
Health Authorities and Independent Ethics Committees (IECs)/Institutional Review Boards (IRBs)
will be informed about the discontinuation of the trial in accordance with applicable regulations.
5.7 Definition of End of Trial
The end of the trial is defined as the last contact date with the last subject who participates in this 
trial (last subject’s last visit).
A clinical trial protocol may not be considered closed as long as:
! Any subject is still receiving any IMP
! Visits specified by the protocol are still taking place
! Procedures or interventions according to the protocol are still being undertaken in any subject
! The post-treatment follow up period, defined in the clinical trial protocol as being part of the 
trial, has not yet been completed for any subject
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6 Investigational Medicinal Product and Other Drugs Used in 
the Trial
The term “Investigational Medicinal Product” refers to the investigational drug undergoing study 
(ie, M2951), the placebo and the reference therapy, Tecfidera.
6.1 Description of the Investigational Medicinal Product
Investigational Medicinal Product M2951 and placebo: dose/mode of administration/ dosing 
schedule:
The drug substance M2951, chemical name 1-(4-{[6-Amino-5-(4-phenoxy-phenyl)-pyrimidin-4-
ylamino]-methyl}-piperidin-1-yl)-propenone, is a white to yellow powder.
M2951 will be administered as white tablets ready for oral administration containing 25 mg of 
drug substance formulated with excipients. The placebo will be administered as white tablets ready 
for oral administration matching the active both in color and in size.
The Sponsor will provide M2951 and placebo to the trial site, manufactured and tested according 
to applicable current Good Manufacturing Practice (GMP) requirements for clinical trial supplies 
and a confirmation of release for human use in clinical trials.
Reference therapy Tecfidera: dose/mode of administration/dosing schedule (17, 18): 
The active control group will receive Tecfidera. For the first 7 days, Tecfidera is given 120 mg 
BID orally. Following this, and for the duration of treatment, it is given 240 mg BID orally. For 
sites in the European Union (EU), Tecfidera will be centrally sourced and provided by the Sponsor. 
For sites in the US, Tecfidera will be locally sourced at each trial site according to local regulations.
Tecfidera should be administered according to the local label and applicable regulations.
6.2 Dosage and Administration
Subjects will receive 25 mg QD, 75 mg QD, or 75 mg BID M2951 or placebo administered as 
tablets for 168 days. To maintain blinding for placebo and M2951 (see Section 6.9), subjects will 
self-administer study medication at a schedule similar to the 75 mg M2951 BID dosing schedule 
(ie, 3 tablets BID). At the end of the 24-week treatment period, it is intended to switch the placebo 
group to M2951 at a dose of 25 mg QD; however, flexibility will be maintained to allow adjusting 
this dose based on data from the IA or primary analysis.
Subjects will self-administer the IMP at a set time each day (every 12 hours ± 2 hours). Subjects 
must take their daily dose more than 1 hour prior to a meal or snack and more than 2 hours after a 
meal or snack. Clear fluids are allowed at any time. On trial visit days, the IMP will be administered 
during the trial visit after the scheduled trial visit procedures (other than post-treatment  
) are completed.
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If a dose is missed, the subject can take the missed dose up to 6 hours after the scheduled time. If 
more than 6 hours have elapsed since the dose was missed, the subject should skip the dose for 
that period, make note of the missed dose, and take the next dose at the regularly scheduled time.
When  visits are scheduled to occur (see Section 7.5) the subject should refrain from taking 
their scheduled morning dose and take their dose of IMP when instructed at the visit.
Subjects will be asked to record the date and time of dosing and food intake around dosing in a 
subject diary. 
Subjects who develop GI or flushing disturbances while receiving Tecfidera may reduce their 
study treatment dose by taking 120 mg BID for 1 month. After 1 month at the reduced dose, 
subjects will resume the 240 mg BID dosing. If the subject is still unable to tolerate the study 
treatment, the subject must permanently discontinue study treatment as described in 
Section 6.4.4.2.
6.3 Assignment to Treatment Groups
Eligible subjects will be randomized 1:1:1:1:1 to treatment with placebo, low-dose M2951 (25 mg 
QD), mid-dose M2951 (75 mg QD), high-dose M2951 (75 mg BID), or Tecfidera (administered 
BID at a final dose of 240 mg), through a central randomization process by an IWRS prior to 
dosing on Day 1. Stratification will occur by region (US or Western Europe, Eastern Europe and 
, Eastern Europe and , RoW). For the first 7 days, Tecfidera is 
administered orally at 120 mg BID. Following this and for the duration of treatment, Tecfidera is 
administered orally at 240 mg BID.
6.4 Concomitant Medications and Therapies
All concomitant medications taken by the subject during the trial, from the date of signature of 
informed consent are to be recorded in the appropriate section of the eCRF, noting the name, dose, 
duration, regimen, and indication of each drug. Nondrug interventions and any changes to a 
concomitant medication or other intervention should also be recorded in the eCRF.
6.4.1 Permitted Medicines
Permitted medications are any medications required per the medical history and not specifically 
prohibited by the protocol during the trial. These standard of care medications are part of the 
subject’s previous treatment and will therefore not be provided by the Sponsor. Any such 
medications prescribed or used should be recorded in the eCRF.
Subjects who experience an MS relapse (see Section 7.3.3) during treatment may receive rescue 
medication subject to the following restrictions:
• Up to 1 g daily of methylprednisolone administered IV for up to 5 consecutive days.
Oral tapering of corticosteroid rescue medication is permitted, with a maximum of 15 days of 
tapering allowed.
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Subjects should not be withdrawn from treatment with trial medication solely because of the 
occurrence of a relapse unless they meet the criteria for withdrawal (see Section 5.5).
Note: Where possible, the use of high dose corticosteroids should be avoided in the 2 weeks prior 
to a scheduled MRI scan. 
Any medications (other than those excluded as per exclusion criteria in Section 5.3.2 or prohibited 
as per Section 6.4.2) that are considered necessary for the subjects’ welfare and will not interfere 
with the trial medication may be given at the Investigator’s discretion.
6.4.2 Prohibited Medicines
Medications prohibited before the trial are listed in the exclusion criteria (Section 5.3.2).
The following medications and therapies are not permitted during the trial and would require 
discontinuation of the trial treatment:
! Initiation of an immunosuppressant or immunomodulator, such as cladribine, 
cyclophosphamide, azathioprine.
! New therapies for MS should not be initiated during the trial. Initiation of any new 
immunosuppressant or immunomodulatory therapy would be considered a treatment failure and 
should result in withdrawal of the subject from the IMP (see Section 5.5.1).
! Oral or parenteral steroids, except rescue medication to treat a relapse of MS, or 
adrenocorticotropic hormone.
! Biologic therapies
! Intravenous Ig therapy and/or plasmapheresis
! Treatment with teriflunomide
! Live and live-attenuated vaccines
! Changes in dalfampridine dose (subject must be on a stable dose)
! Herbal supplements including, but not limited to, St. John’s wort, grapefruit, Seville oranges, 
cranberries, or juices of these fruits.
! Any investigational drug within 1 month or 5 half-lives of the investigational drug, whichever 
is longest, prior to Screening.
! Moderate or strong inhibitors or inducers of CYP3A or drugs mainly metabolized by CYP3A 
with a narrow therapeutic index. The list in Table 3 is not meant to be a complete list of all 
CYP3A inhibitors, inducers, or substrates with a narrow therapeutic range. Study sites should 
consider each medication on a case-by-case basis and discuss with the Medical Monitor. The 
additive effects of weak inhibitors taken in combination must also be taken into account.
! Any investigational drug or experimental procedure for MS.
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Table 3 Examples of Inhibitors or Inducers of CYP3A Enzymes or Substrates 
with Narrow Therapeutic Range
Inhibitors
Strong Moderate Weak 
Boceprevir, clarithromycin, conivaptan,
grapefruit juice,a indinavir, 
itraconazole, ketoconazole, 
lopinavir/ritonavir, mibefradil, 
nefazodone, nelfinavir, posaconazole, 
ritonavir, saquinavir, telaprevir, 
telithromycin, and voriconazole
Amprenavir, aprepitant, atazanavir, 
ciprofloxacin, darunavir/ritonavir, 
diltiazem, erythromycin, fluconazole, 
fosamprenavir, grapefruit juice,a
imatinib, and verapamil
Alprazolam, amiodarone, amlodipine, 
atorvastatin, bicalutamide, cilostazol, 
cimetidine, cyclosporine, fluoxetine, 
fluvoxamine, ginkgo, goldenseal, 
isoniazid, nilotinib, oral contraceptives, 
ranitidine, ranolazine, 
tipranavir/ritonavir, and zileuton
Inducers
Strong Moderate Weak 
Avasimibe, carbamazepine, phenytoin, 
rifampin, and St. John’s wort
Bosentan, efavirenz, etravirine, 
modafinil, and nafcillin
Amprenavir, aprepitant, armodafinil, 
echinacea, pioglitazone, prednisone, 
and rufinamide
Substrates With a Narrow Therapeutic Range
Alfentanil, astemizole,b cisapride,b cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, 
sirolimus, tacrolimus, terfenadineb
CYP=cytochrome P450
a The effect of grapefruit juice varies widely among brands and is concentration, dose, and preparation dependent. Studies have
shown that it can be classified as a “strong CYP3A inhibitor” when a certain preparation is used (eg, high dose, double strength)
or as a “moderate CYP3A inhibitor” when another preparation is used (eg, low dose, single strength).
b Withdrawn from the US and certain other markets because of safety reasons.
Note: This is not an exhaustive list. For an updated list, see Tables 5, 6, and 7 in the following link: 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm080499.htm
Note: A strong inhibitor is defined as an inhibitor that increases the AUC of a substrate sensitive for that CYP ≥ 5-fold or decreases 
clearance by > 80%, and a strong inducer decreases AUC of a substrate by ≥ 80%.
Note: A moderate inhibitor is defined as an inhibitor that increases the AUC of a substrate sensitive for that CYP ≥ 2 fold but 
< 5-fold or decreases clearance by 50%-80%, and a strong inducer decreases AUC by 50%-80%.
Note: A weak inhibitor is defined as an inhibitor that increases the AUC of a sensitive substrate for that CYP < 2-fold or decreases 
clearance 20%-50%, and a weak inducer decreases AUC by 20%-50%.
Note: CYP substrates with narrow therapeutic range refers to drugs whose exposure-response relationship indicates that small 
increases in their exposure levels by the concomitant use of CYP inhibitors may lead to serious safety concerns (eg, Torsades de
pointes).
6.4.3 Other Interventions
Not applicable.
6.4.4 Special Precautions
6.4.4.1 For M2951 Only
The IMP should be temporarily withheld or permanently withdrawn if the following abnormalities 
occur or re-occur, as relevant, and re-initiation following temporarily withholding of IMP should 
be discussed with the Medical Monitor:
?
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! For a neutrophil count < 500/mm3 or platelet count < 25,000/mm3 (Grade 4) or neutrophil count 
500 to 999/mm3 (Grade 3) with fever or platelet count 25,000 to 49,999/mm3 (Grade 3) with 
bleeding, the IMP should be permanently withdrawn
! For a Grade 3 decrease in neutrophil count without fever or Grade 3 decrease in platelet 
count without bleeding, temporarily hold the IMP and recheck the value. If the value is still 
Grade 3, permanently discontinue the IMP. For a decrease to Grade 2, temporarily hold the 
IMP and recheck the value. Re-initiate the IMP after discussion with the Medical Monitor if 
no further downward trend is observed
! For an increase in AST or ALT to > 3X ULN and increase in bilirubin to > 1.5X ULN (Grade 
2 or higher), the IMP should be permanently withdrawn. The subject should be followed with 
additional testing as needed until a return to ULN. Consultations with specialists, such as a 
hepatologist, can be considered at the discretion of the Investigator and in conjunction with the 
Medical Monitor
! For an increase in AST or ALT to > 5X ULN without bilirubin elevation, the IMP should be 
permanently withdrawn. The subject should be followed with additional testing as needed 
until a return to ULN. Consultations with specialists, such as a hepatologist, can be 
considered at the discretion of the Investigator and in conjunction with the Medical Monitor
! For any other increase in AST ALT or bilirubin to Grade 2, temporarily hold the IMP and 
recheck the value. Re-initiate the IMP after discussion with the Medical Monitor if no further 
upward trend is observed
! For an increase in amylase or lipase to > 5X ULN (Grade 4), the IMP should be permanently 
withdrawn
! For an increase in amylase or lipase to > 2 to 5X ULN (Grade 3), temporarily hold the IMP 
and recheck the value within 24 hours of receipt. If the value is still Grade 3, permanently 
discontinue the IMP. For an increase to Grade 2, temporarily hold the IMP and recheck the 
value within 24 hours of receipt. Discontinue the IMP if the value does not decrease, or 
re-initiate the IMP after discussion with the Medical Monitor if a downward trend is 
observed
! For an increase in serum creatinine to > 3X from Baseline (Grade 3 or higher), the IMP should 
be permanently withdrawn
! For any other increase in serum creatinine > 1.5X from Baseline, temporarily hold the IMP 
and recheck the value within 24 hours of receipt. Discontinue the IMP if the value does not 
decrease, or re-initiate the IMP after discussion with the Medical Monitor if a downward 
trend is observed
! For any other laboratory abnormality of Grade 4 severity, the IMP should be permanently 
withdrawn
! For any other laboratory increase/decrease (as relevant) from Baseline to a clinically 
significant higher severity grade, temporarily hold the IMP and recheck the value within 24 
hours of receipt. Discuss restarting the IMP with the Medical Monitor if an improving trend 
is observed
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! For an absolute lymphocyte count < 200/mm3 (Grade 4), should be temporarily withdrawn 
and follow-up testing should be conducted. When the absolute lymphocyte count returns to 
800/mm3 (ie, returns to grade 2), IMP can be resumed.
6.4.4.2 For Tecfidera Only
! For a lymphocyte count < 500/mm3 for > 24 weeks, Tecfidera should be temporarily withheld 
and the subject monitored until lymphocyte counts are back to the lower limit of normal (LLN). 
Once lymphocyte counts are back to LLN, the IMP can be restarted with additional follow-up 
monitoring of lymphocyte counts.
! For an absolute lymphocyte count < 200/mm3 (Grade 4), Tecfidera should be permanently 
withdrawn and the lymphocyte count of the subject monitored.
! For a serious infection, after discussion with the Medical Monitor, consideration should be 
given to temporarily withholding Tecfidera until resolution of the infection.
! At the first sign or symptom suggestive of PML, Tecfidera should be withheld and an 
appropriate diagnostic evaluation conducted. MRI findings may be apparent before clinical 
signs or symptoms. Typical symptoms associated with PML are diverse, progress over days to 
weeks, and include progressive weakness on one side of the body or clumsiness of limbs, 
disturbance of vision, and changes in thinking, memory, and orientation leading to confusion 
and personality changes.
! For a flushing reaction (eg, warmth, redness, itching, and/or burning sensation), Tecfidera
should be temporarily withheld until symptoms have resolved. After the flushing reaction has 
resolved, Tecfidera should be restarted at a reduced dose (see Section 6.2).
! Should a flushing reaction occur again, Tecfidera should be permanently discontinued.
6.4.4.3 Grading Adverse Events for Investigational Medicinal 
Products
Laboratory values corresponding to Common Terminology Criteria for AEs (CTCAE) 
Grades 1 to 4 are presented for selected laboratory parameters in Table 4. For all other laboratory 
abnormalities, refer to the CTCAE, version 4.03.
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Table 4 CTCAE Grades for Relevant Laboratory Parameters
Laboratory Parameter Grade 1 Grade 2 Grade 3 Grade 4
Neutrophil (/mm3) < LLN to 1,500 < 1,500 to 1,000 < 1,000 to 500 < 500
Absolute lymphocyte 
count (/mm3)
< LLN to 800 < 800 to 500 < 500 to 200 < 200
WBC count (/mm3) < LLN to 3000 < 3000 to 2000 < 2000 to 1000 < 1000
Platelets (/mm3) < LLN to 75,000 < 75,000 to 50,000 < 50,000 to 25,000 < 25,000
AST and ALT < ULN to 3X ULN > 3 to 5X ULN > 5 to 20X ULN > 20X ULN
Bilirubin < ULN to 1.5X ULN > 1.5 to 3X ULN > 3 to 10X ULN > 10X ULN
Amylase and lipase < ULN to 1.5X ULN > 1.5 to 2X ULN > 2 to 5X ULN > 5X ULN
Creatinine > Baseline to ≤ 1.5X 
Baseline, or > ULN to 
1.5X ULN
> 1.5 to 3X Baseline 
or > 1.5 to 3X ULN
> 3X Baseline, or 
> 3 to 6X ULN
> 6X ULN
ALT=alanine aminotransferase, AST=aspartate aminotransferase, CTCAE=Common Terminology Criteria for AEs, 
LLN=lower limit of normal, ULN=upper limit of normal; WBC=white blood cell.
The reason for IMP withdrawal and the nature, duration, and results of any planned follow-up 
observations should be recorded in the appropriate section of the eCRF.
6.4.5 Management of Specific Adverse Events or Adverse Drug 
Reactions
No specific measures are proposed at this stage. Standard medical care will be provided at the trial 
site for all AEs occurring during the trial.
6.5 Packaging and Labeling of the Investigational Medicinal 
Product
All IMPs will be supplied in accordance with all applicable regulatory requirements and GMP
Guidelines.
M2951 and placebo tablets will be packaged as alu/alu blister wallets.
6.6 Preparation, Handling, and Storage of the Investigational 
Medicinal Product
IMP must be carefully stored at the trial site in a closed room or cabinet with restricted access and 
separately from other drugs.
M2951 should be stored below 30°C. Any deviations from the recommended storage conditions 
should be immediately reported to the Sponsor, and the medication should not be used until 
authorization has been received from the Sponsor. 
Detailed recommendations for the use of Tecfidera is described in the summary of product 
characteristics or prescribing information, as appropriate.
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The preparation, handling and storage of the IMPs will be documented in a separate Pharmacy 
Manual.
The IMP may not be used for any purpose other than the trial in question. It must be ensured at the 
trial site that IMP is not used after the use-by date. This is to be closely monitored by the 
responsible monitor.
6.7 Investigational Medicinal Product Accountability
The Investigator or designee is responsible for ensuring IMP accountability, including 
reconciliation of drugs and maintenance of records.
! Upon receipt of IMP, the responsible person will check for accurate delivery and acknowledge 
receipt in the IWRS and by signing or initialing and dating the appropriate documentation and 
returning it to the location specified. The original or a copy will be archived for the Investigator 
Site File.
! IMP dispensing will be recorded on the appropriate drug accountability forms so that accurate 
records will be available for verification at each monitoring visit.
! Trial site IMP accountability records will include the following:
! Confirmation of IMP receipt, in good condition and in the defined temperature range
! The inventory of IMP provided for the clinical trial and prepared at the site
! The use of each dose by each subject in case of Tecfidera
! The disposition (including return, if applicable) of any unused IMP
! Dates, quantities, batch numbers, kit numbers, expiry dates, and the individual subject trial 
numbers
The Investigator site should maintain records, which adequately document that subjects were 
provided the doses specified in this protocol, and all IMPs provided were fully reconciled.
Unused IMP must not be discarded or used for any purpose other than the present trial. No IMP 
that is dispensed to a subject may be redispensed to a different subject.
A Trial Monitor will verify and periodically collect the IMP accountability forms. 
After completion of the study, any IMP distributed to the site but not administered, dispensed to 
or taken by the subject(s) will be destroyed at the trial site. Details will be agreed upon between 
the Sponsor and the Investigator. All unused medications will be carefully recorded and 
documented before destruction. 
6.8 Assessment of Investigational Medicinal Product Compliance
The IMP will be administered at the site on trial visit days as defined in Table 1. All other dosing 
will be done by the subject or subject’s caregiver at home throughout the rest of the trial. Subjects 
or subject’s caregiver will be asked to record the date and time of dosing and food intake around 
dosing in a subject diary. 
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Subjects will be instructed to bring all IMP, including the used packaging, to each trial visit to 
allow for the assessment of compliance with trial treatment. Prior to discharge from each scheduled 
visit, subjects will be given sufficient IMP for at-home dosing until the next scheduled visit during 
the treatment period.
Insufficient compliance with the protocol-specified dosing regimen is defined as receiving < 80% 
of the required number of scheduled doses of trial medication.
6.9 Blinding
Treatment with M2951 and placebo will be double-blinded but the Tecfidera group will be open 
label. Tecfidera comes in 2 different colors of capsule (120 mg and 240 mg) with the lower dose 
being used during the initial 7 days of administration.
The assessing neurologist and central radiologist will be blinded to all treatments (placebo, M2951, 
and Tecfidera) throughout the study. The subjects, site staff, and the Investigator will be blinded 
to placebo and M2951 throughout the study, but not Tecfidera. The CRO study team and Sponsor 
study team will be blinded to placebo and M2951 until the database is partially locked for the 
primary analysis. 
A team from the Sponsor, independent of the CRO and Sponsor study teams, will be tasked with 
review of the unblinded IA data as described in the firewall charter and analysis plan. IA results 
will be presented on a limited set of endpoints when the first 50% of subjects enrolled out of the 
planned enrollment have reached Week 24 or prematurely discontinued treatment. The IDMC will 
also be unblinded to treatment, as described in the IDMC charter.
The bioanalytical laboratory(ies) responsible for the analysis of the  and  samples will be 
allowed to be partially unblinded during study conduct using masked subject identifiers, to support 
association of  data with M2951 dose and placebo treatment codes for timely decision 
making, but prevent association of treatment codes with any other clinical data, such as efficacy 
or safety data.
All other staff other than those identified above will remain blinded to the placebo and M2951
treatments. IA results from the independent team will not be communicated back to the sites, the 
CRO study team, or the Sponsor study team. 
Only when the last subject reaches 24 weeks of treatment or discontinues from treatment 
prematurely, the protocol violations are determined, the database is partially locked for the primary 
analysis, and the data file verified, will the drug codes be broken and made available for the 
primary data analysis. At that point, the CRO and Sponsor study teams will be unblinded to 
treatment. Dissemination of results from the primary analysis will be limited to senior 
management. There will be no communication of primary analysis results to the sites.
After the primary analysis, the study will continue as a blinded extension with subjects, site staff, 
and the Investigator blinded to M2951 dose group, and with assessing neurologist and central 
radiologist blinded to all treatments. The final analysis will occur only when the last subject 
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completes all study parts or discontinues from the study prematurely, protocol violations are 
determined, the database is locked for the final analysis, and the data file verified.
All breaks of the trial blind must be adequately documented.
6.10 Emergency Unblinding
The trial blind may be broken for an individual only if knowledge of the IMP is essential for 
clinical management of the subject. The Investigator must promptly explain the reason for any 
unblinding of an IMP to the Sponsor without revealing the result to any Sponsor employee except 
the designated Drug Safety representative (using the Emergency Unblinding Notification Form). 
The Investigator must record the date of unblinding and the reason in the eCRF. Contact 
information for breaking the blind in an emergency is given on the subject emergency card 
provided to each subject (see Section 9.4).
Under certain circumstances, the IDMC or Drug Safety may be required to unblind the treatment 
assignment for an individual subject following a serious adverse event (SAE) or other serious 
event; eg, if an expedited regulatory report is required. See Section 7.4.1.4 for further details on 
expedited reporting and SAEs.
6.11 Treatment of Overdose
An overdose is defined as any dose greater than the highest daily dose included in a clinical trial 
protocol or planned for an individual subject enrolled in the trial. Even if it does not meet other 
criteria for an SAE, any overdose must be recorded in the trial medication section of the eCRF and
reported to Drug Safety in an expedited manner using the SAE Report Form, and following the 
procedure in Section 7.4. No specific treatments for overdose are available.
6.12 Medical Care of Subjects after End of Trial
After a subject has completed the trial or has withdrawn early, the subject is free to access further 
treatment as deemed appropriate by the Treating Investigator. The Sponsor will not provide any 
additional care to subjects after they leave the trial because such care should not differ from what 
is normally expected for subjects with relapsing-remitting MS or SPMS with superimposed
relapses.
7 Trial Procedures and Assessments
During the Screening visit, prior to performing any trial assessments that are not part of routine 
medical care for the subject, the Investigator will obtain written informed consent as described in 
Section 9.2.
Throughout the trial, subjects will undergo the assessments detailed in Table 1, including 
collection of patient-reported HRQoL data and blood sampling. Completion of the HRQoL 
instrument SF-36v2 shall always be done before any other procedure or Investigator interaction of 
the visit takes place. The maximum amount of blood to be obtained during the trial is within the 
commonly accepted maximum of 275 mL over 4 weeks and 550 mL over 8 weeks. Details of the 
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blood volumes to be collected for each sample/visit will be detailed in the Laboratory Manual and 
an estimate is provided in Appendix II. Instructions on how samples will be collected, labeled, 
processed, stored, and shipped as well as specification on bioanalytical methods will be detailed 
in the Laboratory Manual.
All blood and urine tests will be analyzed by a central laboratory, with the following exceptions:
! Urine testing for β-human chorionic gonadotropin will be conducted at the local laboratories.
! Urine dipstick results will be interpreted locally. Please see Table 1, footnote l for information 
regarding abnormal dipstick results. 
!  
! ECGs results will be interpreted locally.
! HIV testing, when required by local regulation, should be conducted and analyzed locally.
The Treating Investigator will be the physician responsible for subject care and should be a 
neurologist experienced in the care of MS patients. The Treating Investigator will have access to 
safety and blinded efficacy data and will make treatment decisions based on the subject’s clinical 
response and laboratory findings. The Treating Investigator will also be responsible for the 
treatment of relapses and determining if non-MS-related factors could account for neurological 
worsening. The Treating Investigator will determine if a relapse has occurred.
The Assessing Neurologist will be a neurologist or other health care practitioner and must be 
trained and certified in administering the Neurostatus Functional System Scores and EDSS
examination prior to study start. The Assessing Neurologist is responsible for all EDSS 
assessments beginning at Screening and including all unscheduled visits initiated by a new or 
changing symptom potentially related to MS, as requested by the Treating Investigator. 
Throughout the trial, the Assessing Neurologist will be blinded to the subject’s treatment, 
laboratory data, adverse event profile, any changes in safety assessments, and prior EDSS scores. 
The Assessing Neurologist must complete the EDSS prior to any treatment with steroids or other 
therapeutics intervention(s) that may alter the subject’s neurological state, where possible. Both 
the Treating Investigator and the subject will be informed of the importance of not discussing these 
issues with the Assessing Neurologist to prevent unblinding.
The Assessing Radiologist will be an independent, blinded, central radiologist provided by 
. A local radiologist will also review all MRI scans for safety and provide a 
report to the Treating Investigator, containing only non-MS pathology information.
The CRO will also provide a qualified neurologist who will adjudicate whether relapses meet the 
definition of a qualifying relapse (see Section 7.3.3) and review systematically the EDSS to 
determine if there is a lack of efficacy/disease progression. The scope of this review will be 
described in detail in the Medical Monitoring Plan.
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7.1 Schedule of Assessments
7.1.1 Screening
The subject’s eligibility will be assessed at the Screening visit that will occur between Day -28 to 
Day -1. See Table 1 for a list of assessments done at Screening to determine the eligibility of the 
subject to participate in the trial. If a subject does not meet eligibility criteria, the subject can be 
retested and rescreened once at the Investigator’s discretion.
If there are no clinically significant findings and the subject meets all protocol-defined inclusion 
criteria and none of the exclusion, the subject will be considered as eligible to be enrolled in the 
trial. Subjects who fail to meet the protocol-specified criteria or who withdraw their consent will 
be considered screen failures. The following information, as a minimum, should be collected for
subjects who failed Screening: informed consent, demographics, reason for screen failure, AEs 
from the date of informed consent until the subject is considered to have failed Screening by the 
Investigator, and the Investigator’s signature.
The following should be performed at the Screening Visit:
! Signing of informed consent before any study procedures
! Review of inclusion/exclusion criteria, including administration of the C-SSRS
! The SF-36v2 HRQoL questionnaire, collection of demographic and other Baseline 
characteristics (MS history and other medical history, including medication history), review of 
concomitant medications and procedures, evaluation of AEs, a physical examination, vital 
signs, a neurological examination, MRI, EDSS.
! 12-lead ECG and chest x-ray
! Blood sample collection for Quantiferon TB test, viral serology testing, HIV testing if required, 
safety assessments (hematology, chemistry, coagulation), and serum pregnancy testing with 
FSH (women only).
! Urine collection for urinalysis and, if necessary, microscopy and protein:creatinine ratio.
7.1.2 Treatment Visits, Including Blinded Treatment Extension 
Phase
At all trial visits, scheduled assessments will be performed before administration of the trial 
medication, with the exception of relevant blood draws (eg,  occupancy as noted in 
Table 1). After Day 1, all scheduled visits during the treatment period may take place within 
± 3 days of the protocol-specified day. Subjects who discontinue early must immediately return 
for the 4-week Safety Follow-up/End of Trial visit (see Section 7.1.5).
See Table 1 for specific assessments to be done during treatment periods.
The following will be performed on Day 1:
! Review of inclusion/exclusion criteria
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! Randomization
! SF-36v2 HRQoL questionnaire
! Review of concomitant medications and procedures, evaluation of AEs, disease activity 
assessment (EDSS), vital signs, and a neurologic exam
! Blood sample collection for Ig levels, B,  cell counts;  
!  
! Urine collection for a urine pregnancy test (women only)
! IMP dispensation
The following will be performed on Days 28, 56, 84, 112, 140, 168, and 252:
! SF-36v2 HRQoL questionnaire
! Review of concomitant medications and procedures; evaluation of AEs; disease activity 
assessment (relapse assessment, EDSS); a complete physical examination (Days 84 and 168
only); vital sign assessment; and a neurologic exam
! IMP compliance
! 12-lead ECG (Day 168 only)
! Blood sample collection for safety assessments (hematology, chemistry); Ig levels (Days 28, 
112, and 168 only); B, cell count and  (Days 28 and 168 only);  
 
! Urine collection for urine pregnancy testing (women only); urinalysis and, if necessary, 
microscopy and protein:creatinine ratio (Days 84 and 168 only).
! MRI assessment (Days 84, 112, 140, and 168 only)
! IMP dispensation
7.1.3 Unscheduled Visit for Neurological Worsening and Relapse 
Assessment
Subjects should be instructed that if, at any point during the trial, they suspect that they are 
experiencing new or worsening neurological symptoms, including possible relapse, they should
contact the Investigator as soon as possible after the onset of symptoms. If necessary, the subject 
should be evaluated by the Investigator within the clinic and every effort should be made to 
complete this evaluation within 1 week after the start of symptoms. Any assessments needed to 
confirm the relapse should be performed at the discretion of the Investigator. Details should be
documented within the relevant section(s) of the eCRF. The definition of a qualifying and non-
qualifying relapse is provided in Section 7.3.3.
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If an MRI scan is indicated at an Unscheduled Visit for Neurological Worsening and Relapse 
Assessment, it should be performed prior to initiating corticosteroid therapy, where possible. In
addition, care should be taken to avoid the subject being exposed to gadolinium more than once in 
a 4-week period, ie, it may be necessary to cancel the MRI scan at the next scheduled visit (all 
other assessments should be completed at the visit as normal).
The following will be performed at an Unscheduled Visit for Neurological Worsening and Relapse 
Assessment:
! Review of concomitant medications and procedures, evaluation of AEs, disease activity 
assessment (relapse assessment, EDSS), complete physical examination, vital signs, and a 
neurologic exam
! 12-lead ECG
! Blood sample collection for safety assessments (hematology, chemistry).
! Urine collection for urinalysis, and, if necessary, microscopy and protein:creatinine ratio
7.1.4 End of Treatment Visit
The following will be performed on Day 336 ± 3 days/End of Treatment visit:
! SF-36v2 HRQoL questionnaire 
! Review of concomitant medications and procedures, evaluation of AEs, disease activity 
assessment (relapse assessment, EDSS), vital signs, and a neurologic exam
! IMP compliance
! 12-lead ECG
! Blood sample collection for safety assessments (hematology, chemistry); Ig levels; B,  and 
cell and 
! Urine collection for urinalysis and, if necessary, microscopy and protein:creatinine ratio; urine 
pregnancy testing (women only).
! MRI assessment 
7.1.5 4-week Safety Follow-up/End of Trial Visit
The Safety Follow-up/End of Trial Visit will be performed on Day 364 ± 5 days.
See Table 1 for specific assessments to be done. The following assessments will be performed:
! Review of concomitant medications and procedures, evaluation of AEs, disease activity 
assessment (relapse assessment, EDSS), vital signs, and a neurologic exam
! Blood sample collection for safety assessments (hematology, chemistry); B,  and  cell 
counts 
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! Urine collection for urinalysis and, if necessary, microscopy and protein:creatinine ratio; urine 
pregnancy testing (women only)
Prior to performing any trial assessments that are not part of routine medical care for the subject, 
the Investigator will obtain written informed consent as described in Section 9.2.
7.2 Demographic and Other Baseline Characteristics
At Screening, the following demographic data will be collected: date of birth, sex (gender), race, 
and ethnicity. Information about previous and concomitant medications taken within 4 weeks prior 
to randomization and the number of documented relapses within 1 year of randomization will be 
collected.
Medical history data (including diagnosis and duration of MS) will be recorded and a complete 
physical exam, will be performed. Vital signs, including oral temperature, heart rate, respiratory 
rate, blood pressure, weight, and height will be obtained. All other Baseline measures, such as 
safety laboratory parameters, Quantiferon TB test, ECG, and chest x-ray will be assessed. Baseline 
disease will be assessed by EDSS and MRI. Baseline QoL using the SF-36v2 questionnaire will 
also be assessed.
7.3 Efficacy Assessments
The following efficacy assessments will be undertaken, as outlined in the Schedule of Assessments 
(Table 1). During treatment, ie, Day 1 to Week 48, all assessments should be completed prior to 
the administration of study medication.
7.3.1 Brain Magnetic Resonance Imaging Scans
MRI scans will be performed at Screening, at 4-week intervals from Weeks 12 to 24, and at the 
End of Treatment Visit at Week 48.
Gadolinium will be used to enhance T1-weighted lesions and to optimize clarity and accuracy of 
reporting. As gadolinium is excreted renally, subjects with acute renal insufficiency (eGFR 
< 45 mL/min/1.73m2) will be excluded from the trial (see Section 5.3.2, exclusion criterion 32).
Brain 1.5T MRI scans will be performed according to a standardized imaging protocol before and 
after the administration of single-dose gadolinium.
Images will be assessed and reported by an independent, blinded, centralized MRI reading service, 
provided by . The assessment will be performed in the absence of clinical 
information. Further details, including the scans required and the optimal MRI workflow, will be 
provided in a separate Imaging Manual that will be provided to each trial site by  
. All MRI images will be reviewed and reported locally by a radiologist for safety. The 
local report will contain only non-MS pathology and will be provided to the Treating Investigator.
?
?
CCI
PPD
PPD
M2951 A Study of Efficacy and Safety of M2951 in Relapsing Multiple Sclerosis
MS200527-0086
54/90
Note: Where possible, the use of high dose corticosteroids should be avoided in the 2-week period 
prior to a scheduled MRI scan. In subjects receiving corticosteroids for an MS relapse, there must 
be a 3-week interval between the last dose of corticosteroids and the scheduled MRI scan.
In addition, if a scheduled MRI scan is delayed or an unscheduled MRI scan is indicated, care 
should be taken to avoid the subject being exposed to gadolinium more than once in a 4-week 
period, ie, it may be necessary to cancel the MRI scan at the next scheduled visit (all other 
assessments should be completed at the visit as normal). If the next scheduled visit is the End of 
Treatment Visit (Week 48), the Week 48 MRI scan should be performed as soon as the 4-week 
period since previous exposure to gadolinium has elapsed. See also Section 7.1.3.
7.3.2 Expanded Disability Status Scale
At Screening and all subsequent study visits, a standard neurological examination will be 
performed by an Assessing Neurologist and the subject’s level of disability will be assessed using 
the EDSS.
The EDSS is an ordinal clinical rating scale ranging from 0 (normal neurological examination) to 
10 (death due to MS) in half-point increments and should be administered in person by a 
neurologist trained in its use (19).
The EDSS score is calculated after neurologic testing and examination of the following eight 
functional systems, areas of the central nervous system that control bodily functions:
! Pyramidal (ability to walk)
! Cerebellar (coordination)
! Brain stem (speech and swallowing)
! Sensory (touch and pain)
! Bowel and bladder functions
! Visual
! Mental
! Other (includes any other neurological findings due to MS).
Steps will be taken to eliminate inter- and intra-rater variability in the administration and
assessment of the EDSS in the trial. The EDSS should be administered by an Assessing
Neurologist who has undergone trial-specific EDSS training prior to the start of the trial and the 
same individual should evaluate a given subject throughout the course of the trial. The EDSS 
assessment should take place at approximately the same time of day and a standardized protocol 
should be followed for the neurologic examination.
Further information regarding the EDSS assessment will be provided in the Laboratory Manual.
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7.3.3 Relapse Assessment
Subjects will be assessed for MS relapse at each visit beginning at Week 4. Relapse will also be 
assessed at any Unscheduled Visit for Neurological Worsening and Relapse Assessment (see 
Section 7.1.3). A qualifying relapse is defined as new, worsening or recurrent neurological 
symptoms attributed to MS that last for at least 24 hours without fever or infection, or adverse 
reaction to prescribed medication, preceded by a stable or improving neurological status of at least 
30 days. This relapse must be accompanied by new clinical signs (ie, changes in the neurological 
examination or an increase in EDSS score). 
All cases of potential relapse should be objectively confirmed by the Investigator regardless of 
whether they are identified during a scheduled or unscheduled visit. Any assessments needed to 
confirm the relapse should be performed, and details of the relapse should be documented within 
the relevant section(s) of the eCRF. The criteria for a protocol-defined relapse should be clear and 
there should be documentation of how each potential relapse did or did not meet the criteria.
Subjects who have a documented relapse during treatment are not required to discontinue treatment 
unless they meet any of the criteria for withdrawal from the trial therapy (see Section 5.5.1) or 
withdrawal from the trial, including the need for treatment with a non-permitted medication (see 
Section 5.5.2).
A non-qualifying relapse is any other relapse as defined by the Investigator that does not meet the 
qualifying relapse definition.
7.4 Assessment of Safety
The safety profile of the IMP will be assessed through the recording, reporting and analysis of 
baseline medical conditions; AEs; physical examination findings including vital signs, ECGs, and 
laboratory tests (including Ig and subclass concentration and B,  cell counts).
Comprehensive assessment of any apparent toxicity experienced by each subject will be performed 
from the time of giving informed consent and throughout the trial. The Investigator will report any 
AEs, whether observed by the Investigator or reported by the subject (see Section 7.4.1.2). The 
reporting period for AEs is described in Section 7.4.1.3.
7.4.1 Adverse Events
7.4.1.1 Adverse Event Definitions
Adverse Event
An AE is any untoward medical occurrence in a subject or clinical investigation subject 
administered a pharmaceutical product, regardless of causal relationship with this treatment. An 
AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease temporally associated with the use of a medicinal product, whether 
or not considered related to the medicinal product. 
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For surgical or diagnostic procedures, the condition/illness leading to such a procedure is 
considered as the AE rather than the procedure itself.
The Investigator is required to grade the severity or toxicity of each AE.
Investigators will reference the National Cancer Institute-Common Terminology Criteria for AEs 
(NCI-CTCAE), version 4.03 (publication date: 14 June 2010) (20), a descriptive terminology that 
will be provided in the Manual of Procedures that can be used for AE reporting.
A general grading (severity/intensity; hereafter referred to as severity) scale is provided at the 
beginning of the above referenced document, and specific event grades are also provided.
Only if a particular AE’s severity is not specifically graded by the guidance document, the 
Investigator is to use the general NCI-CTCAE definitions of Grade 1 through Grade 5 following
his or her best medical judgment.
The 5 general grades are:
! Grade 1 or Mild
! Grade 2 or Moderate
! Grade 3 or Severe 
! Grade 4 or Life-threatening 
! Grade 5 or Death 
According to Sponsor convention, any clinical AE with severity of Grade 4 or 5 must also be 
reported as an SAE. However, a laboratory abnormality of Grade 4, such as anemia or neutropenia,
is considered serious only if the condition meets 1 of the serious criteria described below.
If death occurs, the primary cause of death or event leading to death should be recorded and 
reported as an SAE. “Fatal” will be recorded as the outcome of this specific event and death will 
not be recorded as a separate event. Only, if no cause of death can be reported (eg, sudden death, 
unexplained death), the death per se might then be reported as an SAE.
Investigators must also systematically assess the causal relationship of AEs to IMP using the 
following definitions. Decisive factors for the assessment of causal relationship of an AE to the 
IMP include, but may not be limited to, temporal relationship between the AE and the IMP, known 
side effects of IMP, medical history, concomitant medication, course of the underlying disease, 
trial procedures.
Unrelated: Not reasonably related to the IMP. AE could not medically 
(pharmacologically/clinically) be attributed to the IMP under study in this clinical 
trial protocol. A reasonable alternative explanation must be available.
Related: Reasonably related to the IMP. AE could medically (pharmacologically/clinically) 
be attributed to the IMP under study in this clinical trial protocol. 
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Abnormal Laboratory Findings and Other Abnormal Investigational Findings
Abnormal laboratory findings and other abnormal investigational findings (eg, on an ECG trace) 
should not be reported as AEs unless they are associated with clinical signs and symptoms, lead to 
treatment discontinuation or are considered otherwise medically important by the Investigator. If 
a laboratory abnormality fulfills these criteria, the identified medical condition (eg, anemia, 
increased ALT) must be reported as the AE rather than the abnormal value itself.
Serious Adverse Events
An SAE is any untoward medical occurrence that at any dose:
! Results in death.
! Is life-threatening. (Note: The term “life-threatening” refers to an event in which the subject is 
at risk of death at the time of the event, not an event that hypothetically might have caused death 
if it was more severe)
! Requires inpatient hospitalization or prolongs an existing hospitalization, except in the case of 
hospitalizations due to protocol-defined relapses.
! Results in persistent or significant disability or incapacity.
! Is a congenital anomaly or birth defect.
! Is otherwise considered to be medically important. (Note: Important medical events that may 
not result in death, be life-threatening, or require hospitalization may be considered as SAEs 
when, based upon appropriate medical judgment, they may jeopardize the subject or may 
require medical or surgical intervention to prevent 1 of the outcomes listed above. Examples of 
such events include allergic bronchospasm requiring intensive treatment in an emergency room 
or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the 
development of drug dependency or drug abuse.)
For the purposes of reporting, any suspected transmission of an infectious agent via an IMP is also 
considered an SAE, as described in 7.4.1.4.
Events that Do Not Meet the Definition of an SAE
Elective hospitalizations to administer, or to simplify trial treatment or trial procedures (eg, an
overnight stay to facilitate intravenous therapy) are not considered SAEs. However, all events 
leading to unplanned hospitalizations or unplanned prolongation of an elective hospitalization (eg,
undesirable effects of any administered treatment) must be documented and reported as SAEs, 
except for unplanned hospitalizations due to relapse of MS.
Events Not to Be Considered as AEs/SAEs 
Medical conditions present at the initial trial visit that do not worsen in severity or frequency during 
the trial are defined as Baseline medical conditions and are not to be considered AEs.
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Worsening of the underlying disease is not routinely to be considered an AE or SAE, but is rather 
an efficacy endpoint, unless deemed to be causally related to the IMP.
However, if significant adverse signs or symptoms occur in association with complications or a 
prolonging of a hospitalization originally due to relapse or disease progression, then these specific 
complications or hospital prolongation events should be recorded as AEs.
7.4.1.2 Methods of Recording and Assessing Adverse Events
At each trial visit, the subject will be queried on changes in his or her condition. During the 
reporting period, any unfavorable changes in the subject’s condition will be recorded as AEs, 
whether reported by the subject or observed by the Investigator. 
Complete, accurate and consistent data on all AEs experienced for the duration of the reporting 
period (defined below) will be reported on an ongoing basis in the appropriate section of the eCRF. 
All SAEs must be additionally documented and reported using the appropriate Report Form as 
described in Section 7.4.1.4.
It is important that each AE report include a description of the event, its duration (onset and 
resolution dates (and times when it is important to assess the time of AE onset relative to the 
recorded treatment administration time), its severity, its causal relationship with the trial treatment, 
any other potential causal factors, any treatment given or other action taken, including dose 
modification or discontinuation of the IMP, and its outcome. In addition, serious cases should be 
identified and the appropriate seriousness criteria documented. 
Specific guidance can be found in the eCRF Completion and Monitoring Conventions provided 
by the Sponsor.
7.4.1.3 Definition of the Adverse Event Reporting Period
The AE reporting period for safety surveillance begins when the subject is initially included in the 
trial (date of first signature of informed consent/date of first signature of first informed consent) 
and continues until the 4-week Safety Follow-up/End of Trial Visit.
Any SAE assessed as related to IMP must be reported whenever it occurs, irrespective of the time 
elapsed since the last administration of IMP. 
7.4.1.4 Procedure for Reporting Serious Adverse Events
Serious Adverse Events
In the event of any new SAE occurring during the reporting period, the Investigator must 
immediately (within a maximum of 24 hours after becoming aware of the event) inform the 
Sponsor or its designee using the SAE Report Form, which must be completed by the Investigator
following specific completion instructions.
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For names, addresses, telephone and fax numbers for SAE reporting, see information included in 
the Adverse Event Safety Report Form.
In exceptional circumstances, an SAE (or follow-up information) may be reported by telephone; 
in these cases, the eCRF must be completed.
Relevant pages from the eCRF may be provided in parallel (eg, medical history, concomitant 
drugs). Additional documents may be provided by the Investigator, if available (eg, laboratory 
results, hospital report, autopsy report). In all cases, the information provided on the SAE Report 
Form must be consistent with the data about the event recorded in the eCRF.
The Investigator must respond to any request for follow-up information (eg, additional 
information, outcome, final evaluation, other records where needed) or to any question the 
Sponsor/designee may have on the AE within the same timelines as those noted above for initial 
reports. This is necessary to ensure prompt assessment of the event by the Sponsor or designee and 
(as applicable) to allow the Sponsor to meet strict regulatory timelines associated with expedited 
safety reporting obligations.
Requests for follow-up will usually be made via the responsible Medical Monitor, although in 
exceptional circumstances the Global Drug Safety department may contact the Investigator 
directly to obtain further information or to discuss the event.
7.4.1.5 Safety Reporting to Health Authorities, Independent Ethics 
Committees/ Institutional Review Boards and Investigators
The Sponsor or designee will send appropriate safety notifications to Health Authorities in 
accordance with applicable laws and regulations.
The Investigator must comply with any applicable site-specific requirements related to the 
reporting of SAEs (particularly deaths) involving trial subjects to the IEC/IRB that approved the 
trial.
In accordance with ICH GCP, the Sponsor/designee will inform the Investigator of “findings that 
could adversely affect the safety of subjects, impact the conduct of the trial or alter the IEC’s/IRB’s 
approval/favorable opinion to continue the trial.” In particular and in line with respective 
regulations, the Sponsor/designee will inform the Investigator of AEs that are both serious and 
unexpected and are considered to be related to the administered product (“suspected unexpected 
serious adverse reactions” or SUSARs). The Investigator should place copies of Safety Reports in 
the Investigator Site File. National regulations with regard to Safety Report notifications to 
Investigators will be taken into account.
When specifically required by regulations and guidelines, the Sponsor/designee will provide 
appropriate Safety Reports directly to the concerned lead IEC/IRB and will maintain records of 
these notifications. When direct reporting is not clearly defined by national or site-specific 
regulations, the Investigator will be responsible for promptly notifying the concerned IEC/IRB of 
any Safety Reports provided by the Sponsor/designee and of filing copies of all related 
correspondence in the Investigator Site File.
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For trials covered by the European Directive 2001/20/EC, the Sponsor’s responsibilities regarding 
the reporting of SAEs/SUSARs/Safety Issues will be carried out in accordance with that Directive 
and with the related Detailed Guidance documents.
7.4.1.6 Monitoring of Subjects with Adverse Events
Adverse events are recorded and assessed continuously throughout the trial (see Section 7.4.1.3) 
and are assessed for final outcome at the 4-week Safety Follow-up/End of Trial Visit. All SAEs 
ongoing at the 4-week Safety Follow-up/End of Trial Visit must be monitored and followed up by 
the Investigator until stabilization or until the outcome is known, unless the subject is documented 
as “lost to follow-up”. Reasonable attempts to obtain this information must be made and 
documented. It is also the responsibility of the Investigator to ensure that any necessary additional 
therapeutic measures and follow-up procedures are performed. 
7.4.2 Pregnancy and In Utero Drug Exposure 
Only pregnancies considered by the Investigator to be related to trial treatment (eg, resulting from 
a drug interaction with a contraceptive medication) are considered to be AEs. However, all 
pregnancies with an estimated conception date during the period defined in Section 7.4.1.3 must 
be recorded by convention in the AE page/section of the eCRF. The same rule applies to 
pregnancies in female subjects and to pregnancies in female partners of male subjects. The 
Investigator must notify the Sponsor/designee in an expedited manner of any pregnancy using the 
Pregnancy Report Form, which must be transmitted according to the same timeline as described 
for SAE reporting in Section 7.4.1.4. 
Investigators must actively follow up, document and report on the outcome of all these 
pregnancies, even if the subjects are withdrawn from the trial.
The Investigator must notify the Sponsor/designee of these outcomes using the Pregnancy Report 
Form. If an abnormal outcome occurs, the SAE Report Form will be used if the subject sustains 
an event and the Parent-Child/Fetus Adverse Event Report Form if the child/fetus sustains an 
event.
Any abnormal outcome must be reported in an expedited manner as described in Section 7.4.1.4, 
while normal outcomes must be reported within 45 days after delivery.
In the event of a pregnancy in a subject occurring during the course of the trial, the subject must 
be discontinued from trial medication immediately. The Sponsor/designee must be notified 
without delay and the subject must be followed as mentioned above.
7.4.3 Clinical Laboratory Assessments
Blood and urine samples will be collected for the following clinical laboratory tests, following the 
timing noted in the Schedule of Assessments (Table 1). All samples should be clearly identified. 
Sample collection, preparation, and handling/shipment procedures are described in the Laboratory 
Manual.
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Table 5 Clinical Safety Laboratory Evaluations
Type of 
Evaluation
Tests
Biochemistry ! Albumin
! Aspartate 
aminotransferase
! Alanine aminotransferase
! Alkaline phosphatase
! γ-Glutamyl-transferase
! Lactate dehydrogenase
! Bilirubin (total) 
! Protein (total)
! Creatinine and eGFR 
calculation
! Amylase
! Lipase
! Total carbon dioxide 
! Blood urea nitrogen
! Glucose
! Sodium
! Potassium
! Chloride
! Calcium
! Magnesium
! Phosphate
Hematology ! Hematocrit
! Hemoglobin
! Red blood cell count
! Mean corpuscular 
volume
! Mean corpuscular 
hemoglobin
! Mean corpuscular
hemoglobin 
concentration
! Reticulocyte count
! Platelet count 
! White blood cell count
! B,  cell counta
! Immunoglobulin and 
subclass 
concentrationsa,b
! White blood cell 
differentials and absolute 
counts:
o Basophils
o Eosinophils
o Lymphocytes
o Monocytes
o Neutrophils 
Coagulationa ! International normalized ratio
! Partial thromboplastin time
Urinalysis/micros
copyb and urine 
chemistry
! pH
! Nitrite
! Urobilinogen
! Bilirubin
! Glucose 
! Ketone bodies
! Protein
! βhCG (women only)a
! Microscopyc (white blood 
cells, red blood cells, 
casts)
! Protein/creatinine ratiod
Additional urine 
testing
! βhCG (women only)a
Other Screening 
testse
! HBV core antigen
! HCV antibodies
! Serum βhCG (women 
only)
! HBV IgM antibodies
! HIVf
! FSH
! HBsAg
! Quantiferon tuberculosis 
test
βhCG=β-human chorionic gonadotropin, eGFR=estimated glomerular filtration rate, FSH=follicle stimulating hormone, 
HBsAg=hepatitis B surface antigen, HBV=hepatitis B virus, HCV=hepatitis C virus, HIV=human immunodeficiency 
virus, IgM=immunoglobulin M, .
a. To be done only when specified in Table 1 and not as a standard laboratory evaluation. 
b. Results will not be disclosed to the sites, sponsor, or representative, to avoid unblinding. However, the IDMC 
will have access to these data as applicable.
c. Microscopy will be performed only if urine dipstick is abnormal.
d. Protein/creatinine ratio will only be determined at the central laboratory if urine dipstick is abnormal
e. Performed only at Screening.
f. HIV testing will be done at Screening only where required as per local regulation.
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7.4.4 Vital Signs, Physical Examinations, and Other Assessments
7.4.4.1 Vital Signs
Vital signs, including seated blood pressure, pulse rate, respiratory rate, weight, and oral 
temperature will be assessed predose at all trial visits (Table 1). Height will be measured at 
Screening only.
A semiautomated pulse rate and blood pressure recording device with an appropriate cuff size will 
be utilized. Pulse rate and blood pressure will be measured after 10 minutes rest in the semisupine 
position with the subject’s arm unconstrained by clothing or other material. The blood pressure 
should be assessed on the same arm for each subject throughout the trial.
7.4.4.2 Physical Examinations
Physical examinations will be assessed at each site as indicated in Table 1. Physical examination 
includes assessment of the following: general appearance, skin, head and neck, mouth, lymph 
nodes, thyroid, abdomen, and musculoskeletal, cardiovascular, and respiratory systems. Physical 
examination findings during Screening before obtaining informed consent will be recorded as 
medical history events and new findings or worsening during the trial as AEs.
7.4.4.3 12-Lead ECG and Chest X-ray
A 12-lead ECG will be performed during Screening. The 12-lead ECG recordings will be obtained 
after 10 minutes of rest in a semisupine position.
The following ECG parameters will be obtained directly from the computerized 12-lead ECG 
recordings: rhythm, ventricular rate, PR interval, QRS duration, and QT interval. The corrected 
QT interval will be calculated using Fridericia’s formula. The overall evaluation 
(normal/abnormal) will be recorded on the eCRF, and if abnormal, the specific abnormality will 
be recorded. Abnormal evaluations will be judged as clinically significant or not clinically 
significant by the Investigator.
The printout of the ECG is to be signed, dated, and filed in the Investigator’s Site File along with 
a signed and dated copy (if the printouts are not on archive-quality paper).
Posterioanterior CXRs will be performed during Screening according to local standard practice. 
Subjects who had a CXR performed for clinical reasons within 3 months prior to Day 1 do not 
need to have the CXR repeated. The CXR should show no evidence of active infective process, or 
any other clinically significant abnormalities. The overall evaluation (normal/abnormal) will be 
recorded on the eCRF, and if abnormal, the specific abnormality will be recorded. Abnormal 
evaluations will be judged as clinically significant or not clinically significant by the Investigator.
The 12-lead ECG and CXR will be performed and read locally.
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7.4.5 Total Immunoglobulin Assessments
Blood samples for Ig levels (IgM, IgA, and IgG) will be obtained at predose on Days 1, 28, 112, 
168, and 336.
Samples will be analyzed by the central laboratory selected by the Sponsor. Samples will be 
collected, labeled, processed, stored, and shipped according to the instructions in the Laboratory 
Manual.
7.4.6 B Cell Counts
Blood samples for B,  cell counts will be obtained predose on Days 1, 28, 168, and 336.
An additional sample will be collected at the 4-week Safety Follow-up/End of Trial Visit. 
The actual date and time of each sample will be recorded. Samples will be analyzed by the central 
laboratory selected by the Sponsor using an appropriately validated bioanalytical method. Samples 
will be collected, labeled, processed, stored, and shipped according to the instructions in the 
Laboratory Manual.
7.5
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7.7 Health Related Quality of Life Assessments
7.7.1 Short Form 36-item Health Status Survey
The SF-36v2 is a 36-item questionnaire that measures 8 areas of subject reported health rated from 
0 to 100 for a total score ranging from 0 to 800 (21-25). The areas are: 
! Physical function
! Role limitations due to health problems
! Bodily pain
! Social functioning
! General mental health
! Role limitations due to emotional problems
! Energy/fatigue
?
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! General health perceptions
The SF-36v2 will be measured in all subjects as indicated in Table 1. Completion of the SF-36v2
shall be done before any other procedure or Investigator interaction takes place. The English 
version of the instrument can be found in Appendix III.
7.8 Columbia-Suicide Severity Rating Scale
The C-SSRS will be used for prospective suicidality assessment. The C-SSRS will be a tool used 
at Screening to identify eligible subjects. The structured interview prompts recollection of suicidal 
ideation, including the intensity of the ideation, behavior and attempts with actual/potential 
lethality.
The scale will be administered by the Treating Investigator or a qualified designee at. Please note 
that assessing the risk of suicide is a difficult and complex task when applied to the individual 
patient. No single clinical scale can replace a thorough medical examination and suicide risk 
assessment. Ultimately, the determination of the presence of suicidality depends on clinical 
judgment.
8 Statistics
8.1 Sample Size
A per-group sample size of 44 evaluable subjects provides 85% power to detect a decrease of 90% 
in the total number of gadolinium-enhancing T1 lesions, summed over scans at Weeks 12, 16, 20, 
and 24, between each M2951 group versus placebo at the 2-sided 5% level, using the Wilcoxon 
rank-sum test, where the p-value is evaluated using a continuity-corrected normal approximation 
to the test statistic. Power was evaluated via simulation in R of the Wilcoxon test (wilcox.test) 
applied to lesion count data generated according to a negative binomial (NB) distribution, with 
mean λt = 0.55 and shape parameter ϒt =14.0 for a given M2951 group (ϒt based on rituximab 
data) (2), and mean λc = 5.5 and shape parameter ϒc = 7.256 for the placebo group (λc and ϒc based 
on placebo data) (2), yielding a lesion rate ratio of λt/λc = 0.10. Approximately 50 subjects will be 
randomized per group to protect against a loss of information due to a 12% drop-out rate over one 
year, and to provide for an adequate assessment of safety. (Note that the NB distribution 
parameterization assumed here implies lesion count variance equals λ + λ2 ϒ for a given treatment 
group.)
The IA, if conducted, will test for futility, not efficacy, so will not affect the 0.05 Type I error rate 
available at the primary analysis. The Family-wise Type I error rate (FWER) at the primary
analysis will be controlled at the 2-sided 0.05 significance level for the 3 comparisons of M2951 
dose group versus placebo using the Hochberg procedure. 
8.2 Randomization
Eligible subjects will be randomized 1:1:1:1:1 to treatment with placebo, low-dose M2951 
(25mg QD), mid-dose M2951 (75mg QD), high-dose M2951 (75mg BID), or Tecfidera
(administered BID at a final dose of 240 mg), through a central randomization process by an 
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IWRS, stratified according to region (US or Western Europe, Eastern Europe and , 
Eastern Europe and , RoW). 
8.3 Endpoints
8.3.1 Primary Endpoints
The primary endpoint is the total number of gadolinium-enhancing T1 lesions at Weeks 12, 16, 
20, and 24. The primary analysis is a comparison of each M2951 dose arm versus placebo based 
on this endpoint, with a supportive test for dose-response.
8.3.2 Secondary Endpoints
Key secondary endpoints to evaluate the efficacy and safety of M2951 compared to placebo:
! Annualized relapse rate (ARR), based on protocol-defined qualified relapses, at Week 24 
! Proportion of subjects who remain qualified relapse-free at Week 24 
! Change from Baseline in EDSS at Week 24 
! Safety as assessed by the nature, severity, and incidence of AEs; vital signs; ECGs; absolute 
concentrations and change from Baseline in Ig levels; absolute numbers and change from 
Baseline in B cells; and clinical laboratory safety parameters (duration of placebo treatment 
group limited to 24 weeks).
Additional secondary endpoints:
To evaluate the efficacy of M2951 compared to placebo:
! Total number of new Gd+ T1 lesions at Weeks 12, 16, 20, and 24
! Mean per-scan number of Gd+ T1 lesions at Weeks 12, 16, 20, and 24
! Total number of new or enlarging T2 lesions at Weeks 12, 16, 20, and 24
! Change from Baseline in the volume of Gd+ T1 lesions at Week 24 
! Change from Baseline in the volume of T2 lesions at Week 24 
To evaluate efficacy within M2951 dose groups:
! Total number of Gd+ T1 lesions at Week 48
! Total number of new Gd+ T1 lesions at Week 48
! Annualized relapse rate, based on protocol-defined qualified relapses, at Week 48
! Proportion of subjects who remain qualified relapse-free at Week 48
! Change from Baseline in EDSS at Week 48
! Total number of new or enlarging T2 lesions at Week 48
! Change from Baseline in the volume of Gd+ T1 lesions at Week 48
?
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! Change from Baseline in the volume of T2 lesions at Week 48
To evaluate the efficacy and safety of Tecfidera:
! Total number of gadolinium-enhancing T1 lesions at Weeks 12, 16, 20, and 24
! Annualized relapse rate, based on protocol-defined qualified relapses, at Week 24
! Proportion of subjects who remain qualified relapse-free at Week 24
! Change from Baseline EDSS at Week 24
! Safety as assessed by the nature, severity, and incidence of AEs; vital signs; ECGs; absolute 
concentrations and change from Baseline in Ig levels; absolute numbers and change from 
Baseline in B cells; and clinical laboratory safety parameters 
! Total number of new Gd+ T1 lesions at Weeks 12, 16, 20, and 24
! Mean per-scan number of Gd+ T1 lesions at Weeks 12, 16, 20, and 24
! Total number of new or enlarging T2 lesions at Weeks 12, 16, 20, and 24
! Change from Baseline in the volume of Gd+ T1 lesions at Week 24
! Change from Baseline in the volume of T2 lesions at Week 24
! Total number of Gd+ T1 lesions at Week 48
! Total number of new Gd+ T1 lesions at Week 48
! Annualized relapse rate, based on protocol-defined qualified relapses, by Week 48
! Proportion of subjects who remain qualified relapse-free at Week 48
! Change from Baseline in EDSS at Week 48 
! Total number of new or enlarging T2 lesions at Week 48 
! Change from Baseline in the volume of Gd+ T1 lesions at Week 48 
! Change from Baseline in the volume of T2 lesions at Week 48
8.3.3 Exploratory Endpoints
Exploratory endpoints are as follows:
! Change in HRQoL as measured with SF-36v2 (physical component summary [PCS]/mental 
component summary [MCS] and sub-domains) over time (area under the curve) in all subjects
! Change in HRQoL as measured with SF-36v2 (PCS/MCS and sub-domains) from Baseline to
Week 24 and from Baseline to Week 48 in all subjects
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8.3.4
 
 
8.4 Analysis Sets
For the purposes of analysis, the following analysis sets are defined:
Safety Analysis Set
The Safety Analysis Set consists of all subjects who receive at least one dose of trial treatment. 
Subjects will be analyzed according to the actual treatment they receive.
Intent-To-Treat Analysis Set
The Intent-To-Treat ITT Analysis Set consists of all subjects randomly allocated to a treatment, 
based on the intention to treat “as randomized” principle (ie, the planned treatment regimen rather 
than the actual treatment given in case of any difference).
Modified Intent-To-Treat Analysis Set
The modified ITT (mITT) Analysis Set consists of all subjects who belong to both the ITT and 
Safety Analysis Sets, and who have at least one baseline and one post-baseline MRI assessment.
Per-Protocol (PP) Analysis Set
The PP Analysis Set consists of all subjects who belong to the mITT Analysis Set, complete 
24 weeks of treatment, and do not have any important protocol deviations.
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8.5 Description of Statistical Analyses
8.5.1 General Considerations
A general description of the statistical methods to be used to analyze the efficacy and safety data 
is outlined below. Prior to partial locking the database for the primary analysis, a detailed 
Statistical Analysis Plan (SAP) will be developed.
Continuous variables will be summarized descriptively using the number of observations, mean,
standard deviation (SD), median, first quartile (Q1), third quartile (Q3), minimum, and maximum. 
Categorical variables will be summarized using frequency counts and percentages. The 
denominator for the percentages will be the total number of subjects in the treatment group and 
analysis set being presented, unless otherwise specified (e.g., on some occasions, percentages may 
be calculated out of the total number of subjects with available data at a particular time point).
All tests of treatment effects will be conducted at a 2-sided α-level of 0.05. P-values and the 95% 
confidence intervals (CIs) will be presented where applicable. Actual p-values will be interpreted 
based on the multiple testing strategy. Treatment comparisons for each data type are described in 
later sections. Alternative or additional statistical methods may be used as appropriate as outlined 
in the SAP.
Data from all investigative sites will be pooled for all planned analyses. Analysis of individual site 
findings or country findings will be considered if necessary. For those measures that are analyzed 
using change from baseline scores, observed scores may also be presented descriptively.
The procedures to be followed in relation to handling missing, unused, or spurious data will be 
described in the SAP. The SAP will provide the definition(s) of Baseline measurement as required.
All subjects will be included in individual subject data listings. 
Any changes to the data analysis methods described in the protocol will require an amendment 
only if a principal feature of the protocol is affected. Any other changes to the planned data analysis 
that does not require a protocol amendment will be described in the SAP and the Clinical Trial 
Report (CTR). Additional exploratory analyses will be conducted as deemed appropriate.
8.5.2 Analysis of Primary Endpoint
Primary Efficacy Endpoint
The primary analysis of total number of Gd+ T1 lesions, at Weeks 12, 16, 20, and 24, will be an 
estimate of lesion rate ratio, together with associated 95% CI and p-value, comparing each M2951 
dose group to placebo, based on a negative binomial (NB) model, where the offset will be based 
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on the log of number of scans, with M2951 dose or placebo group as a factor and adjustment for 
covariates based on randomization strata. Other covariates, such as baseline MRI activity, may be 
included in the model. Should the model fail to converge, the primary analysis will be an estimate 
of the shift in location of the distribution of the Gd+T1 lesion count via the Hodges-Lehman 
estimate, together with associated 95% CI and p-value based on the Wilcoxon rank sum test, 
comparing each M2951 dose group to placebo. Descriptive statistics for the total number of Gd+ 
T1 lesions, at Weeks 12, 16, 20, and 24, will be provided for each treatment group. 
The primary analysis of the primary endpoint will be based on the mITT analysis set, with 
supportive analyses based on the ITT and PP analysis sets. If the primary analysis is comprised of 
negative binomial modeling, the computed p-value testing the null hypothesis H0: RR = 1.0 for 
each M2951 dose group will be reported, where RR denotes lesion rate ratio comparing a given 
M2951 dose group to placebo. If the primary analysis must be nonparametric due to model 
non-convergence, the computed p-value testing the null hypothesis H0: P(X < Y) + 0.5*P(X = Y) 
= 0.5, via the Wilcoxon rank sum test, for each M2951 treatment group will be reported, where X 
denotes the primary endpoint evaluated for a subject in a given M2951 treatment group, and Y 
denotes the primary endpoint evaluated for a subject in the placebo group. The FWER, ie, overall 
type I error rate for the primary analysis, will be controlled at the 0.05 level by testing the 3 M2951 
hypotheses for the low, mid, and high dose groups using the Hochberg procedure. A test for a 
monotonic dose-response relationship, between ordered M2951 dose (low, mid, high) and Gd+ T1 
lesion rate ratio relative to placebo, will be performed as a supportive analysis.
No formal comparisons between the Tecfidera arm and any other treatment group will be 
performed for the primary endpoint.
8.5.3 Analysis of Secondary Endpoints
The analysis of secondary endpoints will be based on the mITT analysis set.
Descriptive statistics for MRI and clinical secondary endpoints, will be provided for the M2951 
dose arms, the placebo arm (limited to 24 week endpoints), and the Tecfidera arm. For 48 week 
endpoints, descriptive statistics will be provided for the placebo/M2951 arm. Descriptive statistics 
for ARR will be calculated for each treatment group as the total number of qualified relapses 
divided by the number of subject-years of observation. 
The multiple-comparison procedure for testing the key secondary efficacy endpoints will be 
provided in the SAP. Other secondary efficacy endpoints will be analyzed for exploratory 
purposes. No formal comparisons between the Tecfidera arm and any other treatment group will 
be performed for the secondary efficacy endpoints.
Secondary Efficacy Endpoints: Baseline to 24 weeks
The comparison of a M2951 treatment group to the placebo group using ARR at Week 24 will be 
based on a Poisson model for qualified relapse count, with offset equal to the log of years on study, 
with M2951 dose group or placebo group as a factor and adjustment for covariates based on 
randomization strata. The comparison of a M2951 treatment group to the placebo group using 
proportion qualified relapse-free at Week 24, will be based on a logistic model for the odds of a 
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subject being qualified relapse-free at Week 24, where subjects who discontinue study prior to 
Week 24 without having a qualified relapse are counted as not being qualified relapse-free at 
Week 24, with M2951 dose group or placebo group as a factor and adjustment for covariates based 
on randomization strata. The comparison of a M2951 treatment group to placebo group using 
change from Baseline in EDSS at Week 24 will be based on a rank analysis of covariance 
(ANCOVA) model, with M2951 dose group or placebo group as a factor, and adjustment for
Baseline and covariates based on randomization strata. The analysis of mean per-scan number of 
Gd+ T1 lesions at Weeks 12, 16, 20, and 24, change from Baseline in volume of Gd+ T1 lesions 
at Week 24, and change from Baseline in volume of T2 lesions at Week 24, will be based on an 
ANCOVA model of the appropriately transformed variable. The comparison of a M2951 treatment 
group to placebo using total number of new Gd+ T1 lesions, or total number of new or enlarging 
T2 lesions, at Weeks 12, 16, 20, and 24, will be based on a NB model, similar to that used for the 
primary analysis. In the analysis of each secondary endpoint, other covariates, such as baseline 
MRI activity, may be included in the model.
A test for a monotonic dose-response relationship, between ordered M2951 dose (low, mid, high) 
and each of the key secondary efficacy endpoints, will be performed as supportive analyses.
Secondary Efficacy Endpoints: Baseline to 48 weeks
Descriptive statistics for MRI and clinical endpoints, Baseline to Week 48, will be provided for 
the M2951 dose arms, the placebo/M2951 arm, and the Tecfidera arm.
The total number of Gd+ T1 lesions, total number of new Gd+ T1 lesions, total number of new
and enlarging T2 lesions, the change from Baseline in Gd+ T1 lesion volume, and change from 
Baseline in T2 lesion volume, will be summarized by timepoint (Baseline and Weeks 12, 16, 20, 
24, and 48) and treatment group (placebo, 3 M2951 dose groups, and Tecfidera).
Annualized relapse rate from Baseline to Week 24, and from Baseline to Week 48 will be 
summarized by treatment group. The proportion of subjects remaining qualifying relapse-free at 
Week 24 and at Week 48 will be summarized by treatment group. The change from Baseline in 
EDSS will be summarized by treatment group and timepoint (Weeks 4, 8, 12, 16, 20, 24, 36, and 
48, and the 4-week Safety Follow-up/End of Trial Visit).
8.5.4 Analysis of Safety and Other Endpoints
No formal comparisons between the Tecfidera arm and any other treatment group will be 
performed for the safety, HRQoL,  and  endpoints.
8.5.4.1 Safety
Adverse events will be summarized by treatment group, by severity, and by relationship to IMP.
Serious AEs, AEs leading to treatment discontinuation, and AEs leading to treatment interruption, 
will be summarized by treatment group.
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Summary statistics will be used to present observed values and changes from baseline in 
continuous laboratory, vital sign, and ECG data. Shift tables will be used to present changes in 
categorical laboratory parameters. Figures may be generated to assist safety evaluation.
Adverse events will be coded according to the Medical Dictionary for Regulatory Activities 
(MedDRA). The severity of AEs will be graded using NCI-CTCAE v4.03 toxicity grades (20). 
The number and percentage of subjects experiencing 1 or more treatment-emergent AEs (TEAEs)
will be summarized according to the MedDRA system organ classes and preferred terms by 
treatment group, relationship to IMP, and severity.
Values for all safety variables will be listed by subject and time point.
8.5.4.2 Patient-reported Health Related Quality of Life (HRQoL)
Descriptive statistics for each time point and change from baseline will be provided for each health 
domain score and the physical and mental component summary scores (PCS/MCS) for each 
assessment time point. 
In addition, change in HRQoL for PCS/MCS and sub-domains over time (area under the curve)
will be compared between different M2951 treatment arms and placebo.
Further details on psychometric analyses will be presented in the SAP that will be finalized before 
database lock.
8.5.4.3
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8.5.4.5
 
 
 
 
 
 
 
8.6 Interim and Additional Planned Analyses
There will be three analyses: (1) an IA, triggered when the first 50% of subjects enrolled out of the 
planned enrollment reach Week 24 of treatment, or prematurely discontinue from treatment, (2) a 
primary analysis, triggered when 100% of subjects enrolled reach Week 24 of treatment, or 
prematurely discontinue from treatment, and (3) a final analysis, triggered when 100% of subjects 
enrolled complete all study parts, or discontinue prematurely from study. The Sponsor may decide 
not to perform the IA if the IA trigger date is sufficiently close (i.e., within approximately 
4 months) of the primary analysis trigger date.
Interim Analysis
If performed, the aim of the IA will be to evaluate overall futility based on the highest dose of 
M2951 to determine whether or not to continue the study. It is planned that placebo subjects will 
be continued at the 25 mg QD dose after Week 24, however consideration will be given to changing
this dose based on data from the IA. Pharmacokinetic analysis will not be included in the IA.
The conditional power of a test based on the rate ratio parameter of a NB model, comparing the 
primary efficacy endpoint (total number of Gd+ T1 lesions at Weeks 12, 16, 20, and 24) for the 
highest M2951 group versus the placebo group, will be evaluated, under the assumption that the 
unevaluable subjects will have lesion data for Weeks 12, 16, 20, and 24 following the same 
distribution as that observed among subjects evaluated at the time of the IA. If conditional power 
is sufficiently low, as defined in the SAP, consideration will be given to termination of the study, 
in which case all subjects will be discontinued from IMP and scheduled for a 4-week Safety 
Follow-up Visit/End of Trial Visit. 
If conditional power cannot be ascertained via a NB model, then conditional power will be 
ascertained via a nonparametric analysis, based on the Wilcoxon rank sum test.
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Descriptive statistics for the primary efficacy endpoint will be presented by treatment group. A 
point estimate (rate ratio or Hodges-Lehmann estimate) of the effect of treatment on total number 
of Gd+ T1 lesions at Weeks 12, 16, 20, and 24), comparing each M2951 dose group to the placebo 
group, will be provided, together with a 2-sided 95% CI. A test for a monotonic relationship, 
between ordered M2951 dose (low, mid, high) and Gd+ T1 lesion rate ratio relative to placebo, 
will be performed as a supportive analysis. 
Primary Analysis
When the last subject reaches 24 weeks of treatment or discontinues from treatment prematurely, 
the protocol violations are determined, the database is partially locked for the primary analysis, 
and the data file verified, the drug codes will be broken and made available for the primary data 
analysis. All endpoints based on Baseline to Week 24 data will be evaluated. The FWER associated 
with the multiple comparisons of M2951 dose to placebo based on the primary endpoint will be 
controlled via the Hochberg procedure. The multiple-comparison procedure for testing the key 
secondary endpoints will be provided in the SAP.
Final Analysis
The final analysis will occur only when the last subject completes all study parts, the protocol 
violations are determined, the database is locked for the final analysis, and the data file verified.
All endpoints based on Baseline to Week 48 data will be evaluated.
9 Ethical and Regulatory Aspects
9.1 Responsibilities of the Investigator
The Investigator is responsible for the conduct of the trial at the site and will ensure that the trial 
is performed in accordance with this protocol, the ethical principles outlined in the Declaration of 
Helsinki, ICH GCP, and any other applicable regulations. The Investigator must ensure that only 
subjects who have given informed consent are included in the trial.
According to United States Code of Federal Regulations Part 54.2 (e), for trials conducted in any 
country that could result in a product submission to the US Food and Drug Administration (FDA)
for marketing approval and could contribute significantly to the demonstration of efficacy and 
safety of an IMP (which are considered “covered clinical trials” by the FDA), the Investigator and 
all Sub-investigators are obliged to disclose any financial interest which they, their spouses or their 
dependent children may have in the Sponsor or the Sponsor’s product under study. This 
information is required during the trial and for 12 months following completion of the trial. The 
financial aspects are documented in the Clinical Trial Agreement between the Sponsor and the 
Investigator/institution.
9.2 Subject Information Sheet and Informed Consent
An unconditional prerequisite for each subject prior to participation in the trial is written informed 
consent, which must be given before any trial-related activities are carried out. Adequate 
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information must therefore be given to the subject by the Investigator or an appropriate designee 
(if local regulations permit) before informed consent is obtained. 
A Subject Information Sheet must be prepared in the local language in accordance with ICH GCP
and will be provided by the Sponsor for the purpose of obtaining informed consent. In addition to 
providing this written information to a potential subject, the Investigator or a designate will inform 
the subject verbally of all pertinent aspects of the trial, using language chosen so that the 
information can be fully and readily understood by laypersons. The subject will be given sufficient 
time to read the information and the opportunity to ask questions and to request additional 
information and clarification.
If permitted by national regulations, a person other than the Investigator may inform the subject 
about the trial and sign the Informed Consent Form (ICF), as above.
After the information is provided by the Investigator, the ICF must be signed and dated by the 
subject and the Investigator. 
A separate ICF will be needed for the subset of subjects consenting to .
The signed and dated declaration of informed consent will remain at the Investigator’s site, and 
must be safely archived so that the forms can be retrieved at any time for monitoring, auditing, and 
inspection purposes. A copy of the signed and dated information and ICF should be provided to 
the subject prior to participation.
Whenever important new information becomes available that may be relevant to informed consent, 
the Investigator will revise the Subject Information Sheet and any other written information to be
provided to the subjects and submit them to the IRB for review and opinion. Using the approved 
revised Subject Information Sheet and other written information, the Investigator will explain the 
changes to the previous version to each trial subject and obtain new written consent for continued 
participation in the trial. The subject will be given sufficient time to read the information and the 
opportunity to ask questions and to request additional information and clarification about the 
changes.
9.3 Subject Identification and Privacy
A unique number will be assigned to each subject, immediately after informed consent has been 
obtained. This number will serve as the subject’s identifier in the trial as well as in the clinical trial 
database. All subject data collected in the trial will be stored under the appropriate subject number. 
Only the Investigator will be able to link trial data to an individual subject via an identification list 
kept at the site. For each subject, original medical data will be accessible for the purposes of source 
data verification by the Medical Monitor, audits and regulatory inspections, but subject
confidentiality will be strictly maintained.
Data protection and privacy regulations will be observed in capturing, forwarding, processing, and 
storing subject data. Subjects will be informed accordingly, and will be requested to give their 
consent on data handling procedures in accordance with national regulations.
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9.4 Emergency Medical Support and Subject Card
Subjects will be provided with Emergency Medical Support cards supplied by the Sponsor for use
during trial participation in order to provide clinical trial subjects with a way of identifying 
themselves as participating in a clinical trial and to give health care providers access to any
information about this participation that may be needed to determine the course of medical 
treatment for the subject. The information provided on the Emergency Medical Support card may 
include the process for emergency unblinding (if applicable).
The first point of contact for all emergencies will be the clinical trial Investigator caring for the 
affected subject. The Investigator agrees to provide his or her emergency contact information on 
the card for this purpose. If the Investigator is available when an event occurs, they will answer 
any questions. Any subsequent action (eg, unblinding) will follow the standard process established 
for Investigators.
In cases where the Investigator is not available, the Sponsor provides the appropriate means to 
contact a Sponsor physician. This includes the provision of a 24-hour contact number at a call 
center, whereby the health care providers will be given access to the appropriate Sponsor physician 
to assist with the medical emergency and to provide support for the potential unblinding of the 
subject concerned.
9.5 Clinical Trial Insurance and Compensation to Subjects
Insurance coverage will be provided for each country participating to the trial. Insurance conditions 
shall meet good local standards, as applicable.
9.6 Independent Ethics Committee or Institutional Review Board
Prior to commencement of the trial at a given site, this clinical trial protocol will be submitted 
together with its associated documents to the responsible IEC or IRB for its favorable opinion or 
approval, which will be filed in the Investigator Site File. A copy will be filed in the Sponsor Trial 
Master File at the Sponsor or designee organization.
The IEC or IRB will be asked to document the date of the meeting at which the favorable opinion
or approval was given and the members and voting members present. Written evidence of 
favorable opinion or approval that clearly identifies the trial, the clinical trial protocol version and 
the Subject Information Sheet and ICF version reviewed should be provided. Where possible, 
copies of the meeting minutes should be obtained.
Amendments to this clinical trial protocol will also be submitted to the concerned IEC or IRB, 
before implementation of substantial changes (see Section 10.5). Relevant safety information will 
be submitted to the IEC or IRB during the course of the trial in accordance with national 
regulations and requirements.
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9.7 Health Authorities
The clinical trial protocol and any applicable documentation (eg, IMP Dossier, Subject 
Information Sheet and ICF) will be submitted or notified to the Health Authorities in accordance 
with all local and national regulations for each site.
10 Trial Management
10.1 Case Report Form Handling
Refer to the Manual of Operations for eCRF handling guidelines. 
The main purpose of the eCRF is to obtain data required by the clinical trial protocol in a complete, 
accurate, legible, and timely manner. The data in the eCRF should be consistent with the relevant 
source documents.
The Investigator or designee is responsible for ensuring that the data collected in the course of this 
trial is accurate and documented appropriately on all applicable forms. They will then be 
processed, evaluated, and stored in anonymous form in accordance with applicable data protection 
regulations. The Investigator must ensure that the eCRFs and any other associated documents 
forwarded to Sponsor or its designated organization contain no mention of any subject names.
For patient-reported outcomes, these will be collected either on paper or by means of ePRO.
The data will be entered into a validated database. The Sponsor or its designee will be responsible 
for data processing, in accordance with the Sponsor’s data management procedures. Database lock 
will occur once quality control and quality assurance procedures have been completed. Electronic 
PDF files of the eCRFs will be provided to the Investigators at the completion of the trial.
10.2 Source Data and Subject Files
The Investigator must keep a file (medical file, original medical records) on paper or electronically 
for every subject in the trial. It must be possible to identify each subject by using this subject file. 
This file will contain the demographic and medical information for the subject listed below and 
should be as complete as possible. 
! Subject’s full name, date of birth, sex, height, weight
! Medical history and concomitant diseases
! Prior and concomitant therapies (including changes during the trial)
! Trial identification, ie, the Sponsor trial number for this clinical trial, and subject number
! Dates for entry into the trial (informed consent) and visits to the site
! Any medical examinations and clinical findings predefined in this clinical trial protocol
! All AEs
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! Date that the subject left the trial including any reason for early withdrawal from the trial or 
IMP (if applicable).
All documents containing source data must be filed, including, but not limited to, computerized 
tomography or MRI scan images, ECG recordings, CXRs, and laboratory results. Such documents 
must bear the subject number and the date of the procedure. If possible, this information should be 
printed by the instrument used to perform the assessment or measurement. As necessary, medical 
evaluation of such records should be performed; all evaluations should be documented, signed,
and dated by the Investigator.
For data that may be recorded directly in the eCRF such as a questionnaire or diary, there will be 
no record in the original subject file and therefore the data entered in the eCRF will be considered 
source data. The clinical trial protocol or the Manual of Operations should clearly and completely 
specify all subject data in the eCRF to be considered source data. 
Electronic subject files will be printed whenever the Medical Monitor performs source data 
verification. Printouts must be signed and dated by the Investigator, countersigned by the Medical 
Monitor and kept in a safe place at the site.
10.3 Investigator Site File and Archiving
Upon initiation of the trial, the Investigator will be provided with an Investigator Site File 
containing all necessary trial documents, which will be completed throughout the trial and updated 
as necessary. The file must be available for review by the Medical Monitor, during Sponsor audits
and for inspection by Health Authorities during and after the trial, and must be safely archived for 
at least 15 years (or longer, per local requirements or as otherwise notified by the Sponsor) after 
the end of the trial. The documents to be archived include the Subject Identification List and the 
signed subject ICFs. If archiving of the Investigator Site File is no longer possible at the site, the 
Investigator must notify the Sponsor/designee.
All original subject files (medical records) must be stored at the site (hospital, research institute, 
or practice) for the longest possible time permitted by the applicable regulations, and/or as per ICH 
GCP guidelines, whichever is longer. In any case, the Investigator should ensure that no 
destruction of medical records is performed without the written approval of the Sponsor.
10.4 Monitoring, Quality Assurance and Inspection by Health 
Authorities
This trial will be monitored in accordance with the ICH GCP and any other applicable regulations. 
The site Medical Monitor will perform visits to the trial site at regular intervals.
The clinical trial protocol, each step of the data capture procedure, and the handling of the data, 
including the final clinical trial report, will be subjected to independent Quality Assurance 
activities. Audits may be conducted at any time during or after the trial to ensure the validity and 
integrity of the trial data. Representatives of the Quality Assurance unit from the Sponsor or a 
designated organization, as well as Health Authorities, must be permitted to access all trial
documents and other materials at the site, including the Investigator Site File, the completed 
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eCRFs, all IMP and IMP accountability records, and the original medical records or files for each 
subject.
10.5 Changes to the Clinical Trial Protocol
Changes to the clinical trial protocol will be documented in writing. Substantive amendments will 
usually require submission to the Health Authorities and to the relevant IEC/IRB for approval or 
favorable opinion. In such cases, the amendment will be implemented only after approval or 
favorable opinion has been obtained.
Minor (nonsubstantial) protocol amendments, including administrative changes, will be filed by 
the Sponsor and at the site. They will be submitted to the relevant IEC/IRB or to Health Authorities 
only where requested by pertinent regulations. Any amendment that could affect the subject’s 
agreement to participate in the trial requires additional informed consent prior to implementation 
following the process as described in Section 9.2.
10.6 Clinical Trial Report and Publication Policy
10.6.1 Clinical Trial Report
After completion of the trial, a clinical trial report will be written by the Sponsor in consultation 
with the Coordinating Investigator following the guidance in ICH Topic E3 within the legally 
required period for participating countries. 
10.6.2 Publication
An Investigator will inform the Sponsor in advance about any plans to publish or present data from 
the trial. Any publications and presentations of the results (abstracts in journals or newspapers, 
oral presentations, etc.), either in whole or in part, by Investigators or their representatives will 
require review by the Sponsor before submission. The Sponsor will not suppress publication, but 
maintains the right to delay publication in order to protect intellectual property rights.
Posting of data on clinicaltrials.gov is planned and will occur 12 months after the last clinic visit 
of the final trial subject or another appropriate date to meet applicable requirements.
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Signature Page – Principal Investigator
Trial Title A Randomized, Double-Blind, Placebo-Controlled 
Phase II Study of M2951 with a Parallel, Open-Label, 
Active Control Group (Tecfidera), in Patients with 
Relapsing Multiple Sclerosis to Evaluate Efficacy, 
Safety, Tolerability, Pharmacokinetics, and 
Biological Activity.
IND Number 129428
EudraCT Number 2016-001448-21
Clinical Trial Protocol Date / 
Version
31 May 2016/ Version 1.0
Center Number
Principal Investigator
I, the undersigned, am responsible for the conduct of the trial at this site and affirm that I 
understand and will conduct the trial according to the clinical trial protocol, any approved protocol 
amendments, International Council for Harmonisation Good Clinical Practice (Topic E6) and all 
applicable Health Authority requirements and national laws.
I also affirm that I understand that Health Authorities may require the Sponsors of clinical trials to 
obtain and supply details about ownership interests in the Sponsor or Investigational Medicinal 
Product and any other financial ties with the Sponsor. The Sponsor will use any such information 
solely for the purpose of complying with the regulatory requirements. I therefore agree to supply 
the Sponsor with any necessary information regarding ownership interest and financial ties 
including those of my spouse and dependent children, and to provide updates as necessary to meet 
Health Authority requirements.
_____________________________________ ____________________________
Signature Date of Signature
Name, academic degree:
Function / Title:
Institution:
Address:
Telephone number:
Fax number:
E-mail address:
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Sponsor Responsible Persons not Named on the Cover Page
Name, academic degree:
Function / Title: Clinical Trial Leader
Institution: Merck KGaA 
Address:
Telephone number:
Fax number:
E-mail address:
Name, academic degree:
Function / Title: Biostatistician
Institution: EMD Serono Research & Development Institute, Inc.
Address:
Telephone number:
Fax number:
E-mail address:
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Appendix II: Total Blood Volume
Blood will be drawn on at least 11 separate days/visits. Additional samples may be drawn if 
unscheduled visits occur.  
 The planned maximum 
volume of blood to be drawn in this trial is approximately 327 mL over the 4-week Screening 
Period, 24-week Treatment Period, 24-week Treatment extension Period, and 4-week Safety 
Follow-Up Period (56 weeks total).
Assay
Approximate
Sample
Volume(mL)
Number of 
Samples
Approximate
Subtotal Volume 
(mL)
Screening tests: hematology, chemistry, 
coagulation, FSH, viral serology testing (HBsAg, 
Anti-HCV, HIVa) 19.5 1 19.5
Hematology, chemistryb 12.5 10 125
Immunoglobulins 4 5 20
QuantiFERON-TB test 4.5 1 4.5
B,  cell count 10 5 50
Total 337
ALP=alkaline phosphatase, ALT=Alanine aminotransferase, AST= Aspartate aminotransferase, , 
CYP=cytochrome P450, FSH=follicle stimulating hormone, GGT=gamma-glutamyl transferase, HBsAg= hepatitis B surface 
antigen, HCV=hepatitis C virus, HIV=human immunodeficiency virus, LDH=lactate dehydrogenase,  
, TB=tuberculosis.
a HIV testing will be done at Screening only where required as per local regulations.
b Chemistry will include: albumin, AST, ALT, ALP, GGT, LDH, total bilirubin, total protein, creatinine, amylase, lipase, total CO2, 
blood urea nitrogen, glucose, sodium, potassium, chloride, calcium, magnesium, phosphate as shown in Table 5.
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Appendix III: SF-36v2 Instrument
The questions contained in the SF-36v2 are detailed below.
Item Answer category
In general, would you say your health is: 1)  Excellent
2)  Very good
3)  Good
4)  Fair
5)  Poor
COMPARED TO 1 YEAR AGO, how would you rate your health in 
general NOW?
1)  Much better now than 1 year ago
2)  Somewhat better now than 1 year 
ago
3)  About the same as 1 year ago
4)  Somewhat worse now than 1 year 
ago
5)  Much worse now than 1 year ago
The following questions are about activities you might do during a typical 
day. Does YOUR HEALTH NOW LIMIT YOU in these activities? If so, 
how much?
1)  Yes, limited a lot
2)  Yes, limited a little
3)  No, not limited at all
a)  VIGOROUS ACTIVITIES, such as running, lifting heavy objects, 
participating in strenuous sports
b)  MODERATE ACTIVITIES, such as moving a table, pushing a vacuum 
cleaner, bowling, or playing golf
c)  Lifting or carrying groceries
d)  Climbing SEVERAL flights of stairs
e)  Climbing ONE flight of stairs
f)  Bending, kneeling, or stooping
g)  Walking MORE THAN A MILE
h)  Walking SEVERAL HUNDRED YARDS
i)  Walking ONE HUNDRED YARDS
j)  Bathing or dressing yourself
During the PAST 4 WEEKS, how much of the time have you had any of 
the following problems with your work or other regular daily activities AS A 
RESULT OF YOUR PHYSICAL HEALTH?
1)  All of the time
2)  Most of the time
3)  Some of the time
4)  A little of the time
5)  None of the time
a)  Cut down on the AMOUNT OF TIME you spent on work or other 
activities
b)  ACCOMPLISHED LESS than you would like
c)  Were limited in the KIND of work or other activities
d)  Had DIFFICULTY performing the work or other activities (for example, 
it took extra effort)
During the PAST 4 WEEKS, how much of the time have you had any of 
the following problems with your work or other regular daily activities AS A 
RESULT OF ANY EMOTIONAL PROBLEMS (such as feeling depressed 
or anxious)?
1)  All of the time
2)  Most of the time
3)  Some of the time
4)  A little of the time
5)  None of the timea)  Cut down on the AMOUNT OF TIME you spent on work or other 
activities
b)  ACCOMPLISHED LESS than you would like
c)  Did work or other activities LESS CAREFULLY THAN USUAL
During the PAST 4 WEEKS, to what extent has your PHYSICAL HEALTH 
OR EMOTIONAL PROBLEMS interfered with your normal social activities 
with family, friends, neighbors, or groups?
1)  Not at all
2) Slightly
3)  Moderately
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4) Quite a bit
5)  Extremely
How much BODILY pain have you had during the PAST 4 WEEKS? 1)  None
2)  Very mild
3)  Mild
4)  Moderate
5)  Severe
6) Very Severe
During the PAST 4 WEEKS, how much did PAIN interfere with your 
normal work (including both work outside the home and housework)?
1)  Not at all
2)  A little bit
3)  Moderately
4)  Quite a bit
5)  Extremely
These questions are about how you feel and how things have been with 
you DURING THE PAST 4 WEEKS. For each question, please give the 
one answer that comes closest to the way you have been feeling. How 
much of the time during the PAST 4 WEEKS…
1)  All of the time
2)  Most of the time
3)  Some of the time
4)  A little of the time
5)  None of the timea)  Did you feel full of life?
b)  Have you been very nervous?
c)  Have you felt so down in the dumps that nothing could cheer you up?
d)  Have you felt calm and peaceful?
e)  Did you have a lot of energy?
f)  Have you felt downhearted and depressed?
g)  Did you feel worn out?
h)  Have you been happy?
i)  Did you feel tired?
During the PAST 4 WEEKS, how much of the time has your PHYSICAL 
HEALTH OR EMOTIONAL PROBLEMS interfered with your social 
activities (like visiting with friends, relatives, etc.)?
1)  All of the time
2)  Most of the time
3)  Some of the time
4)  A little of the time
5)  None of the time
How TRUE OR FALSE is EACH of the following statements for you? 1)  Definitely true
2)  Mostly true
3)  Don’t know
4)  Mostly false
5)  Definitely false
a)  I seem to get sick a little easier than other people
b)  I am as healthy as anybody I know.
c)  I expect my health to get worse.
d)  My health is excellent.
?
?
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Protocol Amendment Summary of Changes
Protocol History
Version Number Type Version Date
1.0 Original Protocol 05-Jul-2016
1.1 Local Amendment 1 22-May-2017
2.0 Amendment 1 28-Nov-2017
3.0 Amendment 2 29-May-2018
4.0 Amendment 3 09-August-2018
Protocol Version [4.0] (09-August-2018)
This amendment is nonsubstantial based on the criteria in Article 10(a) of Directive 2001/20/EC 
of the European Parliament and the Council of the European Union because it neither impacts the 
safety or physical/mental integrity of participants nor the scientific value of the study.
Overall Rationale for the Amendment
Following a request from the Czech Republic Regulatory Authority, instructions for re-initiating 
IMP following increase in AST, ALT, or bilirubin to Grade 2 were amended.
Section # and 
Name
Description of Change Brief Rationale
6.4.4.1 For 
M2951 Only
Amended instructions for re-initiating
IMP following increase in AST, ALT, or 
bilirubin to Grade 2.
To include the recommendations from the Czech 
Republic Regulatory Authority
This document is the property of Merck KGaA, Darmstadt, Germany, or one of its subsidiaries. It 
is intended for restricted use only and may not – in full or part – be passed on, reproduced, 
published or used without express permission of Merck KGaA, Darmstadt, Germany, or its 
subsidiary. Copyright © 2018 by Merck KGaA, Darmstadt, Germany, or its subsidiary. All rights 
reserved.
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1 Synopsis
Clinical Trial Protocol Number MS200527-0086
Title A Randomized, Double-Blind, 
Placebo-Controlled Phase II Study of M2951 with 
a Parallel, Open-Label, Active Control Group
(Tecfidera), in Patients with Relapsing Multiple 
Sclerosis to Evaluate Efficacy, Safety, 
Tolerability, Pharmacokinetics, and Biological 
Activity.
Trial Phase II
IND Number 129428
FDA covered trial Yes
EudraCT Number 2016-001448-21
Coordinating Investigator
 
Sponsor For all countries except the USA:
Merck KGaA Frankfurter Str. 250,
64293 Darmstadt, Germany. 
For the USA only:
EMD Serono Research and Development 
Institute, Inc.
45A Middlesex Turnpike
Billerica, MA, 01821 USA
Trial centers/countries This trial will be conducted at approximately 64
sites globally in Europe, USA, and in the rest of 
the world (RoW).
Planned trial period
(first subject in-last subject out)
First subject in: Q2, 2017
Last subject out: Q3, 2020
Trial Registry ClinicalTrials.Gov, EudraCT
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Objectives: 
Primary Objective
The primary objective is to evaluate the efficacy and dose-response of evobrutinib (also 
referred to as M2951) on the number of gadolinium-positive (Gd+) T1 magnetic resonance 
imaging (MRI) lesions versus placebo after 24 weeks of treatment.
Secondary Objectives
The key secondary objectives are as follows:
 To evaluate the efficacy and dose-response of M2951 on clinical endpoints over 24 weeks
versus placebo
 To evaluate the safety of M2951.
Additional secondary objectives are as follows:
 To evaluate the efficacy of M2951 on additional MRI parameters over 24 weeks versus 
placebo 
 To evaluate the efficacy of M2951 on clinical and MRI endpoints from Week 24 to 48
 To evaluate the efficacy of Tecfidera on clinical and MRI endpoints over 24 weeks
 To evaluate the efficacy of Tecfidera on clinical and MRI endpoints from Week 24 to 48
 To evaluate the safety of Tecfidera.
Exploratory Objectives
The exploratory objectives are as follows:
  
 
 
 
 
 To explore the benefit of M2951 treatment on patient-reported health-related quality of 
life (HRQoL) versus placebo, and to evaluate the effect of Tecfidera on HRQoL.
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Methodology: The study will be a randomized, double-blind, placebo-controlled study in 
subjects with relapsing multiple sclerosis (RMS), with a parallel, open-label active control
group (Tecfidera) involving 5 treatment groups with 3 doses of M2951, placebo, and active 
control (Tecfidera). 
The study will consist of 4 major periods: (i) a Screening period of 4 weeks, (ii) active treatment 
with 3 dose groups of M2951, active control (Tecfidera), or placebo for 24 weeks, (iii) a 
24-week extension on active treatment with M2951 or active control (Tecfidera) for 24 weeks, 
where subjects on placebo will be switched to M2951, and (iv) an optional Open-Label 
Extension (OLE) Period. At the end of the 48-week main study, subjects will be in 1 of 
4 treatment groups (M2951 25 mg daily, 75 mg once daily, or 75 mg twice daily or Tecfidera). 
All subjects who choose to enter the OLE Period will be switched to active treatment with 
M2951 at a dose of 75 mg once daily or to the eventual Phase III dose when decided.  
 
 
Following completion or early termination of treatment, subjects will return after 4 weeks for 
safety evaluation. 
It is planned that placebo subjects will be switched to the 25 mg M2951 once daily dose after 
Week 24.
Placebo, M2951, and Tecfidera will be administered orally daily. After Day 1, subjects will 
return every 4 weeks for trial visits and will be assessed for safety and efficacy.
 
 
An independent data monitoring committee (IDMC) will be responsible for safety monitoring
until the last randomized subject completes the blinded phase. The IDMC will consist of at 
least the following core members: 2 clinicians and 1 biostatistician. After the blinded phase, a 
switch to an internally convened Safety Monitoring Committee (SMC) will be considered. The 
SMC will consist of at least the following members: Sponsor and CRO medical advisor, 
Sponsor biostatistician, Sponsor Drug Safety Physician, Sponsor Clinical Pharmacology 
representative and Coordinating Investigator.
Planned number of subjects: Approximately 50 subjects will be enrolled in each treatment 
group, for a total of approximately 250 enrolled subjects.  
.
Primary endpoint: Total number of gadolinium-enhancing T1 lesions at Week 12, 16, 20, and 
24.
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Secondary endpoints: 
Key secondary endpoints to evaluate the efficacy and safety of M2951 compared to placebo:
 Annualized relapse rate (ARR), based on protocol-defined qualified relapses, at Week 24 
 Qualified relapse-free status at Week 24
 Change from Baseline in Expanded Disability Status Scale (EDSS) at Week 24
 Safety as assessed by the nature, severity, and occurrence of adverse events (AEs); vital 
signs; electrocardiograms (ECGs); absolute concentrations and change from Baseline in 
immunoglobulin (Ig) levels; absolute numbers and change from Baseline in B cells; and 
clinical laboratory safety parameters (duration of placebo treatment group is limited to 
24 weeks).
Additional secondary endpoints:
To evaluate the efficacy of M2951 compared to placebo:
 Total number of new Gd+ T1 lesions at Week 12, 16, 20, and 24
 Mean per-scan number of Gd+ T1 lesions at Week 12, 16, 20, and 24
 Total number of new or enlarging T2 lesions at Week 12, 16, 20, and 24
 Change from Baseline in the volume of Gd+ T1 lesions at Week 24
 Change from Baseline in the volume of T2 lesions at Week 24
To evaluate efficacy within M2951 dose groups:
 Number of Gd+ T1 lesions at Week 48
 Number of new Gd+ T1 lesions at Week 48
 Annualized relapse rate, based on protocol-defined qualified relapses, at Week 48
 Qualified relapse-free status at Week 48
 Change from Baseline in EDSS at Week 48
 Number of new or enlarging T2 lesions at Week 48
 Change from Baseline in the volume of Gd+ T1 lesions at Week 48
 Change from Baseline in the volume of T2 lesions at Week 48
To evaluate the efficacy and safety of Tecfidera:
 Total number of gadolinium-enhancing T1 lesions at Week 12, 16, 20, and 24
 Annualized relapse rate, based on protocol-defined qualified relapses at Week 24
 Qualified relapse-free status at Week 24
 Change from Baseline in EDSS at Week 24
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 Safety as assessed by the nature, severity, and occurrence of AEs; vital signs; ECGs;
absolute concentrations and change from Baseline in Ig levels; absolute numbers and 
change from Baseline in B cells; and clinical laboratory safety parameters
 Total number of new Gd+ T1 lesions at Week 12, 16, 20, 24
 Mean per-scan number of Gd+ T1 lesions at Week 12, 16, 20, and 24
 Total number of new or enlarging T2 lesions at Week 12, 16, 20, and 24
 Change from Baseline in the volume of Gd+ T1 lesions at Week 24
 Change from Baseline in the volume of T2 lesions at Week 24
 Number of Gd+ T1 lesions at Week 48
 Number of new Gd+ T1 lesions at Week 48
 Annualized relapse rate, based on protocol-defined qualified relapses, at Week 48 
 Qualified relapse-free status at Week 48 
 Change from Baseline in EDSS at Week 48
 Number of new or enlarging T2 lesions at Week 48
 Change from Baseline in the volume of Gd+ T1 lesions at Week 48
 Change from Baseline in the volume of T2 lesions at Week 48.
Exploratory endpoints: 
  
 Change in HRQoL as measured with SF-36v2 (physical component summary [PCS]/mental 
component summary [MCS] and sub-domains) over time (area under the curve) in all 
subjects
 Change in HRQoL as measured with SF-36v2 (PCS/MCS and sub-domains) from Baseline 
to Week 24 and from Baseline to Week 48 in all subjects
  
.
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Diagnosis and key inclusion and exclusion criteria: Male or female subjects aged 18 to 
65 years with RMS or secondary progressive MS (SPMS) with superimposed relapses. 
Subjects should have 1 or more documented relapses within the 2 years before Screening, with 
either 1 relapse occurring within the year before randomization or the presence of at least 1 
gadolinium-positive T1 lesion within 6 months prior to randomization. The subject should also
have an EDSS score of 0 to 6.
Subjects will be excluded if they are diagnosed with primary progressive MS or SPMS without 
evidence of relapse. Subjects who have a disease duration > 15 years and an EDSS ≤ 2. 
Subjects will be excluded if they have received treatment with: ritixumab, ocrelizumab, 
mitoxantrone, or lymphocyte-depleting therapies (eg, alemtuzumab, cladribine, 
cyclophosphamide, total body irradiation, bone marrow transplantation) within 48 weeks prior 
to randomization; lymphocyte trafficking blockers within 24 weeks prior to randomization (eg, 
natalizumab, fingolimod); intravenous (IV) Ig, plasmapheresis, and immunosuppressive 
treatments within the 4 weeks prior to randomization; glatiramer acetate and B-interferons 
within 4 weeks prior to randomization; systemic glucocorticoids within 4 weeks prior to 
randomization; treatment with teriflunomide or daclizumab within 12 weeks prior to 
randomization; had exposure to Tecfidera within 6 months prior to randomization; has any 
allergy, contraindication, or inability to tolerate Tecfidera; or has not been on a stable dose of 
dalfampridine for ≥ 30 days prior to Screening. Subjects will also be excluded if they have a 
history of splenectomy; any major surgery within 2 months prior to Screening; history of 
myocardial infarction or cerebrovascular event within 6 months prior to Screening; current 
active angina pectoris, symptomatic heart failure, uncontrolled seizures, untreated 
hypertension, gastrointestinal (GI) bleeding; a history of attempted suicide within the last 
6 months prior to Screening; an episode of major depression within the last 6 months prior to 
Screening; significant cytopenia; or any other significant active medical condition in the 
Investigator’s opinion.
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Investigational Medicinal Product: dose/mode of administration/ dosing schedule:
M2951 (25 mg tablets) will be administered orally daily for 48 weeks as needed based on the 
dose (eg, 3 × 25 mg tablets for a 75 mg dose). Dosing will be either 25 mg once daily, 75 mg 
once daily, or 75 mg twice daily. Matched placebo tablets will be provided.  
Reference therapy: dose/mode of administration/dosing schedule: Tecfidera (120 or 
240 mg hard capsules) will be used as an active control. For the first 7 days, Tecfidera is 
administered orally at 120 mg twice daily. Following this and for the duration of treatment, 
Tecfidera is administered orally at 240 mg twice daily orally. Detailed recommendations for 
the use of this product are described in the summary of product characteristics or prescribing 
information.
Planned trial and treatment duration per subject: Total duration of subject participation is 
 approximately 392 days (56 weeks) for subjects who do not participate in the 
optional OLE Period. Total duration includes:
 Screening: 28 days (4 weeks)
 Treatment: 168 days (24 weeks)
 Blinded treatment extension: 168 days (24 weeks)
 Tecfidera Washout for subjects who were in Tecfidera arm: 4 to 8 weeks

 4-week Safety Follow-Up/End of Trial Visit: 28 days (4 weeks).
 
.
Statistical methods:
A per-group sample size of 44 evaluable subjects provides 85% power to detect a decrease of 
90% in the total number of gadolinium-enhancing T1 lesions, summed over scans at Week 12, 
16, 20, and 24, between a given M2951 group versus placebo at the 2-sided 5% level, using 
the Wilcoxon rank-sum test, where the p-value is evaluated using a continuity-corrected normal 
approximation to the test statistic. 
Eligible subjects will be randomized 1:1:1:1:1 to treatment with placebo, low-dose M2951 
(25 mg once daily), mid-dose M2951 (75 mg once daily), high-dose M2951 (75 mg twice 
daily), or Tecfidera (administered twice daily at a final dose of 240 mg), through a central 
randomization process by an Interactive Web Response System (IWRS), stratified according 
to region (USA or Western Europe, Eastern Europe and , Eastern Europe and 
not , Rest of World). Approximately 50 subjects will be randomized per group 
to protect against a loss of information due to a 12% drop-out rate over 1 year.
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There will be 3 analyses: (1) a primary analysis, triggered when 100% of subjects enrolled 
reach Week 24 of treatment, or prematurely discontinue from treatment; (2) a Week 52 
analysis, triggered when 100% of subjects enrolled either reach Week 52 (4-week Safety 
Follow-up Visit) and complete the study, enroll in the OLE, or prematurely discontinue from 
study; and  
The Family-wise Type I error rate (FWER) at the primary analysis, due to multiple 
comparisons of M2951 dose to placebo based on the primary endpoint, will be controlled at 
the 2-sided 0.05 significance level using the Hochberg procedure.
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Primary Endpoint
The primary analysis of total number of Gd+ T1 lesions, Week 12, 16, 20, and 24, will be an 
estimate of lesion rate ratio, together with associated 95% confidence interval (CI) and p-value, 
comparing each M2951 dose group to placebo, based on a negative binomial (NB) model, 
where the offset will be based on the log of number of scans, with M2951 dose or placebo 
group as a factor, and adjustment for covariates based on randomization strata and baseline 
MRI activity. Other covariates may be considered. Should the model fail to converge, the 
primary analysis will be an estimate of the shift in location of the distribution of total number 
of Gd+ T1 lesions via the Hodges-Lehman estimate, together with associated 95% CI and 
p-value based on the stratified Wilcoxon rank-sum test, comparing each M2951 dose group to 
placebo. Descriptive statistics for the total number of Gd+ T1 lesions, Week 12, 16, 20, and 
24, will be provided for each treatment group. The primary analysis will be based on only the 
M2951 dose groups and placebo group.
Other Efficacy Endpoints, Baseline to 24 weeks:
The comparison of a M2951 treatment group to placebo group using ARR at Week 24 will be 
based on the rate ratio estimated from an NB model for qualified relapse count, with offset 
equal to the log of years on study, with M2951 dose group or placebo group as a factor, and 
adjustment for covariates based on randomization strata and pre-baseline relapse activity. The 
comparison of a M2951 treatment group to placebo group using proportion qualified
relapse-free at Week 24 will be based on the odds ratio estimated from a logistic model for the 
odds of a subject being qualified relapse-free, where subjects who discontinue prior to Week 24
without having a qualified relapse are counted as not being qualified relapse-free at Week 24, 
with M2951 dose group or placebo group as a factor, and adjustment for covariates based on 
randomization strata and pre-baseline relapse activity. The comparison of a M2951 treatment 
group to placebo group using change from Baseline in EDSS at Week 24 will be based on a
stratified Wilcoxon rank-sum test, with strata defined by baseline EDSS and randomization 
strata. The analysis of change from Baseline in volume of Gd+ T1 lesions at Week 24, and 
change from Baseline in volume of T2 lesions at Week 24, will be based on an analysis of 
covariance (ANCOVA) model of the appropriately transformed variable, with M2951 dose 
group or placebo group as a factor, randomization strata as a factor and baseline MRI activity 
as a covariate. The comparison of a M2951 treatment group to placebo using total number of 
new Gd+ T1 lesions, or total number of new or enlarging T2 lesions, at Week 12, 16, 20, and 
24, will be based on an NB model, similar to that used for the primary analysis. Estimation of 
mean per-scan number of Gd+ T1 lesions, at Weeks 12, 16, 20, and 24, for each treatment 
group, will be based on the NB model. In the analysis of each secondary endpoint, other 
covariates may be included in the model.
Descriptive statistics for MRI and clinical endpoints, Baseline to Week 24, will be provided 
for the M2951 dose arms, the placebo arm, and the Tecfidera arm. No inferential analyses 
comparing the Tecfidera group to any other treatment group will be conducted. 
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Other Efficacy Endpoints, Baseline to 48 weeks:
Descriptive statistics for MRI and clinical endpoints, Baseline to Week 48, will be provided 
for the M2951 dose arms, the placebo/M2951 arm, and the Tecfidera arm.
The number of Gd+ T1 lesions, number of new Gd+ T1 lesions, number of new and enlarging 
T2 lesions, the observed and change from Baseline values of Gd+ T1 lesion volume, and 
observed and change from Baseline values of T2 lesion volume, will be summarized by 
treatment group (placebo, 3 M2951 dose groups, and Tecfidera) and time point over the 
treatment period.
Annualized relapse rate from Baseline to Week 24, from Week 24 to Week 48, and from 
Baseline to Week 48 will be summarized by treatment group. Qualifying relapse-free status at 
Week 24 and at Week 48 will be summarized by treatment group. Observed and change from 
Baseline values of EDSS will be summarized by treatment group and time point over the 
treatment period.
Safety
Safety data for all treatment groups (M2951 dose groups, placebo group, Tecfidera group) will 
be listed and summarized using descriptive statistics.
Patient-reported HRQoL
HRQoL data for all treatment groups and time points will be summarized using descriptive 
statistics. Change in HRQoL for PCS/MCS and sub-domains over time (area under the curve) 
will be compared between M2951 treatment arms and placebo.
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Table 1 Schedule of Assessments: Screening and Treatment period (All Subjects), End of Trial (Subjects Not 
Entering OLE Period)
Activity/
Assessment S
c
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g
On Treatment Visits U
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s
c
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e
d
u
le
d
 
V
is
it
E
n
d
 o
f 
T
re
a
tm
e
n
t
V
is
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E
n
d
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f 
T
ri
a
l 
V
is
it
Visit number 1 2 3 4 4.1 5 5.1 6 6.1 7 7.1 8 8.1 8.2 8.3 8.4 8.5 9 9.1 9.2 9.4 10 11
Study Week
D
1
W
4
W
8
W
10
W
12
W
14
W
16
W
18
W
20
W
22
W
24
W
26
W
28
W
30
W
32
W
34
W
36
W
38
W
40
W
44
W
48
W
52
Study Day ±
Visit Window
-28 
to -1
1
28
±3
56
±3
70
±3
84
±3
98
±3
112
±3
126
±3
140
±3
154
±3
168
±3
182
±3
196
±3
210
±3
224
±3
238
±3
252
±3
266
±3
280
±3
308
±3
336
±3
364
±5
Obtain ICFa X Xb
Inclusion / 
Exclusion 
criteria
X X
Medical history 
/demographics
X
MS history X
Physical 
examination
X Xc X Xc Xc Xc X Xc Xc Xc Xc Xc Xc Xc Xc X
Vital signsd X X X X X X X X X X X X
Neurological 
examination
X X X X X X X X X X X X
Quantiferon 
tuberculosis 
test, viral 
serology 
testinge
X
Randomizationf X
Hematologyg X X X X X X X X X X X
Clinical 
chemistryg
X X X X X X X X X X X
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Visit number 1 2 3 4 4.1 5 5.1 6 6.1 7 7.1 8 8.1 8.2 8.3 8.4 8.5 9 9.1 9.2 9.4 10 11
Study Week
D
1
W
4
W
8
W
10
W
12
W
14
W
16
W
18
W
20
W
22
W
24
W
26
W
28
W
30
W
32
W
34
W
36
W
38
W
40
W
44
W
48
W
52
Study Day ±
Visit Window
-28 
to -1
1
28
±3
56
±3
70
±3
84
±3
98
±3
112
±3
126
±3
140
±3
154
±3
168
±3
182
±3
196
±3
210
±3
224
±3
238
±3
252
±3
266
±3
280
±3
308
±3
336
±3
364
±5
Supplemental 
Safety Visits 
including LFTs 
h
X X X X X X X X X X X X X X X X X X X X
Immunoglobulin 
levelsi
X X X X X
Urinalysis 
(microscopy, 
urine protein/ 
creatinine ratio)j
X X X X X X
Coagulation 
(INR, PTT)
X X
B,  
cell countk
X X X X X X
Serum 
pregnancy testl
X
Urine 
pregnancy test 
(all countries)l
X X X X X X X Xm Xm X Xm Xm X X
12-lead ECGn X X X X
Chest X-rayn X
EDSS X X X X X X X
Relapse 
assessment
X X X X X X X X X X
MRI scan Xo X X X X X
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V
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Visit number 1 2 3 4 4.1 5 5.1 6 6.1 7 7.1 8 8.1 8.2 8.3 8.4 8.5 9 9.1 9.2 9.4 10 11
Study Week
D
1
W
4
W
8
W
10
W
12
W
14
W
16
W
18
W
20
W
22
W
24
W
26
W
28
W
30
W
32
W
34
W
36
W
38
W
40
W
44
W
48
W
52
Study Day ±
Visit Window
-28 
to -1
1
28
±3
56
±3
70
±3
84
±3
98
±3
112
±3
126
±3
140
±3
154
±3
168
±3
182
±3
196
±3
210
±3
224
±3
238
±3
252
±3
266
±3
280
±3
308
±3
336
±3
364
±5
Concomitant 
medications 
and procedures
X X X X X X X X X X X X X X X X X X X X X X X X
AE evaluation X X X X X X X X X X X X X X X X X X X X X X X X
Dispense IMPp X X X X X X X X
IMP 
Administration
Oral Administration
IMP 
compliance
X X X X X X X X
PK samplingq X X X Xr X Xr X Xr Xr X Xr Xr Xr Xr Xr Xr Xr Xr Xr
BTK occupancy 
samplings
X X X X
Gene 
expression 
analysist
X X X X X
HRQoLu X X X X X X X X X X
C-SSRS
(Screening 
Scale)
X
ESR, hsCRP, 
and fibrinogenw
X
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AE=adverse event, , CMV=cytomegalovirus, C-SSRS=Columbia-Suicide Severity Rating Scale, CXR=chest X-
ray,ECG=electrocardiogram, eCRF=electronic case report form, EDSS=expanded disability status scale, ESR=erythrocyte sedimentation rate, 
FSH=follicle-stimulating hormone, HBsAg=hepatitis B surface antigen, HBV=hepatitis B virus, HCV=hepatitis C virus, HIV=human immunodeficiency virus, 
HRQoL=health-related quality of life, hsCRP=high sensitivity C-reactive protein, ICF=informed consent form, IDMC=independent data monitoring committee, 
Ig=immunoglobulin, IMP=investigational medicinal product, INR=international normalized ratio, MRI=magnetic resonance imaging, MS=multiple sclerosis, 
, OLE=Open-label Extension, , PTT=partial thromboplastin time, SF-36v2=Short Form 36-item Health Status Survey version 
2.0.
a. Informed consent must be obtained at the Screening visit prior to initiating any Screening procedures or collecting any data. An addendum ICF must be 
obtained following the IDMC recommendation (October 2017).
b.  
c. An additional physical examination may be performed at the additional safety visits (eg, 4.1, 5.1) at the Investigator’s discretion.
d. Vital signs are assessed predose. Height is measured at Screening only.
e. Blood samples for tuberculosis (Quantiferon) testing will be obtained at Screening. Additional samples should be taken for viral serology testing at Screening: 
HBV antibodies, HBsAg, and HCV antibodies. HIV testing will be done at Screening only where required as per local regulations. 
f. Randomization should occur on Day 1 after all Screening procedures have been completed; subject eligibility must be reviewed again and confirmed at the 
site on Day 1 prior to randomization. 
g. Blood samples for hematology and chemistry (Table 7) to be obtained at Screening, predose at all Visits when collected except Day 1. 
h. For subjects in the placebo/M2951 arms, supplemental LFT monitoring (Table 7) will be conducted, and additional  samples drawn.
i. Samples for total Ig levels (IgM, IgA, IgG) will be obtained predose (see Section 7.4.5).
j. Urine samples for urinalysis will be obtained at Screening, predose at Weeks 12, 24, 48, and 52. If local urinalysis by dipstick is abnormal, urine microscopy 
should be performed by a central laboratory. If at least 1+ protein is detected, urine protein/creatinine ratio should be determined.
k. Blood samples for B,  cell numbers and B,  cell subclasses will be obtained predose. An additional sample will be collected at the 4-week 
Safety Follow-up/End of Trial Visit (see Sections 7.4.6 and 7.6.3). 
l. Serum pregnancy test collected at Screening, and urine tests collected predose at every monthly trial visit, for women of childbearing potential only. Urine 
pregnancy tests will also be performed at home/site at Weeks 28, 32, 40, and 44 for women of childbearing potential randomized to the M2951/placebo arm. If 
necessary to confirm postmenopausal status, FSH testing will be done at Screening in postmenopausal women.
m. Phone calls: To be done only if urine pregnancy test is completed at home. Subjects will be supplied with at-home test kits. The Principal Investigator and/or 
delegated site staff will call subject at Weeks 28, 32, 40, and 44 to confirm completion of home pregnancy testing and discuss results.
n. ECG and posteroanterior CXR performed at Screening. Subjects who have previously had a CXR for clinical reasons within 3 months prior to Day 1 do not 
need to have the CXR repeated if the results are available and show no sign of active infective process or any other clinically significant abnormalities. ECGs 
will also be conducted at Weeks 24 and 48.
o. The Screening MRI scan should be acquired before randomization and dosing to allow for the readouts to be read by the central MRI reader (approximately 
7 days).
p. The IMP will be dispensed after randomization on Day 1 and at the indicated visits thereafter. All remaining IMP will be collected on Week 48. 
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w. All subjects in the study, regardless of their liver function status, should have at least 1 test during the study period for ESR, hsCRP, and fibrinogen. This test 
may be conducted from a sample at any study visit.
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2 Sponsor, Investigators and Trial Administrative Structure
This clinical trial will be sponsored by:
 EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts, USA.
 Merck KGaA, Darmstadt, Germany in countries outside the USA.
The trial will be conducted at approximately 64 sites in Western and Eastern Europe, in USA, and 
rest of the world (RoW).  
.
The Coordinating Investigator,  
, represents all Investigators for decisions and discussions regarding this trial, 
consistent with the International Council for Harmonisation (ICH) Topic E6 Good Clinical 
Practice (GCP; hereafter referred to as ICH GCP). The Coordinating Investigator will provide
expert medical input and advice relating to trial design and execution and is responsible for the 
review and signoff of the clinical trial report.
Signature pages for the Protocol Lead and the Coordinating Investigator as well as a list of Sponsor 
responsible persons are in Appendix I.
The trial will appear in the following clinical trial registries: ClinicalTrials.Gov and EUDRACT.
The Sponsor will enlist the support of a contract research organization (CRO), to conduct the 
clinical part of the trial including trial set-up, operation of an Interactive Web Response System 
(IWRS) for randomization, coordination, monitoring, medical oversight, data capture, data 
management, statistical analysis, and clinical trial reporting. The Sponsor will also make use of 
the CRO’s central laboratory for sample analyses, storage, and shipment to specialized 
bioanalytical laboratories. The Sponsor will supervise all outsourced activities.
An independent data monitoring committee (IDMC) will be responsible for safety monitoring until 
the last randomized subject completes the blinded phase. The IDMC will consist of at least the 
following core members: 2 clinicians and 1 biostatistician. The full list of IDMC members and 
responsibilities will be included in the IDMC charter. After the blinded phase, a switch to an 
internally convened Safety Monitoring Committee (SMC) will be considered. The SMC will 
consist of at least the following members: Sponsor and CRO medical advisor, Sponsor 
biostatistician, Sponsor Drug Safety Physician, Sponsor Clinical Pharmacology representative and 
Coordinating Investigator. An SMC charter will be provided once the transition from the IDMC 
has been completed.
The CRO will also provide a qualified neurologist who will adjudicate the relapses (to confirm 
qualified relapse) and systematically review the EDSS to determine if there is lack of 
efficacy/disease progression. The scope of this review will be described in detail in the Medical 
Monitoring Plan.
Investigational medicinal product (IMP) will be supplied by the Clinical Trial Supply Department 
at Merck, except Tecfidera for the USA. In the USA Tecfidera will be sourced locally by the 
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clinical trial sites. IMP supplied by the Clinical Trial Supply Department at Merck will be 
packaged and labeled by a designated contract manufacturing organization.
Details of structures and associated procedures will be defined in a separate Manual of Operations, 
which will be prepared under the supervision of the clinical trial leader.
3 Background Information
Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central nervous 
system and the most common cause of serious neurological disability in young adults. 
Approximately 85% of patients with MS initially present with relapsing MS (RMS), which is 
characterized by periodic acute exacerbations of disease activity (multifocal inflammatory lesion, 
relapses) and periods of remission, consisting of partial or complete recovery. With recurring 
relapses, disability tends to accumulate (1).
Currently there is no cure for MS, but the course of the disease can be altered favorably with 
disease-modifying drugs (DMDs) with varying levels of efficacy, and distinct safety and 
tolerability profiles. Most active RMS patients initiate treatment with an interferon-beta or 
glatiramer acetate (Copaxone®) therapy. Tecfidera has recently been added as a first-line therapy 
and is the most prescribed first-line therapy in an oral formulation. If responding suboptimally, 
patients can be treated with an alternative, second-line therapy such as fingolimod (Gilenya®) or 
natalizumab (Tysabri®). Generally, DMDs perceived to be more efficacious have also been shown 
to be associated with more significant adverse effects, ranging from serious infections (ie, 
progressive multifocal leukoencephalopathy [PML]) to autoimmunity and cancer. Switching 
among these DMDs occurs primarily due to perceived lack of efficacy or the occurrence of adverse 
events (AEs), as well as individual patient preferences.
Despite the recent approvals of newer therapies for the treatment of MS, there remains an unmet 
need for highly effective and well-tolerated therapies for patients with RMS at all stages of the 
disease. Early treatment with a highly efficacious, but safe DMD could be extremely advantageous 
for long-term quality of life for MS patients and might slow the process of brain atrophy, which 
accompanies axonal damage and loss in grey and white matter. An oral and safe solution for the 
treatment of MS patients with high disease activity would be an attractive treatment choice for 
patients switching therapy. Using the USA as an example, we assume that there are approximately
20,000 new MS patients (naïve = 8%) per year, and 60,000 patients (24%) that are switching 
therapy per year. If the efficacy and safety profile for evobrutinib (also referred to as M2951) are 
as predicted with a favorable benefit to risk profile, it could be utilized throughout the course of 
the disease (early, mid and late stage) – capturing naïve and early switch patients.
M2951 is an oral, highly selective, irreversible inhibitor of Bruton’s Tyrosine kinase (BTK) in 
development for the treatment of autoimmune and inflammatory diseases, including rheumatoid 
arthritis (RA), systemic lupus erythematosus (SLE) and MS. BTK mediates signaling through the 
B cell receptor and has been described downstream of several other receptors, including Fc 
receptor, Toll Like Receptor (TLR) and Integrin receptors, expressed in innate immune cells. 
Inhibition of BTK blocks both B cell function and innate immune activation and may therefore 
offer advantages over B cell-only directed therapies.
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BTK is a clinically validated target in oncology and although BTKi competitor companies are 
planning for point-of-care in several inflammatory indications including pemphigus/bullous
pemphigoid and rheumatoid arthritis (RA), none of them is currently preparing for the MS 
indication. M2951 has a superior kinase selectivity profile vs. ibrutinib and spebrutinib which may 
translate into a clinically relevant safety advantage.
Robust, high-efficacy clinical proof of concept was recently demonstrated with B cell depleting
anti-CD20 therapies in Phase II and Phase III clinical trials in RMS and progressive MS (2-5).
Ocrelizumab inhibited the formation of new inflammatory magnetic resonance imaging (MRI)
lesions up to 90% (Hauser, 2008) in Phase II RMS trials and high efficacy on MRI (-94%), 
annualized relapse rate (ARR) (-46%) and 6-month disease progression (-40%) was also reached 
in ORACLE Phase I, II, and III trials against interferon-β. Translational mechanism of action
studies in anti-CD20 treated RMS patients show diminished proliferation and proinflammatory 
differentiation of T cells (6), pointing towards abrogation of antigen presenting cell function as the 
primary mechanism. In addition to the role of anti-CD20 in B cell antigen presentation, a recent 
publication of Li et al (7) describes a diminished proinflammatory myeloid cell response in 
Ocrelizumab-treated MS subjects. M2951 shows inhibition of myeloid cell activation by immune 
complexes.
Anti-CD20 like efficacy is anticipated with BTK inhibition given the overlap on B cell-related 
activities of BTKi molecules in key in vitro assays targeting B cell antigen presentation, 
proliferation/differentiation, and cytokine production. Preclinical proof of concept with M2951 
has been demonstrated for systemic lupus erythematous/lupus nephritis, experimental autoimmune 
encephalomyelitis (EAE), RA and passive cutaneous anaphylaxis. Oral M2951 does not deplete 
B cells in the studies carried out to date and, upon withdrawal, restoration of immune function can 
be obtained in days vs. months with anti-CD20 therapies, should the need to interrupt or stop 
therapy arise. This suggests a more favorable benefit to risk profile for M2951 vs. anti-CD20 
therapies. In addition, BTKi might have broader efficacy than B cell depletion alone, due to the 
importance of BTK activation downstream of various receptors expressed in myeloid cells, 
suggesting a direct effect of M2951 on innate immune cell activation induced by immune 
complexes, cytokines/chemokines, or TLR activation (8-10). A direct myeloid silencing activity 
also best explains the significant reduction of clinical score, relapse rate, and time to first relapse 
in T cell-dependent EAE models, in which anti-CD20 antibodies do not work.
3.1 Trial Rationale
This study is designed to determine efficacy and safety of M2951 in patients with RMS, and to 
determine a dose to take forward into Phase III development.  
.
The findings in Section 3 clearly support the pathogenic contribution of B cells to MS damage. In 
contrast, a failed clinical trial with another B cell targeting agent, atacicept, supports the notion 
that certain B cell subtypes may mediate beneficial anti-inflammatory effects (11). Novel 
non-depleting B cell therapies may deliver a more favorable benefit-risk profile than current 
B cell-directed therapeutic approaches.
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Refer to the Investigator’s Brochure for further information about the nonclinical and clinical 
programs and Guidance for the Investigator.
3.2 Benefit-Risk
M2951 is being considered for the treatment of autoimmune diseases, including RA and SLE as 
well as MS. M2951 is the first agent with a mechanism of action that directly targets both B cells 
and myeloid cells, and it is reasonable to anticipate that M2951 may represent a significant advance 
in the treatment of MS and other autoimmune diseases.
No identified risks or new potential risks have emerged from clinical studies thus far. In the first 
in human study EMR200527-001, M2951 was well tolerated at single doses up to 500 mg and at 
multiple doses up to 200 mg for 14 days. In the completed Phase Ib study in subjects with SLE 
(Study EMR200527-002) M2951 was well tolerated. There were no SAEs reported during the 
study and no new safety signals were identified. Evidence of clinical benefit was not expected in 
this 4-week safety study.
Important potential risks to subjects are based on nonclinical safety data of M2951 and clinical 
data on adverse drug effects associated with compounds of a similar pharmacological class. They 
include infection, leukopenia, thrombocytopenia, hemorrhage, gastrointestinal intolerance, renal 
toxicity, hepatocellular injury, atrial fibrillation, drug-drug interactions, and embryo-fetal toxicity. 
Asymptomatic elevations in amylase and/or lipase have been observed in completed clinical 
studies of M2951. The clinical significance and risk status of these observations are being assessed. 
The Sponsor is also assessing the clinical significance of convulsions observed in dogs at very 
high levels of exposure. In view of the observation of asymptomatic elevated transaminases in a 
number of subjects randomized to M2951 or placebo in this study, the frequency of monitoring 
has been adapted to optimize timely implementation of the IMP withdrawal or holding criteria.
With the above modification to monitoring, risk minimization measures inherent to early phase 
clinical trials are considered adequate for the proposed clinical trial. The IDMC continually 
reviews available safety and tolerability data and is mandated to make immediate decisions 
regarding the conduct of the trial.
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The doses of M2951 (up to 150 mg daily) selected for the proposed trial are within the dose ranges 
studied in Trial EMR200527-001 in healthy volunteers and represent doses associated with high 
levels of target occupancy.
Noting the finding of asymptomatic increases in transaminases in subjects in this study, 
evobrutinib has generally been well tolerated and no new safety signals have been confirmed. No 
deaths have been reported in clinical trials of evobrutinib as of the release date of this Investigator’s 
Brochure. There is monitoring of liver function tests in ongoing clinical studies and assessment of 
amylase and lipase following adverse events (AE) of asymptomatic amylase or lipase elevation 
reported in healthy volunteers and subjects with SLE.
Refer to the current Investigator’s Brochure for more detailed results from the completed and 
ongoing clinical studies.
This clinical trial will be conducted in compliance with the clinical trial protocol, ICH GCP, and 
any additional applicable regulatory requirements. Based on the available nonclinical and clinical 
data to date and benefit-risk considerations, the conduct of the trial specified in this protocol is 
considered justifiable.
4 Trial Objectives
4.1 Primary Objective
The primary objective is to evaluate the efficacy and dose-response of M2951 on the number of 
gadolinium-positive (Gd+) T1 MRI lesions versus placebo after 24 weeks of treatment.
4.2 Secondary Objectives
The key secondary objectives are as follows:
 To evaluate the efficacy and dose-response of M2951 on clinical endpoints over 24 weeks 
versus placebo
 To evaluate the safety of M2951.
Additional secondary objectives are as follows:
 To evaluate the efficacy of M2951 on additional MRI parameters over 24 weeks versus placebo
 To evaluate the efficacy of M2951 on clinical and MRI endpoints from Week 24 to 48
 To evaluate the efficacy of Tecfidera on clinical and MRI endpoints over 24 weeks
 To evaluate the efficacy of Tecfidera on clinical and MRI endpoints from Week 24 to 48
 To evaluate the safety of Tecfidera.
4.3 Exploratory Objectives
The exploratory objectives are as follows:
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 To explore the benefit of M2951 treatment on patient-reported health-related quality of life 
(HRQoL) versus placebo, and to evaluate the effect of Tecfidera on HRQoL.
5 Investigational Plan
5.1 Overall Trial Design and Plan
This will be a randomized, double-blind, placebo-controlled study in subjects with RMS, with a 
parallel, open-label active control group (Tecfidera) involving 5 treatment groups with 3 doses of 
M2951, placebo, and active control (Tecfidera). The assessing Investigator and central MRI reader 
will be treatment blinded.
The study will consist of 4 major periods: (i) a Screening period of 4 weeks, (ii) active treatment 
with 3 dose groups of M2951, active control (Tecfidera), or placebo for 24 weeks, (iii) a 24-week 
extension on active treatment with M2951 or active control (Tecfidera) for 24 weeks, where 
subjects on placebo will be switched to M2951(Figure 1), and (iv) an optional OLE Period. At the 
end of the 48-week main study, subjects will be in 1 of 4 treatment groups (M2951 25 mg daily, 
75 mg once daily, or 75 mg twice daily or Tecfidera). 
 
 
 
ollowing completion or early termination of treatment, subjects will 
return after 4 weeks for safety evaluation. It is planned that placebo subjects will be switched to 
the 25 mg M2951 once daily dose after Week 24.
Approximately 50 subjects will be enrolled in each treatment group to obtain 44 evaluable subjects 
per group (total = approximately 250), assuming a 12% drop-out rate per year, and to compile an 
adequate safety database.
 
 
CCI
CCI
CCI
CCI
CCI
Evobrutinib (M2951) A Study of Efficacy and Safety of M2951 in Relapsing Multiple Sclerosis
MS200527-0086
36/106
Figure 1 Trial Design – Main Study
ARR=annualized relapse rate; BID=twice a day; EDSS=expanded disability status scale; EndPt=endpoint; 
Gd+=gadolinium-positive; QD=once a day MRI=magnetic resonance imaging.
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Detailed schedules of study procedures are provided in Table 1, and Table 2. The Tecfidera 
washout period is described in Table 4.
5.2 Discussion of Trial Design
5.2.1 Scientific Rationale for Trial Design
This trial is modeled after the ocrelizumab Phase II trial design (12). The first part of the study 
will compare M2951 versus placebo for the main study objective of evaluating M2951 efficacy 
and dose-response. It is becoming more difficult to perform placebo-controlled trials in MS due to 
the wide range of efficacious therapies. It is still however necessary to have placebo-controlled 
data to accurately measure the size of the treatment effect and assess safety. The number of subjects 
exposed to placebo (up to 50) and short duration (24 weeks) is acceptable. Furthermore, all placebo 
subjects will be switched to M2951 during the blinded treatment extension phase.
An active control group will also be enrolled. Tecfidera has been chosen as the control as it is the 
oral first-line therapy for RMS and has significant efficacy on early MRI endpoints. As it is very 
difficult to blind Tecfidera due to its specific safety profile, it will be administered in an open-label 
fashion.
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The second phase of the study, from Week 24 to 48, will be continued in a blinded fashion.
5.2.2 Justification for Dose
 
 
 
 
 
 
 
 
 
 
 
M2951, at a dose of 75 mg once daily, was used in the 4-week SLE study (Trial EMR200527-002: 
A Phase Ib Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, 
Tolerability, Pharmacokinetics and Biological Effect of MSC2364447C in Systemic Lupus 
Erythematosus). 
 
. Refer to the current Investigator’s Brochure for more 
detailed results from the completed clinical studies.
 
 
 
 
Finally, 1 lower dose (expected suboptimal therapeutic dose) should be chosen.  
From a safety perspective, the doses of M2951 (25 mg once daily, 75 mg once daily, 75 mg twice 
daily) selected for this trial are within the dose ranges studied in clinical trial EMR200527-001.
Single doses up to  were well tolerated in 
healthy volunteers and no safety signals were identified.
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The placebo group will be switched to M2951 25 mg once daily during the second part of the study 
from Week 24 to 48; however, flexibility will be maintained in deciding to use this dose or an 
alternative dose, based on data from the primary analyses.  
 
.
5.2.3 Rationale for Endpoints
The primary endpoint chosen is a standard one for RMS Phase II studies. For early treatment 
effects to be seen, MRI endpoints are used. The most sensitive is the total number of Gd+ T1 
lesions on MRI summed over scans at Weeks 12, 16, 20, and 24. MRIs will be carried out at 
Screening and every 4 weeks from Week 12 to 24. MRIs will also be carried out at Week 48 in the 
blinded treatment extension phase.
Other MRI measures will be used as secondary endpoints. These include the total number of new 
Gd+ T1 lesions, total number of new or enlarging T2 lesions, mean per-scan number of Gd+ T1 
lesions, Gd+ T1 lesion volume change from Baseline, and T2 lesion volume change from Baseline.
MRI measures alone may not predict final clinical outcome. Therefore, ARR will be assessed at 
Week 24 and Week 48 in the blinded treatment extension phase.
Other clinical endpoints will be measured including change from Baseline in Expanded Disability 
Status Scale (EDSS), qualifying relapse-free status, and patient-reported outcome measures.
The SF-36v2 is one of the most widely used generic patient-reported HRQoL instruments and has 
been applied in a number of MS studies. The SF-36v2 is an essential part of a number of other 
more comprehensive MS instruments like the MSQoL-54 or the MSQLI. The SF-36v2 is a 
multi-purpose, short-form health survey with only 36 questions. It yields an 8-scale profile of 
functional health and well-being scores as well as psychometrically-based physical and mental 
health summary (13).
5.2.4 Inclusion of Special Populations
Not applicable.
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5.3 Selection of Trial Population
Only subjects meeting all inclusion criteria and no exclusion criteria may be enrolled into the trial 
as subjects. Prior to performing any trial assessments not part of the subject’s routine medical care, 
the Investigator will ensure that the subject or the subject’s legal representative has provided 
written informed consent following the procedure described in Section 9.2.
Subjects who do not meet the inclusion/exclusion criteria within the first Screening period and are 
considered screen failures may undergo rescreening once after approval by the Medical Monitor. 
The second Screening period is a new 28-day Screening period, and the subject will receive a new 
identification number. All other testing is required to be redone at rescreening.
5.3.1 Inclusion Criteria
1. Subjects with a diagnosis of relapsing multiple sclerosis (may include subjects with 
Secondary PMS [SPMS] with superimposed relapses provided they meet the other criteria)
in accordance with revised McDonald criteria for MS (14, 15) and Lublin and Reingold 
(16).
2. Male or female aged 18 to 65 years
3. One or more documented relapses within the 2 years before Screening with either:
a) One relapse which occurred within the last year prior to randomization
or
b) the presence of at least 1 Gd+ T1 lesion within 6 months prior to randomization would 
make the patient eligible.
4. Expanded Disability Status Scale score of 0 to 6 at Baseline
5. Women of childbearing potential must use a supplementary barrier method together with 
a highly effective method of contraception (according to ICH guidance M3[R2]) for 
4 weeks prior to randomization, throughout the trial, and for 90 days after the last dose of 
IMP. For the purposes of this trial:
 Women are considered of childbearing potential unless they are postmenopausal. 
Females who are postmenopausal (age-related amenorrhea ≥ 12 consecutive months 
and increased follicle-stimulating hormone [FSH] > 40 mIU/mL) or who have 
undergone hysterectomy or bilateral oophorectomy are exempt from pregnancy 
testing. If necessary to confirm postmenopausal status, an FSH will be drawn at 
Screening.
 Highly effective contraception includes:
 Combined (estrogen and progestogen containing) hormonal contraception 
associated with inhibition of ovulation; oral, intravaginal or transdermal
 Progestogen-only hormonal contraception associated with inhibition of 
ovulation; oral, injectable or implantable
 Intrauterine device (IUD)
 Intrauterine hormone-releasing system (IUS)
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 Bilateral tubal occlusion
 Vasectomized partner
 Sexual abstinence
 Supplementary barrier methods include:
 Male or female condom with or without spermicide 
 Cap, diaphragm or sponge with spermicide
 Men must agree to use and have their female partners use a supplementary barrier 
method together with a highly effective contraceptive method as defined above for 
at least 90 days after the last IMP administration.
 Women of childbearing potential must have a negative serum pregnancy test at the 
Screening Visit and a negative urine pregnancy test at randomization on Day 1
before dosing.
6. Signed and dated informed consent (subject must be able to understand the informed 
consent) indicating that the subject has been informed of all the pertinent aspects of the 
trial prior to enrollment and will comply with the requirements of the protocol.
5.3.2 Exclusion Criteria
1. Progressive MS either Primary or Secondary if Secondary is without evidence of relapse.
2. Disease duration > 15 years (subject reported adequate in absence of written medical 
record) in subjects with EDSS of 2 or less.
3. Treatment with rituximab, ocrelizumab, mitoxantrone, or lymphocyte-depleting therapies 
(eg, alemtuzumab, anti-CD4, cladribine, cyclophosphamide, total body irradiation, bone 
marrow transplantation) which should not be used within 48 weeks prior to randomization.
4. Use of lymphocyte trafficking blockers (eg, natalizumab, fingolimod) within 24 weeks
prior to randomization.
5. Use of intravenous (IV) immunoglobulins (Ig), plasmapheresis, and immunosuppressive 
treatments within 4 weeks prior to randomization.
6. Treatment with B-interferons or glatiramer acetate within 4 weeks prior to randomization
7. Systemic glucocorticoids within 4 weeks prior to randomization
8. Treatment with teriflunomide within 12 weeks prior to randomization
9. Treatment with daclizumab within 12 weeks prior to randomization
10. Exposure to Tecfidera within 6 months prior to randomization
11. Any allergy, contraindication, or inability to tolerate Tecfidera
12. Treatment with dalfampridine (fampridine, Ampyra) unless on a stable dose for ≥ 30 days 
prior to randomization
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13. Inability to comply with MRI scanning, including contra-indications to MRI such as known 
allergy to gadolinium contrast media, claustrophobia, presence of a pacemaker, cochlear 
implants, ferromagnetic devices or clips, intracranial vascular clips, insulin pumps, nerve 
stimulators
14. Immunologic disorder other than MS, with the exception of secondary well-controlled 
diabetes or thyroid disorder, or any other condition requiring oral, IV, intramuscular, or 
intra-articular corticosteroid therapy
15. Vaccination with live or live-attenuated virus vaccine within 1 month prior to Screening
16. Severe drug allergy or history of anaphylaxis, or allergy to the IMP or any of its incipients
17. Active, clinically significant viral, bacterial, or fungal infection, or any major episode of 
infection requiring hospitalization or treatment with parenteral anti-infectives within 
4 weeks of Screening, or completion of oral anti-infectives within 2 weeks before or during 
Screening, or a history of recurrent infections (ie, 3 or more of the same type of infection 
in a 12-month rolling period). Vaginal candidiasis, onychomycosis, and genital or oral 
herpes simplex virus considered by the Investigator to be sufficiently controlled would not 
be exclusionary.
18. History of or positive testing for human immunodeficiency virus (HIV), hepatitis C (HCV) 
antibody and/or polymerase chain reaction, hepatitis B surface antigen (HBsAg) (+) and/or 
hepatitis B core total, and/or IgM antibody (+) at Screening. Testing for HIV will only be 
conducted where required as per local regulation.
19. The subject:
 Has a history of or current diagnosis of active tuberculosis (TB)
or
 Is currently undergoing treatment for latent TB infection (LTBI)
or
 Has an untreated LTBI as determined by documented results within 3 months of the 
Screening visit of a positive TB skin test with purified protein derivative with induration 
≥ 5 mm
or
 Has a positive QuantiFERON®-TB test at Screening. 
Subjects with documented completed appropriate LTBI treatment would not be excluded 
and are not required to be tested. 
20. Indeterminate QuantiFERON-TB tests may be repeated once, and will be considered 
positive if retest results are positive or indeterminate.
21. Subjects with current household contacts with active TB will also be excluded
22. History of splenectomy at any time, or any major surgery within 2 months prior to 
Screening
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23. History of myocardial infarction or cerebrovascular event within 6 months prior to 
Screening, or current active angina pectoris, symptomatic heart failure, uncontrolled 
seizures, untreated hypertension, GI bleeding, or any other significant active medical 
condition in the Investigator’s opinion.
24. A history of attempted suicide within 6 months prior to Screening or a positive response to 
items 4 or 5 of Columbia-Suicide Severity Rating Scale (C-SSRS).
25. An episode of major depression within the last 6 months prior to Screening (clinically 
stable minor depression is not exclusionary).
26. On anticoagulation, fish oil supplements, or antiplatelet therapy other than daily aspirin for 
cardioprotection and treatment of Tecfidera induced flushing.
27. History of cancer, except adequately treated basal cell or squamous cell carcinoma of the 
skin (no more than 3 lesions requiring treatment in lifetime) or carcinoma in situ/cervical 
intraepithelial neoplasia of the uterine cervix, unless considered cured ≥ 5 years.
28. Breastfeeding/lactating or pregnant women
29. Participation in any investigational drug trial within 1 month or 5 half-lives of the 
investigational drug, whichever is longest, prior to Screening.
30. Subjects currently receiving (or unable to stop using prior to receiving the first dose of 
IMP) medications or herbal supplements known to be potent inhibitors of 
cytochrome P450 3A (CYP3A) (must stop at least 1 week prior), potent inducers of 
CYP3A (must stop at least 3 weeks prior), or drugs mainly metabolized by CYP3A with a 
narrow therapeutic index (must stop at least 1 day prior).
31. History of or current alcohol or substance abuse
 Excessive alcohol use is defined as alcohol and/or substance abuse or dependence 
(as defined by the Diagnostic and Statistical Manual of Mental Disorders, 
5th edition) in the past year or a history of alcohol or substance abuse, as determined 
by the Investigator.
32. Clinically significant abnormality on electrocardiogram (ECG), or an active infective 
process or any other clinically significant abnormality on Screening chest X-ray (CXR) 
taken within 4 weeks of the first dose, per Investigator opinion. If a CXR has been taken 
within the previous 3 months and results are available and normal, the CXR does not need 
to be carried out.
33. Estimated glomerular filtration rate (eGFR) by the 4-variable Modification of Diet in Renal 
Disease equation of < 45 mL/min/1.73 m2 or any renal condition that would preclude the 
administration of gadolinium (eg, acute renal insufficiency).
34. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), amylase, or lipase 
> 2× above upper limit of normal (ULN) of laboratory reference range, total bilirubin 
> 1.5× ULN, any other clinically significant laboratory abnormality.
35. B cell (CD19) count < 50% of the lower limit of normal at Screening
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36. Significant cytopenia, including neutrophil count < 1,500/mm3, platelet count 
< 75,000/mm3, absolute lymphocyte count < 800/mm3, or a white blood cell count
< 3500/mm3
 
 
5.4 Criteria for Randomization and Initiation of Trial Treatment
Randomization should occur on Day 1 after all Screening procedures have been completed; subject 
eligibility must be reviewed again and confirmed at the site on Day 1 prior to randomization. If a 
subject does not meet eligibility criteria, the subject can be retested and rescreened once after the 
approval of the Medical Monitor as described in Section 5.3.
Eligible subjects will be randomized to treatment with M2951 (25 mg once daily, 75 mg once 
daily, or 75 mg twice daily), Tecfidera, or placebo through a central randomization process by an
IWRS. Stratification will occur by region (USA or Western Europe, Eastern Europe and  
, Eastern Europe and not , and RoW). 
5.5  
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5.6 Criteria for Subject Withdrawal
Subjects will be informed that they have the right to withdraw from the trial at any time, without 
prejudice to their medical care, and they are not obliged to state a reason for withdrawing. Any 
withdrawal must be fully documented in the electronic case report form (eCRF) and source 
documents, and should be followed up by the Investigator.
The Investigator may withdraw a subject at any time if this is considered to be in the subject’s best 
interest.
5.6.1 Withdrawal from Trial Therapy
Subjects who withdraw from therapy (during the 48-week main study or OLE Period) must 
immediately return for an End of Treatment Visit or an OLE End of Treatment Visit followed by 
the 4-week Safety Follow-Up/End of Trial Visit 4 weeks later (see Section 7.1.5 and 7.1.6). A 
subject must be withdrawn if any of the following occur:
 Withdrawn from study (see Section 5.6.2)
 Adverse events, if discontinuation of IMP is desired or considered necessary by the Investigator 
and/or subject
 Use of prohibited medications, as defined in Section 6.4.2. However, any medications that are 
considered necessary for the subject’s well-being may be given at the discretion of the 
Investigator. Use of a prohibited medication may be cause for a subject to withdraw, however 
each incident should be discussed on a case-by-case basis with the study and Medical Monitor.
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 Pregnancy
 Lack of efficacy and/or progression of MS as defined by Investigator judgment or when a 
medication other than protocol-allowed medications is needed for treatment.
 Any events that unacceptably endanger the safety of the subject
 IMP will be discontinued in case of elevated liver tests as defined in protocol Section 6.4.4.
 If any of the following occur while a subject is receiving Tecfidera (17, 18)
 Any instance of lymphocyte counts < 200/mm3 or < 500/mm3 for > 24 weeks
 In the event of serious infection, Tecfidera should be withheld until the infection is resolved
 At the first sign or symptom suggestive of PML
 More than 1 instance of dose reduction due to a flushing reaction (see Section 6.4.4 or the 
local label [17, 18]) and GI disturbances.
Withdrawal due to special precautions is described in Section 6.4.4.
5.6.2 Withdrawal from the Trial
Subjects may withdraw from the trial at any time without giving a reason. Withdrawal of consent 
will be considered withdrawal from the trial. Subjects who withdraw from the trial while still on 
the IMP should return immediately for an End of Treatment Visit upon discontinuation of the IMP 
and a Safety Follow-Up/End of Trial Visit 4 weeks after the last administered dose of IMP. 
Subjects who withdraw and are no longer on the IMP must complete the 4-week Safety 
Follow-up/End of Trial Visit assessments described in Section 7.1.8. 
A subject must be withdrawn if any of the following occur during the trial:
 Pregnancy (for further details in case of pregnancy, see Section 7.4.2)
 Subject withdrew consent
 Participation in another clinical trial
 Lost to follow-up
 Any events that endanger the safety of the subject.
 Sponsor decision to end clinical trial.
If a subject fails to return for the post-treatment safety visit, all attempts should be made to contact 
the subject to ensure the reason for not returning is not an AE. Likewise, if a subject wishes to 
discontinue from the trial (eg, for personal reasons), attempts should be made to establish the true 
reason is not an AE (bearing in mind the subject is not obliged to state the reasons).
If IMP is prematurely discontinued, the primary reason for discontinuation must be recorded in 
the appropriate section of the eCRF, and all efforts will be made to complete and report the 
observations as thoroughly as possible. A complete final evaluation at the time of the subject's 
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withdrawal should be made and any AEs followed up until resolution or a period of 30 days after 
the last Safety Visit (or withdrawal from the trial).
If a subject has failed to attend scheduled trial assessments, the Investigator must determine the 
reasons and the circumstances as completely and accurately as possible.
Subjects who have withdrawn after randomization (eg, due to AEs or lack of efficacy) will not be 
replaced and will not be eligible to participate in the OLE Period.
Subjects who are 
withdrawn from the trial will not be allowed to re-enroll in the trial.
Participation in any other trial during the duration of this trial (including the OLE Period) will not 
be allowed.
At least 3 attempts to contact lost to follow-up subjects should be made and documented (2 phone 
calls and 1 acknowledgement of receipt letter).
5.7 Premature Termination of the Trial
The clinical trial may be terminated prematurely or suspended at the request of Health Authorities 
or if new safety or efficacy information leads to an unfavorable risk benefit judgment for any IMP.
The Sponsor may discontinue the trial if the trial becomes unjustifiable for medical or ethical 
reasons, the trial experiences poor enrollment, or due to discontinuation of clinical development 
of an IMP or withdrawal of an IMP or comparator from the market for safety reasons.
Health Authorities and Independent Ethics Committees (IECs)/Institutional Review Boards (IRBs)
will be informed about the discontinuation of the trial in accordance with applicable regulations.
5.8 Definition of End of Trial
The end of the trial is defined as the last contact date with the last subject who participates in this 
trial (last subject’s last visit).
A clinical trial protocol may not be considered closed as long as:
 Any subject is still receiving any IMP
 Visits specified by the protocol are still taking place
 Procedures or interventions according to the protocol are still being undertaken in any subject
 The post-treatment follow-up period, defined in the clinical trial protocol as being part of the 
trial, has not yet been completed for any subject.
6 Investigational Medicinal Product and Other Drugs Used in 
the Trial
The term “Investigational Medicinal Product” refers to the investigational drug undergoing study 
(ie, M2951), the placebo and the reference therapy, Tecfidera.
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6.1 Description of the Investigational Medicinal Product
Investigational Medicinal Product M2951 and placebo: dose/mode of administration/ dosing 
schedule:
The drug substance M2951, chemical name 1-(4-{[6-Amino-5-(4-phenoxy-phenyl)-pyrimidin-4-
ylamino]-methyl}-piperidin-1-yl)-propenone, is a white to yellow powder.
M2951 will be administered as white tablets ready for oral administration containing 25 mg of 
drug substance formulated with excipients. The placebo will be administered as white tablets ready 
for oral administration matching the active both in color and in size.
The Sponsor will provide M2951 and placebo to the trial site, manufactured and tested according 
to applicable current Good Manufacturing Practice (GMP) requirements for clinical trial supplies 
and a confirmation of release for human use in clinical trials.
Reference therapy Tecfidera: dose/mode of administration/dosing schedule (17, 18): 
The active control group will receive Tecfidera. For the first 7 days, Tecfidera is given 120 mg
twice daily orally. Following this, and for the duration of treatment, it is given 240 mg twice daily 
orally. For sites in the European Union (EU), Tecfidera will be centrally sourced and provided by 
the Sponsor. For sites in the USA, Tecfidera will be locally sourced at each trial site according to 
local regulations. Tecfidera should be administered according to the local label and applicable 
regulations.
6.2 Dosage and Administration
Subjects will receive 25 mg once daily, 75 mg once daily, or 75 mg twice daily M2951 or placebo 
administered as tablets for 168 days. To maintain blinding for placebo and M2951 (see 
Section 6.9), subjects will self-administer study medication at a schedule similar to the 75 mg 
M2951 twice daily dosing schedule (ie, 3 tablets twice daily). At the end of the 24-week treatment 
period, it is intended to switch the placebo group to M2951 at a dose of 25 mg once daily; however, 
flexibility will be maintained to allow adjusting this dose based on data from the primary analysis.
 
Subjects will self-administer the IMP at a set time each day (every 12 hours ± 2 hours). Subjects 
must take their daily dose more than 1 hour prior to a meal or snack and more than 2 hours after a 
meal or snack. Clear fluids are allowed at any time. On trial visit days, the IMP will be 
administered during the trial visit after the scheduled trial visit procedures (other than 
post-treatment ) are completed.
If a dose is missed, the subject can take the missed dose up to 6 hours after the scheduled time. If 
more than 6 hours have elapsed since the dose was missed, the subject should skip the dose for 
that period, make note of the missed dose, and take the next dose at the regularly scheduled time.
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When  visits are scheduled to occur (see Section 7.5) the subject should refrain from taking 
their scheduled morning dose and take their dose of IMP when instructed at the visit.
Subjects will be asked to record the date and time of dosing and food intake around dosing in a 
subject diary. 
Subjects who develop GI or flushing disturbances while receiving Tecfidera may reduce their 
study treatment dose by taking 120 mg twice daily for 1 month at the Investigator’s discretion. 
After 1 month at the reduced dose, subjects will resume the 240 mg twice daily dosing. If the 
subject is still unable to tolerate the study treatment, the subject must permanently discontinue 
study treatment as described in Section 6.4.4.2.
6.3 Assignment to Treatment Groups
Eligible subjects will be randomized 1:1:1:1:1 to treatment with placebo, low-dose M2951 (25 mg 
once daily), mid-dose M2951 (75 mg once daily), high-dose M2951 (75 mg twice daily), or 
Tecfidera (administered twice daily at a final dose of 240 mg), through a central randomization 
process by an IWRS prior to dosing on Day 1. Stratification will occur by region (USA or Western 
Europe, Eastern Europe and , Eastern Europe and not , and RoW). 
For the first 7 days, Tecfidera is administered orally at 120 mg twice daily. Following this and for 
the duration of treatment, Tecfidera is administered orally at 240 mg twice daily.  
 
6.4 Concomitant Medications and Therapies
All concomitant medications taken by the subject during the trial, from the date of signature of 
informed consent are to be recorded in the appropriate section of the eCRF, noting the name, dose, 
duration, regimen, and indication of each drug. Nondrug interventions and any changes to a 
concomitant medication or other intervention should also be recorded in the eCRF. Concomitant 
medications and procedures will be recorded at Screening and Day 1, and any changes 
elicited/recorded at every trial visit.
6.4.1 Permitted Medicines
Permitted medications are any medications required per the medical history and not specifically 
prohibited by the protocol during the trial. These standard of care medications are part of the 
subject’s previous treatment and will therefore not be provided by the Sponsor. Any such 
medications prescribed or used should be recorded in the eCRF.
Subjects who experience an MS relapse (see Section 7.3.3) during treatment may receive rescue 
medication subject to the following restrictions:
•Up to 1 g daily of methylprednisolone administered intravenous for up to 5 consecutive days.
Oral tapering of corticosteroid rescue medication is permitted, with a maximum of 15 days of 
tapering allowed.
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Subjects should not be withdrawn from treatment with trial medication solely because of the 
occurrence of a relapse unless they meet the criteria for withdrawal (see Section 5.6).
Note: Where possible, the use of high dose corticosteroids should be avoided in the 3 weeks prior 
to a scheduled MRI scan. 
Any medications (other than those excluded as per exclusion criteria in Section 5.3.2 or prohibited 
as per Section 6.4.2) that are considered necessary for the subjects’ welfare and will not interfere 
with the trial medication may be given at the Investigator’s discretion.
6.4.2 Prohibited Medicines
Medications prohibited before the trial are listed in the exclusion criteria (Section 5.3.2).
The following medications and therapies are not permitted during the trial and would require 
discontinuation of the trial treatment:
 Initiation of an immunosuppressant or immunomodulator, such as cladribine, 
cyclophosphamide, azathioprine.
 New therapies for MS should not be initiated during the trial. Initiation of any new 
immunosuppressant or immunomodulatory therapy would be considered a treatment failure and 
should result in withdrawal of the subject from the IMP (see Section 5.6.1).
 Oral or parenteral steroids, except rescue medication to treat a relapse of MS, or 
adrenocorticotropic hormone.
 Biologic therapies
 Intravenous Ig therapy and/or plasmapheresis
 Treatment with teriflunomide
 Daclizumab
 Live and live-attenuated vaccines
 Changes in dalfampridine dose (subject must be on a stable dose)
 Herbal supplements including, but not limited to, St. John’s wort, grapefruit, Seville oranges, 
cranberries, or juices of these fruits.
 Any investigational drug within 1 month or 5 half-lives of the investigational drug, whichever 
is longest, prior to Screening.
 Moderate or strong inhibitors or inducers of CYP3A or drugs mainly metabolized by CYP3A 
with a narrow therapeutic index. The list in Table 5 is not meant to be a complete list of all 
CYP3A inhibitors, inducers, or substrates with a narrow therapeutic range. Study sites should 
consider each medication on a case-by-case basis and discuss with the Medical Monitor. The 
additive effects of weak inhibitors taken in combination must also be taken into account.
 Any investigational drug or experimental procedure for MS.
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Table 5 Examples of Inhibitors or Inducers of CYP3A Enzymes or Substrates 
with Narrow Therapeutic Range
Inhibitors
Strong Moderate Weak 
Boceprevir, clarithromycin, conivaptan,
grapefruit juice,a indinavir, 
itraconazole, ketoconazole, 
lopinavir/ritonavir, mibefradil, 
nefazodone, nelfinavir, posaconazole, 
ritonavir, saquinavir, telaprevir, 
telithromycin, and voriconazole
Amprenavir, aprepitant, atazanavir, 
ciprofloxacin, darunavir/ritonavir, 
diltiazem, erythromycin, fluconazole, 
fosamprenavir, grapefruit juice,a
imatinib, and verapamil
Alprazolam, amiodarone, amlodipine, 
atorvastatin, bicalutamide, cilostazol, 
cimetidine, cyclosporine, fluoxetine, 
fluvoxamine, ginkgo, goldenseal, 
isoniazid, nilotinib, oral contraceptives, 
ranitidine, ranolazine, 
tipranavir/ritonavir, and zileuton
Inducers
Strong Moderate Weak 
Avasimibe, carbamazepine, phenytoin, 
rifampin, and St. John’s wort
Bosentan, efavirenz, etravirine, 
modafinil, and nafcillin
Amprenavir, aprepitant, armodafinil, 
echinacea, pioglitazone, prednisone, 
and rufinamide
Substrates With a Narrow Therapeutic Range
Alfentanil, astemizole,b cisapride,b cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, 
sirolimus, tacrolimus, terfenadineb
CYP=cytochrome P450.
a The effect of grapefruit juice varies widely among brands and is concentration, dose, and preparation dependent. 
Studies have shown that it can be classified as a “strong CYP3A inhibitor” when a certain preparation is used (eg, 
high dose, double strength) or as a “moderate CYP3A inhibitor” when another preparation is used (eg, low dose, 
single strength).
b Withdrawn from the USA and certain other markets because of safety reasons.
Note: This is not an exhaustive list. For an updated list, see Tables 5, 6, and 7 in the following link: 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm0804
99.htm
Note: A strong inhibitor is defined as an inhibitor that increases the area under the plasma concentration time-curve 
(AUC) of a substrate sensitive for that CYP ≥ 5-fold or decreases clearance by > 80%, and a strong inducer 
decreases AUC of a substrate by ≥ 80%.
Note: A moderate inhibitor is defined as an inhibitor that increases the AUC of a substrate sensitive for that CYP 
≥ 2-fold but < 5-fold or decreases clearance by 50%-80%, and a strong inducer decreases AUC by 50%-80%.
Note: A weak inhibitor is defined as an inhibitor that increases the AUC of a sensitive substrate for that CYP < 2-fold 
or decreases clearance 20%-50%, and a weak inducer decreases AUC by 20%-50%.
Note: CYP substrates with narrow therapeutic range refers to drugs whose exposure-response relationship indicates 
that small increases in their exposure levels by the concomitant use of CYP inhibitors may lead to serious safety 
concerns (eg, Torsades de pointes).
6.4.3 Other Interventions
Not applicable.
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6.4.4 Special Precautions
6.4.4.1 For M2951 Only
The IMP should be temporarily withheld or permanently withdrawn if the following abnormalities 
occur or re-occur (also see Table 6), as relevant, and re-initiation following temporarily 
withholding of IMP should be discussed with the Medical Monitor:
 For a neutrophil count < 500/mm3 or platelet count < 25,000/mm3 (Grade 4) or neutrophil count 
500 to 999/mm3 (Grade 3) with fever or platelet count 25,000 to 49,999/mm3 (Grade 3) with 
bleeding, the IMP should be permanently withdrawn
 For a Grade 3 decrease in neutrophil count without fever or Grade 3 decrease in platelet 
count without bleeding, temporarily hold the IMP and recheck the value. If the value is still 
Grade 3, permanently discontinue the IMP. 
 For a decrease to Grade 2, temporarily hold the IMP and recheck the value. Re-initiate the 
IMP after discussion with the Medical Monitor if no further downward trend is observed.
 For an increase in AST or ALT to > 3× ULN and increase in bilirubin to > 1.5× ULN (Grade 2 
or higher), the IMP should be permanently withdrawn. The subject should be followed with 
additional testing as needed until a return to ULN. Consultations with specialists, such as a 
hepatologist, can be considered at the discretion of the Investigator and in conjunction with the 
Medical Monitor.
 For an increase in AST or ALT to > 5× ULN without bilirubin elevation, the IMP should be 
permanently withdrawn. The subject should be followed with additional testing as needed 
until a return to ULN. Consultations with specialists, such as a hepatologist, can be 
considered at the discretion of the Investigator and in conjunction with the Medical Monitor.
 For any other increase in AST, ALT, or an increase in bilirubin to Grade 2, temporarily hold 
the IMP and recheck the value. At which time, the Investigator in conjunction with the 
Medical Monitor should review the results and if necessary consult with specialists, such as 
a hepatologist (at the discretion of the Principal Investigator), and then re-initiate the IMP 
after final discussion with the Sponsor.
A comprehensive hepatic panel is requested for subjects for whom withdrawal criteria (see 
Section 5.6.1) are met or who permanently or temporarily discontinue dosing because of elevated 
transaminases. Testing should include screening for the following:
o INR, PTT, fibrinogen, hsCRP
o Hepatitis serology: anti-HAV IgG, anti-HAV IgM, HBsAg, anti-HBc, anti-HBsAg, 
anti-HCV, anti-HEV IgG and IgM, anti-VCA IgG and IgM, anti-EA IgG, anti-EBNA 
IgG, anti-CMV IgG and IgM
o Antinuclear antibody, anti-smooth muscle antibody, antibody to liver-kidney 
microsomes
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o Albumin
 For an increase in amylase or lipase to > 5× ULN (Grade 4), the IMP should be permanently 
withdrawn
 For an increase in amylase or lipase to > 2 to 5× ULN (Grade 3), temporarily hold the IMP 
and recheck the value within 24 hours of receipt. If the value is still Grade 3, permanently 
discontinue the IMP. 
 For an increase to Grade 2, temporarily hold the IMP and recheck the value within 24 hours 
of receipt. Discontinue the IMP if the value does not decrease, or re-initiate the IMP after 
discussion with the Medical Monitor if a downward trend is observed.
 For an increase in serum creatinine to > 3× from Baseline (Grade 3 or higher), the IMP should 
be permanently withdrawn
 For any other increase in serum creatinine > 1.5× from Baseline, temporarily hold the IMP 
and recheck the value within 24 hours of receipt. Discontinue the IMP if the value does not 
decrease, or re-initiate the IMP after discussion with the Medical Monitor if a downward 
trend is observed.
 For any other laboratory abnormality of Grade 4 severity, the IMP should be permanently 
withdrawn
 For any other laboratory increase/decrease (as relevant) from Baseline to a clinically 
significant higher severity grade, temporarily hold the IMP and recheck the value within 
24 hours of receipt. Discuss restarting the IMP with the Medical Monitor if an improving 
trend is observed.
 For an absolute lymphocyte count < 200/mm3 (Grade 4), should be temporarily withdrawn 
and follow-up testing should be conducted. When the absolute lymphocyte count returns to 
800/mm3 (ie, returns to Grade 2), IMP can be resumed.
Table 6 Guidelines for Withholding or Permanent Withdrawal of IMP
Parameters Grade 1 Grade 2 Grade 3 Grade 4b
Neutrophil count 
decreased
No change to IMP No change to IMP < 1000 – 500/mm3;
< 1.0 – 0.5 × 10e9/La
< 500/mm3;
< 0.5 × 10e9/L
Platelet count 
decreased
< 50000 – 25000/mm3;
< 50.0 – 25.0 × 10e9/La
< 25000/mm3;
< 25.0 × 10e9/L
Neutrophil count with 
fever
500/mm3 - 999/mm3
Platelet count with 
bleeding
25000 – 49999/mm3
AST or ALT > 3.0 – 5.0 × ULNa > 5.0 – 20.0 × ULNb > 20.0 × ULN
AST or ALT with 
bilirubin increased >1.5 
× ULN
> 3.0 – 5.0 × ULNb > 5.0 – 20.0 × ULNb > 20.0 × ULN
Bilirubin > ULN - 1.5 × ULNa > 1.5 – 3.0 × ULNb > 3.0 – 10.0 × ULNb > 20.0 × ULN
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ALT=alkaline aminotransferase, AST=aspartate aminotransferase, IMP=investigational medicinal product, 
ULN=upper limit of normal.
        Permanently withdraw IMP.
a. Temporarily withhold and recheck value. The subject should be followed with additional testing as needed until a 
return to the ULN. At which time, the Investigator in conjunction with the Medical Monitor should review the 
results and if necessary consult with specialists, such as a hepatologist (at the discretion of the Principal 
Investigator), and then re-initiate the IMP after final discussion with the Sponsor.
b. Permanently withdraw IMP.
6.4.4.2 For Tecfidera Only
 For a lymphocyte count < 500/mm3 for > 24 weeks, Tecfidera should be temporarily withheld 
and the subject monitored until lymphocyte counts are back to the lower limit of normal (LLN). 
Once lymphocyte counts are back to LLN, the IMP can be restarted with additional follow-up 
monitoring of lymphocyte counts.
 For an absolute lymphocyte count < 200/mm3 (Grade 4), Tecfidera should be permanently 
withdrawn and the lymphocyte count of the subject monitored.
 For a serious infection, after discussion with the Medical Monitor, consideration should be 
given to temporarily withholding Tecfidera until resolution of the infection.
 At the first sign or symptom suggestive of PML, Tecfidera should be withheld and an 
appropriate diagnostic evaluation conducted. MRI findings may be apparent before clinical 
signs or symptoms. Typical symptoms associated with PML are diverse, progress over days to 
weeks, and include progressive weakness on one side of the body or clumsiness of limbs, 
disturbance of vision, and changes in thinking, memory, and orientation leading to confusion 
and personality changes.
 Discontinue Tecfidera if clinically significant liver injury induced by Tecfidera is suspected.
 Patients should be instructed to discontinue Tecfidera and seek immediate medical care should they 
experience signs and symptoms of anaphylaxis or angioedema.
 For a flushing reaction (eg, warmth, redness, itching, and/or burning sensation), Tecfidera
should be temporarily withheld until symptoms have resolved. After the flushing reaction has 
resolved, Tecfidera should be restarted at a reduced dose (see Section 6.2).
 Should a flushing reaction occur again, Tecfidera should be permanently discontinued.
6.4.4.3 Grading Adverse Events for Investigational Medicinal 
Products
For all laboratory abnormalities that correspond to Common Terminology Criteria for AEs 
(CTCAE) Grades 1 to 4, refer to the CTCAE, Version 4.03.
The reason for IMP withdrawal and the nature, duration, and results of any planned follow-up 
observations should be recorded in the appropriate section of the eCRF.
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6.4.5 Management of Specific Adverse Events or Adverse Drug 
Reactions
No specific measures are proposed at this stage. Standard medical care will be provided at the trial 
site for all AEs occurring during the trial.
6.5 Packaging and Labeling of the Investigational Medicinal 
Product
All IMPs will be supplied in accordance with all applicable regulatory requirements and GMP
Guidelines.
M2951 and placebo tablets will be packaged as alu/alu blister wallets.
6.6 Preparation, Handling, and Storage of the Investigational 
Medicinal Product
IMP must be carefully stored at the trial site in a closed room or cabinet with restricted access and 
separately from other drugs.
M2951 should be stored below 30°C. Any deviations from the recommended storage conditions 
should be immediately reported to the Sponsor, and the medication should not be used until 
authorization has been received from the Sponsor. 
Detailed recommendations for the use of Tecfidera is described in the summary of product 
characteristics or prescribing information, as appropriate.
The preparation, handling and storage of the IMPs will be documented in a separate Pharmacy 
Manual.
The IMP may not be used for any purpose other than the trial in question. It must be ensured at the 
trial site that IMP is not used after the use-by date. This is to be closely monitored by the 
responsible monitor.
6.7 Investigational Medicinal Product Accountability
The Investigator or designee is responsible for ensuring IMP accountability, including 
reconciliation of drugs and maintenance of records.
 Upon receipt of IMP, the responsible person will check for accurate delivery and acknowledge 
receipt in the IWRS and by signing or initialing and dating the appropriate documentation and 
returning it to the location specified. The original or a copy will be archived for the Investigator 
Site File.
 IMP dispensing will be recorded on the appropriate drug accountability forms so that accurate 
records will be available for verification at each monitoring visit.
 Trial site IMP accountability records will include the following:
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 Confirmation of IMP receipt, in good condition and in the defined temperature range
 The inventory of IMP provided for the clinical trial and prepared at the site
 The use of each dose by each subject in case of Tecfidera
 The disposition (including return, if applicable) of any unused IMP
 Dates, quantities, batch numbers, kit numbers, expiry dates, and the individual subject trial 
numbers.
The Investigator site should maintain records, which adequately document that subjects were 
provided the doses specified in this protocol, and all IMPs provided were fully reconciled.
Unused IMP must not be discarded or used for any purpose other than the present trial. No IMP 
that is dispensed to a subject may be redispensed to a different subject.
A Trial Monitor will verify and periodically collect the IMP accountability forms. 
After completion of the study, any IMP distributed to the site but not administered, dispensed to 
or taken by the subject(s) will be destroyed at the trial site. Details will be agreed upon between 
the Sponsor and the Investigator. All unused medications will be carefully recorded and 
documented before destruction.
6.8 Assessment of Investigational Medicinal Product Compliance
The IMP will be administered at the site on trial visit days as defined in Table 1 and Table 2. All 
other dosing will be done by the subject or subject’s caregiver at home throughout the rest of the 
trial. Subjects or subject’s caregiver will be asked to record the date and time of dosing and food 
intake around dosing in a subject diary.
Subjects will be instructed to bring all IMP, including the used packaging and all blisters, to each 
trial visit indicated in Table 1 and Table 2, and to allow for the assessment of compliance with trial 
treatment. Prior to discharge from each scheduled visit, subjects will be given sufficient IMP for 
at-home dosing until the next scheduled visit during the treatment period. On trial visit days
indicated in Table 1 and Table 2, the previous week’s IMP adherence will be documented using 
pill counts.
Insufficient compliance with the protocol-specified dosing regimen is defined as receiving < 80% 
of the required number of scheduled doses of trial medication.
6.9 Blinding
Treatment with M2951 and placebo will be double-blinded but the Tecfidera group will be open 
label. Tecfidera comes in 2 different colors of capsule (120 mg and 240 mg) with the lower dose 
being used during the initial 7 days of administration.
The Assessing Neurologist and central MRI reader will be blinded to all treatments (placebo, 
M2951, and Tecfidera) throughout the study. The subjects, site staff, and the Investigator will be 
blinded to placebo and M2951 throughout the study, but not Tecfidera. The CRO study team and 
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Sponsor study team will be blinded to placebo and M2951 until the database is partially locked for
the primary analysis. 
The bioanalytical laboratory(ies) responsible for the analysis of the  and  samples will be 
allowed to be partially unblinded during study conduct using masked subject identifiers, to support 
association of  data with M2951 dose and placebo treatment codes for timely decision 
making, but prevent association of treatment codes with any other clinical data, such as efficacy 
or safety data.
The IDMC will also be unblinded to treatment, as described in the IDMC charter.
All other staff other than those identified above will remain blinded to the placebo and M2951
treatments. 
Only when the last subject reaches 24 weeks of treatment or discontinues from treatment 
prematurely, the protocol violations are determined, and the database is partially locked for the 
primary analysis will the drug codes be broken and made available for the primary data analysis.
At that point, the CRO and Sponsor study teams will be unblinded to treatment. Dissemination of 
results from the primary analysis will be limited to senior management. There will be no 
communication of primary analysis results to the sites.
After the primary analysis, the study will continue as a blinded extension until the Week 52 
Analysis occurs, with subjects, site staff, and the Investigator blinded to M2951 dose group, and 
with the Assessing Neurologist and central MRI reader blinded to all treatments.  
 
  
All breaks of the trial blind must be adequately documented.
6.10 Emergency Unblinding
The trial blind may be broken for an individual only if knowledge of the IMP is essential for 
clinical management of the subject. The Investigator must promptly explain the reason for any 
unblinding of an IMP to the Sponsor without revealing the result to any Sponsor employee except 
the designated Drug Safety representative (using the Emergency Unblinding Notification Form). 
The Investigator must record the date of unblinding and the reason in the eCRF. Contact 
information for breaking the blind in an emergency is given on the subject emergency card 
provided to each subject (see Section 9.4).
Under certain circumstances, the IDMC or Drug Safety may be required to unblind the treatment 
assignment for an individual subject following a serious adverse event (SAE) or other serious 
event; eg, if an expedited regulatory report is required. See Section 7.4.1.4 for further details on 
expedited reporting and SAEs.
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6.11 Treatment of Overdose
An overdose is defined as any dose greater than the highest daily dose included in a clinical trial 
protocol or planned for an individual subject enrolled in the trial. Even if it does not meet other 
criteria for an SAE, any overdose must be recorded in the trial medication section of the eCRF and
reported to Drug Safety in an expedited manner using the SAE Report Form, and following the 
procedure in Section 7.4. No specific treatments for overdose are available.
6.12 Medical Care of Subjects after End of Trial
After a subject has completed the trial or has withdrawn early, the subject is free to access further 
treatment as deemed appropriate by the Treating Investigator. The Sponsor will not provide any 
additional care to subjects after they leave the trial because such care should not differ from what 
is normally expected for subjects with relapsing-remitting MS or SPMS with superimposed 
relapses.
7 Trial Procedures and Assessments
During the Screening visit, prior to performing any trial assessments that are not part of routine 
medical care for the subject, the Investigator will obtain written informed consent as described in 
Section 9.2.
Throughout the trial, subjects will undergo the assessments detailed in Table 1 and Table 2,
including collection of patient-reported HRQoL data and blood sampling. Completion of the 
HRQoL instrument SF-36v2 shall always be done before any other procedure or Investigator 
interaction of the visit takes place. The maximum amount of blood to be obtained during the trial 
is within the commonly accepted maximum of 275 mL over 4 weeks and 550 mL over 8 weeks. 
Details of the blood volumes to be collected for each sample/visit will be detailed in the Laboratory 
Manual and an estimate is provided in Appendix II. Instructions on how samples will be collected, 
labeled, processed, stored, and shipped as well as specification on bioanalytical methods will be 
detailed in the Laboratory Manual.
All blood and urine tests will be analyzed by a central laboratory, with the following exceptions:
 Urine testing for β-human chorionic gonadotropin will be conducted at the local laboratories.
 Urine dipstick results will be interpreted locally. Please see Table 1 for information regarding 
abnormal dipstick results. 
 
 HIV testing, when required by local regulation, should be conducted and analyzed locally.
 In addition, ECGs results will be interpreted locally.
 Additional safety monitoring as noted in Section 7.1.3.
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The Treating Investigator will be the physician responsible for subject care and should be a 
neurologist experienced in the care of MS patients. The Treating Investigator will have access to 
safety and blinded efficacy data and will make treatment decisions based on the subject’s clinical 
response and laboratory findings. The Treating Investigator will also be responsible for the 
treatment of relapses and determining if non-MS-related factors could account for neurological 
worsening. The Treating Investigator will determine if a relapse has occurred.
The Assessing Neurologist will be a neurologist or other health care practitioner and must be 
trained and certified in administering the Neurostatus Functional System Scores and EDSS
examination prior to study start. The Assessing Neurologist is responsible for all EDSS 
assessments beginning at Screening and including all unscheduled visits initiated by a new or 
changing symptom potentially related to MS, as requested by the Treating Investigator. 
Throughout the trial, the Assessing Neurologist will be blinded to the subject’s treatment, 
laboratory data, adverse event profile, any changes in safety assessments, and prior EDSS scores. 
The Assessing Neurologist must complete the EDSS prior to any treatment with steroids or other 
therapeutics intervention(s) that may alter the subject’s neurological state, where possible. Both 
the Treating Investigator and the subject will be informed of the importance of not discussing these 
issues with the Assessing Neurologist to prevent unblinding.
The Assessing MRI reader will be an independent, blinded, central MRI reader provided by 
. A local radiologist will also review all MRI scans for safety and provide a 
report to the Treating Investigator, containing only non-MS pathology information.
The CRO will also provide a qualified neurologist who will adjudicate whether relapses meet the 
definition of a qualifying relapse (see Section 7.3.3) and review systematically the EDSS to 
determine if there is a lack of efficacy/disease progression. The scope of this review will be 
described in detail in the Medical Monitoring Plan.
7.1 Schedule of Assessments
7.1.1 Screening
The subject’s eligibility will be assessed at the Screening visit that will occur between Day -28 to 
Day -1 (within 28 days prior to the first administration of placebo/M2951 or Tecfidera). See 
Table 1 for a list of assessments done at Screening to determine the eligibility of the subject to 
participate in the trial. If a subject does not meet eligibility criteria, the subject can be retested and 
rescreened once at the Investigator’s discretion.
If there are no clinically significant findings and the subject meets all protocol-defined inclusion 
criteria and none of the exclusion, the subject will be considered as eligible to be enrolled in the 
trial. Subjects who fail to meet the protocol-specified criteria or who withdraw their consent will 
be considered screen failures. The following information, as a minimum, should be collected for
subjects who failed Screening: informed consent, demographics, reason for screen failure, AEs 
from the date of informed consent until the subject is considered to have failed Screening by the 
Investigator, and the Investigator’s signature.
The following should be performed at the Screening Visit:
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 Signing of informed consent before any study procedures
 Review of inclusion/exclusion criteria, including administration of the C-SSRS
 The SF-36v2 HRQoL questionnaire, collection of demographic and other Baseline 
characteristics (MS history and other medical history, including medication history), review of 
concomitant medications and procedures, evaluation of AEs, a physical examination, vital 
signs, a neurological examination, MRI, EDSS. The MRI scan should be acquired before 
randomization and dosing to allow for the readouts to be read by the central MRI reader 
(approximately 7 days). 
 12-lead ECG and CXR
 Blood sample collection for Quantiferon-TB test, viral serology testing, HIV testing if required, 
safety assessments (hematology, clinical chemistry, coagulation), and serum pregnancy testing 
with FSH (women only).
 Urine collection for urinalysis and, if necessary, microscopy and protein/creatinine ratio.
7.1.2 Treatment Visits, Including Blinded Treatment Extension 
Phase
At all trial visits, scheduled assessments will be performed before administration of the trial 
medication, with the exception of relevant blood draws (eg,  and  occupancy as noted in 
Table 1). After Day 1, all scheduled visits during the treatment period may take place within 
± 3 days of the protocol-specified day. Subjects who discontinue early must immediately return 
for the 4-week Safety Follow-up/End of Trial Visit (see Section 7.1.8).
See Table 1 for specific assessments to be done during treatment periods.
The following will be performed on Day 1:
 Review of inclusion/exclusion criteria
 Randomization
 SF-36v2 HRQoL questionnaire
 Review of concomitant medications and procedures, evaluation of AEs, disease activity 
assessment (EDSS), vital signs, and a neurologic exam
 Blood sample collection for Ig levels, B, cell counts;  occupancy; and  
  
 
 Urine collection for a urine pregnancy test (women only)
 IMP dispensation
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The following will be performed at Week 4, 8, 12, 16, 20, 24, and 36:
 SF-36v2 HRQoL questionnaire
 Review of concomitant medications and procedures; evaluation of AEs; disease activity 
assessment (relapse assessment, EDSS [Week 12, 24, and 36 only]); a complete physical 
examination (Week 12 and 24 only); vital sign assessment; and a neurologic exam
 IMP compliance
 12-lead ECG (Week 24 only)
 Blood sample collection for safety assessments (hematology, chemistry); Ig levels (Week 4, 16,
and 24 only); B, cell count and  (Week 4 and 24 only);  
 
 Blood tests (ESR, hsCRP, and fibrinogen) at Week 36
 Urine collection for urine pregnancy testing (women only); urinalysis and, if necessary, 
microscopy and protein:creatinine ratio (Weeks 12 and 24 only).
The following will be performed at Weeks 28, 32, 40, and 44 for women of childbearing 
potential: urine pregnancy testing will be performed at home or at the site. Urine pregnancy test
kits will be provided to the subject at Week 24 (for testing at Weeks 28 and 32) and at Week 36
(for testing at Weeks 40 and 44). At and/or prior to the Week 24 Visit, the Principal Investigator 
and/or delegated site staff will train the relevant subjects to self-administer the urine pregnancy 
test, and will contact the subject by telephone at Week 28 (± 3 days), 32 (± 3 days), 
40 (± 3 days), and 44 (± 3 days) to confirm completion of urine pregnancy testing and discuss 
results.
 MRI assessment (Weeks 12, 16, 20, and 24 only)
 IMP dispensation
7.1.3 Supplemental Safety Visits
Additional chemistry monitoring (including ALT, AST, alkaline phosphatase, 
γ-glutamyl-transferase, and bilirubin) will be conducted every 2 weeks until 16 weeks of treatment 
with evobrutinib (or an increase in the dose of evobrutinib). Subsequently, this will be conducted 
monthly (every 4 weeks).
 In the main study, for subjects in the placebo/M2951 arm, safety visits will be conducted every 
2 weeks until Week 40, then monthly at Weeks 44 and 48 (see Table 1)

 
Safety visits will be conducted after obtaining subject’s informed consent. These safety evaluations
have been implemented by a letter to Investigators as an urgent safety measure. Given the current 
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status of most patients, these evaluations will start after Visit 4. It is preferable for chemistry 
monitoring to be performed at the Investigator’s site. Patients who are visiting the site will be 
asked for additional blood samples for  evaluation at these visits. An additional physical 
examination may be performed at the Investigator’s discretion based on the subject’s history at the 
time of the visit. Any new or change in AEs and concomitant medications should be documented. 
Patient compliance to additional safety monitoring will be overseen to evaluate continuation in the 
trial.
These visits should be done at the Investigator’s site and blood samples sent to Central Laboratory. 
In the event that the subject cannot return to the site for the additional blood draws, chemistry 
monitoring should be done locally; any subjects completing a supplemental safety visit locally will 
not have  samples collected at that visit.
7.1.4 Unscheduled Visit for Neurological Worsening and Relapse 
Assessment
Subjects should be instructed that if, at any point during the trial, they suspect that they are 
experiencing new or worsening neurological symptoms, including possible relapse, they should
contact the Investigator as soon as possible after the onset of symptoms. If necessary, the subject 
should be evaluated by the Investigator within the clinic and every effort should be made to 
complete this evaluation within 1 week after the start of symptoms. Any assessments needed to 
confirm the relapse should be performed at the discretion of the Investigator. Details should be
documented within the relevant section(s) of the eCRF. The definition of a qualifying and 
non-qualifying relapse is provided in Section 7.3.3.
If an MRI scan is indicated at an Unscheduled Visit for Neurological Worsening and Relapse 
Assessment, it should be performed prior to initiating corticosteroid therapy, where possible. In
addition, care should be taken to avoid the subject being exposed to gadolinium more than once in 
a 4-week period, ie, it may be necessary to cancel the MRI scan at the next scheduled visit (all 
other assessments should be completed at the visit as normal).
The following will be performed at an Unscheduled Visit for Neurological Worsening and Relapse 
Assessment:
 Review of concomitant medications and procedures, evaluation of AEs, disease activity 
assessment (relapse assessment, EDSS), complete physical examination, vital signs, and a 
neurologic exam
 12-lead ECG
 Blood sample collection for safety assessments (hematology, chemistry).
 Urine collection for urinalysis, and, if necessary, microscopy and protein:creatinine ratio.
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7.1.5 End of Treatment Visit
The following will be performed at Week 48 ± 3 days/End of Treatment visit (for subjects who do 
not continue in the OLE or subjects who received Tecfidera during the 48-week main study and 
choose to participate in the OLE):
 SF-36v2 HRQoL questionnaire 
 Review of concomitant medications and procedures, evaluation of AEs, disease activity 
assessment (relapse assessment, EDSS), vital signs, and a neurologic exam
 IMP compliance
 12-lead ECG
 Blood sample collection for safety assessments (hematology, chemistry, coagulation); Ig levels;
B, cell and subtype count; and .
 Urine collection for urinalysis and, if necessary, microscopy and protein:creatinine ratio; urine 
pregnancy testing (women only).
 MRI assessment.
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7.1.8 4-week Safety Follow-up/End of Trial Visit
The Safety Follow-up/End of Trial Visit will be performed at Week 52 ± 5 days for subjects who 
do not participate in the OLE Period or 28 days (± 7-day window) after the OLE End of Treatment 
Visit for subjects who participate in the OLE Period. There will be only one 4-week Safety 
Follow-up/End of Trial Visit per subject, and the assessments performed will be the same if this 
visit occurs at the end of the main study or the end of the OLE Period. If a subject is not eligible 
to enter the OLE Period by Tecfidera Washout Visit 2, he or she will need to return for the End of 
Trial Visit. This End of Trial Visit should be completed within 14 days ± 7 days from the time the 
decision is reached that the subject is not eligible to enter the OLE Period.
See Table 1 and Table 2 for specific assessments to be done. The following assessments will be 
performed:
 Review of concomitant medications and procedures, evaluation of AEs, disease activity 
assessment (relapse assessment), vital signs, and a neurologic exam
 Blood sample collection for safety assessments (hematology, chemistry); B, cell 
counts and 
Urine collection for urinalysis and, if necessary, microscopy and protein:creatinine ratio; urine 
pregnancy testing (women only). Prior to performing any trial assessments that are not part of 
routine medical care for the subject, the Investigator will obtain written informed consent as
described in Section 9.2.
7.2 Demographic and Other Baseline Characteristics
At Screening, the following demographic data will be collected: date of birth, sex (gender), race, 
and ethnicity. Information about previous and concomitant medications taken within 4 weeks prior 
to randomization and the number of documented relapses within 1 year of randomization will be 
collected.
Medical history data (including diagnosis and duration of MS) will be recorded and a complete 
physical exam, will be performed. Medical history includes both disease and medication history. 
Vital signs, including oral temperature, heart rate, respiratory rate, semisupine blood pressure,
weight, and height will be obtained. All other Baseline measures, such as safety laboratory 
parameters, Quantiferon-TB test, ECG, and chest X-ray will be assessed. Baseline disease will be 
assessed by EDSS and MRI. Baseline QoL using the SF-36v2 questionnaire will also be assessed.
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7.3 Efficacy Assessments
The following efficacy assessments will be undertaken, as outlined in the Schedule of Assessments 
(Table 1 and Table 2). During treatment, ie, Day 1 to Week 48 ( ), 
all assessments should be completed prior to the administration of study medication.
7.3.1 Brain Magnetic Resonance Imaging Scans
MRI scans will be performed at Screening, at 4-week intervals from Week 12 to 24, and at the End 
of Treatment Visit at Week 48 (including for subjects receiving Tecfidera who choose to enter the 
 
 
If a 
subject discontinues the study more than 4 weeks after his or her most recent MRI, an MRI may 
be obtained at the 4-week Safety Follow-up Visit. The Screening MRI scan should be acquired 
before randomization and dosing to allow for the readouts to be read by the central MRI reader 
(approximately 7 days).
Gadolinium will be used to enhance T1-weighted lesions and to optimize clarity and accuracy of 
reporting. As gadolinium is excreted renally, subjects with acute renal insufficiency (eGFR 
< 45 mL/min/1.73m2) will be excluded from the trial (see Section 5.3.2, exclusion criterion 33).
Brain MRI scans will be performed according to a standardized imaging protocol before and after 
the administration of single-dose gadolinium.
Images will be assessed and reported by an independent, blinded, centralized MRI reading service, 
provided by . The assessment will be performed in the absence of clinical 
information. Further details, including the scans required and the optimal MRI workflow, will be 
provided in a separate Imaging Manual that will be provided to each trial site by  
. All MRI images will be reviewed and reported locally by a radiologist for safety. The 
local report will contain only non-MS pathology and will be provided to the Treating Investigator.
Note: Where possible, the use of high dose corticosteroids should be avoided in the 3-week period 
prior to a scheduled MRI scan. In subjects receiving corticosteroids for an MS relapse, there must 
be a 3-week interval between the last dose of corticosteroids and the scheduled MRI scan.
In addition, if a scheduled MRI scan is delayed or an unscheduled MRI scan is indicated, care 
should be taken to avoid the subject being exposed to gadolinium more than once in a 4-week 
period, ie, it may be necessary to cancel the MRI scan at the next scheduled visit (all other 
assessments should be completed at the visit as normal). If the next scheduled visit is the End of 
Treatment Visit (Week 48), the Week 48 MRI scan should be performed as soon as the 4-week 
period since previous exposure to gadolinium has elapsed. See also Section 7.1.3.
7.3.2 Expanded Disability Status Scale
A standard neurological examination will be performed by an Assessing Neurologist and the 
subject’s level of disability will be assessed using the EDSS as outlined in Table 1 and Table 2.
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The EDSS is an ordinal clinical rating scale ranging from 0 (normal neurological examination) to 
10 (death due to MS) in half-point increments and should be administered in person by a 
neurologist trained in its use (19).
The EDSS score is calculated after neurologic testing and examination of the following eight 
functional systems, areas of the central nervous system that control bodily functions:
 Pyramidal (ability to walk)
 Cerebellar (coordination)
 Brain stem (speech and swallowing)
 Sensory (touch and pain)
 Bowel and bladder functions
 Visual
 Mental
 Other (includes any other neurological findings due to MS).
Steps will be taken to eliminate inter- and intra-rater variability in the administration and
assessment of the EDSS in the trial. The EDSS should be administered by an Assessing
Neurologist who has undergone trial-specific EDSS training prior to the start of the trial and the 
same individual should evaluate a given subject throughout the course of the trial. The EDSS 
assessment should take place at approximately the same time of day and a standardized protocol 
should be followed for the neurologic examination.
Further information regarding the EDSS assessment will be provided in the Laboratory Manual.
7.3.3 Relapse Assessment
Subjects will be assessed for MS relapse at visits as outlined in Table 1and Table 2 beginning at 
Week 4. Relapse will also be assessed at any Unscheduled Visit for Neurological Worsening and 
Relapse Assessment (see Section 7.1.4).  
A qualifying relapse is defined as new, worsening or recurrent neurological 
symptoms attributed to MS that last for at least 24 hours without fever or infection, or adverse 
reaction to prescribed medication, preceded by a stable or improving neurological status of at least 
30 days. This relapse must be accompanied by new clinical signs (ie, changes in the neurological 
examination or an increase in EDSS score). 
All cases of potential relapse should be objectively confirmed by the Investigator regardless of 
whether they are identified during a scheduled or unscheduled visit. Any assessments needed to 
confirm the relapse should be performed, and details of the relapse should be documented within 
the relevant section(s) of the eCRF. The criteria for a protocol-defined relapse should be clear and 
there should be documentation of how each potential relapse did or did not meet the criteria.
Subjects who have a documented relapse during treatment are not required to discontinue treatment 
unless they meet any of the criteria for withdrawal from the trial therapy (see Section 5.6.1) or 
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withdrawal from the trial, including the need for treatment with a non-permitted medication (see 
Section 5.6.2).
A non-qualifying relapse is any other relapse as defined by the Investigator that does not meet the 
qualifying relapse definition.
7.4 Assessment of Safety
The safety profile of the IMP will be assessed through the recording, reporting and analysis of 
baseline medical conditions; AEs; physical examination findings including vital signs, ECGs, and 
laboratory tests (including Ig and subclass concentration and B, cell counts).
Comprehensive assessment of any apparent toxicity experienced by each subject will be performed 
from the time of giving informed consent and throughout the trial. The Investigator will report any 
AEs, whether observed by the Investigator or reported by the subject (see Section 7.4.1.2). The 
reporting period for AEs is described in Section 7.4.1.3.
7.4.1 Adverse Events
7.4.1.1 Adverse Event Definitions
Adverse Event
An AE is any untoward medical occurrence in a subject or clinical investigation subject 
administered a pharmaceutical product, regardless of causal relationship with this treatment. An 
AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease temporally associated with the use of a medicinal product, whether 
or not considered related to the medicinal product. 
For surgical or diagnostic procedures, the condition/illness leading to such a procedure is 
considered as the AE rather than the procedure itself.
The Investigator is required to grade the severity or toxicity of each AE.
Investigators will reference the National Cancer Institute-Common Terminology Criteria for AEs 
(NCI-CTCAE), Version 4.03 (publication date: 14 June 2010) (20), a descriptive terminology that 
will be provided in the Manual of Procedures that can be used for AE reporting.
A general grading (severity/intensity; hereafter referred to as severity) scale is provided at the 
beginning of the above referenced document, and specific event grades are also provided.
Only if a particular AE’s severity is not specifically graded by the guidance document, the 
Investigator is to use the general NCI-CTCAE definitions of Grade 1 through Grade 5 following
his or her best medical judgment.
The 5 general grades are:
 Grade 1 or Mild
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 Grade 2 or Moderate
 Grade 3 or Severe 
 Grade 4 or Life-threatening 
 Grade 5 or Death 
According to Sponsor convention, any clinical AE with severity of Grade 4 or Grade 5 must also 
be reported as an SAE. However, a laboratory abnormality of Grade 4, such as anemia or 
neutropenia, is considered serious only if the condition meets 1 of the serious criteria described 
below.
If death occurs, the primary cause of death or event leading to death should be recorded and 
reported as an SAE. “Fatal” will be recorded as the outcome of this specific event and death will 
not be recorded as a separate event. Only, if no cause of death can be reported (eg, sudden death, 
unexplained death), the death per se might then be reported as an SAE.
Investigators must also systematically assess the causal relationship of AEs to IMP using the 
following definitions. Decisive factors for the assessment of causal relationship of an AE to the 
IMP include, but may not be limited to, temporal relationship between the AE and the IMP, known 
side effects of IMP, medical history, concomitant medication, course of the underlying disease, 
trial procedures.
Unrelated: Not reasonably related to the IMP. AE could not medically 
(pharmacologically/clinically) be attributed to the IMP under study in this clinical 
trial protocol. A reasonable alternative explanation must be available.
Related: Reasonably related to the IMP. AE could medically (pharmacologically/clinically) 
be attributed to the IMP under study in this clinical trial protocol. 
Abnormal Laboratory Findings and Other Abnormal Investigational Findings
Abnormal laboratory findings and other abnormal investigational findings (eg, on an ECG trace) 
should not be reported as AEs unless they are associated with clinical signs and symptoms, lead to 
treatment discontinuation or are considered otherwise medically important by the Investigator. If 
a laboratory abnormality fulfills these criteria, the identified medical condition (eg, anemia, 
increased ALT) must be reported as the AE rather than the abnormal value itself.
Serious Adverse Events
An SAE is any untoward medical occurrence that at any dose:
 Results in death.
 Is life-threatening. (Note: The term “life-threatening” refers to an event in which the subject is 
at risk of death at the time of the event, not an event that hypothetically might have caused death 
if it was more severe)
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 Requires inpatient hospitalization or prolongs an existing hospitalization, except in the case of 
hospitalizations due to protocol-defined relapses.
 Results in persistent or significant disability or incapacity.
 Is a congenital anomaly or birth defect.
 Is otherwise considered to be medically important. (Note: Important medical events that may 
not result in death, be life-threatening, or require hospitalization may be considered as SAEs 
when, based upon appropriate medical judgment, they may jeopardize the subject or may 
require medical or surgical intervention to prevent 1 of the outcomes listed above. Examples of 
such events include allergic bronchospasm requiring intensive treatment in an emergency room 
or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the 
development of drug dependency or drug abuse.)
For the purposes of reporting, any suspected transmission of an infectious agent via an IMP is also 
considered an SAE, as described in 7.4.1.4.
Events that Do Not Meet the Definition of an SAE
Elective hospitalizations to administer, or to simplify trial treatment or trial procedures (eg, an
overnight stay to facilitate intravenous therapy) are not considered SAEs. However, all events 
leading to unplanned hospitalizations or unplanned prolongation of an elective hospitalization (eg,
undesirable effects of any administered treatment) must be documented and reported as SAEs, 
except for unplanned hospitalizations due to relapse of MS.
Events Not to Be Considered as AEs/SAEs 
Medical conditions present at the initial trial visit that do not worsen in severity or frequency during 
the trial are defined as Baseline medical conditions and are not to be considered AEs.
Worsening of the underlying disease is not routinely to be considered an AE or SAE, but is rather 
an efficacy endpoint, unless deemed to be causally related to the IMP.
However, if significant adverse signs or symptoms occur in association with complications or a 
prolonging of a hospitalization originally due to relapse or disease progression, then these specific 
complications or hospital prolongation events should be recorded as AEs.
7.4.1.2 Methods of Recording and Assessing Adverse Events
At each trial visit, the subject will be queried on changes in his or her condition. During the 
reporting period, any unfavorable changes in the subject’s condition will be recorded as AEs, 
whether reported by the subject or observed by the Investigator. 
Complete, accurate and consistent data on all AEs experienced for the duration of the reporting 
period (defined below) will be reported on an ongoing basis in the appropriate section of the eCRF. 
All SAEs must be additionally documented and reported using the appropriate Report Form as 
described in Section 7.4.1.4.
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It is important that each AE report include a description of the event, its duration (onset and 
resolution dates and times when it is important to assess the time of AE onset relative to the 
recorded treatment administration time), its severity, its causal relationship with the trial treatment, 
any other potential causal factors, any treatment given or other action taken, including dose 
modification or discontinuation of the IMP, and its outcome. In addition, serious cases should be 
identified and the appropriate seriousness criteria documented. 
Specific guidance can be found in the eCRF Completion and Monitoring Conventions provided 
by the Sponsor.
7.4.1.3 Definition of the Adverse Event Reporting Period
The AE reporting period for safety surveillance begins when the subject is initially included in the 
trial (date of first signature of informed consent/date of first signature of first informed consent) 
and continues until the 4-week Safety Follow-up/End of Trial Visit.
Any SAE assessed as related to IMP must be reported whenever it occurs, irrespective of the time 
elapsed since the last administration of IMP. 
7.4.1.4 Procedure for Reporting Serious Adverse Events
Serious Adverse Events
In the event of any new SAE occurring during the reporting period, the Investigator must 
immediately (within a maximum of 24 hours after becoming aware of the event) inform the 
Sponsor or its designee using the SAE Report Form, which must be completed by the Investigator
following specific completion instructions.
For names, addresses, telephone and fax numbers for SAE reporting, see information included in 
the Adverse Event Safety Report Form.
In exceptional circumstances, an SAE (or follow-up information) may be reported by telephone; 
in these cases, the eCRF must be completed.
Relevant pages from the eCRF may be provided in parallel (eg, medical history, concomitant 
drugs). Additional documents may be provided by the Investigator, if available (eg, laboratory 
results, hospital report, autopsy report). In all cases, the information provided on the SAE Report 
Form must be consistent with the data about the event recorded in the eCRF.
The Investigator must respond to any request for follow-up information (eg, additional 
information, outcome, final evaluation, other records where needed) or to any question the 
Sponsor/designee may have on the AE within the same timelines as those noted above for initial 
reports. This is necessary to ensure prompt assessment of the event by the Sponsor or designee and 
(as applicable) to allow the Sponsor to meet strict regulatory timelines associated with expedited 
safety reporting obligations.
 
 
Evobrutinib (M2951) A Study of Efficacy and Safety of M2951 in Relapsing Multiple Sclerosis
MS200527-0086
71/106
Requests for follow-up will usually be made via the responsible Medical Monitor, although in 
exceptional circumstances the Global Drug Safety department may contact the Investigator 
directly to obtain further information or to discuss the event.
7.4.1.5 Safety Reporting to Health Authorities, Independent Ethics 
Committees/ Institutional Review Boards and Investigators
The Sponsor or designee will send appropriate safety notifications to Health Authorities in 
accordance with applicable laws and regulations.
The Investigator must comply with any applicable site-specific requirements related to the 
reporting of SAEs (particularly deaths) involving trial subjects to the IEC/IRB that approved the 
trial.
In accordance with ICH GCP, the Sponsor/designee will inform the Investigator of “findings that 
could adversely affect the safety of subjects, impact the conduct of the trial or alter the IEC’s/IRB’s 
approval/favorable opinion to continue the trial.” In particular and in line with respective 
regulations, the Sponsor/designee will inform the Investigator of AEs that are both serious and 
unexpected and are considered to be related to the administered product (“suspected unexpected 
serious adverse reactions” or SUSARs). The Investigator should place copies of Safety Reports in 
the Investigator Site File. National regulations with regard to Safety Report notifications to 
Investigators will be taken into account.
When specifically required by regulations and guidelines, the Sponsor/designee will provide 
appropriate Safety Reports directly to the concerned lead IEC/IRB and will maintain records of 
these notifications. When direct reporting is not clearly defined by national or site-specific 
regulations, the Investigator will be responsible for promptly notifying the concerned IEC/IRB of 
any Safety Reports provided by the Sponsor/designee and of filing copies of all related 
correspondence in the Investigator Site File.
For trials covered by the European Directive 2001/20/EC, the Sponsor’s responsibilities regarding 
the reporting of SAEs/SUSARs/Safety Issues will be carried out in accordance with that Directive 
and with the related Detailed Guidance documents.
7.4.1.6 Monitoring of Subjects with Adverse Events
Adverse events are recorded and assessed continuously throughout the trial (see Section 7.4.1.3) 
and are assessed for final outcome at the 4-week Safety Follow-up/End of Trial Visit. All SAEs 
ongoing at the 4-week Safety Follow-up/End of Trial Visit must be monitored and followed up by 
the Investigator until stabilization or until the outcome is known, unless the subject is documented 
as “lost to follow-up”. Reasonable attempts to obtain this information must be made and 
documented. It is also the responsibility of the Investigator to ensure that any necessary additional 
therapeutic measures and follow-up procedures are performed. 
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7.4.2 Pregnancy and In Utero Drug Exposure 
Only pregnancies considered by the Investigator to be related to trial treatment (eg, resulting from 
a drug interaction with a contraceptive medication) are considered to be AEs. However, all 
pregnancies with an estimated conception date during the period defined in Section 7.4.1.3 must 
be recorded by convention in the AE page/section of the eCRF. The same rule applies to 
pregnancies in female subjects and to pregnancies in female partners of male subjects. The 
Investigator must notify the Sponsor/designee in an expedited manner of any pregnancy using the 
Pregnancy Report Form, which must be transmitted according to the same timeline as described 
for SAE reporting in Section 7.4.1.4. 
Investigators must actively follow up, document and report on the outcome of all these 
pregnancies, even if the subjects are withdrawn from the trial.
The Investigator must notify the Sponsor/designee of these outcomes using the Pregnancy Report 
Form. If an abnormal outcome occurs, the SAE Report Form will be used if the subject sustains 
an event and the Parent-Child/Fetus Adverse Event Report Form if the child/fetus sustains an 
event.
Any abnormal outcome must be reported in an expedited manner as described in Section 7.4.1.4, 
while normal outcomes must be reported within 45 days after delivery.
In the event of a pregnancy in a subject occurring during the course of the trial, the subject must 
be discontinued from trial medication immediately. The Sponsor/designee must be notified 
without delay and the subject must be followed as mentioned above.
7.4.3 Clinical Laboratory Assessments
Blood and urine samples will be collected for the following clinical laboratory tests, following the 
timing noted in the Schedule of Assessments (Table 1 and Table 2). All samples should be clearly 
identified. Sample collection, preparation, and handling/shipment procedures are described in the 
Laboratory Manual.
Table 7 Clinical Safety Laboratory Evaluations
Type of 
Evaluation
Tests
Biochemistry  Albumin
 Aspartate 
aminotransferase
 Alanine aminotransferase
 Alkaline phosphatase
 γ-Glutamyl-transferase
 Lactate dehydrogenase
 Bilirubin (total) 
 Protein (total)
 Creatinine and eGFR 
calculation
 Amylase
 Lipase
 Total carbon dioxide 
 Blood urea nitrogen
 Glucose
 Sodium
 Potassium
 Chloride
 Calcium
 Magnesium
 Phosphate
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Supplementary 
LFT visits
 Aspartate 
aminotransferase
 Alanine aminotransferase
 Alkaline phosphatase
 γ-Glutamyl-transferase
 Bilirubin (total) 
Hepatic panel  International normalized 
ratio
 Partial thromboplastin 
time
 Fibrinogen
 hsCRP
 Hepatitis serology: 
anti-HAV IgG, anti-HAV 
IgM, HBsAg, anti-HBc, 
anti-HBsAg, anti-HCV, 
anti-HEV IgG and IgM, 
anti-VCA IgG and IgM, 
anti-EA IgG, anti- EBNA 
IgG, anti-CMV IgG and 
IgM
 Antinuclear antibody, 
anti-smooth muscle 
antibody,  antibody to 
liver-kidney 
microsomes
 Albumin
Hematology  Hematocrit
 Hemoglobin
 Red blood cell count
 Mean corpuscular 
volume
 Mean corpuscular 
hemoglobin
 Mean corpuscular 
hemoglobin 
concentration
 Reticulocyte count
 Platelet count 
 White blood cell count
 B,  cell counta
 Immunoglobulin and 
subclass 
concentrationsa,b
 White blood cell 
differentials and absolute 
counts:
o Basophils
o Eosinophils
o Lymphocytes
o Monocytes
o Neutrophils 
Coagulationa  International normalized ratio
 Partial thromboplastin time
Urinalysis/micros
copyc and urine 
chemistry
 pH
 Nitrite
 Urobilinogen
 Bilirubin
 Glucose 
 Ketone bodies
 Protein
 βhCG (women only)a
 Microscopyc (white blood 
cells, red blood cells, 
casts)
 Protein/creatinine ratiod
Additional urine 
testing
 βhCG (women only)a
Other Screening 
testse
 HCV antibodies
 Serum βhCG (women 
only)
 HBV IgM antibodies
 HIVf
 FSH
 HBsAg
 Quantiferon tuberculosis 
test
βhCG=β-human chorionic gonadotropin, CMV=cytomegalovirus, EA=early antigen, EBNA=Epstein-Barr nuclear 
antigen, eGFR=estimated glomerular filtration rate, ESR=erythrocyte sedimentation rate, FSH=follicle-stimulating 
hormone, HAV=hepatitis A virus, HBc=hepatitis B core antigen, HBsAg=hepatitis B surface antigen, HBV=hepatitis B 
virus, HCV=hepatitis C virus, HEV=hepatitis E virus, HIV=human immunodeficiency virus, hsCRP=high sensitivity 
C-reactive protein, IDMC=independent data monitoring committee, Ig=immunoglobulin,  
VCA=viral capsid antigen.
a. To be done only when specified in Table 1 and Table 2 and not as a standard laboratory evaluation. 
b. Results will not be disclosed to the sites, Sponsor, or representative, to avoid unblinding. However, the IDMC 
will have access to these data as applicable.
c.. Microscopy will be performed only if urine dipstick is abnormal.
d. Protein/creatinine ratio will only be determined at the central laboratory if urine dipstick is abnormal
e. Performed only at Screening.
f. HIV testing will be done at Screening only where required as per local regulation.
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7.4.4 Vital Signs, Physical Examinations, and Other Assessments
7.4.4.1 Vital Signs
Vital signs, including semisupine blood pressure, pulse rate, respiratory rate, weight, and oral 
temperature will be assessed predose at all specified trial visits (Table 1 and Table 2). Height will 
be measured at Screening only.
A semiautomated pulse rate and blood pressure recording device with an appropriate cuff size will 
be utilized. Pulse rate and blood pressure will be measured after 10 minutes rest in the semisupine 
position with the subject’s arm unconstrained by clothing or other material. The blood pressure 
should be assessed on the same arm for each subject throughout the trial.
7.4.4.2 Physical Examinations
Physical examinations will be assessed at each site as indicated in Table 1 and Table 2. Physical 
examination includes assessment of the following: general appearance, skin, head and neck, 
mouth, lymph nodes, thyroid, abdomen, and musculoskeletal, cardiovascular, and respiratory
systems. Physical examination findings during Screening before obtaining informed consent will 
be recorded as medical history events and new findings or worsening during the trial as AEs.
Records from physical examinations will be retained at each site and will not be captured in the 
eCRF. 
7.4.4.3 12-Lead ECG and Chest X-ray
A 12-lead ECG will be performed during Screening.  
 
. The 12-lead ECG recordings will be obtained after 10 minutes of rest in a 
semisupine position.
The following ECG parameters will be obtained directly from the computerized 12-lead ECG 
recordings: rhythm, ventricular rate, PR interval, QRS duration, and QT interval. The corrected 
QT interval will be calculated using Fridericia’s formula. The overall evaluation 
(normal/abnormal) will be recorded on the eCRF, and if abnormal, the specific abnormality will 
be recorded. Abnormal evaluations will be judged as clinically significant or not clinically 
significant by the Investigator.
The printout of the ECG is to be signed, dated, and filed in the Investigator’s Site File along with 
a signed and dated copy (if the printouts are not on archive-quality paper).
Posterioanterior CXRs will be performed during Screening according to local standard practice. 
 Subjects who had a CXR 
performed for clinical reasons within 3 months prior to Day 1 do not need to have the CXR 
repeated. The CXR should show no evidence of active infective process, or any other clinically 
significant abnormalities. The overall evaluation (normal/abnormal) will be recorded on the eCRF, 
and if abnormal, the specific abnormality will be recorded. Abnormal evaluations will be judged 
as clinically significant or not clinically significant by the Investigator.
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The 12-lead ECG and CXR will be performed and read locally.
7.4.5 Total Immunoglobulin Assessments
Blood samples for Ig levels (IgM, IgA, and IgG) will be collected as noted in Table 1 and Table 2.
Samples will be analyzed by the central laboratory selected by the Sponsor. Samples will be 
collected, labeled, processed, stored, and shipped according to the instructions in the Laboratory 
Manual.
Results will not be disclosed to the sites, Sponsor, or representative, to avoid unblinding. However, 
the IDMC will have access to these data as applicable.
7.4.6 B Cell Counts
Blood samples for B cell counts will be obtained predose at Screening, on Day 1, and at Weeks 4, 
24, and 48. An additional sample will be collected at the 4-week Safety Follow-up/End of Trial
Visit (main and OLE study).  
The actual date and time of each sample will be recorded. Samples will be analyzed by the central 
laboratory selected by the Sponsor using an appropriately validated bioanalytical method. Samples 
will be collected, labeled, processed, stored, and shipped according to the instructions in the 
Laboratory Manual.
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7.6.5 Use of Samples for Additional Analysis
 
 
 
7.7 Health-Related Quality of Life Assessments
7.7.1 Short Form 36-item Health Status Survey
The SF-36v2 is a 36-item questionnaire that measures 8 areas of subject reported health rated from 
0 to 100 for a total score ranging from 0 to 800 (21-25). The areas are: 
 Physical function
 Role limitations due to health problems
 Bodily pain
 Social functioning
 General mental health
 Role limitations due to emotional problems
 Energy/fatigue
 General health perceptions
The SF-36v2 will be measured in all subjects as indicated in Table 1 and Table 2. Completion of 
the SF-36v2 shall be done before any other procedure or Investigator interaction takes place.
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7.8 Columbia-Suicide Severity Rating Scale
The C-SSRS will be used for prospective suicidality assessment. The C-SSRS will be a tool used 
at Screening to identify eligible subjects. The C-SSRS will be measured in all subjects as indicated 
in Table 1 and Table 2. The C-SSRS Screening Scale will be used in the main study and  
 The structured interview prompts recollection of 
suicidal ideation, including the intensity of the ideation, behavior and attempts with 
actual/potential lethality.
The scale will be administered by the Treating Investigator or a qualified designee. Please note 
that assessing the risk of suicide is a difficult and complex task when applied to the individual 
patient. No single clinical scale can replace a thorough medical examination and suicide risk 
assessment. Ultimately, the determination of the presence of suicidality depends on clinical 
judgment.
8 Statistics
8.1 Sample Size
A per-group sample size of 44 evaluable subjects provides 85% power to detect a decrease of 90% 
in the total number of gadolinium-enhancing T1 lesions, summed over scans at Week 12, 16, 20, 
and 24, between each M2951 group versus placebo at the 2-sided 5% level, using the Wilcoxon 
rank-sum test, where the p-value is evaluated using a continuity-corrected normal approximation 
to the test statistic. Power was evaluated via simulation in R of the Wilcoxon test (wilcox.test) 
applied to lesion count data generated according to a negative binomial (NB) distribution, with 
mean λt = 0.55 and shape parameter ϒt = 14.0 for a given M2951 group (ϒt based on rituximab 
data) (2), and mean λc = 5.5 and shape parameter ϒc = 7.256 for the placebo group (λc and ϒc based 
on placebo data) (2), yielding a lesion rate ratio of λt/λc = 0.10. Approximately 50 subjects will be 
randomized per group to protect against a loss of information due to a 12% drop-out rate over 
1 year, and to provide for an adequate assessment of safety. (Note that the NB distribution 
parameterization assumed here implies lesion count variance equals λ + λ2 ϒ for a given treatment 
group.)
Approximately 250 subjects will enter the main study.  
The Family-wise Type I error rate (FWER) at the primary analysis will be controlled at the 2-sided 
0.05 significance level for the 3 comparisons of M2951 dose group versus placebo using the 
Hochberg procedure. 
8.2 Randomization
Eligible subjects will be randomized 1:1:1:1:1 to treatment with placebo, low-dose M2951 
(25 mg once daily), mid-dose M2951 (75 mg once daily), high-dose M2951 (75 mg twice daily), 
or Tecfidera (administered twice daily at a final dose of 240 mg), through a central randomization 
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process by an IWRS, stratified according to region (USA or Western Europe, Eastern Europe and 
, Eastern Europe and not , and RoW). 
8.3 Endpoints
8.3.1 Primary Endpoints
The primary endpoint is the total number of gadolinium-enhancing T1 lesions at Week 12, 16, 20, 
and 24. The primary analysis is a comparison of each M2951 dose arm versus placebo based on 
this endpoint, with a supportive test for dose-response.
8.3.2 Secondary Endpoints
Key secondary endpoints to evaluate the efficacy and safety of M2951 compared to placebo:
 Annualized relapse rate (ARR), based on protocol-defined qualified relapses, at Week 24 
 Qualified relapse-free status at Week 24 
 Change from Baseline in EDSS at Week 24 
 Safety as assessed by the nature, severity, and occurrence of AEs; vital signs; ECGs; absolute 
concentrations and change from Baseline in Ig levels; absolute numbers and change from 
Baseline in B cells; and clinical laboratory safety parameters (duration of placebo treatment 
group limited to 24 weeks).
Additional secondary endpoints:
To evaluate the efficacy of M2951 compared to placebo:
 Total number of new Gd+ T1 lesions at Week 12, 16, 20, and 24
 Mean per-scan number of Gd+ T1 lesions at Week 12, 16, 20, and 24
 Total number of new or enlarging T2 lesions at Week 12, 16, 20, and 24
 Change from Baseline in the volume of Gd+ T1 lesions at Week 24 
 Change from Baseline in the volume of T2 lesions at Week 24.
To evaluate efficacy within M2951 dose groups:
 Number of Gd+ T1 lesions at Week 48
 Number of new Gd+ T1 lesions at Week 48
 Annualized relapse rate, based on protocol-defined qualified relapses, at Week 48
 Qualified relapse-free status at Week 48
 Change from Baseline in EDSS at Week 48
 Number of new or enlarging T2 lesions at Week 48
 Change from Baseline in the volume of Gd+ T1 lesions at Week 48
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 Change from Baseline in the volume of T2 lesions at Week 48.
To evaluate the efficacy and safety of Tecfidera:
 Total number of gadolinium-enhancing T1 lesions at Week 12, 16, 20, and 24
 Annualized relapse rate, based on protocol-defined qualified relapses, at Week 24
 Qualified relapse-free status at Week 24
 Change from Baseline in EDSS at Week 24
 Safety as assessed by the nature, severity, and occurrence of AEs; vital signs; ECGs; absolute 
concentrations and change from Baseline in Ig levels; absolute numbers and change from 
Baseline in B cells; and clinical laboratory safety parameters 
 Total number of new Gd+ T1 lesions at Week 12, 16, 20, and 24
 Mean per-scan number of Gd+ T1 lesions at Week 12, 16, 20, and 24
 Total number of new or enlarging T2 lesions at Week 12, 16, 20, and 24
 Change from Baseline in the volume of Gd+ T1 lesions at Week 24
 Change from Baseline in the volume of T2 lesions at Week 24
 Number of Gd+ T1 lesions at Week 48
 Number of new Gd+ T1 lesions at Week 48
 Annualized relapse rate, based on protocol-defined qualified relapses, by Week 48
 Qualified relapse-free status at Week 48
 Change from Baseline in EDSS at Week 48 
 Number of new or enlarging T2 lesions at Week 48 
 Change from Baseline in the volume of Gd+ T1 lesions at Week 48 
 Change from Baseline in the volume of T2 lesions at Week 48.
8.3.3 Exploratory Endpoints
Exploratory endpoints are as follows:
 
 Change in HRQoL as measured with SF-36v2 (physical component summary [PCS]/mental 
component summary [MCS] and sub-domains) over time (area under the curve) in all subjects
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Change in HRQoL as measured with SF-36v2 (PCS/MCS and sub-domains) from Baseline to
Week 24 and from Baseline to Week 48 in all subjects
  
 
 
 
 
 
 
8.4 Analysis Sets
For the purposes of analysis, the following analysis sets are defined:
Safety Analysis Set
The Safety Analysis Set consists of all subjects who receive at least 1 dose of trial treatment. 
Subjects will be analyzed according to the actual treatment they receive.
Intent-To-Treat Analysis Set
The Intent-To-Treat ITT Analysis Set consists of all subjects randomly allocated to a treatment, 
based on the intention to treat “as randomized” principle (ie, the planned treatment regimen rather 
than the actual treatment given in case of any difference).
Modified Intent-To-Treat Analysis Set
The modified ITT (mITT) Analysis Set consists of all subjects who belong to both the ITT and 
Safety Analysis Sets, and who have at least one baseline and one post-baseline MRI assessment.
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Per-Protocol (PP) Analysis Set
The PP Analysis Set consists of all subjects who belong to the mITT Analysis Set, complete 
24 weeks of treatment, and do not have any important protocol deviations.
 
 
 
 
 
 
 
 
 
 
8.5 Description of Statistical Analyses
8.5.1 General Considerations
A general description of the statistical methods to be used to analyze the efficacy and safety data 
is outlined below. Prior to partial locking the database for the primary analysis, a detailed 
integrated analysis plan (IAP) will be developed.
Continuous variables will be summarized descriptively using the number of observations, mean,
standard deviation (SD), median, first quartile (Q1), third quartile (Q3), minimum, and maximum. 
Categorical variables will be summarized using frequency counts and percentages. The 
denominator for the percentages will be the total number of subjects in the treatment group and 
analysis set being presented, unless otherwise specified (eg, on some occasions, percentages may 
be calculated out of the total number of subjects with available data at a particular time point).
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All tests of treatment effects will be conducted at a 2-sided α-level of 0.05. P-values and the 95% 
confidence intervals (CIs) will be presented where applicable. Actual p-values will be interpreted 
based on the multiple testing strategy. Treatment comparisons for each data type are described in 
later sections. Alternative or additional statistical methods may be used as appropriate as outlined 
in the IAP.
Data from all investigative sites will be pooled for all planned analyses. Analysis of individual site 
findings or country findings will be considered if necessary. For those measures that are analyzed 
using change from baseline scores, observed scores may also be presented descriptively.
The procedures to be followed in relation to handling missing, unused, or spurious data will be 
described in the IAP. The IAP will provide the definition(s) of Baseline measurement as required.
All subjects will be included in individual subject data listings. 
Any changes to the data analysis methods described in the protocol will require an amendment 
only if a principal feature of the protocol is affected. Any other changes to the planned data analysis 
that does not require a protocol amendment will be described in the IAP and the Clinical Trial
Report (CTR). Additional exploratory analyses will be conducted as deemed appropriate.
8.5.2 Analysis of Primary Endpoint
Primary Efficacy Endpoint
The primary analysis of total number of Gd+ T1 lesions, at Week 12, 16, 20, and 24, will be an 
estimate of lesion rate ratio, together with associated 95% CI and p-value, comparing each M2951 
dose group to placebo, based on a negative binomial (NB) model, where the offset will be based 
on the log of number of scans, with M2951 dose or placebo group as a factor and adjustment for 
covariates based on randomization strata and baseline MRI activity. Other covariates may be 
considered. Should the model fail to converge, the primary analysis will be an estimate of the shift 
in location of the distribution of the Gd+T1 lesion count via the Hodges-Lehman estimate, together 
with associated 95% CI and p-value based on the stratified Wilcoxon rank-sum test, comparing 
each M2951 dose group to placebo. Descriptive statistics for the total number of Gd+ T1 lesions, 
at Week 12, 16, 20, and 24, will be provided for each treatment group. 
The primary analysis of the primary endpoint will be based on the mITT analysis set, with 
supportive analyses based on the ITT and PP analysis sets. If the primary analysis is comprised of 
negative binomial modeling, the computed p-value testing the null hypothesis H0: RR = 1.0 for 
each M2951 dose group will be reported, where RR denotes lesion rate ratio comparing a given 
M2951 dose group to placebo. If the primary analysis must be nonparametric due to model 
nonconvergence, the computed p-value testing the null hypothesis H0: P(X < Y) + 0.5×P(X = Y) 
= 0.5, via the stratified Wilcoxon rank-sum test, for each M2951 treatment group will be reported, 
where X denotes the primary endpoint evaluated for a subject in a given M2951 treatment group, 
and Y denotes the primary endpoint evaluated for a subject in the placebo group. The FWER, ie, 
overall type I error rate for the primary analysis, will be controlled at the 0.05 level by testing the 
3 M2951 hypotheses for the low, mid, and high dose groups using the Hochberg procedure. A test 
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for a monotonic dose-response relationship, between ordered M2951 dose (low, mid, high) and 
the primary efficacy endpoint, will be performed as a supportive analysis.
No formal comparisons between the Tecfidera arm and any other treatment group will be 
performed for the primary endpoint.
8.5.3 Analysis of Secondary Endpoints
The analysis of secondary endpoints will be based on the mITT analysis set.
Descriptive statistics for MRI and clinical secondary endpoints, will be provided for the M2951 
dose arms, the placebo arm (limited to 24 week endpoints), and the Tecfidera arm. For 48 week
endpoints, descriptive statistics will be provided for the placebo/M2951 arm. Descriptive statistics 
for ARR will be calculated for each treatment group as the total number of qualified relapses 
divided by the number of subject-years of observation. 
The multiple-comparison procedure for testing the key secondary efficacy endpoints will be 
provided in the IAP. Other secondary efficacy endpoints will be analyzed for exploratory purposes.
No formal comparisons between the Tecfidera arm and any other treatment group will be 
performed for the secondary efficacy endpoints.
Secondary Efficacy Endpoints: Baseline to 24 weeks
The comparison of a M2951 treatment group to the placebo group using ARR at Week 24 will be 
based on the rate ratio estimated from an NB model for qualified relapse count, with offset equal 
to the log of years on study, with M2951 dose group or placebo group as a factor and adjustment 
for covariates based on randomization strata and pre-baseline relapse activity. The comparison of 
a M2951 treatment group to the placebo group using proportion qualified relapse-free at Week 24,
will be based on the odds ratio estimated from a logistic model for the odds of a subject being 
qualified relapse-free at Week 24, where subjects who discontinue study prior to Week 24 without 
having a qualified relapse are counted as not being qualified relapse-free at Week 24, with M2951 
dose group or placebo group as a factor and adjustment for covariates based on randomization 
strata. The comparison of a M2951 treatment group to placebo group using change from Baseline 
in EDSS at Week 24 will be based on a stratified Wilcoxon rank-sum test, with strata defined by 
baseline EDSS and randomization strata and pre-baseline relapse activity. The analysis of change 
from Baseline in volume of Gd+ T1 lesions at Week 24, and change from Baseline in volume of 
T2 lesions at Week 24, will be based on an analysis of covariance (ANCOVA) model of the 
appropriately transformed variable, with M2951 dose group or placebo group as a factor, 
randomization strata as a factor and baseline MRI activity as a covariate. The comparison of a 
M2951 treatment group to placebo using total number of new Gd+ T1 lesions, or total number of 
new or enlarging T2 lesions, at Week 12, 16, 20, and 24, will be based on an NB model, similar to 
that used for the primary analysis. Estimation of mean per-scan number of Gd+ T1 lesions at 
Weeks 12, 16, 20, and 24, for each treatment group, will be based on the NB model. In the analysis 
of each secondary endpoint, other covariates may be included in the model.
A test for a monotonic dose-response relationship, between ordered M2951 dose (low, mid, high) 
and each of the key secondary efficacy endpoints, will be performed as supportive analyses.
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Secondary Efficacy Endpoints: Baseline to 48 weeks
Descriptive statistics for MRI and clinical endpoints, Baseline to Week 48, will be provided for 
the M2951 dose arms, the placebo/M2951 arm, and the Tecfidera arm.
The number of Gd+ T1 lesions, number of new Gd+ T1 lesions, number of new and enlarging T2 
lesions, the observed and change from Baseline values of Gd+ T1 lesion volume, and observed 
and change from Baseline values of T2 lesion volume, will be summarized by treatment group 
(placebo, 3 M2951 dose groups, and Tecfidera) and time point over the treatment period.
Annualized relapse rate from Baseline to Week 24, from Week 24 to Week 48, and from Baseline 
to Week 48 will be summarized by treatment group. Qualifying relapse-free status at Week 24 and 
at Week 48 will be summarized by treatment group. Observed and change from Baseline values 
of EDSS will be summarized by treatment group and time point over the treatment period.
8.5.4 Analysis of Safety and Other Endpoints
No formal comparisons between the Tecfidera arm and any other treatment group will be 
performed for the safety, HRQoL,  and  endpoints.
8.5.4.1 Safety
Adverse events will be summarized by treatment group, by severity, and by relationship to IMP.
Serious AEs, AEs leading to treatment discontinuation, and AEs leading to treatment interruption, 
will be summarized by treatment group.
Summary statistics will be used to present observed values and changes from baseline in 
continuous laboratory, vital sign, and ECG data. Shift tables will be used to present changes in 
categorical laboratory parameters. Figures may be generated to assist safety evaluation.
Adverse events will be coded according to the Medical Dictionary for Regulatory Activities 
(MedDRA). The severity of AEs will be graded using NCI-CTCAE v4.03 toxicity grades (20). 
The number and percentage of subjects experiencing 1 or more treatment-emergent AEs will be 
summarized according to the MedDRA system organ classes and preferred terms by treatment 
group, relationship to IMP, and severity.
Values for all safety variables will be listed by subject and time point.
8.5.4.2 Patient-reported Health-Related Quality of Life (HRQoL)
Descriptive statistics for each time point and change from baseline will be provided for each health 
domain score and the physical and mental component summary scores (PCS/MCS) for each 
assessment time point. 
In addition, change in HRQoL for PCS/MCS and sub-domains over time (area under the curve)
will be compared between different M2951 treatment arms and placebo.
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Further details on psychometric analyses will be presented in the IAP that will be finalized before 
database lock.
8.5.4.3
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8.6 Interim and Additional Planned Analyses
There will be 3 analyses: (1) a primary analysis, triggered when 100% of subjects enrolled reach 
Week 24 of treatment, or prematurely discontinue from treatment; (2) a Week 52 analysis, 
triggered when 100% of subjects enrolled either reach Week 52 (4-week Safety Follow-up Visit) 
and complete the study, enroll in the OLE, or prematurely discontinue from study; and (  
 
No interim analyses are planned.
Primary Analysis
When the last subject reaches 24 weeks of treatment or discontinues from treatment prematurely, 
the protocol violations are determined, and the database is partially locked for the primary analysis, 
the drug codes will be broken and made available for the primary data analysis. All endpoints 
based on Baseline to Week 24 data will be evaluated. The FWER associated with the multiple 
comparisons of M2951 dose to placebo based on the primary endpoint will be controlled via the 
Hochberg procedure. The multiple-comparison procedure for testing the key secondary endpoints 
will be provided in the IAP.
Week 52 Analysis
The Week 52 analysis will occur when the last subject completes 48 weeks of treatment (either 
completing the 4-week Safety Follow-up Visit at Week 52, or enrolling in the OLE), or 
discontinues from the study prematurely. Protocol violations will be determined and the database 
partially locked prior to the Week 52 analysis. All endpoints based on Baseline to Week 52 data
will be evaluated.
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9 Ethical and Regulatory Aspects
9.1 Responsibilities of the Investigator
The Investigator is responsible for the conduct of the trial at the site and will ensure that the trial 
is performed in accordance with this protocol, the ethical principles outlined in the Declaration of 
Helsinki, ICH GCP, and any other applicable regulations. The Investigator must ensure that only 
subjects who have given informed consent are included in the trial.
According to United States Code of Federal Regulations Part 54.2 (e), for trials conducted in any 
country that could result in a product submission to the US Food and Drug Administration (FDA)
for marketing approval and could contribute significantly to the demonstration of efficacy and 
safety of an IMP (which are considered “covered clinical trials” by the FDA), the Investigator and 
all Sub-investigators are obliged to disclose any financial interest which they, their spouses or their 
dependent children may have in the Sponsor or the Sponsor’s product under study. This 
information is required during the trial and for 12 months following completion of the trial. The 
financial aspects are documented in the Clinical Trial Agreement between the Sponsor and the 
Investigator/institution.
9.2 Subject Information Sheet and Informed Consent
An unconditional prerequisite for each subject prior to participation in the trial is written informed 
consent, which must be given before any trial-related activities are carried out. Adequate 
information must therefore be given to the subject by the Investigator or an appropriate designee 
(if local regulations permit) before informed consent is obtained. 
A Subject Information Sheet must be prepared in the local language in accordance with ICH GCP
and will be provided by the Sponsor for the purpose of obtaining informed consent. In addition to 
providing this written information to a potential subject, the Investigator or a designate will inform 
the subject verbally of all pertinent aspects of the trial, using language chosen so that the 
information can be fully and readily understood by laypersons. The subject will be given sufficient 
time to read the information and the opportunity to ask questions and to request additional 
information and clarification.
If permitted by national regulations, a person other than the Investigator may inform the subject 
about the trial and sign the ICF, as above.
After the information is provided by the Investigator, the ICF must be signed and dated by the 
subject and the Investigator. 
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A separate ICF will be needed for the subset of subjects consenting to
 
A separate ICF will be needed for volunteers prior to performing the MRI dummy run. 
The signed and dated declaration of informed consent will remain at the Investigator’s site, and 
must be safely archived so that the forms can be retrieved at any time for monitoring, auditing, and 
inspection purposes. A copy of the signed and dated information and ICF should be provided to 
the subject prior to participation.
Whenever important new information becomes available that may be relevant to informed consent, 
the Investigator will revise the Subject Information Sheet and any other written information to be
provided to the subjects and submit them to the IRB for review and opinion. Using the approved 
revised Subject Information Sheet and other written information, the Investigator will explain the 
changes to the previous version to each trial subject and obtain new written consent for continued 
participation in the trial. The subject will be given sufficient time to read the information and the 
opportunity to ask questions and to request additional information and clarification about the 
changes.
9.3 Subject Identification and Privacy
A unique number will be assigned to each subject, immediately after informed consent has been 
obtained. This number will serve as the subject’s identifier in the trial as well as in the clinical trial 
database. All subject data collected in the trial will be stored under the appropriate subject number. 
Only the Investigator will be able to link trial data to an individual subject via an identification list 
kept at the site. For each subject, original medical data will be accessible for the purposes of source 
data verification by the Medical Monitor, audits and regulatory inspections, but subject
confidentiality will be strictly maintained.
Data protection and privacy regulations will be observed in capturing, forwarding, processing, and 
storing subject data. Subjects will be informed accordingly, and will be requested to give their 
consent on data handling procedures in accordance with national regulations.
9.4 Emergency Medical Support and Subject Card
Subjects will be provided with Emergency Medical Support cards supplied by the Sponsor for use
during trial participation in order to provide clinical trial subjects with a way of identifying 
themselves as participating in a clinical trial and to give health care providers access to any
information about this participation that may be needed to determine the course of medical 
treatment for the subject. The information provided on the Emergency Medical Support card may 
include the process for emergency unblinding (if applicable).
The first point of contact for all emergencies will be the clinical trial Investigator caring for the 
affected subject. The Investigator agrees to provide his or her emergency contact information on 
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the card for this purpose. If the Investigator is available when an event occurs, they will answer 
any questions. Any subsequent action (eg, unblinding) will follow the standard process established 
for Investigators.
In cases where the Investigator is not available, the Sponsor provides the appropriate means to 
contact a Sponsor physician. This includes the provision of a 24-hour contact number at a call 
center, whereby the health care providers will be given access to the appropriate Sponsor physician 
to assist with the medical emergency and to provide support for the potential unblinding of the 
subject concerned.
9.5 Clinical Trial Insurance and Compensation to Subjects
Insurance coverage will be provided for each country participating to the trial. Insurance 
conditions shall meet good local standards, as applicable.
9.6 Independent Ethics Committee or Institutional Review Board
Prior to commencement of the trial at a given site, this clinical trial protocol will be submitted 
together with its associated documents to the responsible IEC or IRB for its favorable opinion or 
approval, which will be filed in the Investigator Site File. A copy will be filed in the Sponsor Trial 
Master File at the Sponsor or designee organization.
The IEC or IRB will be asked to document the date of the meeting at which the favorable opinion
or approval was given and the members and voting members present. Written evidence of 
favorable opinion or approval that clearly identifies the trial, the clinical trial protocol version and 
the Subject Information Sheet and ICF version reviewed should be provided. Where possible, 
copies of the meeting minutes should be obtained.
Amendments to this clinical trial protocol will also be submitted to the concerned IEC or IRB, 
before implementation of substantial changes (see Section 10.5). Relevant safety information will 
be submitted to the IEC or IRB during the course of the trial in accordance with national 
regulations and requirements.
9.7 Health Authorities
The clinical trial protocol and any applicable documentation (eg, IMP Dossier, Subject 
Information Sheet and ICF) will be submitted or notified to the Health Authorities in accordance 
with all local and national regulations for each site.
10 Trial Management
10.1 Case Report Form Handling
Refer to the Manual of Operations for eCRF handling guidelines. 
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The main purpose of the eCRF is to obtain data required by the clinical trial protocol in a complete, 
accurate, legible, and timely manner. The data in the eCRF should be consistent with the relevant 
source documents.
The Investigator or designee is responsible for ensuring that the data collected in the course of this 
trial is accurate and documented appropriately on all applicable forms. They will then be 
processed, evaluated, and stored in anonymous form in accordance with applicable data protection 
regulations. The Investigator must ensure that the eCRFs and any other associated documents 
forwarded to Sponsor or its designated organization contain no mention of any subject names.
For patient-reported outcomes, these will be collected on paper.
The data will be entered into a validated database. The Sponsor or its designee will be responsible 
for data processing, in accordance with the Sponsor’s data management procedures. Database lock 
will occur once quality control and quality assurance procedures have been completed. Electronic 
PDF files of the eCRFs will be provided to the Investigators at the completion of the trial.
10.2 Source Data and Subject Files
The Investigator must keep a file (medical file, original medical records) on paper or electronically 
for every subject in the trial. It must be possible to identify each subject by using this subject file. 
This file will contain the demographic and medical information for the subject listed below and 
should be as complete as possible. 
 Subject’s full name, date of birth, sex, height, weight
 Medical history and concomitant diseases
 Prior and concomitant therapies (including changes during the trial)
 Trial identification, ie, the Sponsor trial number for this clinical trial, and subject number
 Dates for entry into the trial (informed consent) and visits to the site
 Any medical examinations and clinical findings predefined in this clinical trial protocol
 All AEs
 Date that the subject left the trial including any reason for early withdrawal from the trial or 
IMP (if applicable).
All documents containing source data must be filed, including, but not limited to, computerized 
tomography or MRI scan images, ECG recordings, CXRs, and laboratory results. Such documents 
must bear the subject number and the date of the procedure. If possible, this information should be 
printed by the instrument used to perform the assessment or measurement. As necessary, medical 
evaluation of such records should be performed; all evaluations should be documented, signed,
and dated by the Investigator.
For data that may be recorded directly in the eCRF such as a questionnaire or diary, there will be 
no record in the original subject file and therefore the data entered in the eCRF will be considered 
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source data. The clinical trial protocol or the Manual of Operations should clearly and completely 
specify all subject data in the eCRF to be considered source data. 
Electronic subject files will be printed whenever the Medical Monitor performs source data 
verification. Printouts must be signed and dated by the Investigator, countersigned by the Medical 
Monitor and kept in a safe place at the site.
10.3 Investigator Site File and Archiving
Upon initiation of the trial, the Investigator will be provided with an Investigator Site File 
containing all necessary trial documents, which will be completed throughout the trial and updated 
as necessary. The file must be available for review by the Medical Monitor, during Sponsor audits
and for inspection by Health Authorities during and after the trial, and must be safely archived for 
at least 15 years (or longer, per local requirements or as otherwise notified by the Sponsor) after 
the end of the trial. The documents to be archived include the Subject Identification List and the 
signed subject ICFs. If archiving of the Investigator Site File is no longer possible at the site, the 
Investigator must notify the Sponsor/designee.
All original subject files (medical records) must be stored at the site (hospital, research institute, 
or practice) for the longest possible time permitted by the applicable regulations, and/or as per ICH 
GCP guidelines, whichever is longer. In any case, the Investigator should ensure that no 
destruction of medical records is performed without the written approval of the Sponsor.
10.4 Monitoring, Quality Assurance and Inspection by Health 
Authorities
This trial will be monitored in accordance with the ICH GCP and any other applicable regulations. 
The site Medical Monitor will perform visits to the trial site at regular intervals.
The clinical trial protocol, each step of the data capture procedure, and the handling of the data, 
including the final clinical trial report, will be subjected to independent Quality Assurance 
activities. Audits may be conducted at any time during or after the trial to ensure the validity and 
integrity of the trial data. Representatives of the Quality Assurance unit from the Sponsor or a 
designated organization, as well as Health Authorities, must be permitted to access all trial
documents and other materials at the site, including the Investigator Site File, the completed 
eCRFs, all IMP and IMP accountability records, and the original medical records or files for each 
subject.
10.5 Changes to the Clinical Trial Protocol
Changes to the clinical trial protocol will be documented in writing. Substantive amendments will 
usually require submission to the Health Authorities and to the relevant IEC/IRB for approval or 
favorable opinion. In such cases, the amendment will be implemented only after approval or 
favorable opinion has been obtained.
Minor (nonsubstantial) protocol amendments, including administrative changes, will be filed by 
the Sponsor and at the site. They will be submitted to the relevant IEC/IRB or to Health Authorities 
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only where requested by pertinent regulations. Any amendment that could affect the subject’s 
agreement to participate in the trial requires additional informed consent prior to implementation 
following the process as described in Section 9.2.
10.6 Clinical Trial Report and Publication Policy
10.6.1 Clinical Trial Report
After completion of the 48-week main study, a clinical trial report will be written by the Sponsor 
in consultation with the Coordinating Investigator following the guidance in ICH Topic E3 within 
the legally required period for participating countries.  
 
 
10.6.2 Publication
An Investigator will inform the Sponsor in advance about any plans to publish or present data from 
the trial. Any publications and presentations of the results (abstracts in journals or newspapers, 
oral presentations, etc.), either in whole or in part, by Investigators or their representatives will 
require review by the Sponsor before submission. The Sponsor will not suppress publication, but 
maintains the right to delay publication in order to protect intellectual property rights.
Posting of data on clinicaltrials.gov is planned and will occur 12 months after the last clinic visit 
of the final trial subject or another appropriate date to meet applicable requirements.
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Appendix II: Total Blood Volume
Blood will be drawn on at least 23 separate days/visits. Additional samples may be drawn if 
unscheduled visits occur.  
 The planned maximum 
volume of blood to be drawn in this trial is approximately 604 mL over the 4-week Screening 
Period, 24-week Treatment Period, 24-week Treatment Extension Period, and 4-week Safety 
Follow-Up Period (56 weeks total). For subjects participating in the optional Open-label Long 
Term Extension Period, an additional 382 mL of blood (approximately) will be collected over the
100 weeks of participation.
Total Blood Volume during Main Study
Assay
Approximate
Sample
Volume (mL)
Number of 
Samples
Approximate
Subtotal Volume 
(mL)
Screening tests: hematology, chemistry, 
coagulation, FSH, viral serology testing (HBsAg, 
Anti-HCV, HIVa) 19.5 1 19.5
Hematology, chemistryb,c 12.5 24 300
Immunoglobulins 4 5 20
QuantiFERON-TB test 4.5 1 4.5
B,  cell count 10 5 50
Total 604
ALP=alkaline phosphatase, ALT=Alanine aminotransferase, AST=Aspartate aminotransferase,  
, FSH=follicle-stimulating hormone, GGT=γ-glutamyl-transferase, HBsAg=hepatitis B surface antigen, 
HCV=hepatitis C virus, HIV=human immunodeficiency virus, LDH=lactate dehydrogenase,  
 TB=tuberculosis.
a HIV testing will be done at Screening only where required as per local regulations.
b Chemistry will include: albumin, AST, ALT, ALP, GGT, LDH, total bilirubin, total protein, creatinine, amylase, lipase, 
total CO2, blood urea nitrogen, glucose, sodium, potassium, chloride, calcium, magnesium, phosphate as shown in
Table 7.
c Supplemental LFTs are included in this row as shown in Table 7.
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Total Blood Volume during Open-label Extension Period
Assay
Approximate
Sample 
Volume(mL)
Number of 
Samples
Approximate
Subtotal Volume 
(mL)
Hematology, chemistrya,b 5 48 240
Immunoglobulins 5 4 20
B,  cell count 6 4 24
Total 382
ALP=alkaline phosphatase, ALT=alanine aminotransferase, AST=aspartate aminotransferase, 
GGT=γ-glutamyl-transferase, LDH=lactate dehydrogenase, , .
a Chemistry will include: albumin, AST, ALT, ALP, GGT, LDH, total bilirubin, total protein, creatinine, amylase, lipase, 
total CO2, blood urea nitrogen, glucose, sodium, potassium, chloride, calcium, magnesium, phosphate as shown in
Table 7.
b
Supplemental LFTs are included in this row as shown in Table 7.
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Appendix III: Protocol Amendments and List of Changes
The information for the current amendment is on the title page.
Protocol Version 1.0 (05 July 2016) was the original protocol and a revised global amended protocol 
(Version 2.0) was issued on 28 November 2017. The revised global amended protocol (Version 3.0) 
was issued on 29 May 2018. 
Amendment # 2
Rationale
The protocol was revised to include the recommendations from the Czech Republic Regulatory 
Authority (RA) to provide clarification to guidelines on withholding or permanent withdrawal of IMP, 
remove interim/futility analyses since primary analyses could be reached earlier due to fast 
recruitment, update the visit schedule according to the Modification of Visit Schedule for Monitoring 
of Liver Function Tests based on IDMC recommendations (16 April 2018), clarify that monthly urine 
pregnancy testing would occur at all sites in all countries, as well as other administrative changes.
Major Scientific Changes
Changes to the protocol were made to include the recommendations from the Czech Republic RA, 
include clarification on urine pregnancy testing for all sites, modify the supplemental safety visit 
schedule in the Schedules of Assessment based on the visit schedule memo issued to sites (16 April 
2018), include a table on withholding and permanent withdrawal of IMP. 
The key reasons for Global Amendment 2, Protocol Version 3.0, are summarized below:
 Update exploratory endpoints
 Remove Futility analyses (also referred to as interim analyses)
 Remove 2-week additional safety visits after Week 16 and update to a monthly (4-week) 
schedule
 Clarify that phone calls for confirmation of home pregnancy testing is required only if urine 
pregnancy tests are completed at home
 Include monthly urine pregnancy tests for all sites in all countries during the main study and 
OLE period
 Clarify the schedule of collection of additional PK samples
 Update Section 5.6.1 to reference to Section 6.4.4 and add a table (in Section 6.4.4.1) with 
guidelines on withholding and withdrawal of IMP
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 Add sub bullets to Section 6.4.4.1 and 6.4.4.2 for increased clarity on management of 
laboratory evaluation abnormalities
 Update Section 6.4.4.2 to match SmPC for tecfidera
 Include a new Table 6 to provide guidelines for withholding and modification of IMP
 Update Table 7 (previously Table 6) to include a superscript to the footnote on urine 
microscopy.
Amendment # 1
Rationale
For Poland only, a local amendment (Version 1.1) was created to provide additional at-home 
pregnancy testing at the request of the Polish Health Authority. The protocol was further revised to 
include the changes from the local Poland amendment, recommendations from the IDMC meeting on 
05 October 2017, and to add an optional Long Term Open-label Extension Period.
Major Scientific Changes
The key reasons for Global Amendment 1, Protocol Version 2.0, are summarized below:
 Addition of 2-week safety visits for chemistry monitoring (including ALT, AST, alkaline 
phosphatase, GGT, and bilirubin) until the IDMC determines the optimum monitoring interval
for subject randomized to the M2951/placebo arm
 Addition of a comprehensive hepatic panel for subjects randomized to the M2951/placebo arm 
for whom withdrawal criteria are met or who permanently discontinue dosing because of 
elevated transaminases
 Addition of blood tests (ESR, hsCRP, and fibrinogen) for all subjects at any 1 point during the 
trial.
 Addition of Open-label extension period, with modifications to planned trial period, addition 
of objective and endpoints, addition of statistical analyses and analysis set, addition of 
informed consent prior to participation, and clarification that there will be a second clinical 
trial report
 Addition of pharmacokinetic endpoints and statistical analyses
 Clarification of pharmacodynamics endpoints
 Clarification that separate informed consent will be collected for the MRI dummy run
 Clarification that soluble factors may be measured from pharmacokinetic blood samples if 
there is sufficient volume
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 Clarification that blood pressure will be collected in a semisupine position
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2 List of Abbreviations and Definition of Terms
ADaM Analysis Data Model
AE Adverse Event
AIC Akaike Information Criterion
ALT Alanine Amino-Transferase
ARR Annualized Relapse Ratio
AST Aspartate Amino-Transferase
ATC Anatomical Therapeutic Class
BE Blinded Extension
BEA Blinded Extension Analysis
BID Twice daily
BOA Biostatistics Outputs Assembly
BTK Bruton’s tyrosine kinase
CFB Change From Baseline
CI Confidence Interval
CDF Cumulative distribution function
CS Clinically Significant
CSR Clinical Study Report
C-SSRS Columbia- Suicide Severity Rating Scale
CXR Chest X-Ray
EAIR Exposure Adjusted Incidence Rate
eCRF Electronic Case Report Form
ECG Electrocardiogram
EEA European Economic Area
ETA Inter-individual random error estimate 
FOCE(I) First order conditional estimation (with interaction)
FSFD First subject first dose
FWER Family-wise Type I error rate
Gd+ Gladolinium-positive
GI Gastrointestinal
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GLMM Generalized Linear Mixed Model
HRQoL Health-related quality of life
IA Interim Analysis
IAP Integrated Analysis Plan
IDMC Independent Data Monitoring Committee
Ig Immunoglobulin
IMP Investigational Medical Product
IOV Interoccasion variability
IV Intravenous
IWRS
LOCF
Interactive Web Response System
Last Observation Carried Forward
MAR Missing At Random
MCAR Missing Completely At Random
MCS Mental component summary
MedDRA Medical Dictionary for Regulatory Activities
mITT
MMRM
Modified Intention to Treat  
Mixed-effect Model for Repeated Measures
MRI Magnetic resonance imaging
MS Multiple sclerosis
M&S Modeling and simulation
NB Negative binomial
NCI-CTCAE National Cancer Institute – Common Terminology Criteria for Adverse 
Events
NONMEM Non-linear mixed effects modeling software
(Δ)OFV (Difference in) Objective function value
PCS Physical component summary
PD Pharmacodynamics
PiC Powder in capsule
PK Pharmacokinetics
PsN Perl-speaks-NONMEM
PT Preferred Term
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QD Once daily
Q1 25th Percentile
Q3 75th Percentile
RoW Rest of the World
RRMS Relapsing-Remitting Multiple Sclerosis
SAF Safety Analysis Set
SAP Statistical Analysis Plan
SCR Screening Analysis Set
SDTM Study Data Tabulation Model
SD
SE
Standard Deviation
Standard Error
SF-36v2 Short Form 36-item Health Status Survey version 2.0
SLDR Subject Level Data Review
SOC System Organ Class
SPMS Secondary progressive multiple sclerosis
TEAE Treatment Emergent Adverse Event
TLF Table /Listing/Figure
ULN Upper Limit of Normal
VPC Visual predictive check
VS Vital Signs
WHO-DD World Health Organization Drug Dictionary
3 Modification History
Unique
Identifier for
SAP Version
Date of
SAP Version
Author Changes from the Previous Version
1.0 14 Feb 2018 NA – first version
4 Purpose of the Integrated Analysis Plan
The purpose of this Integrated Analysis Plan (IAP) is to document technical and detailed 
specifications for analyses of data collected for protocol MS200527-0086 dated 05 July 2016 
(version 1.0). The IAP is based upon Section 8 (Statistics) of the trial protocol and is prepared in 
compliance with International Conference on Harmonization E9. 
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The first version (version 1.0) of the IAP includes details for the primary and blinded extension 
statistical analyses.
Results of the analyses described in this IAP will be included in the Clinical Study Report 
(CSR). Additionally, the planned analyses identified in this IAP will be included in regulatory 
submissions or future manuscripts. Any post-hoc, or unplanned analyses performed to provide 
results for inclusion in the CSR but not identified in this prospective IAP will be clearly 
identified in the CSR. 
The final clinical database cannot be locked until the final IAP has been approved and signed.
Another SAP document (MS200527-0086_IDMC_SAP_v1.0) detailed specifications for the 
Independent Data Monitoring Committee (IDMC) analyses.
5 Objectives and Endpoints
Objective Endpoint IAP 
section
Primary
Objective
The primary objective is to 
evaluate the efficacy and 
dose-response of Evobrutinib
on the number of 
gadolinium-positive (Gd+) T1 
magnetic resonance imaging 
(MRI) lesions versus placebo 
after 24 weeks of treatment.
Primary Endpoint:
 Total number of gadolinium-enhancing T1 lesions 
at Weeks 12, 16, 20, and 24
14.1
Key 
Secondary 
Objectives
To evaluate the efficacy and 
dose-response of Evobrutinib
on clinical endpoints over 24 
weeks versus placebo
Secondary Endpoints:
 Annualized relapse rate (ARR), based on protocol-
defined qualified relapses, at Week 24 
 Qualified relapse-free status at Week 24
 Change from Baseline in Expanded Disability 
Status Scale (EDSS) at Week 24
14.2.1
To evaluate the safety of 
Evobrutinib
Secondary Endpoint: 
 Safety as assessed by the nature, severity, and 
incidence of adverse events (AEs); vital signs; 
electrocardiograms (ECGs); absolute 
concentrations and change from Baseline in 
immunoglobulin (Ig) levels; absolute numbers and 
change from Baseline in B cells; and clinical 
laboratory safety parameters (duration of placebo 
treatment group is limited to 24 weeks).
15
Other 
Secondary 
Objectives
To evaluate the efficacy of 
Evobrutinib on additional MRI 
parameters over 24 weeks 
versus placebo 
Secondary Endpoints:
 Total number of new Gd+ T1 lesions at Weeks 12, 
16, 20, and 24
 Mean per-scan number of Gd+ T1 lesions at
Weeks 12, 16, 20, and 24
 Total number of new or enlarging T2 lesions at
Weeks 12, 16, 20, and 24
14.2.2
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 Change from Baseline in the volume of Gd+ T1 
lesions at Week 24
 Change from Baseline in the volume of T2 lesions 
at Week 24
To evaluate the efficacy of 
Evobrutinib on clinical and MRI 
endpoints from Weeks 24 to 48
Secondary Endpoints:
 Number of Gd+ T1 lesions at Week 48
 Number of new Gd+ T1 lesions at Week 48
 Annualized relapse rate, based on protocol-
defined qualified relapses, at Week 48
 Qualified relapse-free status at Week 48
 Change from Baseline in EDSS at Week 48
 Number of new or enlarging T2 lesions at Week 
48
 Change from Baseline in the volume of Gd+ T1 
lesions at Week 48
 Change from Baseline in the volume of T2 lesions 
at Week 48
14.2.2
To evaluate the efficacy of 
Tecfidera on clinical and MRI 
endpoints over 24 weeks 
Secondary Endpoints:
 Total number of gadolinium-enhancing T1 lesions 
at Weeks 12, 16, 20, and 24
 Mean per-scan number of Gd+ T1 lesions at
Weeks 12, 16, 20, and 24
 Annualized relapse rate, based on protocol-
defined qualified relapses at Week 24
 Qualified relapse-free status at Week 24
 Change from Baseline EDSS at Week 24
 Total number of new Gd+ T1 lesions at Weeks 12, 
16, 20, 24
 Total number of new or enlarging T2 lesions at 
Weeks 12, 16, 20, 24
 Change from Baseline in the volume of Gd+ T1 
lesions at Week 24
 Change from Baseline in the volume of T2 lesions 
at Week 24
14.2.2
To evaluate the efficacy of 
Tecfidera on clinical and MRI 
endpoints from Weeks 24 to 48
Secondary Endpoints:
 Number of Gd+ T1 lesions at Week 48
 Number of new Gd+ T1 lesions at Week 48
 Annualized relapse rate, based on protocol-
defined qualified relapses, at Week 48 
 Qualified relapse-free status at Week 48
 Change from Baseline in EDSS at Week 48
 Number of new or enlarging T2 lesions at Week 
48
 Change from Baseline in the volume of Gd+ T1 
lesions at Week 48
 Change from Baseline in the volume of T2 lesions 
at Week 48
14.2.2
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To evaluate the safety of 
Tecfidera
Secondary Endpoint:
 Safety as assessed by the nature, severity, and 
incidence of AEs; vital signs; ECGs; absolute 
concentrations and change from Baseline in Ig 
levels; absolute numbers and change from 
Baseline in B cells; and clinical laboratory safety 
parameters
15
Exploratory
Objective
 
 
 
 
 
 
 
 
 
  
14.2.9
To explore the benefit of 
Evobrutinib treatment on 
patient-reported health related 
quality of life (HRQoL) versus 
placebo, and to evaluate the 
effect of Tecfidera on HRQoL
Exploratory Endpoints:
 Change in HRQoL as measured with SF-36v2 
(physical component summary [PCS]/mental 
component summary [MCS] and sub-domains) 
over time (area under the curve) in all subjects
 Change in HRQoL as measured with SF-36v2 
(PCS/MCS and sub-domains) from Baseline to 
Week 24 and from Baseline to Week 48 in all 
subjects
14.2.3
6 Overview of Planned Analyses
This IAP (Version 1.0) covers the analyses for futility, efficacy,  
, and safety based on the data cut-offs for the primary and blinded 
extension analyses. Section 9 describes how data collected after the cut-off date will be handled. 
6.1 Independent Monitoring Committee review
An IDMC will be set up to continually review available safety and tolerability data and will be 
mandated to make immediate decisions regarding the conduct of the trial; no additional risk 
minimization measures are proposed. IDMC meetings will take place every 4 months or as 
requested by the IDMC members. Details of the statistical analyses of the IDMC are provided in 
the IDMC SAP v1.0 and the IDMC charter v1.0.
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6.2 Interim Analysis
If performed, the aim of the Interim Analysis (IA) was to evaluate overall futility based on the 
highest dose of Evobrutinib to determine whether or not to continue the study. The IA was to be 
triggered when the first 50% of subjects enrolled out of the planned enrollment reach Week 24 of 
treatment. It was planned that placebo subjects would continue at the 25 mg QD dose after Week 
24, with consideration given to changing this dose based on data from the IA.  
 analyses were not to be included in the IA.
When the last subject was enrolled in the study in July 2017, it was determined that only 
approximately 14 weeks would elapse between the first 50% of enrolled subjects reaching Week 
24 (IA trigger point) and 100% of enrolled subjects reaching Week 24 (primary analysis trigger 
point). It was decided that the IA would not be conducted, as it would occur too late to support 
early decision-making, and IA conduct would interfere with preparations for the primary 
analysis. Thus this IAP does not provide specifications for the analysis of IA endpoints.
6.3 Primary Analysis
When the last subject reaches 24 weeks of treatment or discontinues from treatment prematurely, 
the protocol violations are determined, and the database is partially locked for the primary 
analysis, the drug codes will be broken and made available for the primary data analysis. All 
endpoints based on Baseline to Week 24 data will be evaluated (including ).
6.4 Blinded Extension Analysis
The blinded extension analysis will occur only when the last subject completes the Week 52 
safety follow-up or discontinues early, the protocol violations are determined, and the database is 
locked for the blinded extension analysis. All endpoints based on Baseline to Week 52 data will 
be evaluated (except for  endpoints collected to Week 24 which will have been fully 
evaluated at the Primary Analysis).
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7 Changes to the Planned Analyses in the Clinical Trial 
Protocol
CTCAE Grades for Relevant Laboratory Parameters
The Grade 1 definitions for the laboratory parameters AST, ALT, bilirubin, amylase, and lipase 
in Table 4 in the protocol Version 1.0 were cited incorrectly. All laboratory abnormalities will be 
graded as specified in CTCAE (2), version 4.03. This table is also now removed from protocol 
version 2.0.
 
 
 
 
Region Randomization Stratum
Due to extreme imbalance in enrollment between Eastern Europe and Western Europe, region 
will not be used for adjustment or stratification in the different analyses.
Secondary Endpoints wording
In the description of lesion endpoints in this protocol, the word “total” refers to summing over 
assessments at weeks 12, 16, 20, 24.  So “total” does not apply to the lesion count observed at a 
single timepoint, such as week 48. To avoid confusion, wording of MRI secondary endpoints at 
Week 48 was changed by removing the word “total”.
Wording of “Proportion of subjects who remain qualified relapse-free at Week 24” endpoint 
was changed to “Qualified relapse-free status at Week 24”. The same correction was applied to 
this endpoint at Week 48. This update is also performed in protocol version 2.0.
Per-Protocol (PP) Analysis Set definition
The protocol defined the PP analysis set as all subjects who belong to the mITT Analysis Set, 
complete 24 weeks of treatment, and do not have any important protocol deviations. The 
definition has been clarified to specify “do not have any clinically important protocol deviations.
“Clinically important” protocol deviations comprise the subset of important protocol deviations 
that lead to exclusion of  a subject from an analysis set.
Pharmacodynamic (PD) Analysis Set definition
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The protocol defined the PD analysis set as all subjects who receive at least 1 dose of 
Evobrutinib or placebo and have at least 1 measured PD endpoint, not including  
, at a scheduled PD time point postdose without deviations or important events 
affecting PD, and who provide evaluable PD data. 
Postdose is to be understood as post-baseline which can be confusing given the fact PD 
parameters are evaluated predose. Therefore, to avoid confusion, postdose was replaced with 
post-baseline.
Analysis of Secondary Endpoints
In the analysis of the key secondary endpoint, change from baseline (CFB) in EDSS at Week 24, 
the rank ANCOVA analysis decribed in Section 8.5.3 of the protocol will be replaced with 
Hodges-Lehmann estimation of the shift in distribution location, and a stratified Wilcoxon rank-
sum test [Healy et al 2011], one test for each Evobrutinib versus placebo comparison, where the 
stratification will at a minimum adjust for categorical baseline EDSS. Categories such as  ≤ 3.0 
versus > 3.0, corresponding to a clinically meaningful threshold close to the median baseline 
(BL) value, will be considered. Descriptive statistics for Week 24 EDSS CFB values treated as 
continuous variables (i.e., mean, median, and range) will be reported. Per EMA Guideline on 
Clinical Investigation of Medicinal Products for the Treatment of Multiple Sclerosis (2015), 
mean EDSS CFB is not considered an appropriate efficacy parameter. Therefore, descriptive 
statistics for categorical Week 24 EDSS CFB, i.e., number and proportion improving, stable, or 
worsening, will also be reported. Here improvement is defined as a decrease of 1.0 point or 
more, stable condition as a change of no more than half a point in either direction, and worsening 
as an increase of 1.0 point or more.
In the analysis of the secondary endpoint CFB in T2 lesion volume at Week 24, the ANCOVA 
model of the appropriately transformed variable, described in Section 8.5.3 of the protocol, will 
be replaced with a Mixed-effect Model for Repeated Measures (MMRM) approach for the 
appropriately transformed variable.  This approach will better exploit the data available at earlier 
timepoints (i.e., weeks 12, 16, 20) for subjects missing the Week 24 assessment, assuming data 
are missing at random (MAR). At a minimum, the model will adjust for baseline T2 lesion 
volume.
In the analysis of the secondary endpoint CFB in Gd+ T1 lesion volume at Week 24, the 
ANCOVA model of the appropriately transformed variable, described in Section 8.5.3 of the 
protocol, will be replaced with Hodges-Lehmann estimation of the shift in distribution location, 
and a stratified Wilcoxon rank-sum test, one test for each Evobrutinib versus placebo 
comparison, where the stratification will adjust for categorical baseline disease activity.  
Categories such as presence versus absence of Gd+ T1 lesion at baseline will be considered.  The 
distribution of enhancing lesion volume has considerable probability mass at zero [van den 
Elskamp et al 2011], so Gd+ T1 lesion volume CFB is not amenable to transformation to an 
approximately normal random variable.  
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SF-36 Exploratory Analysis
In the analysis of SF-36 endpoints, the analysis of area under the curve (AUC), i.e, curve of SF-
36 CFB versus time through Week 24, or through Week 48, will be omitted. The analysis of SF-
36 score CFB at Week 24, or SF-36 score CFB at Week 48, will be retained and will be based on
MMRM. Each model will include treatment, week of visit, and treatment-by-week interaction as 
fixed effects, random effect for subject and baseline adjustment for the corresponding SF-36 
endpoint.
For each SF-36 endpoint, a figure will be added describing the distribution of % CFB at Week 
24, with one curve for each treatment group (Evobrutinib or placebo). The estimated cumulative 
distribution function (CDF) curve for % CFB at Week 24 will display proportion of subjects 
having a value for % CFB at Week 24 ≤ x, where the range of x depends on the data.  Based on 
blinded baseline data, the minimum baseline value of each SF-36 endpoint is strictly positive, so 
the % CFB values are well defined for each of the SF-36 endpoints.
Protocol Version 1.0 references to the Final Analysis
An open label extension has been added to the study in version 2.0 of the protocol. Assuming 
that there will be an analysis at the end of the open label extension period, the analysis planned 
for the end of the blinded extension period, identified as “final” in version 1.0 of the protocol, 
will not be the final analysis of the study. Therefore, the analysis planned for the end of the 
blinded extension period has been renamed as the blinded extension analysis (BEA) in this IAP.
8 Protocol Deviations and Analysis Sets
8.1 Definition of Protocol Deviations and Analysis Sets
Important protocol deviations are protocol deviations that might significantly affect the 
completeness, accuracy, and/or reliability of the study data or that might significantly affect a 
subject's rights, safety, or well-being. 
The following important deviations will be identified and confirmed prior to or at the Data 
Review Meeting at the latest.
 Subjects who are dosed on the study despite not satisfying the inclusion criteria
 Subjects who develop withdrawal criteria whilst on the study but are not withdrawn
 Subjects who receive the wrong treatment or an incorrect dose
 Subjects who receive an excluded concomitant medication
 Deviation from Good Clinical Practice
 Inclusion and exclusion criteria violations
 Concomitant medication violations
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 Other violations/events that may have a relevant influence on the 
 (e.g., adverse events (AEs), vomiting, 
sample processing errors, inaccurate dosing, etc.)
Any important protocol deviations that lead to the exclusion of a subject from an analysis set will 
be considered clinically important (see Section 10.2).
In addition to protocol deviations that lead to exclusion of a subject from an analysis set, this 
study will allow for protocol deviations that lead to exclusion of a specific assessment on a 
subject from an analysis, but not all assessments for that subject. For example, if a subject uses 
high dose corticosteroids in the 3 weeks prior to a scheduled MRI scan, lesion data from that 
scan will be excluded from certain analyses and treated as missing.
All important protocol deviations should be documented in Clinical Data Interchange Standards 
Consortium Study Data Tabulation Model (SDTM) whether identified through sites monitoring, 
medical review and/or programming based on the inclusion/exclusion criteria presented in the 
protocol. Important protocol deviations are listed and described in MS200527-
0086_List_of_deviations_v1.0.
8.2 Definition of Analysis Sets and Subgroups
Screening Analysis Set (SCR)
The SCR Analysis Set includes all subjects who signed the informed consent. 
Safety Analysis Set (SAF)
The SAF consists of all subjects who receive at least one dose of trial treatment. Subjects will be 
analyzed according to the actual treatment they receive.
For safety analyses based only on the second 24-week treatment period, safety analysis set will 
be restricted to subjects having entered this period. This restriction will be identified as SAF-BE
(Blinded Extension).
Intent-To-Treat Analysis Set (ITT)
The ITT Analysis Set consists of all subjects randomly allocated to a treatment, based on the 
intention to treat “as randomized” principle (ie, the planned treatment regimen rather than the 
actual treatment given in case of any difference).
Modified Intent-To-Treat Analysis Set (mITT)
The mITT Analysis Set consists of all subjects who belong to both the ITT and Safety Analysis 
Sets, and who have at least one baseline and one post-baseline MRI assessment. Subjects will be 
analyzed according to the treatment they were randomized to.
For efficacy analyses based only on the second 24-week treatment period, mITT will be 
restricted to subjects having an MRI assessment in this period. This restriction will be identified
as mITT-BE.
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Per-Protocol (PP) Analysis Set
The PP Analysis Set consists of all subjects who belong to the mITT Analysis Set, complete 
24 weeks of treatment, and do not have any clinically important protocol deviations.
 
 
 
 
 
 
 
 
.
 
 
 
The use of the analysis sets in the different analyses is summarized in the following table:
Table 1: Analysis sets
Analyses
SCR
Analysis 
Set
ITT
Analysis 
Set
SAF
Analysis 
Set
SAF-BE 
Analysis 
Set
PP
Analysis
Set
mITT
Analysis
Set
mITT-BE
Analysis
Set
Subject 
Disposition
status

Analysis sets 
Important 
Protocol 
Deviations

Demographic 
and Baseline 
Assessments

Prior 
Medications

Concomitant 
Medications
 
Concurrent 
procedures
 
Compliance 
and Exposure
 
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Analyses
SCR
Analysis 
Set
ITT
Analysis 
Set
SAF
Analysis 
Set
SAF-BE 
Analysis 
Set
PP
Analysis
Set
mITT
Analysis
Set
mITT-BE
Analysis
Set
Safety 
Analysis
 
Primary 
Efficacy 
Analysis
 

Secondary 
Efficacy 
Analysis and 
exploratory 
HRQoL 
Analysis
 
Randomization 
listing

Descriptive statistics for number of Gd+ T1 lesions over time until Week 24 will be presented 
for the following subgroups:
 ≤ 1 versus ≥ 2 relapses in last 2 yrs (i.e., approximately low versus high disease activity)
 EDSS ≤ 3.0 vs EDSS ≥ 3.5 (i.e., approximately lower versus higher risk of  
transitioning from RRMS to SPMS with relapses).
9 General Specifications for Statistical Analyses
All statistical analyses will be performed by .
 
 
PPD
CCI
CCI
CCI
CCI
C
CI
Evobrutinib Phase II in Relapsing Multiple Sclerosis
MS200527-0086 14 Feb 2018 / Version 1.0
20/86
Treatment groups and Investigational Medical Product (IMP)
Treatment groups are defined as placebo, Evobrutinib 25 mg QD, Evobrutinib 75 mg QD, 
Evobrutinib 75 mg BID, and Tecfidera. Unless otherwise indicated, all analyses will be 
presented separately for the five treatment groups. The IMPs are placebo, Evobrutinib, and 
Tecfidera.
Actual Treatment Assignment
For the first 24-week treatment period, a subject who received 2 different types of kits over the 
course of treatment, should be tabulated according to the kit received most frequently. If there is 
a “tie”,  the highest dose will be chosen.
For the second 24-week treatment period, the same rule as for the first 24-week treatment period 
will be applied, with a distinction between subjects taking Placebo in the first period and 
Evobrutinib 25 mg in the second period.
If by mistake, a subject taking placebo in the first period was to take Evobrutinib 75 mg QD in 
the second period, this subject would be analyzed in “Evobrutinib 75 mg QD” treatment group.
For overall tables that do not present within-group analyses, only subjects assigned to 
Evobrutinib or Tecfidera in the first period will be analyzed. Each subject will be tabulated 
according to the type of kit he/she received most frequently overall.
Presentation of Tables/Figures/Listings 
For all analyses, Tables and Figures will be produced using true treatment groups. When data 
from only the first 24 weeks are reported, the following labels will be used: ‘Placebo’, 
‘Evobrutinib 25 mg QD’, ‘Evobrutinib 75 mg QD’, ‘Evobrutinib 75 mg BID’, ‘Tecfidera’. When 
data from week 24-48 or week 0-48 are reported, the Placebo label will be changed to ‘Placebo + 
Evobrutinib 25 mg QD’.
Tables and figures will be sorted by treatment group (in the order stated above) and 
chronological scheduled time point (where applicable).
All data recorded during the trial will be presented in individual data listings, performed on the 
Safety Analysis Set (SAF), unless otherwise specified. All listings will be sorted by treatment 
group, subject, and scheduled time point (where applicable), if not otherwise stated. Further 
details are provided in the appropriate section for the analysis of the specific parameter.
Listings presented on the actual treatment, will consider the overall treatment assigned for 
subjects taking either Evobrutinib or Tecfidera in the first period. For subjects taking placebo in 
the first treatment period, treatment label will be either “Placebo” or “Placebo + Evobrutinib 25 
mg QD” depending on whether they have entered the second period or not.
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Presentation by Time Period 
The time period corresponding to the first 24 weeks of treatment is of special interest, as the 
primary endpoint of the study is at Week 24, and subjects randomized to placebo will be 
switched to Evobrutinib at Week 24. Therefore, tabular summaries may include data from the 
period up through Week 24, from the period after Week 24, and from the overall study period.
Listings will always present all available data in the database transfer.
For previous/concomitant medications, exposure duration, cumulative dose, compliance and 
safety (AEs, Labs, ECGs, vital signs, Ig levels, total B cell number), tables will be presented as 
follows:
For the primary analysis 
When applicable, three sets of tables will be made based on data overall, data through Week 24
(first 24-week treatment period, including data from Safety Follow-up where appropriate), and 
data after Week 24 through Week 48 (second 24-week treatment period, including data from 
Week 52 Safety Follow-up visit where appropriate). 
For the blinded extension analysis
When applicable, two sets of tables will be made. One set considering data overall and another 
one only considering data from after Week 24 through Week 48 (second 24-week treatment 
period,  including data from Week 52 Safety Follow-up visit where appropriate).
Overall tables that do not present within-group analyses will be restricted to subjects receiving 
either Evobrutinib or Tecfidera in the first period. Overall tables that present within-group 
analyses will include all treatment groups, including subjects who receive placebo in the first 
period, and switch to Evobrutinib in the second.
For safety analyses not including biochemistry parameters or adverse events, any assessment 
performed until 30 minutes after drug intake on Week 24 will considered in the first 24-week 
treatment period.
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Data handling after cut-off date for a planned analysis
A cut-off date will be applied at the SDTM level: for the primary analysis (resp. blinded 
extension analysis), all data posterior to the last dose of the last patient during the first (resp. 
second) 24-week treatment period will be removed from the database. Details on the 
implementation of this cut-off date are available in the document named SDTM Cut-off date 
implementation rules_BTKi(M2951)-Compound_v2.0.docx
Subjects discontinuing treatment early will have their data from the Safety Follow-up visit 
included in the primary analysis (resp. blinded extension analysis) if the Safety Follow-up visit 
occurs prior to the planned cut-off date. If there are subjects discontinuing treatment early whose 
Safety Follow-up visit occurred after the planned cut-off date, the exclusion of their Safety 
Follow-up data due to data cut-off will be mentioned in a footnote, where appropriate.
Data other than the date of death obtained after the cut-off will not be displayed in any listings or 
used for summary statistics.
Presentation of continuous and qualitative variables
Continuous variables including  but not will be summarized using the following 
descriptive statistics:
 number of subjects (N)
 number and percentage of non-missing values
 number and percentage of missing values. 
 mean, standard deviation (SD)
 median, 25th Percentile - 75th Percentile (Q1-Q3)
 minimum, and maximum
The number of digits for non-derived and derived data, presented in outputs or available in 
ADaM (Analysis Data Model) datasets, is specified in the Biostatistics Outputs Assembly (BOA) 
document.
For both continuous and qualitative variables, percentages such as 0% or 100% should be 
reported with the same format used for the column, together with the count of observations. For 
example, if the count of observations is zero, then display ‘0 (  0.0)’; if the count of observations
is 100% then display ‘xx (100.0)’.
Qualitative variables will be summarized by counts and percentages. The “Missing” category 
should always be displayed at baseline – even when there are no missing data at baseline. At 
timepoints other than baseline, the “Missing” category should only be displayed when there are 
missing data.
 
 
CCI
CC
I
CC
I
Evobrutinib Phase II in Relapsing Multiple Sclerosis
MS200527-0086 14 Feb 2018 / Version 1.0
23/86
Unless otherwise stated, the calculation of proportions will be based on the number of subjects in
the analysis set of interest. Therefore counts of missing observations will be included in the 
denominator and presented as a separate category.
The total of missing and non-missing observations at each timepoint will reflect the population 
still in the trial at that time. For example, if a subject is still in the trial at the timepoint but with 
missing data, that subject should be counted in the number of missing observations.
 
 
 
 
 
 
Definition of baseline
For the purpose of statistical analysis, baseline is defined as the last non-missing measurement 
(including those collected at an Unscheduled visit) prior to the first dose of study drug, as 
described in the following table. If baseline cannot be defined, then the baseline value will be 
treated as missing.
Table 2: Definition of baseline.
Randomized Time Period Baseline
Placebo Initial 24-week treatment period Last non-missing measurement prior to the 
first dose of study drug in the initial 24-week 
treatment period
Blinded Extension (second 24-week 
treatment period)
Last non-missing measurement prior to the 
first dose of study drug in the Blinded 
Extension.
Overall treatment period Baseline definition will depend on whether 
the assessment being compared to baseline is 
from the initial 24-week treatment period or 
the Blinded Extension. 
Evobrutinib/Tecfidera All treatment periods Last non-missing measurement prior to the 
first dose of study drug in the initial 24-week 
treatment period
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Definition of change from baseline (CFB)
CFB and percent CFB at a given post-baseline visit will be computed as follows: 
 CFB = visit value – baseline value
 Percent CFB = 100 * (visit value – baseline value) / baseline value
At the baseline visit, the CFB will be equal to zero and the percent CFB will be missing. For a 
given post-baseline visit, when the baseline value and the absolute value are both equal to zero, 
then the CFB and the percent CFB will be equal to zero as well. 
Definition of duration
Duration will be calculated as the difference between start and stop dates plus 1 (eg, AE duration
(days) = AE end date - AE start date + 1). Durations will be calculated only when both dates are 
available (imputed dates cannot be used for the duration computation) unless otherwise 
specified.
The time since an event will be calculated as:
 reference date minus date of event +1 (eg, days in study at onset of AE = AE start date - date 
of randomization + 1) if date of event is equal or greater than reference date
 reference date minus date of event (eg, days in study at onset of AE = AE start date - date of 
randomization) otherwise.
Conversion factors
The following conversion factors will be used to convert days into months or years: 1 month = 
30.4375 days, 1 year = 365.25 days. For time windows calculation, 1 month is expressed as 30 
days.
Presentation of missing data
In all subject data listings, partial dates, which are not to be imputed according to this IAP, will 
be presented using the format “_____YYYY”. 
When presented, imputed dates will be flagged (ie, D for day, M for month).
Missing statistics, eg, when they cannot be calculated, should be presented as ‘nd’, with ‘nd’ 
standing for ‘not done’. For example, if n = 1, the measure of variability (SD) cannot be 
computed and should be presented as ‘nd’.
In case of zero records available for presentation in a given TLF, an empty output with 0 
occurrence or a sentence stating that there are no data will be provided. For tables of Adverse 
Events and Deaths (outputs required for EudraCT and/or clinicaltrial.gov), if there is no 
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observation, the output must contain the first line ‘Subject with…’ or ‘Subject who died’ 
displayed with 0 occurrence.
If a System Organ Class (SOC) or Anatomical Therapeutic Class (ATC) term is missing/not 
coded yet, then ‘Uncoded SOC’ (or ‘Uncoded ATC’) will be indicated at the ADaM level. When 
a Preferred Term (PT) is missing, it will be set to ‘Uncoded PT:’ TEAE verbatim text.
Handling of missing efficacy and HRQoL data
Total number of lesions at Weeks 12, 16, 20, 24
The imputation approach for the total number of lesions endpoint depends on whether the 
analysis is model-based or nonparametric.
When analyzing the total number of lesions endpoint using a NB model, no imputation is needed 
for subjects missing 1-3 of the 4 planned scans, as the offset parameter adjusts for the number of 
available scans. If a subject lacks any post-baseline evaluable MRI assessment, then scan count 
and lesion count are imputed using median values for scan count and lesions per-scan among 
subjects with available post-baseline scans, who are in the same treatment group, and who have 
the same value for the categorical baseline covariate. For example, a subject’s imputed lesion 
count would be the product of the median number of scans (i.e., 4) and median lesions per-scan 
(i.e., 0.2), where the median values are based on subjects in the same treatment group, with the 
same value for the categorical baseline covariate. The imputed count (i.e., 0.8) will be rounded to 
an integer value (i.e., 1) as the NB model requires that the response variable be integer-valued.
In the longitudinal Poisson analysis of number of lesions at a single scan, which makes use of 
assessments at Weeks 12, 16, 20, and 24, no imputation is needed for subjects having at least one 
post-baseline score assessment prior to Week 24. If a subject lacks any post-baseline evaluable 
MRI assessment, then lesion count will be imputed for only the first post-baseline timepoint used 
in the GLMM analysis (i.e., Week 12), using the median lesion count at that timepoint among 
subjects with a scan at that timepoint, who are in the same treatment group, and who have the 
same value for the categorical baseline covariate.
When analyzing the total number of lesions endpoint using a nonparametric method (H-L 
estimate, Wilcoxon rank-sum test, Jonckheere test), the method assumes that the response 
variable arises from the same observation effort for each subject, so missing data must be 
imputed. If a subject is missing 1-3 of the 4 planned scans, missing scan values will be imputed 
with the average of available scan values. For example, if a subject has a lesion count of 3 from 
the week 12 scan, 1 from the week 16 scan, 1 from the week 20 scan, and missing value for the 
week 24 scan, a count of 1.67 will be imputed for week 24, leading to a total count of 6.67 for 
weeks 12-24. If a subject lacks any post-baseline evaluable MRI assessment, lesion count is 
imputed as the product of “4” and the median lesions per-scan, where the median is among 
subjects with available post-baseline scans, who are in the same treatment group, and who have 
the same value for the categorical baseline covariate. The imputed count will not be rounded to 
an integer value as the nonparametric analysis does not require that the response variable be 
integer-valued.
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Mean lesions per-scan at Weeks 12, 16, 20, 24
No imputation is needed for subjects missing 1-3 of the 4 planned scans, as the variable amount 
of scans experienced by a subject is accounted for in the mean lesions per-scan response 
variable. If a subject lacks any post-baseline scan, then the endpoint is imputed using the median 
value for mean lesions per-scan, where the median is among subjects with available post-
baseline scans, who are in the same treatment group, and who have the same value for the 
categorical baseline covariate.
Number of lesions at Week 48
In the analysis of lesion count at Week 48, a missing assessment at Week 48 will be imputed by 
the median Week 48 value among subjects having a Week 48 scan, who are in the same 
treatment group, and who have the same value for the categorical baseline covariate. 
CFB in volume of T2 lesions at Week 24 
In the MMRM analysis of the Week 24 CFB in volume of T2 lesions, appropriately transformed,  
which makes use of assessments at Weeks 12, 16, 20, and 24,  no imputation is needed for 
subjects having at least one post-baseline volume assessment prior to Week 24. If a subject lacks 
any post-baseline evaluable MRI assessment, then Week 24 CFB in transformed T2 lesion 
volume will be imputed for only the first post-baseline timepoint used in the MMRM analysis 
(i.e., Week 12), using the mean CFB in transformed T2 lesion volume at that timepoint among 
subjects with an assessment at that timepoint, who are in the same treatment group, and who 
have a baseline covariate in the same quartile. 
CFB in volume of T2 lesions at Week 48
In the nonparametric analysis of CFB in T2 lesion volume at Week 48, a missing scan value at 
Week 48 will be imputed by the median Week 48 CFB value among subjects having a Week 48 
scan, who are in the same treatment group, and who have the same value for the categorical 
baseline covariate. 
CFB in volume of Gd+ T1 lesions at Week 24 or Week 48
In the nonparametric analysis of CFB in T1 Gd+ lesion volume at Week 24, a missing scan value 
at Week 24 will be imputed by the median Week 24 CFB value among subjects having a Week 
24 scan, who are in the same treatment group, and who have the same value for the categorical 
baseline covariate. The same approach will be used for CFB in T1 Gd+ lesion volume at Week 
48. 
ARR at Week 24 or Week 48
Subjects discontinuing treatment before Week 24 or Week 48 will be followed for relapse 
through Safety Follow-up visit.
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When analyzing the ARR endpoint using a NB model, no imputation is needed, as the offset 
parameter specifies the time under observation, which adjusts for subjects who discontinue 
treatment before Week 24 or Week 48.
When analyzing the ARR endpoint using the Jonckheere test applied to subject-specific ARR 
(i.e., number of relapses experienced by the subject divided by follow-up experienced by the 
subject), there is again no need for imputation, as the variable amount of follow-up experienced 
by a subject is accounted for in the subject-specific ARR response variable.
Qualified relapse-free status at Week 24 or Week 48
In the analysis of proportion qualified relapse-free at Week 24, subjects who discontinue study 
prior to Week 24, without having a qualified relapse are counted as not being qualified 
relapse-free at Week 24. This imputation approach will be used for both the logistic model 
analysis and the Cochran-Armitage test. The same approach used for qualified relapse-free status 
Week 0-24 will be used for qualified relapse-free status Week 25-48.  
Sensitivity analyses of this endpoint will apply other methods of imputation, as described in 
Section 14.2.1.  
CFB in EDSS at Week 24 or Week 48
In the analysis of change from baseline (CFB) in EDSS at Week 24 using nonparametric 
analyses (H-L estimate, Wilcoxon rank-sum test, Jonckheere test), a missing assessment at Week 
24 will be imputed by the median Week 24 CFB value among subjects who have a Week 24 
assessment, who are in the same treatment group, and who have the same value for the 
categorical baseline covariate. The same approach will be used for CFB in EDSS at Week 48. A 
sensitivity analysis of this endpoint will apply another method of imputation, as described in 
Section 14.2.1.
CFB in HRQoL SF-36 score at Week 24 or Week 48
In the MMRM analysis of CFB in HRQoL (SF-36v2) score at Week 24, which makes use of 
assessments at Weeks 4, 8, 12, 16, 20, and 24, no imputation is needed for subjects having at 
least one post-baseline score assessment prior to Week 24.  If a subject lacks any post-baseline 
score assessment, then Week 24 CFB in score will be imputed for only the first post-baseline 
timepoint used in the MMRM analysis (i.e., Week 4), using the mean CFB in score at that 
timepoint among subjects with an assessment at that timepoint, who are in the same treatment 
group, and who have a baseline covariate in the same quartile.
The same approach will be used for the MMRM analysis of CFB in HRQoL score at Week 48, 
which makes use of assessments at Weeks 12, 24, 36, and 48.
CDF for % CFB at Week 24 
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In the estimation of the CDF curve for % CFB at Week 24 (for each SF-36 endpoint and 
treatment group), a subject missing an assessment at Week 24 will have the assessment imputed 
via the last-observation-carried-forward (LOCF) value.  
Descriptive Statistics
Missing data will not be imputed for descriptive statistics.
Handling of missing or partial adverse events dates
For defining the TEAE flag, missing or partial adverse event dates will be imputed as follows:
 In case the onset date is missing completely or missing partially but the onset month and year, 
or the onset year are equal to the start of IMP, then the onset date will be replaced by the 
minimum of start of IMP and AE resolution date. 
 In all other cases the missing onset day or missing onset month will be replaced by 1.
 Incomplete stop dates will be replaced by the last day of the month (if day is missing only), if 
not resulting in a date later than the date of subject's death. In the latter case the date of death 
will be used to impute the incomplete stop date. 
 Further information collected after the cut-off for an analysis (such as a fatal outcome) may be 
extracted from the Safety data base and presented separately in the CSR.
Imputed dates will be used for defining the TEAE flag only. 
Handling of partially missing MS onset or diagnosis date
For time since MS onset or MS diagnosis, a missing onset day/month will be replaced by 1 for 
the duration derivation.
Trial day / Treatment day
Trial day is defined relative to the date of randomization. Treatment day is defined relative to the 
date of start of treatment.  
In the case of subjects initially randomized to placebo, there will be a second start of treatment 
on the day of first administration of Evobrutinib in the second 24-week treatment period.   
The day before the start date of treatment is defined as treatment day -1, i.e., there is no treatment 
day zero.
Repeated and unscheduled measurements
An assessment (safety or efficacy) at an unscheduled time point is linked to the previous 
scheduled visit in the SDTM dataset. Per schedule of assessments, EDSS and relapse data are 
collected at an unscheduled visit for neurological worsening and relapse assessment. Per the 
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eCRF package for the study, EDSS, relapse, and HRQoL data may be collected at any 
unscheduled visit.   
Any relapse assessment for a subject at an unscheduled visit will contribute to the ARR estimate
for that subject’s treatment group, for the period including that timepoint. 
EDSS and SF-36 assessments at unscheduled visits will contribute to by-visit summaries and 
inferential analyses (i.e., analysis of Week 24 CFB in EDSS, analysis of lesions summed over 
visits at Weeks 12-24, analysis of Week 24 CFB in SF-36 score via MMRM with visit as a 
covariate) based on analysis visit windowing, as defined in Tables 3-5.
For safety shift tables, assessments associated with unscheduled time points will be used in the 
definition of the worst assessment during the study.  
Unique to this study, additional biochemistry assessments were associated with Unscheduled 
visits, necessitating the definition of windows for by-visit tabulations. Apart from biochemistry 
parameters, for by-visit tabulations, in case of multiple assessments (including unscheduled) 
linked to the same visit, the first available assessment (in chronological order) will be included in 
the summary of a visit.
Repeated and unscheduled measurements will be reported in the listings. 
Early treatment and early trial termination assessments
EDSS, relapse, MRI, and HRQoL data are collected at the early treatment termination visit.  In 
addition, relapse is assessed at the early trial termination visit.
By-visit summary statistics should be programmed such that the summary for the Early 
Treatment Termination visit is distinct from the summary for the Week 48 visit, and the
summary for the Early Trial Termination visit is distinct from the summary for the Week 52 
visit. This will support convenient comparison between treatment completers (at week 48) and 
discontinuers, and trial completers (at week 52) and discontinuers.
Any relapse assessment at an early treatment termination or early trial termination visit will 
contribute to the ARR estimate for the period including that timepoint.
EDSS, MRI, and SF-36 assessments at early treatment termination visits will contribute to 
inferential analyses (i.e., analysis of Week 24 CFB in EDSS, analysis of lesions summed over 
visits at Weeks 12-24, analysis of Week 24 CFB in SF-36 score via MMRM with visit as a 
covariate) based on analysis visit windowing, as defined in Tables 3-5.   
For analyses by time period, data from safety follow-up will be included in the period in which 
the subject has discontinued.
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Analysis visit windows
Assessments may be made at times other than the nominal times of planned visits, due to patient 
scheduling issues, unscheduled visits for neurological worsening or relapse assessment, or early 
treatment termination visits. 
Explicit analysis visit windows for efficacy and HRQoL assessments, defined below, will be 
used to incorporate unscheduled assessments in by-visit summaries of EDSS, MRI endpoints, 
and SF-36v2, or inferential analyses that depend on assessments at specific visits. (Relapse will 
be summarized by time period, not by visit, so analysis visit windows are not needed.) 
In by-visit summaries, assessments collected at early treatment termination visits will be 
summarized separately (i.e., visit windowing will not be applied), to support convenient 
comparison between treatment completers and discontinuers. However, in inferential analyses, 
analysis visit windows will be used to incorporate assessments collected at early treatment 
termination visits.
Table 3: Analysis visit windows for EDSS through Week 48
Analysis visit Nominal analysis visit day Analysis visit window (days)
All treatment groups
Day 1 1 [1, 1]
Week 12 84 [2, 126)
Week 24 168 [126, 189)
Week 36 252 [189, 294)
Week 48 336 [294, 339)
Table 4: Analysis visit windows for MRI through Week 48
Analysis visit Nominal analysis visit day Analysis visit window (days)
All treatment groups
Week 12 84 [2, 98)
Week 16 112 [98, 126)
Week 20 140 [126, 154)
Week 24 168 [154, 189)
Week 48 336 [189, 339)
Table 5: Analysis visit windows for HRQoL through Week 48
Analysis visit Nominal analysis visit day Analysis visit window (days)
All treatment groups
Day 1 1 [1, 1]
Week 4 28 [2, 42)
Week 8 56 [42, 70)
Week 12 84 [70, 96)
Week 16 112 [96, 126)
Week 20 140 [126, 154)
Week 24 168 [154, 189) 
Week 36 252 [189, 294)
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Week 48 336 [294, 339)
After the first IDMC meeting, additional biochemistry assessments were added to the Schedule 
of Assessments. Sites were instructed to record these additional assessments as Unscheduled 
visits. Analysis visit windows, defined below, will be used to incorporate unscheduled 
assessments in by-visit summaries of the biochemistry parameters. By-visit summaries will 
summarize assessments collected at early treatment termination visits separately (i.e, visit 
windowing will not be applied to assessments collected at the early treatment termination visit), 
to support convenient comparison between treatment completers (at week 48) and discontinuers.
Table 6: Analysis visit windows for biochemistry parameters through Week 48
Analysis visit Nominal analysis visit day Analysis visit window (days)
All treatment groups
Day 1 1 [1, 1]
Week 4 28 [2, 42)
Week 8 56 [42, 63)
Week 10 70 [63, 77)
Week 12 84 [77, 91)
Week 14 98 [91, 105)
Week 16 112 [105, 119)
Week 18 126 [119, 133)
Week 20 140 [133, 147)
Week 22 154 [147, 161)
Week 24 168 [161, X[1]]
Week 26 182 (X[1], X[1] + 21)
Week 28 196 [X[1] + 21, X[1] + 35)
Week 30 210 [X[1] + 35, X[1] + 49)
Week 32 224 [X[1] + 49, X[1] + 63)
Week 34 238 [X[1] + 63, X[1] + 77)
Week 36 252 [X[1] + 77, X[1] + 91)
Week 38 266 [X[1] + 91, X[1] + 105)
Week 40 280 [X[1] + 105, X[1] + 119)
Week 42 294 [X[1] + 119, X[1] + 133)
Week 44 308 [X[1] + 133, X[1] + 147)
Week 46 322 [X[1] + 147, X[1] + 161)
Week 48 336 [X[1] + 161, X[1] + 171)
X[1] corresponds to the time + 30 minutes where subjects are exposed for the first time to
Evobrutinib in the second 24-week treatment period.
Control of multiplicity
The truncated Hochberg test and a multistage testing algorithm (Dmitrienko et al 2011) will be 
used to control the family-wise error rate (FWER) due to multiple comparisons associated with 
evaluating 3 dose groups based on one primary endpoint and 3 key secondary efficacy endpoints. 
The 3 hypotheses associated with the primary endpoint will be considered family F1.
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Consider the ordered p-values that arise from comparing the 3 Evobrutinib treatment groups to 
placebo on the basis of the primary endpoint: p(1) ≤ p(2) ≤ p(3). The truncated Hochberg test is a 
step-up test based on the following critical values:
   =  
 
4 −  
+
1 −  
3
    ,   = 1, … , 3
where 0 ≤ γ < 1 is the truncation fraction (γ = 1 implies the regular Hochberg test, while γ = 0 
implies Bonferroni). Starting with F1, the family of 3 hypotheses associated with the primary 
endpoint, the truncated Hochberg’s step-up method proceeds as follows:
 Step 1.  If p(3) < a3, reject H(1), H(2), and H(3) (i.e., conclude all 3 dose groups are 
more efficacious than placebo on the basis of the primary endpoint) and then stop; 
otherwise go to Step 2.
 Step 2.  If p(2) < a2, reject H(1) and H(2), and then stop; otherwise go to Step 3.
 Step 3.  If p(1) < a1, reject H(1) (i.e., conclude that only the dose group associated 
with the smallest p-value is more efficacious than placebo on the basis of the 
primary endpoint) and stop.
Given 2-sided α = 0.05 for family F1, the critical values (a1, a2, a3) equal (0.0167, 0.0242, 
0.0467) and (0.0167, 0.025, 0.05) for γ = 0.9 (truncated Hochberg) and γ = 1.0 (regular 
Hochberg), respectively.  
The error rate function e(I) of the truncated Hochberg test, where I is the index set {1, …, |I|},  
and |I| is the size of the index set, is given by:
e({1}) = 1-P(a1) = a1
e({1, 2}) = 1-P(a1, a2) = 1 – (1-a2)(1-2a1+a2)
e({1, 2, 3}) = 1-P(a1, a2, a3) = 1- (1-a3)(1-3a1+a3-3(a2)2 + 6a1a2 -3 a1a3 + (a3)2 )
Using the critical values calculated for family F1, the error values ( e({1}), e({1, 2}), e({1, 2, 3}) 
) are equal to  approximately (0.0167, 0.0332, 0.0495) for both γ = 0.9 (truncated Hochberg) and 
γ = 1.0 (regular Hochberg), respectively.
Let F2 be the family of hypotheses associated with the key secondary endpoint ARR at Week 24, 
F3 be the family of hypotheses associated with the key secondary endpoint qualified relapse-free 
status at Week 24, and F4 be the family of hypotheses associated with the key secondary 
endpoint EDSS CFB at Week 24. Let Ai denote the index set corresponding to the retained 
hypotheses in Fi and ei(I) denote the error rate used in Fi, i=1, .., 3. The multistage testing 
algorithm for testing primary and key secondary endpoints in this study is as follows:
 Family F1: The 3 hypotheses (concerning the primary endpoint) are tested at an α1
level using the truncated Hochberg test (γ < 1) described above, with α1 = α = 
0.05.
 Family F2: The 3 hypotheses (concerning the key secondary endpoint ARR at 24 
weeks) are tested at an α2 level using the truncated Hochberg test (γ < 1) 
described above, with α2 = α1 – e1(A1).
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 Family F3: The 3 hypotheses (concerning the key secondary endpoint qualified 
relapse-free status at Week 24) are tested at an α3 level using the truncated 
Hochberg test (γ < 1) described above, with α3 = α2 – e2(A2).
 Family F4: The 3 hypotheses (concerning the key secondary endpoint EDSS CFB 
at Week 24) are tested at an α4 level using the regular Hochberg test (γ = 1) 
described above, with α4 = α3 – e3(A3).
With this algorithm, the type 1 error rate is controlled over the multiple families of hypotheses 
due to the primary and key secondary endpoints at the 0.05 2-sided level. Other endpoints 
specified in the protocol will be assessed at a nominal significance level of 0.05, 2-sided, but the 
results will be viewed as exploratory.
Note that the portion of α to be carried from F1 to F2 depends on the set of primary null 
hypotheses retained by the 2-stage gatekeeping procedure, and is quantified via the error rate 
function of the first component of the 2-stage procedure. For this portion to be positive when at 
least one primary null hypothesis is rejected, it is required that the procedure be separable, i.e., 
e1(I1|α) < α for all proper subsets I1 of N1, where N1 is the index set of hypotheses included in 
family F1. The Bonferronni procedure is separable, but the regular Hochberg procedure (γ = 1) is 
not. The truncated Hochberg procedure is separable and allows the multistage testing algorithm 
to be able to carry positive α from F1 to F2, from F2 to F3, and from F3 to F4. For the F4 family, 
the regular Hochberg procedure (γ=1) may be used.
It is prespecified that γ = 0.9 will be used in the multistage testing algorithm whenever the 
truncated Hochberg test is used, although γ  could be any value ≥ 0 and < 1, and could differ 
from family to family.
The penalty paid for performing multiple inferences in the families corresponding to the key 
secondary endpoints, Fi, i=2, 3, 4, depends on the number of hypotheses rejected at earlier stages. 
The sequence α1,  α2, α3,  α4 is non-increasing, so a hypothesis tested later in the sequence faces a 
higher hurdle unless all hypotheses are rejected in previously examined families.  
A table summarizing the results of the multi-stage testing procedure will be provided that 
includes the p-values for each comparison of Evobrutinib treatment group to placebo treatment 
group, for the hypothesis family corresponding to the primary endpoint, and for the hypothesis 
families corresponding to each of the 3 key secondary endpoints. The critical value used to 
assess each p-value for significance will be reported next to the p-value, with an annotation 
indicating significance, illustrating the point in the procedure at which hypothesis testing halted.  
This summary table will be in addition to tables that summarize the analysis of a given endpoint.
Software
All statistical analyses will be performed using SAS® (Statistical Analysis System, 
SAS-Institute, Cary, North Carolina Windows Version 9.4 or higher). Graphics may be prepared 
with SAS Version 9.4, or higher; or Sigmaplot® 12.5, or higher (Systat Software, Inc., San Jose, 
California).
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10 Trial Subjects
The subsections in this section include specifications for reporting subject disposition and 
treatment/trial discontinuations. Additionally procedures for reporting protocol deviations are 
provided.
10.1 Disposition of Subjects and Discontinuations
A table on screened subjects describing the number and percent of subjects in each of following 
disposition categories will be produced by treatment group:
 Total number of screened subjects, ie, subjects that gave informed consent (overall summary 
only);
 Number of subjects who discontinued prior to randomization and reason (overall summary 
only)
 Number of randomized subjects
 Number of randomized subjects who did not start treatment
 Number of randomized subjects who started treatment
 Number of randomized subjects with on-going treatment prior to Week 24 (applicable for dry 
run of the primary analysis) 
 Number of randomized subjects who completed the first 24 weeks of treatment
 Number of randomized subjects who permanently discontinued treatment prior to Week 24 
and reason
 Number of randomized subjects who were treated after Week 24
 Number of randomized subjects with on-going treatment after Week 24
 Number of randomized subjects who completed 48 weeks of treatment
 Number of randomized subjects who permanently discontinued treatment after Week 24 and 
prior to Week 48 and reason
 Number of randomized subjects in the follow-up phase who have not completed the trial (ie, 
treatment completed or discontinued and lack Safety Follow-up/End of Trial Visit)
 Number of randomized subjects who completed the trial 
 Number of randomized subjects who discontinued from trial after randomization and reason
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A table of randomized subjects not treated as randomized in the first (resp. second) double blind 
treatment period, including reason for not being treated as randomized will be produced by 
randomized treatment group for the primary (resp. blinded extension) analysis.
A table based on screened subjects describing the number and percent of subjects in each 
analysis set by treatment groups, will be produced:
 Number of screened subjects
 Number of subjects included in the ITT
 Number of subjects included in the SAF
 Number of subjects included in the SAF-BE
 Number of subjects included in the mITT
 Number of subjects in the mITT-BE
 Number of subjects included in the PP
 Number of subjects included in the 
 Number of subjects included in the 
 Number of subjects included in the 
A table based on screened subjects describing the number of subjects by region, country within 
region and site will be produced by analysis set.
For the primary analysis, a listing of randomized subjects with subject number, randomization 
date, and randomized treatment group, ordered by randomization number within randomization 
stratum, will be produced for the purpose of assessing whether randomization was conducted as 
planned.
Subjects’ information on informed consent, screening and randomization will be listed.
Subjects who discontinued/completed treatment or study will be listed with their reason for
discontinuation (if applicable). 
The list of re-screened subjects and corresponding subject identifiers will be provided. Only the 
second subject identifier will be used in statistical descriptions and analyses.  The first identifier 
will not be considered in the disposition counts.
10.2 Protocol Deviations
10.2.1 Important Protocol Deviations
For the primary analysis and the blinded extension analysis, the following summary tables and 
listings of important protocol deviations will be provided (separately for pre-/post inclusion 
deviations):
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 Table providing frequency for each type of important protocol deviation
 Listing of important protocol deviations
10.2.2 Reasons Leading to the Exclusion from an Analysis Set
For the primary and blinded extension analyses, for subjects excluded from the mITT or PP
analysis sets, the reasons for exclusion will be summarized, and the subjects excluded will be 
listed:
 By-reason table of number of subjects excluded from the mITT or PP analysis set, where a 
subject is counted for every reason that excludes that subject from the respective analysis set.
 By-subject listing of all reasons that excluded the subject from the mITT or PP analysis set
High dose corticosteroid use
If a subject uses high dose corticosteroids in the 3 weeks prior to a scheduled MRI scan, lesion 
data from that scan will be excluded from the primary analysis based on the mITT analysis set 
and treated as missing. A by-subject listing will be provided of all subjects who have at least one 
scan excluded from the primary analysis on the basis of high dose corticosteroid use. The listing 
will indicate the date of use, identity of the corticosteroid used, and dose and frequency of use.
Corticosteroid use is considered “high dose” when the cumulative dose in prednisone equivalent 
over the 21 days preceding the MRI assessment is ≥ 210 mg.
The worst case scenario will be applied in case missing or partial corticosteroid use dates are not 
definitively outside the 3 weeks windows preceding the MRI scan.
In such a situation, missing or partial start dates will be treated as follows:
- Same month as MRI scan and day missing, then corticosteroid use day start will be 
imputed to 01.
- Same year as MRI scan and month missing, then corticosteroid day/month start will be 
imputed to 01.
- Date completely missing, then corticosteroid start date is considered 3 weeks before the 
MRI scan.
Missing end dates will be imputed to the day of the MRI scan.
If the dose of the corticosteroid is missing then a dose of 10 will be considered. In case unit is 
missing then mg will be used. When frequency is missing QD will be considered.
A concomitant medication will be defined as a corticosteroid if the ATC code begins with 
“H02A”
The tables below will be used to define the cumulative dose:
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Table 7: Conversion factors in prednisone equivalent
WHO-drug Term Conversion factor in prednisone equivalent
METHYLPREDNISOLONE 1,25
METHYLPREDNISOLONE SODIUM SUCCINATE 1,25
METHYLPREDNISOLONE ACETATE 1,25
HYDROCORTISONE 0,25
BETAMETHASONE 6,667
BETAMETHASONE DIPROPIONATE 6,667
BETAMETHASONE VALERATE 6,667
DEXAMETHASONE 6,667
TRIAMCINOLONE 1,25
CORTISONE 0,2
PREDNISOLONE 1
PREDNISONE 1
DEFLAZACORT 0,83333
MEPREDNISONE 1,25
PARAMETHASONE 2,5
CRONOLEVEL 8,333
BETROSPAM 8,333
Table 8: Frequency conversions for corticosteroids
Frequency Conversion factor Numerical Conversion factor
OAM 1/30 0,0333
QOD 1/2 0,5000
QW 1/7 0,1429
QWK 1/7 0,1429
BID 2 2,0000
TID 3 3,0000
QD 1 1,0000
ONCE 1 1,0000
QAM 1 1,0000
Q2H 12 12,0000
Q3H 8 8,0000
Q4H 6 6,0000
Q6H 4 4,0000
Q8H 3 3,0000
QHS 1 1,0000
QID 4 4,0000
QPM 1 1,0000
QH 24 24,0000
Q3W 1/21 0,0476
TIW 3/7 0,4286
Q4W 1/28 0,0357
BIW or Twice a week 2/7 0,2857
EVERY 3 HOURS 8 8,0000
X1 1 1,0000
EVERY OTHER DAY 1/2 0,5000
EVERY OTHER DAY ALTERNTATLY 
WITH30 MG Q0D
1/2 0,5000
EVERY OTHER DAY ALTERNTATLY 1/2 0,5000
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Frequency Conversion factor Numerical Conversion factor
WITH 20 MG QOD
ONCE A WEEK 1/7 0,1429
QD(EVERY MORNING) 1 1,0000
SINGLE DOSES 1 1,0000
ALTERNATE DAYS 1/2 0,5000
11 Demographics and Other Baseline Characteristics
For the primary analysis, demographics, baseline disease characteristics, and other baseline 
characteristics will be summarized based on the mITT analysis set, presented by treatment group 
and overall.
Supportive listings will be based on the ITT analysis set, with subjects flagged according to 
membership in the mITT and SAF analysis sets.
11.1 Demographics
 Demographic characteristics 
- Sex: male, female 
- Race: White, Black or African American, Asian, American Indian or Alaska Native, 
Native Hawaiian or Other Pacific Islander, Other
- Ethnicity: Hispanic or Latino, Not Hispanic or Latino
- Age (years) at informed consent: summary statistics 
 Pooled Region (US or Western Europe, Eastern Europe, Rest of the World)
 Geographic/Capability Region (US, Western Europe, Eastern Europe and BTKO capable,
Eastern Europe and not BTKO capable, Rest of the World)
 European Economic Area (EEA)
Specifications for computation:
 Age (years):
1. (date of given informed consent - date of birth + 1) / 365.25
2. In case of missing day for at least one date, but month and year available for both dates, the 
day of informed consent and the day of birth will be set to 1 and the formula above will be 
used.
3. In case of missing month for at least one date, but year available for both dates, the month 
of informed consent and the day and month of birth will be set to 1 and the formula above 
will be used. 
 Site codes will be used for the determination of the subject’s geographic region.
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11.2 Medical History
For the primary analysis, the medical history will be summarized using Medical Dictionary for 
Regulatory Activities (MedDRA), current version, PT as event category and MedDRA SOC
body term as Body System category. The MedDRA version used will be indicated in footnote. 
Medical history will be tabulated by SOC and PT. SOC and PT will be alphabetically sorted. 
Medical history will be also listed.   
11.3 Other Baseline Characteristics
11.3.1 Disease history
For the primary analysis, information on MS baseline disease characteristics based on data on 
Day 1 predose and during screening will be summarized in total and listed. Descriptive statistics 
will be presented for:
 Type of MS, either relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS)
 Time (years) since MS onset (first symptom)
 Time (years) since MS diagnosis
 Major systems affected
 Number of relapses in the year prior to randomization
 Number of relapses in the last 2 years
 EDSS score
 Scores for each of the 7 Functional Systems (Visual, Brainstem, Pyramidal, Cerebellar, 
Sensory, Bowel/Bladder, Cerebral) and score for Ambulation used to derive EDSS score.
 Presence of at least 1 Gadolinium-positive (Gd+) T1 lesion within 6 months prior to 
randomization
 Number of Gd+ T1 lesions
 Volume of Gd+ T1 lesions 
 Volume of T2 lesions 
 Short Form 36-item Health Status Survey Version 2.0 (SF-36v2) normalized score for each 
of the 8 health domain scales
 SF-36v2 Physical Component Summary score (PCS) and Mental Component Summary score 
(MCS)
For SF-36v2 score derivation, refer to Appendix 2.
11.3.2 Other
For the primary analysis, descriptive statistics and listings will be presented for:
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 Physical examination as continuous variables: Height (cm), Weight (kg) and BMI (kg/m²)
 CXR interpretation category (Normal, Abnormal Not Clinically Significant, Abnormal 
Clinically Significant, and Abnormal Overall). 
Other screening baseline characteristics like viral serology, β-human chorionic gonadotropin, 
follicle stimulating hormone, quantiferon TB test, hepatitis B surface antigen and prior surgeries 
will be listed only.
Baseline characteristics such as ECG, vital signs and laboratory values will be presented in the 
safety summary tables by visit.
11.3.3 Columbia- Suicide Severity Rating Scale (C-SSRS)
The Columbia-Suicide Severity Rating Scale (C-SSRS) is a numerical score derived from 10 
categories. The C-SSRS assesses the suicidal behavior and suicidal ideation in subjects. 
Occurrence of suicidal behavior is defined as having answered “yes” to a least 1 of the 4 suicidal 
behavior subcategories (actual attempt, interrupted attempt, aborted attempt, and preparatory acts 
or behavior). 
Occurrence of suicidal ideation is defined as having answered “yes” to at least one of the suicidal 
ideation sub-categories (wish to be dead, non-specific active suicidal thoughts, active suicidal 
ideation with any methods [not plan] without intent to act, active suicidal ideation with some 
intent to act [without specific plan], and active suicidal ideation with specific plan and intent). 
Occurrence of suicidality is defined as having at least one occurrence of suicidal ideation or at 
least one occurrence of suicidal behavior.
For the primary analysis, the number and percentage of subjects with occurrence of suicidal 
behavior, occurrence of suicidal ideation and occurrence of suicidality at screening will be 
summarized.
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12 Previous or Concomitant Medications/Procedures
Medications/procedures will be presented according to table 9.
Table 9: Data handling for medications/procedures
Analysis Period covered Data summarized Treatment groups Analysis sets
Primary 
analysis
Initial 24-week 
treatment period + 
safety follow-up
Previous medications +
concomitant 
medications + 
concomitant procedures
ALL SAF
Blinded 
Extension
analysis
Second 24-week 
treatment period + 
safety follow-up
Concomitant 
medications
+ concomitant
procedures
ALL SAF-BE
Blinded 
Extension
analysis
Overall
Concomitant 
medications
+ concomitant
procedures
Evobrutinib 25 mg QD
Evobrutinib 75 mg QD
Evobrutinib 75 mg BID
Tecfidera
SAF
Concomitant medications are medications, other than IMPs, which are taken by subjects any 
time on-trial (on or after the first day of IMP treatment for each subject). Concomitant 
medications include those started prior to and continued during administration of IMP, as well as 
those that were started after first administration of IMP. If the date values do not allow a 
medication to be classified as a non-concomitant medication, the medication will be considered 
as a concomitant medication.
Previous medications are medications, other than trial medications, which started before first 
administration of IMP. Previous medications include those that were continued during 
administration of IMP, as well as those discontinued prior to first administration of IMP. If the 
date values do not allow a medication to be classified as a non-previous medication, the 
medication will be considered as a previous medication.
The ATC-second level and preferred term will be tabulated as given from the World Health 
Organization Drug Dictionary (WHO-DD) current version. In case multiple ATCs are assigned 
to a drug, all ATC-2nd level terms will be used for reporting. 
Tables will be presented by descending frequency of ATC 2nd level term and then by descending 
frequency of PT in total column. If multiple ATCs/PTs have the same frequency, they will be 
sorted alphabetically. The WHO-DD version used will be indicated in footnote.
Concomitant procedures are procedures which were undertaken any time on trial.
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The number and proportion of subjects with previous medications or concomitant medications
will be separately summarized by treatment group and listed. 
Concomitant procedures will be classified by medical review. Number of subjects with 
concomitant procedures (prior, on or after the first day of IMP) and by type of procedure (as 
classified by medical review) will be summarized by treatment group and listed.
13 Treatment Compliance and Exposure
Exposure will be presented according to table 10.
Table 10: Data handling for exposure
Analysis
Period 
covered
Data summarized Treatment groups
Analysis 
set
Primary 
analysis
Initial 24-week 
treatment 
period
Exposure time + 
Cumulative dose + 
Compliance
ALL
SAF
Second 24-
week treatment 
period
Exposure time ALL
SAF-BE
Overall Exposure time
Evobrutinib 25 mg QD
Evobrutinib 75 mg QD
Evobrutinib 75 mg BID
Tecfidera
SAF
Blinded 
Extension 
Analysis
Second 24-
week treatment 
period
Exposure time + 
Cumulative dose + 
Compliance
ALL SAF-BE
Overall
Exposure time + 
Cumulative dose + 
Compliance
Evobrutinib 25 mg QD
Evobrutinib 75 mg QD
Evobrutinib 75 mg BID
Tecfidera
SAF
Planned administration of Placebo and Evobrutinib
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Each treatment kit contains 17 wallets of 12 tablets which is enough medication for the 
administration of 6 tablets per day for 4 weeks and 6 days (ie, 204 tablets). From Day 1 until 
Week 20, subjects will receive one treatment kit per planned visit. At the Week 24 and Week 36 
visits, subjects will receive 3 treatment kits at each visit. At each trial visit, subjects will be given 
treatment kits containing the number of tablets needed up to the next planned trial visit. Subjects 
will self-administer IMP in a blinded manner at a set time each day (every 12 hours ± 2 hours) as 
three matching tablets BID for 48 weeks. Subjects must take their daily dose more than 1 hour 
prior to a meal or snack and more than 2 hours after a meal or snack.
 Subjects randomized to placebo arm will take 6 placebo tablets filled with mannitol for the 
first 24 weeks. For the 24 weeks following, it is planned that these subjects will be switched 
to 5 placebo tablets and one tablet filled with 25 mg of Evobrutinib. 
 Subjects randomized to Evobrutinib 25 mg QD arm will take 5 tablets filled with mannitol 
and one tablet filled with 25 mg of Evobrutinib.
 Subjects randomized to Evobrutinib 75 mg QD arm will take 3 tablets filled with mannitol
and 3 tablets filled with 25 mg of Evobrutinib.
 Subjects randomized to Evobrutinib 75 mg BID arm will take 3 tablets BID filled with 25 mg 
of Evobrutinib.
Planned administration of Tecfidera
At the Day 1 visit, the treatment kit contains 14 capsules of 120 mg and 112 capsules of 240 mg 
which is enough medication for administration for 9 weeks. For the subsequent trial visits, 
subjects randomized to Tecfidera arm will be given treatment kits wherein the quantity of 
capsules will not be fixed due to the possibility of down titration in case of adverse event. 
Subjects randomized to Tecfidera arm will be given 120 mg of Tecfidera BID orally for the first 
7 days. Following this, and for the duration of treatment, Tecfidera is given 240 mg BID orally.
On trial visit days, IMP will be administered during the trial visit after the scheduled trial visit 
procedures (other than post treatment  sampling) are completed.
Exposure
Exposure time in weeks will be calculated according to the following formula: 
exposure (weeks) = (date of last dose - date of first dose of the corresponding period + 1)/7
If the end date of the last dose is missing or after the cut-off date then the date of last dose will be 
replaced by the cut-off date.
If a subject is lost to follow up and hasn’t performed end of treatment (EOT) visit, then end of 
study date will be considered as the end of treatment date.
Exposure time will be presented by summary statistics and according to the following categories
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 ≤ 1 week
 > 1 to 8 weeks
 > 8 to 16 weeks
 > 16 to 24 weeks
 > 24 to 36 weeks
 > 36 to 48 weeks
For subjects randomized to placebo, and switched to Evobrutinib after Week 24, any exposure 
time after Week 24 represents exposure to Evobrutinib.
Cumulative actual dose (mg) per subject will be summarized by treatment groups.
 For Evobrutinib treatment groups, the cumulative actual dose is the number of tablets taken 
during that period, multiplied by the fraction of tablets that contain Evobrutinib 25 mg 
according to the actual treatment group, multiplied by 25 mg (dosage of one tablet). The 
number of tablets ingested will be deduced from the BATCH1 electronic case report form 
(eCRF).
 For the Tecfidera treatment group, the cumulative actual dose is the number of capsules 
ingested during that period multiplied by the appropriate dosage of one capsule (either 
120 mg or 240 mg). The number of capsules ingested will be deduced from start date, end 
date, and dose, as recorded on the EXPOSUREDT2 eCRF.
 For subjects randomized to placebo, and switched to Evobrutinib after Week 24, the 
Evobrutinib cumulative actual dose will be calculated in the same manner as for the 
Evobrutinib treatment groups, using data from the BATCH1 eCRF, starting with Week 24. 
 Study drug administrations will also be listed by treatment group, and subject, with start/end 
dates of administration and reason for dose change (if applicable). 
Compliance
For Evobrutinib or Placebo groups
Compliance with treatment is defined as the number of tablets taken during a period divided by 
the number of tablets that should have been taken during that period, multiplied by 100 to yield a 
percentage, ie:
Compliance with  treatment = 100*(
(N )
6 ∗ N 
)
where N1 = number of tablets given minus number of tablets returned over N2 days, deduced 
from the BATCH1 eCRF,
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and N2 = number of days between treatment start and treatment termination visit (or last visit 
before cut-off if treatment is ongoing).
For Tecfidera dose group
Compliance with treatment is defined as the actual cumulative dose divided by the planned 
cumulative dose, multiplied by 100 to yield a percentage, ie:
Compliance with treatment = 100*(
  
  
)
where N3 = actual cumulative dose for the given time period,
and N4 = planned cumulative dose for the given time period.
Compliance with treatment and number of ingested tablets/capsules will be tabulated.
The following listings will be provided:
 listing of Evobrutinib/placebo kit numbers with date of dispense, and number of tablets 
returned (from BATCH1), and Tecfidera kit numbers with date of dispense, and number of 
capsules returned (from BATCH2) limited to Week 24 for the primary analysis and Week 48 
for the blinded extension analysis.
 listing of Evobrutinib/placebo start/end dates with number ingested tablets (from 
EXPOSUREDT1), and Tecfidera start/end dates with dose (120 or 240 mg) (from    
EXPOSUREDT2) limited to Week 24 for the primary analysis and Week 48 for the blinded 
extension analysis.
 listing with exposure time, cumulative dose, and compliance by time period limited to Week 
24 for the primary analysis and Week 48 for the blinded extension analysis.
14 Efficacy Analyses
Efficacy endpoints will be included in listings for the primary analysis and the blinded extension
analysis.
14.1 Primary Endpoint Analyses
The primary endpoint, total number of Gd+ T1 lesions at Weeks 12, 16, 20, and 24, will be 
analyzed at the time of the primary analysis. The primary analysis will be based on the mITT 
analysis set. This analysis will be repeated for the ITT and PP analysis sets only if the respective 
analysis set differs from the mITT analysis set by > 4 subjects.
The primary analysis of total number of Gd+ T1 lesions, at Weeks 12, 16, 20, and 24, will be an 
estimate of lesion rate ratio, comparing each Evobrutinib dose group to placebo, together with 
associated 95% confidence interval (CI) and p-value, based on a negative binomial (NB) model, 
with offset equal to the log of number of scans. In general, missing scan assessments will be 
handled via the offset in the NB model, as the offset reflects the number of scans available for a 
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given subject. Details on missing data handling for subjects lacking any post-baseline scan 
assessments are provided in Section 9.
In this model, Evobrutinib dose group or placebo group will be a factor and there will be 
adjustment for baseline disease activity (i.e., presence/absence of Gd+ T1 lesions at baseline). 
The placebo treatment group and the lower category of baseline disease activity, will be used as 
references in the model.  The p-value reported for each Evobrutinib treatment group tests the null 
hypothesis that adjusted lesion rate ratio, comparing Evobrutinib treatment to placebo, is equal to 
1.
In the primary analysis, if a subject uses high dose corticosteroids in the 3 weeks prior to a 
scheduled MRI scan, lesion data from that scan will be excluded from the analysis and treated as 
missing.
The NB regression will be computed with the SAS® GENMOD procedure, using the 
DIST=NEGBIN option. In addition to the estimates of lesion rate ratio due to treatment and 
baseline disease activity, the estimates of the intercept and dispersion parameters will be 
reported.
Sensitivity Analyses
The first sensitivity analysis will analyse the Gd+ T1 lesion count at a single scan using a 
longitudinal Poisson approach (generalized linear mixed model) via PROC GLIMMIX (i.e., 
MODEL statement with DIST=POISSON) , based on the mITT analysis set. The model for the 
lesion rate corresponding to a single scan will include treatment (Evobrutinib dose group or 
placebo group) and visit (weeks 12, 16, 20, 24) as fixed effects, and a covariate for 
presence/absence of Gd+ T1 lesions at baseline. No offset parameter is needed as the lesion 
count data used to fit the model correspond to a single scan. A treatment-by-visit interaction will 
not be included (i.e., treatment effect assumed constant over time). As in the primary analysis, if 
a subject uses high dose corticosteroids in the 3 weeks prior to a scheduled MRI scan, lesion data 
from that scan will be excluded from the analysis and treated as missing. In general, missing scan 
assessments will be handled via the MAR assumption of the GLMM model. Details on missing 
data handling for subjects lacking any post-baseline scan assessments are provided in Section 9.
It is planned that both AR(1) correlation between repeated measures (i.e., RANDOM visit / 
SUBJECT=subjid TYPE=AR(1) RESIDUAL) and a random effect for subject (i.e., RANDOM 
subjid) will be modeled, yielding estimated lesion rate ratios that have a subject-specific, not 
population-average, interpretation. However, if there are convergence issues with this approach, 
the random effect for subject will be omitted, and the correlation between repeated measures will 
be modeled using a compound symmetric (i.e., RANDOM visit / SUBJECT=subjid TYPE=CS  
RESIDUAL) or variance components structure.
For each Evobrutinib dose group, the estimated lesion rate ratio relative to placebo will be 
reported, with 95% CI, and p-value. Assuming a random effect for subject is retained in the 
model, the p-value reported for each Evobrutinib treatment group tests the null hypothesis that 
adjusted lesion rate ratio, comparing Evobrutinib treatment to placebo, conditional on random 
effects, is equal to 1. Other statistics to be reported include the estimated lesion rate (adjusted for 
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visit and baseline), with 95% CI, for each dose group (Evobrutinib or placebo), estimated lesion 
rate ratio due to baseline disease activity, intercept, and covariance structure parameters.
The second sensitivity analysis will be based on the same NB model as in the primary analysis,
applied to the mITT analysis set, but where all scans will be included in this analysis, regardless 
of subject use of high dose corticosteroids.
Supplemental Analyses
As a supplemental nonparametric analysis, the stratified Hodges-Lehman estimate of the shift in 
location of the lesion count distribution, comparing each Evobrutinib dose group to placebo, will 
be reported, together with associated 95% CI and p-value, based on a stratified Wilcoxon rank-
sum test. Strata will be defined according to categorical baseline disease activity, following the 
approach to covariate adjustment in the NB model. In general, missing scan values for a subject 
will be imputed with the average of available scan values for that subject. Details on missing 
data handling for subjects lacking any post-baseline scan assessments are provided in Section 9.
An unstratified version of this nonparametric analysis will be reported as a sensitivity analysis.
The second sensitivity analysis will be a stratified analysis that will include all scans, regardless 
of subject use of high dose corticosteroids.
The p-value reported for each Evobrutinib treatment group tests the null hypothesis that P(X < 
Y) + 0.5*P(X = Y) = 0.5, where X denotes the Gd+ T1 lesion count for a subject in a given
Evobrutinib treatment group, Y denotes the Gd+ T1 lesion count for subjects in the placebo 
group, and P denotes probability. 
If the NB model fails to converge, the results of the supplemental nonparametric analysis will be 
considered as the primary analysis. The supplemental analysis will be repeated for the ITT and 
PP analysis sets only if the respective analysis set differs from the mITT analysis set by > 4 
subjects.
Multiplicity
The truncated Hochberg procedure will be used to adjust for multiplicity in testing the primary 
endpoint for the 3 Evobrutinib dose groups, to preserve alpha for testing key secondary 
endpoints (see Section 9). Both raw and multiplicity-adjusted p-values will be reported.
Dose-Response
A monotonic dose-response relationship, between ordered dose groups (placebo, Evobrutinib
25mg QD, Evobrutinib 75mg QD, and Evobrutinib 75mg BID) and ordered categories of Gd+ 
T1 lesion count for wks 12, 16, 20, 24, will be assessed via the Jonckheere-Terpstra trend test, 
both without and with stratification by BL factors (i.e., presence/absence of Gd+ T1 lesions at 
baseline). Prior to defining suitable categories for Gd+ T1 lesion count for wks 12, 16, 20, 14, 
missing scan data for a subject will be imputed using the same approach as used in the 
supplemental nonparametric analysis of this endpoint.
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After imputation, the categories of Gd+ T1 lesion count (summed over wks 12, 16, 20, 24) will 
be defined by the quartiles of the distribution as observed when all subjects from the 4 treatment 
groups are combined. Thus, the unstratified table will be 4x4, and the stratified table will be 
4x4x2, assuming a binary stratum covariate. The p-value reported tests the null hypothesis that 
the lesion count distribution is the same across dose groups, against the alternative that the 
location of the lesion count distribution is ordered (from largest value to smallest) according to 
increasing dose group.
In addition to the nonparametric test of monotonic dose-response, a test of linear trend in log 
lesion rate with increasing dose, adjusted for baseline, will be based on an appropriate contrast 
from the NB model (i.e., (3, 1, -1, -3)). The p-value reported tests the null hypothesis that the log 
lesion rate is the same across dose groups, against the alternative that the log lesion rate 
decreases linearly with increasing dose group order.
Descriptive Analyses
Descriptive statistics for the total number of Gd+ T1 lesions by timepoint through Week 24 will 
be provided by treatment group (including Tecfidera), based on the mITT analysis set. This 
analysis will be repeated for the ITT and PP analysis sets only if the respective analysis set 
differs from the mITT analysis set by > 4 subjects.
Mean number of Gd+ T1 lesions will be presented as a by-visit line plot for each treatment 
group, with a vertical line segment at each visit representing ± SE (jittered if needed for 
legibility), and with all treatment groups included in a single figure. Proportion of subjects who 
are Gd+ T1 lesion-free will be presented as a by-visit line plot for each treatment group (vertical 
line segment at each visit representing 95% CI may be omitted for legibility), and with all 
treatment groups included in a single figure. Mean total number of Gd+ T1 lesions from Weeks 
12, 16, 20, and 24, will be presented as a by-treatment group bar chart, with a vertical line 
segment for each bar representing 95% CI, and with the p-value for the comparison with placebo 
(based on NB model) displayed above each evobrutinib dose group bar.
14.2 Secondary Endpoint Analyses
The analysis of secondary endpoints will be based on the mITT analysis set.
14.2.1 Key secondary endpoint analyses
The key secondary endpoints will be analyzed at the time of the primary analysis. The key 
secondary efficacy endpoints are:
1. Annualized relapse rate (ARR), based on protocol-defined qualified relapses, at Week 24. 
The unadjusted ARR is defined as the total number of qualified relapses divided by the 
number of subject-years of observation on treatment. 
2. Qualified relapse-free status at Week 24
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3. Change from baseline in EDSS score at Week 24
Collectively, safety endpoints are also considered to be a key secondary endpoint, but are not 
part of multiplicity adjustment required to control overall type I error rate at the two-sided 
α=0.05 level. Analyses of safety endpoints are described in Section 15. The multi-stage testing 
procedure for controlling family-wise error rate (FWER) across the 4 hypothesis families defined 
by the primary endpoint and the 3 key secondary efficacy endpoints, is described in Section 9.  
Inferential analyses of key secondary endpoints will not include the Tecfidera arm. In modeling, 
the placebo group will be the reference treatment group. If an appropriate categorical BL 
MRI/relapse/EDSS assessment is adjusted for in the analysis of a key secondary endpoint, the 
lower disease-activity category will be the reference. For each of the key secondary endpoints, a 
test for a monotonic dose-response relationship and descriptive statistics will be provided. If the 
key secondary endpoint is analyzed via a parametric model, then a test of linear trend will also be 
reported.
ARR at Week 24
The comparison of a Evobrutinib treatment group to the placebo group using ARR at 
Week 24 will be based on a NB model for qualified relapse count, with offset equal to the log 
of years on study, with Evobrutinib dose group or placebo group as a factor and adjustment 
for categorical number of relapses in the last 2 years before randomization (≤ 1 relapse, > 1 
relapse). Subjects discontinuing early are analyzed according to number of years of follow-
up on treatment and number of qualified relapses observed at the time of discontinuation, 
including data (both follow-up time and relapse events) from the 4-week Safety Follow-up 
period. The NB regression will be computed with the SAS® GENMOD procedure, using the 
dist=NB option in the MODEL statement.
Two sensitivity analyses will be reported, based on early discontinuers, as described below:
- In the first sensitivity analysis, a subject discontinuing early without any qualified relapse 
in the 30 days prior to discontinuation will be counted as having a relapse on day of 
discontinuation.
- In the second sensitivity analysis, a subject discontinuing early without any qualified 
relapse in the 30 days prior to discontinuation will be counted as having a relapse on day of 
discontinuation if and only if the subject belongs to an Evobrutinib treatment group.
In the table summarizing inferential results (Evobrutinib dose group versus placebo group), 
the following will be reported for each group: number of qualified relapses, number of total 
relapses, follow-up on treatment (in subject-years), unadjusted ARR (number of qualified 
relapses divided by follow-up on treatment), and point estimate of adjusted ARR with 95% 
CI. For each treatment comparison (Evobrutinib group versus placebo group), the following 
will be reported: adjusted qualified relapse rate ratio with 95% CI, and p-value for the test 
that the qualified relapse rate ratio, adjusted for categorical BL relapse activity, is equal to 1.
A monotonic dose-response relationship, between ordered dose groups and ordered 
categories of ARR estimated on a subject level (i.e., number of qualified relapses 
experienced by a subject divided by the subject’s follow-up), will be assessed via the 
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Jonckheere-Terpstra trend test, both without and with stratification by categorical BL relapse 
count (i.e., ≤ 1 relapse, > 1 relapse in the last 2 years before randomization). The categories 
of subject-level ARR will be defined by the quartiles of the distribution as observed when all 
subjects from the 4 treatment groups are combined. Thus, the unstratified table will be 4x4, 
and the stratified table will be 4x4x2, assuming a binary stratum covariate. The p-value 
reported tests the null hypothesis that the relapse count distribution is the same across dose 
groups, against the alternative that the location of the relapse count distribution is ordered 
(from largest value to smallest) according to increasing dose group.
In addition to the nonparametric test of monotonic dose-response, a test of linear trend in log 
relapse rate with increasing dose, adjusted for baseline, will be based on an appropriate 
contrast from the NB model (i.e., (3, 1, -1, -3)). The p-value reported tests the null hypothesis 
that the log relapse rate is the same across dose groups, against the alternative that the log 
relapse rate decreases linearly with increasing dose group order.
Descriptive statistics for the ARR at Week 24 will be provided by treatment group (including 
Tecfidera). In particular, at the treatment-group-level, number of qualified relapses, number 
of total relapses, follow-up on treatment (in subject-years), and unadjusted ARR (number of 
qualified relapses divided by follow-up on treatment) will be reported. In addition, 
descriptive statistics of subject-level ARR (number of qualified relapses experienced by a 
subject by week 24, divided by the follow-up experienced by a subject by week 24) will be 
summarized for each treatment group, in terms of mean, SD, median, Q1, Q3, min, and max.
ARR at Week 24 will be presented as a by-treatment group bar chart, with a vertical line 
segment for each bar representing 95% CI, and with the p-value for the comparison between 
Evobrutinib dose group and placebo (based on NB model) displayed above each Evobrutinib 
dose group bar.
Qualified relapse-free status at Week 24
The comparison of a Evobrutinib treatment group to the placebo group using proportion 
qualified relapse-free at Week 24, will be based on a logistic model for the odds of qualified 
relapse-free status at Week 24, with Evobrutinib dose group or placebo group as a factor and 
adjustment for categorical number of relapses in the last 2 years before randomization (≤ 1 
relapse, > 1 relapse). Subjects who discontinue treatment prior to Week 24 without having a 
qualified relapse will be counted as not being qualified relapse-free at Week 24.
Two sensitivity analyses will be reported , based on early discontinuers, as described below:
- In the first sensitivity analysis, a subject who discontinues treatment prior to Week 24 
without having a qualified relapse is considered as qualified relapse-free at Week 24.
- In the second sensitivity analysis, a subject who discontinues treatment prior to Week 24 
without having a qualified relapse is considered as not qualified relapse-free if member of 
Evobrutinib group, and qualified relapse-free if member of placebo group.
In the table summarizing inferential results (Evobrutinib dose group versus placebo group), 
the following will be reported for each group: number (proportion) of subjects with ≥ 1 
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relapse through Week 24 (either treatment discontinuer or completer of 24 weeks of 
treatment), number (proportion) of subjects with 0 relapses through Week 24, number 
(proportion) of subjects discontinuing treatment prior to Week 24 among subjects with 0 
relapses in that period., and number (proportion) of subjects who are relapse-free at Week 24, 
using imputation for treatment discontinuers, with 95% CI. For each treatment comparison 
(Evobrutinib group versus placebo group), the following will be reported: adjusted odds ratio 
(OR) with 95% CI, and p-value for the test that the OR, adjusted for categorical BL relapse 
count, is equal to 1.
A monotonic dose-response relationship, between ordered dose groups and proportion 
qualified relapse-free at Week 24, will be assessed via the Cochran-Armitage trend test, both 
without and with stratification by BL factor (i.e., ≤ 1 relapse, > 1 relapse in the last 2 years
before randomization). The p-value reported tests the null hypothesis that the proportion 
qualified relapse-free is the same across dose groups, against the alternative that the 
proportion is ordered (from smallest value to largest) according to increasing dose group. In 
the Cochran-Armitage test, missing data are handled the same as in the main logistic 
modeling analysis.  
In addition to the nonparametric test of monotonic dose-response, a test of linear trend in log 
odds of qualified relapse-free status with increasing dose, adjusted for baseline, will be based 
on an appropriate contrast from the logistic model (i.e., (3, 1, -1, -3)). The p-value reported 
tests the null hypothesis that the log odds of being qualified relapse-free is the same across 
dose groups, against the alternative that the log odds increases linearly with increasing dose 
group order.
Descriptive statistics for qualified relapse-free status up to Week 24 will be provided by 
treatment group (including Tecfidera), with and without stratification by BL factor (i.e., ≤ 1 
relapse, > 1 relapse in the last 2 years before randomization). In particular, number 
(proportion) of subjects with ≥ 1 relapse,  number (proportion) of subjects with 0 relapses, 
number (proportion) of subjects discontinuing treatment prior to Week 24 among subjects 
with 0 relapses will be reported.
For each treatment group, the Kaplan-Meier estimate of proportion surviving qualified 
relapse-free as a function of time (i.e., proportion qualified relapse-free between Week 0 and 
Week 24) will be presented, with all KM curves in a single figure. A subject discontinuing 
study prior to Week 24 without relapse will have his/her time to first relapse right-censored 
at the time of study discontinuation (i.e., the last time at which he/she is at risk of relapse on 
study). A subject completing 24 weeks of treatment without relapse will have his/her time to 
first relapse right-censored at 24 weeks. Below the horizontal axis, number of events and 
number of subjects at risk for the event will be depicted at each event time. The vertical axis 
may be restricted to 0.50 – 1.0, if none of the curves reach 50%. This KM estimate may be 
biased if the reason for study discontinuation is informative for relapse.  
Change from baseline in EDSS score at Week 24
The comparison of a Evobrutinib treatment group to placebo group using CFB in EDSS at 
Week 24 will be based on a stratified Wilcoxon rank-sum test, with stratum defined by 
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categorical BL EDSS score (≤ 3.0 and > 3.0). A subject’s missing value for EDSS CFB at 
Week 24 will be imputed by the median value among subjects having a Week 24 assessment, 
who are in the same treatment group, and who have the same value for the categorical 
baseline covariate.
Two sensitivity analyses will be reported as described below:
- Same analysis without any adjustment for strata.
- Same analysis using last observation carried forward (LOCF) post baseline to impute a 
missing value at Week 24. (Note that the only scheduled assessment of EDSS between 
baseline and Week 24 is at Week 12.)
In the table summarizing inferential results (Evobrutinib dose group versus placebo group), 
the following will be reported for each group: mean, median, and range of raw EDSS and 
EDSS CFB at Week 24. For each treatment comparison (Evobrutinib group versus placebo 
group), the following will be reported: p-value for the test that the shift in location of the 
distribution of the Week 24 EDSS CFB value, adjusted for categorical BL EDSS, is zero.
A monotonic dose-response relationship, between ordered dose groups (placebo, Evobrutinib
25mg QD, Evobrutinib 75mg QD, and Evobrutinib 75mg BID) and ordered categories of 
Week 24 EDSS CFB,  will be assessed via the Jonckheere-Terpstra trend test, both without 
and with stratification by categorical BL EDSS. Prior to defining suitable categories for 
Week 24 EDSS CFB, missing values will be imputed as described in the main analysis for 
this endpoint. The categories of EDSS CFB will be defined by the quartiles of the 
distribution as observed when all subjects from the 4 treatment groups are combined. Thus, 
the unstratified table will be 4x4, and the stratified table will be 4x4x2, assuming a binary 
stratum covariate. The p-value reported tests the null hypothesis that the Week 24 EDSS 
CFB distribution is the same across dose groups, against the alternative that the location of 
the Week 24 EDSS CFB distribution is ordered (from largest signed CFB value to smallest 
signed CFB value) according to increasing dose group.
Descriptive statistics for the EDSS score at Week 24 will be provided by treatment group 
(including Tecfidera). In particular, mean, median, and range of raw EDSS and EDSS CFB at  
Week 24 will be reported. Mean CFB in EDSS will be presented as a by-visit line plot (BL, 
Week 12, Week 24) for each treatment group, with a vertical line segment at each visit 
representing ± SE (jittered if needed for legibility), and with all treatment groups included in 
a single figure.
14.2.2 Additional secondary endpoint analyses
Secondary efficacy endpoints : baseline to 24 weeks
The following additional secondary endpoints will be evaluated at the time of the primary 
analysis. Reported p-values will be considered nominal, as these endpoints are not included in 
the multiple testing strategy. There will be no sensitivity analyses, nor test for trend, as was the 
case for the primary and key secondary analyses.
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Inferential analyses will not include Tecfidera arm, and placebo will be used as a reference for 
parameter estimates. 
Descriptive statistics will be provided for these endpoints along with inferential results, as 
described below. Another table will describe these endpoints by treatment group (including 
Tecfidera), without imputed data.
Total number of new Gd+ T1 lesions at Weeks 12, 16, 20, 24
This endpoint will be analyzed similarly to the primary endpoint, using an NB model 
adjusted for baseline MRI value, with the offset based on the number of scans. Here the 
baseline MRI value will be presence/absence of Gd+ T1 lesions at baseline, as it is not 
possible to define “new” Gd+ T1 lesions at baseline. The same strategy as that used for the 
primary endpoint will be used.  
Descriptive statistics for new Gd+ T1 lesions at Weeks 12, 16, 20, 24, similar to those for the 
primary endpoint, will be provided by treatment group (including Tecfidera). Mean number 
of new Gd+ T1 lesions will be presented as a by-visit line plot for each treatment group, with 
a vertical line segment at each visit representing the ±SE, and with all treatment groups 
included in a single figure.  
Total number of new or enlarging T2 lesions at Weeks 12, 16, 20, 24
This endpoint will be analyzed similarly to the primary endpoint, using an NB model 
adjusted for baseline MRI value, with the offset based on the number of scans. Here the 
baseline MRI value will be categorical BL T2 lesion volume (≤ 13 cc, > 13cc), as it is not 
possible to define “new or enlarging” T2 lesions at baseline. In the present study, median T2
volume at baseline was 12.6 cc among the combined Evobrutinib/placebo group.
Descriptive statistics for new and newly enlarging T2 lesions at Weeks 12, 16, 20, 24, similar 
to those for the primary endpoint, will be provided by treatment group (including Tecfidera). 
Mean number of new or newly enlarging T2 lesions will be presented as a by-visit line plot 
for each treatment group, with a vertical line segment at each visit representing ±SE, and 
with all treatment groups included in a single figure.  
Mean per-scan number of Gd+ T1 lesions at Weeks 12, 16, 20, 24
This endpoint will be analyzed similarly to the key secondary endpoint EDSS score CFB at 
Week 24, using a nonparametric approach. With this endpoint, no imputation is required if a 
subject is missing 1-3 post-baseline scans, as the endpoint is based on available scans. Details 
on missing data handling for subjects lacking any post-baseline scan assessments are 
provided in Section 9. The mean per-scan value (based on scans available from Weeks 12, 
16, 20, 24) will be analyzed via Hodges-Lehmann estimation of the shift in distribution 
location due to Evobrutinib treatment group versus placebo. Each Evobrutinib dose group 
will be compared to placebo via a stratified Wilcoxon rank-sum test, where the stratification 
will adjust for categorical baseline disease activity, defined as presence/absence of Gd+ T1 
lesions at baseline.
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Descriptive statistics for the mean per-scan number of Gd+ T1 lesions, with mean value for 
each subject based on available scans for that subject at Weeks 12, 16, 20, 24, will be 
provided by treatment group (including Tecfidera), overall and by baseline disease activity 
subgroup.
Change from baseline in volume of Gd+ T1 lesions at Week 24
This endpoint will be analyzed similarly to the key secondary endpoint EDSS score CFB at
Week 24, using a nonparametric approach, as neither endpoint is expected to be able to be 
transformed to follow a standard parametric distribution. The distribution of enhanced lesion 
volume is expected to have substantial probability mass at zero (van den Elskamp et al
2011).  In the present study, median Gd+ T1 lesion volume at baseline was zero among the 
combined Evobrutinib/placebo group. The CFB in Gd+ T1 lesion volume at Week 24 will be 
analyzed via Hodges-Lehmann estimation of the shift in distribution location due to 
Evobrutinib treatment group versus placebo. Each Evobrutinib dose group will be compared 
to placebo via a stratified Wilcoxon rank-sum test, where the stratification will adjust for 
categorical baseline disease activity. A categorical covariate such as zero versus nonzero 
Gd+ T1 lesion volume at baseline will be considered. A missing value for CFB in Gd+ T1 
lesion volume at Week 24 will be imputed using the median value among subjects having an 
assessment at Week 24, who are in the same treatment group and stratum.
Descriptive statistics for Gd+ T1 lesion volume CFB at Week 24 treated as a continuous 
variable  (i.e., mean, median, and range), and as a categorical variable (i.e., number and 
proportion with decreasing, constant, or increasing volume), will be provided by treatment 
group (including Tecfidera). Mean CFB in volume of Gd+ T1 lesions will be presented as a 
by-visit line plot for each treatment group, with a vertical line segment at each visit 
representing ±SE, and with all treatment groups included in a single figure.
Change from baseline in volume of T2 lesions at Week 24
The Change from Baseline (CFB) in cube root transformed T2 lesion volume (van den 
Elskamp et al 2011), will be analyzed using MMRM via PROC MIXED. The model for 
mean CFB in the cube root of T2 lesion volume will include treatment (Evobrutinib dose 
group or placebo group), visit (weeks 12, 16, 20, 24), and treatment-by-visit interaction as 
fixed effects, a covariate for the baseline value of the cube root of T2 lesion volume, and 
account for correlation between repeated measures (i.e., residual random effects). The AR(1) 
covariance structure will be considered initially for the equally spaced repeated measures, but 
other structures (i.e., CS, VC) will be considered if there are convergence issues. For each 
Evobrutinib dose group, the LSMeans estimate of an appropriate contrast expressing the 
effect of Evobrutinib on mean cube root of T2 lesion volume CFB at week 24, relative to 
placebo, will be reported, with 95% CI, and p-value. In addition, the LSMeans estimate of 
the cube root of T2 lesion volume CFB at week 24 (adjusted for baseline), with 95% CI, will 
be reported for each dose group (Evobrutinib or placebo). In general, missing scan 
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assessments will be handled via the MAR assumption of the MMRM model. Details on 
missing data handling for subjects lacking any post-baseline scan assessments are provided in 
Section 9.
Descriptive statistics for T2 lesion volume at Week 24, similar to those for Gd+ T1 lesion 
volume at Week 24, will be provided by treatment group (including Tecfidera). Mean CFB in 
volume of T2 lesions will be presented as a by-visit line plot for each treatment group, with a 
vertical line segment at each visit representing ±SE, and with all treatment groups included in 
a single figure.
Secondary efficacy endpoints: baseline to 48 weeks
The following additional secondary endpoints will be evaluated at the time of the blinded 
extension analysis. When all subjects will have reached Week 48 or discontinued treatment 
prematurely, inferential analyses involving Week 48 endpoints will be performed. Reported p-
values will be considered nominal, as type-1 error was not controlled for comparisons involving 
these endpoints.
For each of these endpoints, descriptive statistics at Week 48, similar to those provided at Week 
24, will be provided for each treatment group, including Tecfidera, based on the mITT and the 
mITT-BE analysis sets.
Number of Gd+ T1 lesions at Week 48
The within-group comparison of number of Gd+ T1 lesions at Week 24 and Week 48 will be 
based on a stratified Wilcoxon signed-rank test, with stratum defined by presence/absence of 
Gd+ T1 lesions at baseline. A missing value for Gd+ T1 lesion count at Week 24 or Week 48 
will be imputed using the median value among subjects having an assessment at that 
timepoint, who are in the same treatment group and stratum.
For each treatment group, the following will be reported: mean, median, and range of the 
Gd+ T1 lesion count at weeks 24 and 48, and a p-value for the test that the shift in location of 
the distribution of Gd+ T1 lesion count between Weeks 24 and 48, adjusted for baseline, is 
zero. For each dose group, the number of subjects with imputed Week 24 value, and number 
of subjects with imputed Week 48 value, will be reported.
The by-visit line plots for mean number of Gd+ T1 lesions, and proportion of subjects who 
are Gd+ T1 lesion-free, for weeks 0-24, provided at the time of the primary analysis, will be 
extended to include Week 48 at the time of the blinded extension analysis. 
Mean total number of Gd+ T1 lesions at Week 24 and Mean total number of Gd+ T1 lesions 
at Week 48 will be presented as a by-treatment group bar chart, two bars for each treatment 
group displayed adjacently in a “cluster” (i.e., Week 24, Week 48), with a vertical line 
segment representing 95% CI extending from each bar, and with the p-value for the 
Wilcoxon signed-rank test displayed above each dose group “cluster” of 2 bars.
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Number of new Gd+ T1 lesions at Week 48, Number of new and enlarging T2 lesions at Week 
48, Change from baseline in Gd+ T1 lesion volume at Week 48, Change from baseline in T2 
lesion volume at Week 48, Change from baseline in EDSS score at Week 48 
These endpoints will be used to compare Week 48 with Week 24 using the same 
nonparametric approach as with “Number of Gd+ T1 lesions at Week 48.”  For “Number of 
new Gd+ T1 lesions at Week 48”, the strata will be defined by presence/absence of Gd+ T1 
lesions at baseline. For “Number of new and enlarging T2 lesions at Week 48”, the strata will 
be defined by categorical BL T2 lesion volume (≤ 13 cc, > 13cc).  For “Change from 
baseline in Gd+ T1 lesion volume at Week 48”, the covariate   zero/nonzero Gd+ T1 lesion 
volume at baseline  will be considered for strata definition.  For “Change from baseline in T2 
lesion volume at Week 48”, the strata will be defined by categorical BL T2 lesion volume (≤ 
13 cc, > 13cc).  For “Change from baseline in EDSS score at Week 48”, the strata will be 
defined by categorical BL EDSS score (≤ 3.0, > 3.0).
A missing value at Week 24 or Week 48 will be imputed using the median value among 
subjects having an assessment at that timepoint, who are in the same treatment group and 
stratum.
The descriptive statistics, relevant by-visit lineplots, and barchart figure provided for the 
“Number of Gd+ T1 lesions at Week 48” endpoint will also be provided for these endpoints.
Qualified relapse-free analysis status at Week 48
The within-group comparison of qualified relapse-free status for Week 0-24 and Week 25-48
will be based on a stratified McNemar (SMN) test, with strata defined by categorical number 
of relapses in the last 2 years before randomization (≤ 1 relapse, > 1 relapse). Subjects who 
discontinue treatment between Week 24 and Week 48 without having a qualified relapse will 
be counted as not being qualified relapse-free for the period Week 25-48.
For each treatment group, the following statistics will be reported describing the period Week 
25-48: number (proportion) of subjects with ≥ 1 relapse between Week 24 and Week 48
(either discontinuer or completer of 48 weeks of treatment), number (proportion) of subjects 
with 0 relapses between Week 24 and Week 48, number (proportion) of subjects 
discontinuing treatment between Week 24 and Week 48, among subjects with 0 relapses in 
that period, and number (proportion) of subjects who are relapse-free during Week 25 - 48, 
using imputation for treatment discontinuers, with 95% CI.
For each treatment group, the following statistics will be reported comparing the period 
Week 0-24 with the period Week 25-48:
 number (proportion) of subjects whose relapse-free status improves from the period 
Week 0-24 to the period Week 25-48 (using imputation for treatment discontinuers 
during Week 25-48), by stratum 
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 number (proportion) of subjects whose relapse-free status worsens from the period 
Week 0-24 to the period Week 25-48 (using imputation for treatment discontinuers 
during Week 25-48), by stratum
 p-value for the test that the proportion of subjects whose relapse-free status improves 
equals the proportion of subjects whose relapse-free status worsens (using imputation 
for treatment discontinuers during Week 25-48) adjusted for baseline.
For treatment groups that received a consistent regimen for the entire 48 weeks, the 
following will be reported:
 proportion relapse-free during Week 0-48, with 95% CI, without and with imputation 
for treatment discontinuers.
 Kaplan-Meier estimate of proportion surviving qualified relapse-free as a function of 
time (i.e., proportion qualified relapse-free between Week 0 and Week 48) for each 
treatment group, with all KM curves in a single figure. A subject discontinuing study 
prior to Week 48 without relapse will have his/her time to first relapse right-censored 
at the time of study discontinuation (i.e., the last time at which he/she is at risk of 
relapse on study). A subject completing 48 weeks of treatment without relapse will 
have his/her time to first relapse right-censored at 48 weeks. Below the horizontal 
axis, number of events and number of subjects at risk for the event will be depicted at 
each event time. The vertical axis may be restricted to 0.50 – 1.0, if none of the 
curves reach 50%. This KM estimate may be biased if the reason for study 
discontinuation is informative for relapse.  
Annualized relapse rate at Week 48
For each treatment group, the following will be reported: number of qualified relapses during 
Week 25-48, number of total relapses during Week 25-48, follow-up (in subject-years) 
during Week 25-48, and unadjusted ARR during Week 25-48 (number of qualified relapses 
divided by follow-up), with 95% CI.
For treatment groups that receive a consistent regimen for the entire 48 weeks, the following 
will be reported: number of qualified relapses during Wk 0-48, number of total relapses 
during Week 0-48, follow-up (in subject-years) during Wk 0-48, and unadjusted ARR at 
Week 48 (number of qualified relapses divided by follow-up), with 95% CI.
The estimates of ARR at Week 24 and ARR during Week 25-48 will be presented as a by-
treatment group bar chart, two bars for each treatment group displayed adjacently in a 
“cluster” (i.e., 0-24 week, 25-48 week), with a vertical line segment representing 95% CI 
extending from each bar. The number of subjects contributing to the ARR estimate will be 
displayed below each bar.
No within-group analysis related to the endpoint ARR at Week 48 is planned.
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15 Safety Evaluation
The subsections in this section include specifications for summarizing safety endpoints that are 
common across clinical trials such as adverse events, laboratory tests and vital signs.
15.1 Adverse Events
Pre-treatment adverse events are defined as those AEs with an onset date on or after the date 
of informed consent and prior to the date of first dose of IMP.
Treatment-emergent adverse events (TEAEs) are defined as those AEs with an onset date on 
or after the date of first IMP administration.
The initial 24-week treatment period will include the following TEAEs:
- TEAEs with an onset date on or after first IMP administration and strictly before the first 
administration in the second 24-week period.
- All TEAEs for subjects discontinuing during the initial 24-week treatment period.
The second 24-week treatment period will include all TEAEs with an onset date on or after the 
first administration in the second period.  
IMP related Adverse Events are those AEs with relationship to study treatment reported by the 
investigator as related or those of unknown relationship.
Serious Adverse Events are those events reported on the AE eCRF form with the serious field 
ticked “Yes” or with unknown seriousness.
Adverse Events leading to withdrawal of IMP are those AEs with action taken regarding study 
treatment as “Drug withdrawn” (as recorded on the AEs eCRF page). 
Adverse Events leading to study termination are those AEs with other action taken as “Led to 
study termination” (as recorded on the AEs eCRF page). 
Adverse events will be coded according to the latest MedDRA version available at the time of 
analysis. The severity of AEs will be graded using National Cancer Institute - Common 
Terminology Criteria for AEs (NCI-CTCAE version 4.03) toxicity grades. 
All Adverse Events recorded during the course of the trial (ie, assessed from signature of 
informed consent until the end of the Follow-up/End of Trial visit) will be coded according to the 
MedDRA and assigned to a SOC and PT. 
Group/SOC terms will be sorted alphabetically. Preferred terms within each group/SOC will be 
sorted by the highest active dose of Evobrutinib descending frequency, and alphabetically if 
multiple preferred terms have the same frequency. 
If a subject experiences more than one occurrence of the same TEAE during the trial, the subject 
will only be counted once for that treatment (the worst severity and the worst relationship to trial 
treatment will be tabulated).
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In case a subject had events with missing and non-missing grades, the maximum of the 
non-missing grades will be displayed.
All analyses described in Section 15.1 will be based on Treatment Emergent Adverse Events 
(TEAEs) if not otherwise specified.
15.1.1 All Adverse Events
A TEAE summary table will include a row for the overall frequency of TEAEs of the following 
types: 
 any TEAE
 IMP-related TEAE
 serious TEAE
 IMP-related serious TEAE
 TEAE by intensity (NCI-CTCAE grade 1 to 4)
 IMP-related TEAE by intensity (NCI-CTCAE grade 1 to 4)
 TEAE leading to death
 IMP-related TEAE leading to death 
Exposure adjusted incidence rates (EAIR) are calculated as the number of subjects with TEAE 
divided by the sum of the individual times of all subjects in the safety population from start of 
treatment to first onset of TEAE in the corresponding time period. The incidence rate multiplied
with 1000 would give the number of AEs expected in 1000 subjects within 1 time unit (year). 
EAIR of TEAEs will be presented by SOC and PT.  If a subject has multiple events, the exposure 
period of the first event will be used. For a subject with no event, the exposure period will be
censored at the last follow-up time within the AE summarization period.
The TEAE tables to be prepared are listed below:
Table design
Overall 
frequency
By 
primary 
SOC and 
PT
By 
SOC
only
By PT 
only
By 
HLGT 
only
By 
HLT 
only
TEAE Overview Summary X NA NA
TEAE by SOC and PT X X
TEAE by SOC X X
TEAE by PT X X
TEAE by HLGT X X
TEAE by HLT X X
IMP-related TEAE by SOC and PT X X
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Non-Serious TEAE by SOC and PT* X X
TEAE by worst grade, SOC and PT X
IMP-related TEAE by worst grade, 
SOC and PT
X
EAIR of TEAEs X X
*A table with all TEAEs will be first provided and then only TEAEs exceeding a frequency of 5% in at least one of 
the treatment groups (>5%), by SOC and PT will be provided.
Pretreatment and TEAEs will be listed separately by treatment group and subject.
Three-tier Approach to Summarizing and Analysing AEs
The 3-tier approach is a systematic way to summarize and analyze adverse events (AEs) in 
clinical trials (Crowe 2009). AEs in different tiers are analyzed using different levels of 
statistical analyses.
This study will not include Tier 1 analyses, as no Tier 1 AEs were identified prior to the bulk of 
the data being collected. Tier 3 analyses will not be provided, due to the relatively small sample 
size per treatment group. Only Tier 2 AEs will be defined and the respective analyses provided.
AEs will be classified into Tier 2 based on the Rule-of-3. If there are 3 or more patients with the 
reported term in any treatment group, that term will be included in Tier 2. 
For Tier 2 AEs, the difference in crude rates (between Evobrutinib dose group and placebo 
group), and the CI for the difference, will be reported. The CI will be based on the unconditional 
MN method (Miettinen 1985, G.F. Liu 2006). No multiplicity adjustment will be applied for Tier 
2 AEs.
EAIR of TEAEs will be presented for Tier 2 AEs, by SOC and PT. The difference in EAIR 
between Evobrutinib dose group and placebo group will be summarized.
15.1.2 Adverse Events Leading to Treatment Discontinuation
A TEAE summary table will include a row for the overall frequency of TEAEs of the following 
types: 
 TEAE leading to interruption of IMP 
 IMP-related TEAE leading to interruption of IMP
 TEAE leading to withdrawal of IMP
 IMP-related TEAE leading to withdrawal of IMP 
 TEAE leading to dose reduction of Tecfidera 
 IMP-related TEAE leading to dose reduction of Tecfidera 
 TEAE leading to concomitant medication
 IMP-related TEAE leading to concomitant medication
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 TEAE leading to concomitant procedure
 IMP-related TEAE leading to concomitant procedure
 TEAE leading to study termination
 IMP-related TEAE leading to study termination
The TEAE tables to be prepared are listed below:
Table design
Overall 
frequency
By primary 
SOC and PT
By PT only
TEAE leading to discontinuation of IMP/study
Overview Summary
X NA NA
TEAE leading to IMP withdrawal by SOC and PT X X
IMP-related TEAE leading to IMP withdrawal by 
SOC and PT
X X
TEAE leading to study termination X X
IMP-related TEAE leading to study termination X X
A listing of TEAEs leading to withdrawal of IMP, and a listing of TEAEs leading to study 
termination, will be provided.
15.2 Deaths, Other Serious Adverse Events, and Other Significant 
Adverse Events
15.2.1 Deaths
A summary of deaths will be provided including (clinicaltrials.gov requirement):
 Number and percentage of (all) deaths
 Number and percentage of the primary cause of death (categories: disease progression, 
adverse event, unknown, other)
TEAEs leading to death and IMP-related TEAEs leading to death will be tabulated by SOC and 
PT along with overall frequency. A listing of deaths, if any, will be provided.
In case there is no death in the trial, only the summary of death required by clinicaltrials.gov will 
be performed, neither tabulation of TEAE leading to death will be edited, nor the listing of death.
15.2.2 Serious Adverse Events
Serious TEAEs and IMP-related serious TEAEs will be tabulated by SOC and PT along with 
overall frequency.
A subject listing of serious TEAEs will be provided.
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15.3 Clinical Laboratory Evaluation
The clinical laboratory safety parameters measured in this trial , and reported as part of the safety 
evaluation of hematology, biochemistry, and urinalysis, are specified in the protocol (Table 5 of 
the Clinical Trial Protocol, Section 7.4.3). Ig levels, B,  cell count are not considered
in this section.
Summaries of Clinical Laboratory Data
Laboratory results will be classified according to the grades defined in NCI-CTCAE Version 
4.03 as provided by the central laboratory. If a laboratory parameter has bi-directional toxicities 
(eg, Potassium), both directions will be presented for the given parameter (ie, Potassium Low 
and Potassium High). On-treatment values are defined as results of assessments made after the 
first IMP administration on Day 1. Laboratory results containing a modifier such as “<” or “>=”
will be handled case by case for summary statistics and will be reported as collected in the 
database in subject data listings.
All parameters will also be presented according to the categories based on normal ranges: below 
normal limits (Low), within normal limits (Normal) and above normal limits (High).
Protocol-specified clinical laboratory parameters (hematology, biochemistry, urinalysis) will be 
summarized using descriptive statistics appropriate to continuous-valued random variables (see 
Section 9) by time point and by treatment group. At each time point, both observed value and 
CFB value will be summarized.
Shift tables of baseline value (low, normal, high) versus worst on-treatment value, presented by 
treatment group, will be provided for hematology, biochemistry, and urinalysis parameters.
Shift tables of baseline grade versus worst post-baseline grade, presented by treatment group, 
will be provided for hematology and biochemistry parameters.
Directional laboratory tests (hematology, biochemistry) (Appendix 1) will be summarized by 
worst on-treatment value and by treatment group.
Graphical Display of Clinical Laboratory Data
Boxplots of laboratory values by treatment arm and timepoint will be provided for the following 
hematology and biochemistry parameters:
 hemoglobin
 white blood cell count
 absolute neutrophil count
 absolute lymphocyte count
 platelet count
 Alanine Amino-Transferase (ALT)
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 Aspartate Amino-Transferase (AST)
 Alkaline Phosphatase (ALP)
 total bilirubin
 Gamma-Glutamyl Transferase (GGT)
 glucose
 creatinine
 sodium
 potassium
 calcium
 lipase
 amylase
Boxplots for the laboratory parameters listed above will be displayed using the unit of 
measurement. If consistent with BOA standards, the ULN and LLN will be added to the lab 
parameter boxplot, for any lab parameter where the normal range is the same for all subjects in 
the analysis set.
For the primary analysis, a by-subject line plot of log ALT by time point (through Week 24), one 
curve per subject, (i.e., “spaghetti” plot) will be provided. One panel will include subjects from 
the Evobrutinib treatment groups, displayed so that curves from subjects in the same group have 
the same color or line type. A second panel will include subjects from the Tecfidera and placebo 
groups, displayed in a similar manner.
Kaplan-Meier estimates of proportion surviving event-free as a function of time will be 
presented for the following 3 types of events based on the ALT parameter:
 Time from first dose to first assessment of ≥ Grade 2 ALT (days)
 Time from first dose to first increase in ALT ≥ 1 grade above BL grade (days)
 Time from first dose to first increase in ALT ≥ 2 grade above BL grade (days)
For the primary analysis, the 3 time-to-event figures will be based on data from weeks 0-24; a 
subject reaching week 24 without experiencing the event will have his/her event time right-
censored at the time of the last ALT assessment. A separate KM curve will be estimated for each 
group: Evobrutinib (any dose), placebo, tecfidera.  
For the blinded extension analysis, the 3 time-to-event figures will be based on data from weeks 
0-48; a subject reaching week 48 without experiencing the event will have his/her event time 
right-censored at the time of the last ALT assessment. A separate KM curve will be estimated for 
each group: Evobrutinib (any dose), tecfidera (i.e., no curve for the group of subjects who switch 
from placebo to Evobrutinib at week 24).  
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To be included in a time-to-event figure, a group must have at least one event. Below the 
horizontal axis of the time-to-event figure, # of events and # of subjects at risk will be displayed 
at each event time. The vertical axis may be restricted to 0.50 – 1.0, if none of the curves reach 
50%.
eDISH (Evaluation of Drug-Induced Serious Hepatotoxicity) figures, as described in Merz et al
(2014), will be presented for both the primary analysis (limited to data from weeks 0-24) and the 
blinded extension analysis (all data from weeks 0-48). The figure produced for the primary 
analysis will include 6 panels: one for each Evobrutinib dose group, one for all dose groups 
combined, one for placebo, and one for tecfidera. The figure produced for the blinded extension 
analysis will include only 5 panels, as there will not be a panel for the subjects who switch from 
placebo to Evobrutinib at week 24.
Listings of Clinical Laboratory Data
By-subject listings of all individual hematology, biochemistry, urinalysis and coagulation values 
present in the database will be provided.
Laboratory values that are outside the normal range will be flagged in the data listings, along 
with corresponding normal ranges.
In this study, clinically significant lab abnormalities were recorded as adverse events. In lieu of a 
listing of clinically significant lab abnormalities for each domain, the following by-subject lab 
value listings will be provided:
 Listing of Grade ≥ 3 hematology values
 Listing of Grade ≥ 3 biochemistry values
 Listing of urinalysis values with Grade ≥ 3, value ≥ 2 times ULN (not to include values 
for Specific Gravity or pH parameters), or an increase of “++” for non gradable 
parameters when applicable.
15.4 Vital Signs
Vital signs (body temperature (°C), SBP (mmHg), DBP (mmHg), respiratory rate (breaths/min) 
and pulse rate (beats/min)) will be summarized by treatment group using descriptive statistics 
(see Section 9) for baseline, each applicable time point and CFB to each time point. 
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Body temperature, SBP, DBP, respiratory rate and pulse rate will be analyzed with shift tables of 
maximum CFB using the categories defined below:
Table 21: Vital sign categories
Parameter Unit Shift Baseline categories Post-baseline categories
(absolute change)
Temperature °C Increase <37 / ≥37 - <38 / ≥38 -
<39 /≥39 - <40 / ≥ 40
≤0* / >0 - <1 / ≥1 - <2 /≥2 - <3 / 
≥3
Pulse rate bpm Increase
and decrease
<100 / ≥100 ≤0* / >0 - ≤20 / >20 - ≤40 / >40
SBP mmHg Increase
and decrease
<140 / ≥140 ≤0* / >0 - ≤20 / >20 - ≤40 / >40
DBP mmHg Increase
and decrease
<90 / ≥90 ≤0* / >0 - ≤ 20 / >20 - ≤40 / >40
Respiratory rate breaths/min Increase
and decrease
<20 / ≥20 ≤0* / >0 - ≤5 / >5 - ≤10 / >10
* This category will include the subjects with no changes or decrease/increase in the 
increase/decrease part of the table respectively.
A listing of maximum CFB and a listing of all vital signs data will be provided. 
15.5 12-Lead Electrocardiogram (ECG)
For the 12-lead ECG parameters listed below, observed values and CFB values will be 
summarized by treatment group using descriptive statistics for continuous random variables:
 Ventricular rate (beats/min)
 Pulse rate interval (msec)
 QRS (msec)
 QT (msec)
 Fridericia corrected QT (QTcF) (msec).
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The QTcF parameter will be categorized by observed value into the categories
 ≤ 430 msec,
 > 430 – 450 msec,
 > 450 – 480 msec,
 > 480 – 500 msec, 
 > 500 msec
and by CFB value into the categories
 ≤ 30 msec,
 > 30 – 60 msec,
 > 60 msec.
Number and percentage of subjects within each category listed above, based on their post-
baseline QTcF data, will be presented by treatment group.  
A shift table of rhythm results (Sinus rhythm, Atrial fibrillation, Other, Missing) from baseline to 
last on treatment category, presented by treatment group, will be provided.
A shift table of morphological assessments (Normal, Abnormal, Missing) from baseline to 
maximum on treatment category, presented by treatment group, will be provided.
A listing of ECG quantitative values, morphological and rhythm results will be produced.
15.6 Chest X-ray Evaluations
Investigator reported abnormalities in chest x-ray will be listed, refer to Section 11.3.2.
15.7 Physical Examination
No summary table will be provided since physical examination findings during screening will be 
recorded as medical history events and findings during the trial as AEs.
15.8 Safety/Pharmacodynamic Endpoints:  
and Immunoglobulin levels
Safety/pharmacodynamic endpoints include  and immunoglobulin (Ig) levels.   
Immunoglobulin (IgM, 
IgA, and IgG and subclass) levels will be assessed prior to the morning dose on Day 1, Day 28, 
Day 112, Day 168, and Day 336 (End of Treatment).
For each Safety/PD endpoint, observed value, change from baseline, will be summarized. 
Descriptive statistics for these variables will be presented as described in Section 9.
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15.9 Pregnancy test
Results of pregnancy test (serum and urine beta human chorionic gonadotropin for women only) 
will be listed for the primary analysis and blinded extension analysis.
16 Analyses of Other Endpoints
16.1
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16.2.3
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16.2.3.6
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16.3 Quality of Life: 36-item Short Form Health Survey (SF-36)
The Medical Outcomes Study SF-36 form asks subjects to reply to questions (items) according to 
how they have felt over a specifically defined period of time. Items yield scale scores for each of 
8 health domains, and 2 summary measures of health: the PCS and the MCS. For more 
information on the scoring see Appendix 2.
Baseline to 24 weeks
For the primary analysis, data will be available for SF-36 assessments through Week 24. For 
each treatment group, descriptive statistics appropriate for a continuous random variable will be 
presented for absolute (raw) value and CFB value for SF-36 endpoints at the following time 
points: BL, W4, W8, W12, W16, W20, W24, and premature EOT (assuming premature EOT 
was prior to W24). In addition, for each SF-36 endpoint, the number (proportion) of subjects not 
worsening, and number (proportion) of subjects worsening, between baseline and Week 24 will 
be summarized by treatment group.
SF-36 score CFB at Week 24 will be analyzed using MMRM via PROC MIXED. The model for 
mean SF-36 score CFB will include treatment (Evobrutinib dose group or placebo group), visit 
(weeks 4, 8, 12, 16, 20, 24), and treatment-by-visit interaction as fixed effects, a covariate for the 
baseline value of the SF-36 score, and account for correlation between repeated measures (i.e., 
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residual random effects). The AR(1) covariance structure will be considered initially for the 
equally spaced repeated measures, but other structures (i.e., CS, VC) will be considered if there 
are convergence issues. For each Evobrutinib dose group, the LSMeans estimate of an 
appropriate contrast expressing the effect of Evobrutinib on mean SF-36 score CFB at week 24, 
relative to placebo, will be reported, with 95% CI, and p-value. In addition, the LSMeans 
estimate of the SF-36 score CFB at week 24 (adjusted for baseline), with 95% CI, will be 
reported for each dose group (Evobrutinib or placebo). In general, missing assessments will be 
handled via the MAR assumption of the MMRM model. Details on missing data handling for 
subjects lacking any post-baseline assessments are provided in Section 9.
A figure depicting line plots of Mean CFB at Week 24 for SF-36 sub-domain score versus sub-
domain score type (PF, RP, BP, GH, VT, SF, RE, MH), one curve per treatment group, displayed 
together, will be provided. Mean PCS CFB will be presented as a by-visit line plot for each 
treatment group, with all treatment groups included in a single figure, and horizontal axis 
extending to Week 24. A similar by-visit figure will be provided for mean MCS CFB.
For each SF-36 endpoint, a figure will be provided describing the distribution of % CFB at Week 
24, one curve per treatment group (Evobrutinib dose group or placebo group). The estimated 
CDF curve for % CFB at Week 24 will display proportion of subjects having a value for % CFB 
at Week 24 ≤ x, where the range of x depends on the data.  For the purpose of estimating the 
CDF, a subject missing an assessment at Week 24 will have the assessment imputed via the last-
observation-carried-forward (LOCF) value.
Baseline to 48 weeks
For the blinded extension analysis, additional data will be available for assessments at Weeks 36 
and 48. For each treatment group, descriptive statistics appropriate for a continuous random 
variable will be presented for absolute (raw) value and CFB value for SF-36 endpoints at the 
following time points: W36, W48, and premature EOT (assuming premature EOT was prior to 
W48). In addition, for each SF-36 endpoint, the number (proportion) of subjects not worsening, 
and number (proportion) of subjects worsening, between baseline and Week 48 will be 
summarized by treatment group.
SF-36 score CFB at Week 48 will be analyzed using MMRM via PROC MIXED. The model for 
mean SF-36 score CFB will include treatment (Evobrutinib dose groups only), visit (weeks 12, 
24, 36, 48), and treatment-by-visit interaction as fixed effects, a covariate for the baseline value 
of the SF-36 score, and account for correlation between repeated measures. The AR(1) 
covariance structure will be considered initially for the equally spaced repeated measures, but 
other structures (i.e., CS, VC) will be considered if there are convergence issues. For each 
Evobrutinib dose group, the LSMeans estimate of the SF-36 score CFB at week 48 (adjusted for 
baseline), will be reported, with 95% CI. Missing data are handled as in the Baseline to 24 weeks 
analysis.
A figure depicting line plots of Mean CFB at Week 48 for SF-36 sub-domain score versus sub-
domain score type, one curve per Evobrutinib dose group, displayed together in a single figure, 
will be provided. The by-visit figures of mean PCS CFB and mean MCS CFB covering the first 
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24 weeks provided at the primary analysis, will be extended through 48 weeks for the blinded 
extension analysis.
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18 Appendices
18.1 Appendix 1: Worst on treatment value based on normal 
range of laboratory evaluations
Names of Clinical Safety Laboratory 
Evaluations in Protocol version 1.0, 05 July
2016
If gradable parameter, corresponding 
evaluation names in NCI-CTCAE 4.03
Worst on treatment 
value based on normal 
range 
Albumin Hypoalbuminemia LOW
Aspartate aminotransferase Aspartate aminotransferase increased HIGH
Alanine aminotransferase Alanine aminotransferase increased HIGH
Alkaline phosphatase Alkaline phosphatase increased HIGH
γ-Glutamyl-transferase GGT increased HIGH
Lactate dehydrogenase HIGH
Bilirubin (total) Blood bilirubin increased HIGH
Protein (total) LOW
Creatinine Creatinine increased HIGH
Estimated Glomerular Filtration Rate LOW
Amylase Serum amylase increased HIGH
Lipase Lipase increased HIGH
Total carbon dioxide LOW
Blood urea nitrogen HIGH
Glucose Hyperglycemia HIGH
Glucose Hypoglycemia LOW
Sodium Hypernatremia HIGH
Sodium Hyponatremia LOW
Potassium Hyperkalemia HIGH
Potassium Hypokalemia LOW
Chloride NA
Calcium Hypercalcemia HIGH
Calcium Hypocalcemia LOW
Magnesium Hypermagnesemia HIGH
Magnesium Hypomagnesemia LOW
Phosphate Hypophosphatemia LOW
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Names of Clinical Safety Laboratory 
Evaluations in Protocol version 1.0, 05 July
2016
If gradable parameter, corresponding 
evaluation names in NCI-CTCAE 4.03
Worst on treatment 
value based on normal 
range 
Hematocrit LOW/HIGH
Hemoglobin Hemoglobin increased HIGH
Hemoglobin Anemia LOW
Red blood cell count NA
Mean corpuscular volume NA
Mean corpuscular hemoglobin NA
Mean corpuscular hemoglobin 
concentration
NA
Reticulocyte count NA
Platelet count Platelet count decreased LOW
White blood cell count Leukocytosis HIGH
White blood cell count White blood cell decreased LOW
B,  cell count LOW
Immunoglobulin and subclass 
concentrations
LOW
Total IgG LOW
Total IgA LOW
Total IgM LOW
White blood cell differentials and absolute 
counts: Basophils
NA
White blood cell differentials and absolute 
counts: Eosinophils
NA
White blood cell differentials and absolute 
counts: Lymphocytes
Lymphocyte count increased HIGH
White blood cell differentials and absolute 
counts: Lymphocytes
Lymphocyte count decreased LOW
White blood cell differentials and absolute 
counts: Monocytes
NA
White blood cell differentials and absolute 
counts: Neutrophils
Neutrophil count decreased LOW
pH NA
Nitrite NA
Urobilinogen NA
Bilirubin (urinalysis) NA
Glucose (urinalysis) NA
Ketones bodies NA
Protein (urinalysis) NA
Microscopy: white blood cells HIGH
Microscopy: red blood cells HIGH
Microscopy: casts NA
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Names of Clinical Safety Laboratory 
Evaluations in Protocol version 1.0, 05 July
2016
If gradable parameter, corresponding 
evaluation names in NCI-CTCAE 4.03
Worst on treatment 
value based on normal 
range 
Protein/creatinine ratio HIGH
18.2 Appendix 2: SF-36 VERSION 2 (1998 US POPULATION)
The SF-36v2 (3) is a multi-purpose questionnaire that measures general health status. It is a self-
administered generic measure of health-related quality of life comprised of 36 items illustrating 8 
health concepts (see Table A2.1): physical function (PF), bodily pain (BP), general mental health 
(MH), vitality (VT) (energy and fatigue), social function (SF), physical role (RP) (role 
limitations due to physical health), emotional role (RE) (role limitations due to personal or 
emotional problems), general health perceptions (GH). The recall period is 4 weeks. SF-36 also 
includes a Reported Health Transition (HT) single-item, evaluating the change in health status 
during the past year, which is not part of any of the above subscales. This item is to be analysed 
as a categorical variable. Scores for the 8 dimensions/subscales are standardised in order to range 
from 0 to 100, with higher scores representing better QoL. It is to be noted that 5 of the 8 scales 
(PF, RP, BP, SF, and RE) define health status as the absence of limitations or disability. This 
condition is sufficient to reach a high score. For the other three scales (GH, VT, and MH), a high 
score is reached when the subjects report positive states and evaluate their health favourably.
The SF-36v2 multi-item scales yield a health profile (8 scores) or can be aggregated into two 
summary scores, the Physical Component Summary score (PCS) and Mental Component 
Summary score (MCS) obtained through a linear combination of weighted transformed scores 
from the 8 subscales. PCS and MCS are standardised, with an average of 50 and a standard 
deviation of 10 in the general American population. PCS and MCS are computed only if all of 
the 8 scale scores are available. 
Table A2.1: Abbreviated Item Content for the SF-36v2 Health Domain Scales
Scale
Original 
item#
Item# in 
RMS study
Abbreviated Item Content
Physical Functioning (PF) 3a 3
Vigorous activities, such as running, 
lifting heavy objects, or participating in 
strenuous sports
3b 4
Moderate activities, such as moving a 
table, pushing a vacuum cleaner, 
bowling, or playing golf
3c 5 Lifting or carrying groceries
3d 6 Climbing several flights of stairs
3e 7 Climbing one flight of stairs
3f 8 Bending, kneeling, or stooping
3g 9 Walking more than a mile
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Scale
Original 
item#
Item# in 
RMS study
Abbreviated Item Content
3h 10 Walking several hundred yards
3i 11 Walking one hundred yards
3j 12 Bathing or dressing oneself
Role-Physical (RP) 4a 13
Cut down the amount of time spent on 
work or other activities
4b 14 Accomplished less than you would like
4c 15
Limited in kind of work or other 
activities
4d 16
Had difficulty performing work or 
other activities (eg, it took extra effort)
Bodily Pain (BP) 7 21 Intensity of bodily pain
8 22
Extent pain interfered with normal 
work
General Health (GH) 1 1
Is your health: excellent, very good, 
good, fair, poor
11a 33
Seem to get sick a little easier than 
other people
11b 34 As healthy as anybody I know
11c 35 Expect my health to get worse
11d 36 Health is excellent
Vitality (VT) 9a 23 Feel full of life
9e 27 Have a lot of energy
9g 29 Feel worn out
9i 31 Feel tired
Social Functioning (SF) 6 20
Extent health problems interfered with 
normal social activities
10 32
Frequency health problems interfered 
with social activities
Role-Emotional (RE) 5a 17
Cut down the amount of time spent on 
work or other activities
5b 18 Accomplished less than you would like
5c 19
Did work or other activities less 
carefully than usual
Mental Health (MH) 9b 24 Been very nervous
9c 25
Felt so down in the dumps that nothing 
could cheer you up
9d 26 Felt calm and peaceful
9f 28 Felt downhearted and depressed
9h 30 Been happy
Self-Evaluated Transition 
(SET)
2 2
How health is now compared to 1 year 
ago
Step 1: Recoding Item Response Values
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Some of the SF-36v2 items will be re-coded so that across all questions, a higher score will 
indicate a better health state.  Questions 2, 3a-3j, 4a-4d, 5a-5c, 9b, 9c, 9f, 9g, 9i, 10, 11a, 11c will 
be scored as recorded; the other questions will have the scores transformed as shown in Table 
A2.2. If multiple answers are given to the same item, then the item score will be left as missing.
Table A2.2: SF-36 Re-Coding
Question Original code and re-code response
Question number: 1
    Original response 1 2 3 4 5
    Re-coded response 5 4.4 3.4 2 1
Questions numbers:  6, 11b, 11d 
    Original response 1 2 3 4 5
    Re-coded response 5 4 3 2 1
Question number:  7
    Original response 1 2 3 4 5 6
    Re-coded response 6 5.4 4.2 3.1 2.2 1
Question number:  8 (if question number 7 is answered)
    Original response to #8 1 1 2 3 4 5
    Original response to #7 1 2-6 1-6 1-6 1-6 1-6
    Re-coded response 6 5 4 3 2 1
Question number:  8 (if question number 7 is NOT answered)
    Original response 1 2 3 4 5
    Re-coded response 6 4.75 3.5 2.25 1
Questions number:  9a, 9d, 9e, 9h
    Original response 1 2 3 4 5
    Re-coded response 5 4 3 2 1
 
 
CCI
Evobrutinib Phase II in Relapsing Multiple Sclerosis
MS200527-0086 14 Feb 2018 / Version 1.0
80/86
Step 2: Determining Health Domain Scale Scores (0-100 Scores)
After item recoding, a total raw score is computed for each health domain scale. The total raw 
score is the simple algebraic sum of the final response values for all items in a given scale, as 
shown in Table A2.3. The total raw score for each scale is transformed to a 0-100 scale score 
using the following formula:
(Raw score – Lowest possible raw score) / Possible raw score range × 100
Table A2.3: Values used in transforming SF-36v2 Health Survey Health Domain Scale 
Total Raw Scores on the 0-100 Scale
Scale Sum of Final Response Values Lowest and highest
possible total raw scores
Possible total
raw score range
PF 3a+3b+3c+3d+3e+3f+3g+3h+3i+3j 10, 30 20
RP 4a+4b+4c+4d 4, 20 16
BP 7+8 2, 12 10
GH 1+11a+11b+11c+11d 5, 25 20
VT 9a+9e+9g+9i 4, 20 16
SF 6+10 2, 10 8
RE 5a+5b+5c 3, 15 12
MH 9b+9c+9d+9f+9h 5, 25 20
Raw and transformed scale scores are not calculated for the Reported Health Transition (HT)
item.
As recommended by the developers of the questionnaire, missing item responses will be treated 
using the “Half-scale rule”, which states that a score can be calculated if the respondent answers 
at least 50% of the items in a multi-item scale. In such cases, the missing item data will be 
replaced by the mean of the answered items of its scale. If more than 50% of the items are 
missing within a scale, the scale score will be missing.
Step 3: Calculating Normalized Health Domain Scores
The normalized scale scores will then be calculated using the following formulas:
1/ Health Domain Z-score = (Health Domain 0-100 score – a) / b
2/ Normalized Health Domain score = 50 + (Health Domain Z-score × 10)
where a and b are the Mean and Standard Deviation of the Health Domain scale in the 1998 U.S.
general population as shown in Table A2.4.
Table A2.4: 1998 General US Population Means and Standard Deviations used to Calculate 
Normalized Health Domain Scores
Health Domain Scales Mean Standard Deviation
PF 83.29094 23.75883
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RP 82.50964 25.52028
BP 71.32527 23.66224
GH 70.84570 20.97821
VT 58.31411 20.01923
SF 84.30250 22.91921
RE 87.39733 21.43778
MH 74.98685 17.75604
The advantages of the normalization of the eight health domain scales are that results for one 
health domain scale can be meaningfully compared with those from the other scales and that 
domain scores have a direct interpretation in relation to the distribution of scores in the 1998 
U.S. general population.
Step 4: Scoring the Physical and Mental Component Summary Measures
The Physical Component Summary (PCS) and Mental Component Summary (MCS) measures 
are scored using a three-step procedure. First, the 8 health domain scale scores are standardized 
using means and standards deviations from the 1998 U.S. general population (see Table A2.4).
Second, these Z-scores are aggregated using weights (factor score coefficient) from the 1990 U.S
general population. Third, aggregate PCS and MCS scores are standardized by multiplying the 
standardized scale by 10 and adding 50. 
U.S. general population statistics used in the standardization and in the aggregation of SF-36v2
Health Survey health domain scale scores are presented in Table A2.5.
Table A2.5: Factor Score Coefficients used to Calculate PCS and MCS Scores for the SF-
36v2
Summary component measure factor score coefficients
Scales PCS MCS
PF 0.42402 -0.22999
RP 0.35119 -0.12329
BP 0.31754 -0.09731
GH 0.24954 -0.01571
VT 0.028877 0.23534
SF -0.00753 0.26876
RE -0.19206 0.43407
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18.3 Appendix 3: Details on Pharmacometry Evaluation
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